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Transmissible spongiform encephalopathy (TSE) strains are defined by their 
biological properties on transmission to wild-type mice, specifically by their 
characteristic incubation periods and patterns of vacuolar pathology (‘lesion 
profiles’) in the brain. Whilst a single TSE strain has been identified in variant 
Creutzfeldt-Jakob disease (vCJD), the phenotypic heterogeneity observed in sporadic 
CJD (sCJD) implies the existence of multiple strains of agent. These distinct strains 
are proposed to be enciphered by the different conformers of abnormal prion protein 
(PrP), recognised as different protease resistant PrP (PrPres) types by Western 
blotting (type 1 or type 2) and are thought to be substantially influenced by the 
different prion protein gene (PRNP) codon 129 polymorphism (MM, MV and VV).  
 
To test the relationship between disease phenotype and agent strain, this study 
carried out a full characterisation of the sCJD agent by primary transmission of brain 
tissue from 27 sCJD cases (comprising all six possible combinations of PRNP codon 
129 genotype and PrPres type) in panels of wild-type mice using the standard strain 
typing properties of incubation period and lesion profiles, plus a full analysis of PrP 
in the mouse brain and the PrPres molecular subtypes present. Results were directly 
compared with the transmission characteristics of brain tissue from 10 vCJD cases. 
The characterisation of the agent strain in sCJD and vCJD was extended to include 
analysis of subsequent mouse-to-mouse passages. In an additional investigation, 
wild-type mice were experimentally challenged with a wide-range of lymphoid 
tissues, neural tissues and biological fluids from vCJD and sCJD patients in order to 
investigate the extent of peripheral involvement in CJD and to determine whether the 
agent is subject to any tissue-specific modifications. 
 
Analysis of all 27 sCJD sources demonstrated the existence of two strains of agent, 
one associated with the MM1/MV1 subgroups and the other associated with the 
MM2 subgroup, which could be distinguished by their transmission properties in the 
mice. The lack of transmission in mice challenged with VV1, MV2 and VV2 tissues 
provided evidence of at least one further sCJD strain. In contrast, all 10 vCJD 
 v 
sources resulted in consistent incubation periods and lesion profiles, suggesting that 
all 10 patients investigated were infected with the same strain of agent.  Overall, the 
observation that PrPres type in sCJD and vCJD was maintained on transmission is 
consistent with the proposition that PrPres type plays a role in enciphering strain-
specific information. Experimental transmissions from peripheral tissues extended 
the evidence for a peripheral infection in vCJD. However, comparison of incubation 
periods and lesion profiles from transmission of brain and peripheral tissues showed 
no evidence of tissue-specific modification in the biological properties of the agent. 
Furthermore, the detection of low levels of infectivity in a sCJD buffy coat sample 
provides supporting evidence for a peripheral involvement in sCJD.  
 
This study highlights the complex relationship between disease phenotype, PRNP 
codon 129 genotype, PrPres type and agent strain in sCJD and vCJD. Overall, this 
study confirms that multiple strains of agent are associated with sCJD, some of 
which successfully propagate in wild-type mice but none of which are identical to the 
agent responsible for vCJD. Importantly, the sCJD strains identified here by their 
biological properties partially correlated with the current sub-classification system 
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Chapter 1: Transmissible spongiform encephalopathies 
 
1.1 General Introduction 
Transmissible spongiform encephalopathies (TSEs) are a group of rare degenerative 
and invariably fatal diseases affecting the central nervous system (CNS), which can 
occur in humans as well as a number of animal species. Scrapie in sheep and goats, 
bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) 
in mule deer and elk and Creutzfeldt-Jakob disease (CJD) in humans are just some of 
the more familiar members of this group of diseases (Table 1.1). These disorders are 
defined as ‘transmissible’, referring to the ability of infected tissue to induce disease 
following inoculation into or ingestion by subjects from the same species and in 
some instances individuals of a different species. Recent reports of five probable 
cases of transmission of variant CJD (vCJD) infectivity through transfusion with 
blood and blood products from asymptomatic donors who went on to develop vCJD, 
is a clear example of TSE transmission within a single species (Llewelyn et al., 2004; 
Peden et al., 2004; Wroe et al., 2006; Health Protection Agency, 2009a; Peden et al., 
2010). Furthermore, the now convincing evidence supporting the initial hypothesis 
that vCJD is caused by human infection with the BSE agent is a recent demonstration 
of cross-species transmission between cattle and human (Collinge et al., 1996; 
Lasmezas et al., 1996; Bruce et al., 1997; Hill et al., 1997; Scott et al., 1999).  
 
The term ‘spongiform’ derives from the characteristic lesions or vacuoles that occur 
within the neuropil of the brain of an affected subject (human or animal).  Vacuoles 
can vary in size from 2-20 microns and in some TSEs become confluent, resulting in 
irregular cavities within the neuropil. Examination of spongiform change has shown 
that the majority of vacuoles occur within neuronal processes (mainly neurites) and 
cell bodies, depending on strain of TSE, and ultrastructural studies suggest that they 
can originate in several sub-cellular organelles or processes (Jeffrey et al., 1995). In 
experimental models of TSEs, vacuolation has been shown to vary between the 
different TSE sources and the host species (Fraser and Dickinson, 1968). Although 
not absolutely specific for TSEs, the appearance of vacuolar pathology is of 
 2 
considerable diagnostic importance. The term encephalopathy is given to these 
diseases as the majority of the pathological changes are associated with the brain.  
 
In humans, TSEs are unique in that they can have an idiopathic (sporadic), familial 
(genetic) or acquired (infectious) nature (Prusiner and DeArmond, 1994; Gambetti et 
al., 2003) (Table 1.1). Acquired TSEs are characterised by a prolonged, 
asymptomatic incubation period which is generally followed by a relatively short 
progressive clinical illness that invariably ends in death. Although a number of 
different types of TSE have been identified, the majority are associated with a 
common pathology generally confined to the CNS including a variable degree of 
spongiform vacuolation throughout the cerebral grey matter, reactive proliferation of 
astrocytes and microglial, neuronal loss and in certain TSEs the formation and 
deposition of amyloid plaques within the brain (Figure 1.1a-c) (Ironside, 1996; 
Budka, 2003).   In addition, the advent of immunohistochemical techniques have 
shown that disease is normally, but not always, associated with the deposition of an 
abnormal and protease-resistant form of a normal host encoded-cell surface 
sialoglycoprotein, the prion protein (PrP), denoted PrPSc within CNS tissue and in 
some cases peripheral tissues of affected individuals (Figure 1.1d-f) (Bruce et al., 
1989; van Keulen et al., 1996; Bell et al., 1997; van Keulen et al., 1999; Hill et al., 
1999; Groschup et al., 1999; Head et al., 2004b).  The relevance of the prion protein 
in these diseases is highlighted by the fact that TSEs have become most commonly 
referred to as “prion diseases”.  
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Sporadic Creutzfeldt-Jakob Disease (sCJD)a  








Familial CJD (fCJD)d 
Gerstmann-Sträusler-Scheinker (GSS)e 









Iatrogenic CJD (iCJD)h 
Variant CJD (vCJD)i 
Bovine Spongiform Encephalopathy (BSE)j 
Feline Spongiform Encephalopathy (FSE)k 





Cats (domestic and large) 






Atypical BSE (H or L type)o 
Transmissible Mink Encephalopathy 
(TME)p 
Chronic Wasting Disease (CWD)q 





Mule deer, white tailed 
deer and Elk 
 
First  reported;   
a(Creutzfeldt, 1920; Jakob, 1921), b(Mastrianni et al., 1997), c(Gambetti et 
al., 2008), d(Meggendorfer, 1930; Masters et al., 1981b), e(Gerstmann, 1928), f(Lugaresi et 
al., 1986), g(Zigas  and Gajdusek, 1957), h(Duffy et al., 1974), i(Will et al., 1996), j(Wells et 
al., 1987), k(Wyatt et al., 1990), l(Kirkwood and Cunningham, 1994), m(Chelle, 1942), 
n(Benestad et al., 2003), o(Biacabe et al., 2004; Casalone et al., 2004), p(Hartsough and 





Figure 1.1: Pathological features in TSEs 
 
Pathological changes in human TSEs. (a) microvacuolar degeneration in the frontal 
cortex of an MM1 sporadic CJD case (haematoxylin and eosin stain). (b) Astrocytes 
immunolabelled for glial fibrillary acidic protein in the thalamus of a variant CJD 
case. (c) A kuru plaque (arrow) within the granular layer of the cerebellum in an 
MV2A sporadic CJD case (haematoxylin and eosin stain). Prion protein 
immunohistochemistry in frontal cortex tissue in (d) variant CJD and (e) iatrogenic 
CJD. (f) Prion protein immunohistochemistry within the spleen in variant CJD. 




The first indication that TSEs may be transmissible came from the accidental 
transmission of scrapie in sheep following inoculation of sheep with a scrapie 
contaminated vaccine aimed at controlling louping ill (Gordon, 1946). The first 
evidence for the transmissibility of these diseases occurred during the 1930s with the 
successful transmission of scrapie in previously healthy sheep following intraocular 
injection with spinal cord tissue from sheep affected by scrapie (Cuillé and Chelle, 
1936). Experimental transmission of scrapie to goats (Cuillé and Chelle, 1939) 
followed confirming the cross-species transmissibility of scrapie while 
demonstrating the unusually long incubation periods obtained in these experiments.  
However, it was not until 1959 and the work of William Hadlow, comparing the 
strikingly similar neuropathological features of scrapie with that of Kuru, an obscure 
neurological disease affecting the Fore-speaking people of the Eastern highlands of 
Papua New Guinea, that the first clues to the aetiology of human TSEs emerged 
(Hadlow, 1959). Subsequent transmission studies in which chimpanzees were 
inoculated with brain homogenate from kuru cases provided the first demonstration 
of the transmissible nature of human TSEs (Gajdusek et al., 1966). The inclusion of 
CJD as a TSE resulted from similar observations that the neuropathological features 
of kuru and CJD were remarkably similar (Klatzo et al., 1959). Again, it was 
experimental transmission studies which confirmed CJD as a member of the TSEs 
(Gibbs, Jr. et al., 1968).  
 
A significant advance in TSE research came with the successful transmission of 
brain extracts from sheep scrapie to mice (Chandler, 1961) and subsequently to 
hamsters (Marsh and Kimberlin 1975, Kimberlin and Walker 1977). The 
development of rodent models provided, and continues to provide a practical model 
in which to study TSEs producing significantly shorter incubation periods (around 3-
5 months) compared to that observed in sheep, goats and non-human primates (> 1 
year) while maintaining high titres of infectivity in the brain. More recently, the 
generation of mice expressing novel transgenes has ushered a new era in the use of 
rodent models for the investigation of TSEs.  
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Mouse models play a key role in defining TSE strains. The existence of different 
strains of TSE was first suggested  following the observation of two distinct clinical 
syndromes of scrapie in goats (“scratching” and “drowsy”) (Pattison and Millson, 
1961), the clinical signs of which were reproduced on further transmission to goats. 
Following this, several distinct TSE strains have been identified in mice after serial 
passage of scrapie, BSE or CJD isolates from a range of sheep, goat, cattle or human 
sources. Such strains are distinguished by their unique biological properties, 
specifically incubation periods and patterns of neuropathological targeting (the 
“lesion profile”) after serial passage in mouse lines carrying different alleles of the 
mouse PrP gene (Prn-p) (Dickinson and Mackay, 1964; Dickinson et al., 1968; 
Bruce et al., 1991). These same strain-typing methods confirmed that the agent strain 
in vCJD was indistinguishable from that of BSE, providing compelling evidence that 
vCJD represented human infection with the BSE agent (Bruce et al., 1997).  
 
Enormous public and scientific attention has focused on TSEs, not only because of 
their unique biological properties, but also more recently because of their impact on 
animal and public health, particularly with the appearance of BSE and vCJD in the 
United Kingdom. To date (December 2011), there have been a limited number of 
clinical cases (n=176) of vCJD in the UK (http:www.cjd.ed.ac.uk/figures.htm), much 
lower than first predicted and fears over an epidemic have receded. Concerns now 
focus on limiting the spread of vCJD by secondary human transmission from 
possible asymptomatic carriers, particularly through surgical procedures and surgical 
instruments, with the infectious agent showing an alarming resistance to 
conventional decontamination methods (Dunstan and Alpers, 2005). In addition, the 
observation that vCJD appears to be efficiently transmitted via transfusion with 
blood and blood products (Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 
2006; Health Protection Agency., 2009; Peden et al., 2010) raises concerns over the 
secondary human transmission via this medical procedure. Such concerns have 
focused much of the current research on the development of a diagnostic and 
screening assay which could be applicable for use on biological fluids such as blood.  
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1.2 The infectious agent 
Several hypotheses have been advanced to account for the atypical nature of the 
infectious agent causing TSEs. This remains an area of much controversy and one 
that has yet to be fully resolved. For many years the idea that these were “slow 
viruses” was accepted by much of the scientific community (Sigurdsson, 1954).  
Slow viruses were characterised by a prolonged incubation period of several months 
to decades; a brief, progressive clinical course leading to death; pathology confined 
to a single organ and a natural host usually confined to a single species, all of which 
are associated with scrapie (Sigurdsson, 1954). However, unlike most viruses, the 
scrapie agent showed resistance to many of the physical and chemical treatments that 
modify nucleic acids or decontaminate viruses. The resistance of the agent to 
formalin treatment (Gordon, 1946; Pattison, 1965), heat treatment (Alper et al., 
1967) and the ability to withstand ultraviolet and ionizing radiation (Adams et al., 
1969; Alper et al., 1978; Alper, 1985) suggested that the presence of a nucleic acid 
may not be essential, casting doubt that the agent is a virus. These observations led to 
a new focus and determination in elucidating the nature of the infectious agent and, a 
number of hypotheses were put forward, ranging from an abnormal, replicating 
polysaccharide with membranes (Gibbons and Hunter, 1967; Hunter et al., 1968) to a 
nucleoprotein complex (Latarjet et al., 1970), to a hybrid structure containing a host-
independent informational molecule, protected by a host coded molecule (Bruce and 
Dickinson, 1987).  
 
It was the British mathematician John Griffiths who first put forward the proposal 
that protein may be the causative agent of scrapie and other related TSEs. Griffiths 
suggested that under certain circumstances proteins might be able to self-replicate in 
the absence of nucleic acid.  Two basic mechanisms were proposed, both involving 
the host's own protein. The first suggested that the scrapie agent was a protein with 
the ability to activate a damaging reaction normally suppressed in the host. The 
second proposed that the agent was an abnormal form of the host's own protein that 
could be spontaneously produced (Griffiths, 1967). Crucially, both these proposals 
allowed for the possibility that disease could occur spontaneously in previously 
healthy animals. Griffiths’ work was the first account of what was to become known 
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as the ‘protein-only’ hypotheses.  This proposal would remain unsupported until the 
1980s, by which time it was clear that any hypothesis regarding the infectious agent 
would have to accommodate a number of distinct characteristics displayed by the 
agent. Not only would it have to explain the complex physico-chemical properties of 
the agent, but it would also have to account for the acquired, familial and sporadic 
forms of the disease. Furthermore, the existence of distinct TSE strains would also 
have to be accounted for by the ‘protein-only’ theory. It is this disease phenotype 
problem that has been, and continues to be, the most difficult to accommodate within 
a ‘protein-only’ hypothesis.  
 
The ‘protein-only’ hypothesis was re-addressed and refined in the early 1980’s by 
Stanley Prusiner with the development of a partial purification protocol for scrapie 
infectivity (Prusiner et al., 1981; Prusiner, 1982). By subjecting scrapie-infected 
hamster brain to treatments which modify nucleic acids or destroy viruses, Prusiner 
was able to further demonstrate that these treatments were unable to inactivate the 
scrapie agent. However, on exposing the same brain fractions to proteases, sodium 
dodecyl sulphate (SDS),  phenol and urea; substances that are known to damage or 
destroy protein, the brain fractions became less or non-infectious (Prusiner et al., 
1981; Prusiner, 1982).  These findings lead Prusiner to deduce that the infectious 
agent must be composed of protein and a new term 'prion' was introduced to denote 
these unusual small proteinaceous infectious particles. Having shown that protein 
was a part of the infectious agent the search was on to isolate the protein or proteins 
that were present in the infectious agent. 
 
1.2.1 The prion protein 
Investigations of purified fractions from scrapie-infected hamster brain, identified a 
protease-resistant protein with a molecular mass of around 27-30 kiloDaltons (kDa), 
which was found in abundance in scrapie-infected brain tissue but which was absent 
in normal healthy control tissue (Bolton et al., 1982; Prusiner et al., 1982; McKinley 
et al., 1983).  This unique protein was designated the prion protein (PrP) and termed 
PrP 27-30 after proteolytic treatment (Bolton et al., 1982). Further purification of the 
prion protein identified the N-terminal amino acid sequence (Prusiner et al., 1984) 
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from which oligonucleotides were synthesised to produce complimentary DNA 
(cDNA) (Oesch et al., 1985; Chesebro et al., 1985). Using this cDNA, a larger 
protein with a molecular mass of 33-35 kDa was identified. Investigation of 
messenger RNA levels of the prion protein identified showed similar levels in both 
the scrapie infected hamster brain and in the normal control tissue (Oesch et al., 
1985).  The discovery of a single gene, the human prion protein gene (PRNP) which 
encodes the prion protein, was a surprising and important discovery indicating that 
this was in fact a host encoded protein and not a viral protein as had been expected 
(Oesch et al., 1985; Chesebro et al., 1985). To distinguish between the two forms of 
the protein, the abnormal, disease-associated form was termed PrPSc for the scrapie-
infected isoform or PrPres for the protease resistant isoform after treatment with 
proteases (Caughey et al., 1990), whilst the normal cellular protease sensitive 
isoform was referred to as PrPC or PrPsen when defined by protease-sensitivity. More 
recently, the abnormal, and disease specific form of the protein has also been referred 
to as PrPd to denote its disease specificity (Jeffrey et al., 2003) or PrPTSE to denote 
TSE disease-specificity, irrespective of species and TSE agent involved (Herzog et 
al., 2005). However these later terms are less commonly used in the literature at 
present. For the purpose of this thesis the term PrPSc will be used when refering to 
the abnormal and disease-associated prion protein and PrPres to designate PrPSc, when 
oporationally defined by its resistance to proteolytic digestion, usually with, 
proteinase K.  
 
The accumulation of PrPSc within CNS tissue is considered a hallmark of TSEs, 
whether in sporadic, familial or acquired forms. Indeed, the presence of PrPSc within 
CNS tissues is generally regarded as the surrogate marker for infectivity (Prusiner, 
1998). Early investigations using infrared spectroscopy, circular dichroism and 
computer modelling demonstrated that, PrPC and PrPSc have an identical primary 
structure, differing only in their structural conformation (Caughey et al., 1991). PrPC 
is rich in α-helix content (40%) with little (3%) or no β-sheet content, whereas PrPSc 
is dominated by β-sheet (45%) with a much smaller α-helix content (20%) (Pan et al., 
1993; Safar et al., 1993) (Figure 1.2). This basic structure of PrP is also found to be 
highly conserved between different species. The change in conformation alters the 
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physico-chemical properties of the prion protein in terms of degradation by 
proteinase K (and other proteases) and solubility in non-ionic detergents. In normal 
healthy cells, PrPC is susceptible to digestion with proteases and is solubilized with 
non-ionic detergents, whereas in scrapie infected tissue, PrPSc demonstrates a partial 
resistance to protease treatment and polymerises into amyloid rods after detergent 
extraction (Oesch et al., 1985; Meyer et al., 1986).  The changes, both structural and 
biochemical, which occur during the conversion of PrPC to PrPSc are summarised in 
Table 1.2.  
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PrPC is composed of mainly of α-helical structures (red shaped spirals) whereas PrPSc 
is remodelled into a β-helical structure (green rods). N-terminus and C–terminus are 
not shown (adapted from Soto et al 2001). 
 



















Present in normal tissue Present in TSE affected tissue only 
Mr 33-35 kDa Mr 33-35 kDa 
Predominantly α-helix structure Increased β-sheet structure 
Sensitive to protease treatment Protease resistant core Mr ~27-30 
Soluble in detergents Insoluble in detergents forming aggregates 
Attached to cell surface by a GPI 
anchor 
Accumulates on the cell surface or 
internalised within cells or as extracellular 
fibrils, plaques or amorphous deposits 
GPI anchor sensitive to cleavage 
with phosphatidylinositol-specific 
phospholipase C (PIPLC) 
GPI anchor only sensitive to cleavage after 
denaturation 
Rapid synthesis and turn over  Accumulation slow, resistant to degradation 
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1.3 The prion protein gene 
A single gene, the prion protein gene was found to encode PrPC (Oesch et al., 1985). 
This gene was found to be highly conserved within mammals, with only minor 
differences in the amino acid sequence between species (Prusiner et al., 1998). This 
gene plays a key role in TSEs, with polymorphisms in the coding region in mouse 
and human that influences the incubation period and disease susceptibility. The prion 
protein gene in human and in mouse is described in detail in the following section. 
Three further genes have been identified; Doppel (PRND) (Moore et al., 1999), 
Shadoo (SPRN) (Premzl et al., 2003) and PRNT (Makrinou et al., 2002), which are 
related to the prion gene in terms of sequence homology, and in two of the genes by 
genomic location. However, direct involvement of these three genes in TSEs remains 
to be shown. 
 
1.3.1 The human prion protein gene 
The human prion protein gene, PRNP, was first described in 1986 (Liao et al., 1986) 
and is a single copy gene located on the short arm of chromosome 20. The gene 
contains two exons separated by a 10kb intron with the entire protein-coding region 
of the prion protein contained within the second exon, encoding a protein of 253 
amino acids (Puckett et al., 1991). More than 20 distinct point mutations together 
with insertions and deletions within the octapeptide repeat region have been 
identified within the human PrP gene which are directly linked with the familial 
forms of human prion disease (Prusiner and Scott, 1997; Kovacs et al., 2002b; Mead, 
2006) (Figure 1.3). The role these mutations in the PRNP gene play in the 
development of disease is unclear.  However, it is possible that these mutations either 
cause the prion protein to become less stable making it more likely to cause the 
conversion of PrPC to PrPSc (Prusiner, 1997) or that individuals with such mutations 









1.3.1.1 PRNP codon 129 polymorphism 
In addition to mutations in the PRNP gene, numerous polymorphisms have been 
identified in the PrP gene. Polymorphisms differ to mutations in TSEs in that they do 
not directly cause disease but rather affect the susceptibility of an individual to 
disease or alter the course of the disease. In humans, a naturally occurring 
polymorphism found at codon 129 on PRNP is a recognised risk factor for human 
TSEs either on its own or in conjunction with other mutations in the prion protein. It 
has important effects on the susceptibility to disease, clinical manifestations and the 
incubation period (in acquired forms) (Palmer et al., 1991; Collinge et al., 1991; 
Parchi et al., 1996; Zeidler et al., 1997; Deslys et al., 1998; Alperovitch et al., 1999; 
Lee et al., 2001; Brandel et al., 2003). At codon 129, an ATG or GTC amino acid 
sequence results in either the presence of methionine (M) or valine (V). The presence 
of M or V at codon 129 can be either homozygous or heterozygous. Both M and V 
homozygotes are over represented in human TSEs when compared to the normal 
population while heterozygotes are under represented (Palmer et al., 1991; 
Alperovitch et al., 1999). In sporadic CJD (sCJD), analysis of PRNP has 
demonstrated that around 70% of all cases reported are found in M homozygous 
individuals (Alperovitch et al., 1999) with this figure rising to 100% in the case of 
vCJD (Bishop et al., 2009). These figures have been shown to be statistically 
significant when compared to the 40% normal population frequencies for the MM 
genotype (Collinge et al., 1991; Nurmi et al., 2003). Therefore, homozygosity for 
methionine is clearly a risk factor in the development of sCJD and vCJD.  PrP codon 
129 distributions in sporadic and vCJD compared with the normal UK population are 
shown in Table 1.3.  
 
The PRNP codon 129 polymorphism is also believed to play and important role in 
disease phenotype as demonstrated in sCJD (Parchi et al., 1996) and in cases of 
familial disease, most clearly demonstrated in the D178N mutation. In these familial 
cases, a mis-sense mutation at codon 178 coupled with the presence of M at codon 
129 on the mutant allele results in the clinical picture of fatal familial insomnia (FFI). 
Whereas, the same mutation at codon 178 when coupled with V at codon 129 on the 
mutant allele on PRNP results in the disease phenotype of familial CJD (fCJD) 
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(Monari et al., 1994; Cortelli et al., 1999). The role that PRNP codon 129 plays in the 
disease phenotype in sCJD is discussed later on in Chapter 1. 
 
 
Figure 1.3: Mutations and polymorphic variants of the human PRNP  
 
The human prion protein gene showing positions of common pathogenic mutations 
(red) and non-pathogenic polymorphisms (green). (By kind permission of Matthew 
Bishop) 
 
Table 1.3: PrP codon 129 genotype distributions  
 
 
 MM (%) MV (%) VV (%) 
*Normal population 42 47 11 
†sCJD (UK 1990-2002) 68 16 16 
†vCJD 100 0 0 
 
* Codon 129 genotype frequency data from Nurmi et al. (Nurmi et al., 2003) 





1.3.2 The mouse prion protein gene 
The mouse prion protein gene maps to the homologous region of chromosome 20 
(Sparkes et al., 1986; Lee et al., 1998) and is designated Prn-p. The mouse PrP gene 
has a third exon which contains the entire open reading frame encoding a protein of 
254 amino acids long. In the mouse, three alleles of the Prn-p gene have been 
identified, encoding proteins that differ by two amino acids at codon 108 and 189; 
these are Prn-pa (Leu-108, Thr-189), Prn-pb (Phe-108, Val-189) and Prn-pc (Phe-
108, Thr-189) (Westaway et al., 1987; Lloyd et al., 2004b). The vast majority of 
mouse lines analysed, and those used in this thesis, are either from the Prn-pa or Prn-
p
b genotype (Westaway et al., 1987).  
 
It is now confirmed that the mouse Prn-p gene is congruent to another gene 
identified in the mouse, the Sinc gene, which had been identified much earlier 
(Dickinson et al., 1968). The Sinc gene (short for scrapie incubation) was found to 
have a major influence on the incubation period of scrapie and other TSEs in mice. 
The effect of the Sinc gene was first demonstrated with the experimental 
transmission of the ME7 scrapie strain in which two alleles of the Sinc gene, 
designated s7 and p7, produced short and long incubation periods, respectively 
(Dickinson and Mackay, 1964; Dickinson et al., 1968). Subsequent studies showed 
that the incubation period in other TSE strains were also controlled by the Sinc gene 
(Dickinson and Meikle, 1971; Bruce et al., 1991).  It is now established that the 
Sincs7 allele corresponds to Prn-pa with the Sincp7 allele corresponding to Prn-pb 
(Hunter et al., 1992; Moore et al., 1998). In the routine strain typing of different TSE 
isolates, groups of Sincs7/Prn-pa, Sincp7/Prn-pb, and Sincs7p7/Prn-pab mice are 
included which results in highly reproducible patterns of incubation period in each 




1.4 Cell biology and function of PrPC 
PrPC is a glycosyl-phosphatidylinositol (GPI)-linked cell surface membrane protein 
which is expressed early in embryogenesis and which reaches adult levels soon after 
birth (Kretzschmar et al., 1986; Manson et al., 1992).  PrPC is predominantly 
expressed in neuronal cells of the brain and spinal cord, but has been found at lower 
levels in a wide range of peripheral tissues (Linden et al., 2008). The protein, which 
is encoded by the prion protein gene, contains several distinct domains including an 
N-terminus, which has a series of five proline and lysine-rich octapeptide repeats, a 
highly conserved central hydrophobic region and a C-terminal globular domain 
(Figure 1.4). NMR studies have shown that the N-terminus of the prion protein is 
very flexible and lacks any secondary structure, whereas the C-terminus region 
contains a well-defined folded domain (Prusiner, 1998). The central region of the 
protein is arranged in three α-helices (residues 144-154, residues 173-194 and 
residues 200-228) interspersed with two β-pleated sheet formations (residues 128-
131 and residues 161-164). A single di-sulphide bond is present between Cysteine 
residues 179 and 214 in α-helix two and three respectively. In addition, PrPC contains 
two consensuses sequences for N-linked glycosylation (Asn 181 and Asn 197) and 
can be found in the cell in the un-, mono- and di-glycosylated forms (Stahl and 
Prusiner, 1991). 
 
PrPC is highly conserved between species suggesting that the prion protein plays a 
fundamental physiological role. Defining this role may be crucial in the 
understanding of TSEs, since the protein may fail to perform its normal function 
once converted to the disease-associated form. Much work has been carried out on 
the phenotype of PrP null mice, in which the Prn-p gene has been inactivated or 
deleted. PrP null mice are resistant to scrapie challenge and show no signs of 
infectivity or accumulation of PrPSc after inoculation with TSEs (Bueler et al., 1993; 
Sailer et al., 1994). The generation of different PrP null mice has resulted in the 
demonstration of different phenotypes. Some studies reported no obvious 
abnormalities in the phenotype of null mice, other than a resistance to prion infection 
(Bueler et al., 1993; Manson et al., 1994), whereas others reported several 
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Figure 1.4: Structure of the human prion protein  
 
Schematic diagram of the structure of the cellular prion protein following (a) synthesis and (b) after post-translational modification. The 
numbers correspond to the positions of the amino acids in the human prion protein. The two N-glycan attachment at amino acids 181 and 





neurological abnormalities including; disturbance of synaptic transmission (Collinge 
et al., 1994), nerve cell organisation (Colling et al., 1997) and spatial learning  
(Criado et al., 2005), and alterations in circadian rhythm, sleep pattern (Tobler et al., 
1996) and olfaction (Le Pichon et al., 2009). 
 
Although the normal function of PrPC is not known, a number of roles for PrPC have 
been proposed.  Like many membrane bound proteins, PrPC is synthesised and co-
translocated into the rough endoplasmic reticulum (ER), transits the Golgi apparatus, 
before appearing attached to the cell surface where it resides predominantly in lipid 
rafts (Harris, 2003).  The cellular localisation of PrPC would be consistent with a role 
for PrPC as a membrane receptor, cell adhesion molecule (Schmitt-Ulms et al., 2001; 
Mange et al., 2002) or linked to a signal transduction pathway (Spielhaupter 2001, 
Mouillet-Richard 2000). As PrPC expression is not restricted to neurons it is unlikely 
that it has a purely synaptic function. There is increasing evidence that PrPC may 
have a role in copper metabolism. The binding of metals, in particular copper ions 
(Cu2+), indicates that PrPC may be a metal-binding protein functioning as a metal 
transporter (Brown et al., 1997a; Stockel et al., 1998; Kramer et al., 2001). Several 
lines of experimental evidence indicate that PrPC has a role in protecting cells against 
oxidative stress. Cerebellar granular or neocortical neurons cultured from PrP null 
mice were found to be more susceptible to treatments that induce oxidative stress, 
including copper ions and hydrogen peroxide when compared to neurons cultured 
from wild-type mice (Brown et al., 1997b; Brown et al., 2002). Consistent with these 
studies, scrapie-infected brain tissue has been shown to have increased levels of 
oxidative stress markers (Wong et al., 2001). Later studies confirmed that the brain 
infarct induced by hypoxia or ischemia are significantly larger in PrP null compared 
to wild-type mice (McLennan et al., 2004; Sakurai-Yamashita et al., 2005; Spudich 
et al., 2005). More recently, two studies have proposed a role for PrPC in the 
proliferation and differentiation of hematopoietic stem cells (Zhang et al., 2006)  and 
neural precursor cells (Steele et al., 2006). The studies described all suggest that 
TSEs could result from the loss of function of PrPC. However, as the phenotype of 
null mice is so mild, disease resulting from a gain in function from the accumulation 
PrPSc is also possible 
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1.5 The prion hypothesis 
The pathogenesis of TSEs is associated with the conversion of PrPC to PrPSc. The 
mechanism or mechanisms underlying this protein conversion are yet to be fully 
resolved, but have been attributed to conformational changes in which portions of the 
α-helical and coil structure of PrPC are refolded into a β-sheet complex. At present, 
the prion hypothesis, which is refined from the ‘protein only’ theory, is the most 
widely accepted of the models put forward but remains to be conclusively proven 
(Prusiner, 1991). According to the prion hypothesis, PrPSc is the principal and 
possibly the sole constituent of the transmissible agent.  It predicts that replication 
occurs through the post-translational conversion of PrPC to PrPSc via direct 
interaction of the two proteins resulting in the generation of further PrPSc. PrPSc 
therefore acts as a conformational template, promoting the conversion of PrPC to the 
abnormal and disease-associated form of the protein. This conversion initiates a 
chain reaction in which the newly formed PrPSc converts further PrPC into the 
disease-associated form. This hypothesis proposes that it is the accumulation of PrPSc 
within the brain that results in the characteristic pathology of TSEs, which in turn 
leads to the presentation of clinical symptoms.  
 
An important and early support for a link between PrP and the development of TSE 
disease came from the identification and cloning of the PRNP gene (Oesch et al., 
1985) and the observation that inherited forms of human TSEs were consistently 
associated with point mutations in the PRNP gene (Hsiao et al., 1989; Doh-ura et al., 
1989; Goldgaber et al., 1989; Goldfarb et al., 1990; Hsiao et al., 1991; Goldfarb et 
al., 1991). However, the most convincing support for the prion hypothesis came from 
the finding that PrP null mice were completely resistant to scrapie infection (Bueler 
et al., 1993; Sailer et al., 1994). Furthermore, susceptibility to scrapie infection in 
these PrP null mice is fully restored with the introduction of the murine PrP gene 
(Prn-p) (Brandner et al., 1996; Fischer et al., 1996). The resistance of PrP null mice 
to scrapie infection demonstrates that PrP is a vital requirement in the pathogenesis 
of the disease but does not rule out the possibility that PrP may simply be a receptor 
for the agent.  
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The development of in vitro models for the generation of infectious PrP aggregates 
has provided the most recent support for the prion hypothesis. The earliest in vitro 
models demonstrated that under certain conditions, PrPC generated from cultured 
cells could be transformed into PrPSc when mixed with PrPSc from scrapie-infected 
brain samples (Kocisko et al., 1994; Caughey et al., 1995).  These experiments 
demonstrated that there are two steps in the conversion of PrPC to PrPSc; firstly, the 
binding of PrPC to the PrPSc oligomer and secondly the conversion of the bound PrPC 
to the disease-associated conformation. However, these early reactions suffered from 
low yields of newly generated PrPSc making it difficult to assess any infectivity 
present in the in vitro generated protein. The demonstration of infectivity and 
transmissibility from PrPSc generated in vitro would provide further convincing 
support for the acceptance of the prion hypothesis.  
 
Recently, two novel methods of generating PrPSc in vitro have demonstrated TSE 
infectivity associated with the generated PrPSc. In the first study, TSE infectivity was 
demonstrated in transgenic mice over-expressing a truncated form of PrP (Tg9949) 
following inoculation with PrP aggregates (‘synthetic prions’) generated by refolding 
of recombinant PrP (Legname et al., 2004; Legname et al., 2005). However, given 
that these synthetic prions were only infectious to this transgenic model and the 
resulting infectious titres obtained were very low, the possibility that the infectivity 
was a result of spontaneous disease in these PrP over expressing mice can not be 
discounted. Further support for the prion hypothesis has come from studies using the 
protein misfolding cyclic amplification (PMCA) system for the in vitro amplification 
of PrPSc. In PMCA, a sample containing PrPSc (seed) is diluted into a substrate 
containing excess PrPC (substrate). Using successive rounds of sonication and 
incubation, the PrPSc seed is amplified at an accelerated rate (Saborio et al., 2001). 
PMCA has been successfully applied to a number of animal models of TSE using 
substrates prepared from either PrPC from brain tissue (Castilla et al., 2005; Weber et 
al., 2006; Castilla et al., 2008; Green et al., 2008);  PrPC purified from brain 
(Deleault et al., 2003; Deleault et al., 2005; Deleault et al., 2007) or bacterially 
expressed purified recombinant PrP (Kim et al., 2010; Wang et al., 2010). Infectivity 
has been successfully demonstrated with the PMCA amplified products. However, 
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all these studies suggest that the successful conversion of PrPC to PrPSc may require 
either an additional seed of PrPSc (Kim et al., 2010) or other cofactors such as 
phospholipids or polyanionic molecules (such as RNA) (Deleault et al., 2003; 
Deleault et al., 2005; Deleault et al., 2007; Wang et al., 2010).  Nevertheless, the 
generation of PrPSc in vitro has gone a long way in providing support for the prion 
hypothesis demonstrating that the crucial step in TSEs is the conformational 
transmission of PrPSc. The precise molecular mechanism of conversion of PrPC to 
PrPSc remains unclear; however, two models have been proposed (Figure 1.5).  
 
1.5.1 The ‘template assisted conversion’ model  
The first was originally described as the ‘template assisted conversion model’ 
(Prusiner, 1991; Telling et al., 1995). This model (Figure 1.5a) postulates that PrPSc 
is inherently more stable than the normal cellular protein PrPC. However, there is a 
kinetic barrier before reaching this stable conformation.  This model, proposes that a 
transient conformational intermediate exists (PrP*) in equilibrium with PrPC. This 
intermediate form has the ability to heterodimerize with PrPSc monomers after 
binding to a molecular chaperone, postulated as another protein termed protein X 
(Telling et al., 1995; Prusiner, 1997; Kaneko et al., 1997). This heterodimer is able to 
spontaneously convert into a PrPSc homodimer consisting of the old and newly 
formed PrPSc. Once produced PrPSc is then able to induce further conversion of PrPC 
to PrPSc generating an exponential growth of PrPSc.  Genetic mutations in PRNP, 
may influence a shift in the levels of PrPC and PrP*, favouring PrP*. This would 
present an increased risk in the formation of PrPSc. However, to date the majority of 
experimental data suggests that PrP conversion is associated with the aggregation 
process, with little or no evidence of a stable PrPSc monomer.  
 
1.5.2 The ‘nucleation-polymerization’ model  
The second model is described in the “nucleation-polymerization model” (Jarrett and 
Lansbury, Jr., 1993).  This model (Figure 1.5b) proposes that PrPC and PrPSc coexist 
in relative equilibrium. In this model, PrPSc has a relatively unstable conformation, 
which becomes stabilized upon aggregation with other PrPSc molecules. The 
presence of PrPSc aggregates acts as a seed, promoting the conversion of further 
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PrPSc by binding to and stabilizing the otherwise favoured PrPC. This displaces the 
equilibrium between PrPC and PrPSc favouring the formation of the pathological 
conformer. The rate limiting step in this model is the initial nucleation process in 
which the production of PrPSc and in turn, PrPSc aggregates is not favoured.  Support 
for this model is described earlier in this section with the demonstration that PrPC can 
be converted to PrPSc by incubation with PrPSc from infected animals (Kocisko et al., 
1994; Caughey et al., 1995) and more recently from amplification of PrPSc in vitro 
using PMCA (Castilla et al., 2005; Weber et al., 2006; Castilla et al., 2008; Green et 
al., 2008).  In inherited TSEs, it is believed that point mutations in the prion protein 
gene, favour the spontaneous conversion of PrPC into PrPSc without the need for 
contact with the infectious agent. Sporadic forms of the disease, which include 
around 85% of all CJD cases, may be a result of either spontaneous conversion of 
PrPC or as a result of an undetected somatic mutation in the protein favouring the 




Figure 1.5: Schematic diagrams for different models of prion replication  
 
Theoretical models of PrPSc formation. (a) In the ‘template assisted conversion 
model’ the key step is in the formation of PrPSc, which acts as a template for further 
conversion. (b) In the ‘nucleation polymerisation model’ the key step is in the 
formation of PrPSc aggregates which act as a seed for the further formation of PrPSc 
aggregates. This moves the equilibrium towards formation of the pathological 
protein. See text for details. 
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1.6 The virino hypothesis 
An alternative to the prion hypotheisis which is supported by some TSE researchers 
is outlined in the ‘virino’ theory (Bruce and Dickinson, 1987; Dickinson and Outram, 
1988; Hope, 1994; Farquhar et al., 1998). This theory predicted the involvement of a 
host encoded component in the infectious agent, which is recruited into the infectious 
particle by a host-independent informational molecule yet to be identified. This 
hypothetical molecule, most probably a small, non-translated nucleic acid has the 
ability of carrying strain-specific genetic information whilst protected against 
degradation and inactivation by a host protein, PrP. Although this would fulfil all the 
biological requirements for the agent, attempts to identify TSE-specific nucleic acids 
have as yet proved unsuccessful.  
 
1.7 Strain diversity 
The demonstration of distinct TSE strains, a feature shared with nucleic acid-based 
pathogens, remains a challenge to the overall acceptance to the prion hypothesis. The 
existence of unique strains questions how a single misfolded protein that lacks any 
detectable nucleic acid can encipher all the information for multiple phenotypes 
within a single species. Such strain diversity found within TSEs continues to be the 
main supporting evidence for an independently replicating informational molecule or 
genome (Bruce and Dickinson, 1987). 
  
Research by Alan Dickinson and co-workers demonstrated that distinct disease 
phenotypes could be raised and propagated in lines of inbred mice following 
experimental challenge with scrapie isolates (Dickinson et al., 1968; Fraser and 
Dickinson, 1973).  Historically, these individual rodent-adapted TSE strains or 
varieties of TSEs are differentiated by a number of well defined clinical and 
pathological ‘strain typing’ methods that depend primarily on incubation period of 
the disease following inoculation (Dickinson et al., 1968) and regional patterns of 
spongiform change in nine defined brain regions which is referred to as the ‘lesion 
profile’ (Fraser and Dickinson, 1973). More recently, variations in the pattern of 
PrPSc deposition in mice following challenge with TSE isolates has also been 
associated with variations in strain (Hecker et al., 1992; DeArmond et al., 1993). 
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1.7.1 Incubation period 
The incubation period in mice experimentally challenged with different TSE agents 
is defined as the period between initial infection and the clinical end-point of disease 
which is determined by a range of clinical presentations (Dickinson et al., 1968). In 
non-transgenic (wild-type) mice incubation period can range between 4 months and 
the life span of the mouse (over 2 years).  In addition to strain, incubation period in 
mice is influenced by route of inoculation and dose. The Prn-p genotype of the 
mouse is also a major determinant of incubation period as described previously 
(Chapter 1, section 1.3.2) and can make a difference of hundreds of days to the 
incubation period of a single TSE strain.  In some strains the shortest incubation 
period occurs in Prn-pa mice whereas with other strains Prn-pb mice produce the 
shortest incubation period.  It is often the case that the incubation period in Prn-pab 
mice lies somewhere between the two homozygotes. Transmission of individual TSE 
agents into mice with the three different PrP genotypes, produce highly reproducible 
incubation periods, often sufficient on their own to identify the strain of agent. 
 
 
1.7.2 Lesion profile 
The lesion profile depends on the assessment of severity and distribution of TSE-
associated spongiform change or vacuolation within the brain of the challenged mice 
(Fraser and Dickinson, 1968). For construction of a lesion profile, a semi-
quantitative assessment is made of the severity of vacuolation in nine anatomically 
defined regions of the grey matter and three defined white matter regions of the 
infected mouse, known as the scoring regions (detailed in Chapter 2, section 2.6.3). 
Mean scores for each area are then plotted to produce a characteristic ‘lesion profile’ 
(Fraser and Dickinson, 1968). An example of the lesion profiles for three scrapie 
strains (ME7, 87V and 79A) in the grey matter regions in a single Prn-pb (VM) 
mouse line is shown in Figure 1.6.  
 
Together the incubation period and lesion profile in an inbred mouse line provides a 
‘signature’ of the biological properties of the TSE agent. A number of distinct strains 
derived from natural sheep scrapie have been identified through incubation period 
and lesion profiling whereas passage of cattle BSE through panels of inbred mice has 
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indicated that BSE is associated with a single strain of agent (Bruce et al., 1994). 
Lesion profiling along with incubation period played a pivotal role in establishing the 
relationship between vCJD in humans and BSE. Transmission of vCJD to a panel of 
inbred mice produced a lesion profile which differed greatly from those of scrapie 






Figure 1.6: Examples of lesion profiles in mouse adapted scrapie strains 
 
Lesion profiles for the ME7, 79A and 87V mouse adapted scrapie strains in a single 
Prn-p










1.7.3 Molecular basis of strains 
As TSE strains can be propagated in mice with the same Prn-p genotype, it is clear 
that strain-specific information can not be encoded by differences in the PrP amino 
acid sequence. Furthermore, a defined strain can be re-isolated in mice after passage 
in intermediate species with different PrP sequences (Bruce et al., 1994).  In order to 
be accommodated within the prion hypothesis, it has been proposed that strain-
specific properties are enciphered by differences in the biochemical properties in the 
propagated PrPSc, specifically in the different conformation and glycosylation states 
of PrPSc (Collinge et al., 1996; Telling et al., 1996).  
 
In seminal experiments, Besson and Marsh identified two strains of transmissible 
mink encephalopathy (TME); the so-called ‘hyper’ (HY) and ‘drowsy’ (DY) strains. 
These two strains were identified by differences in their behavioural phenotype, 
incubation period and pathological profile after passage of a single TME isolate in 
Syrian hamsters (Bessen and Marsh, 1992b). In addition, strain-specific differences 
were observed in the PK resistant cores of the PrPSc associated with these different 
TME strains. These differences were represented by different migration patterns of 
PrPres on polyacrylamide gels, and were attributed to differences in the N-terminal 
truncation sites of HY and DY PrPSc, clearly implying that HY and DY have 
different PrPSc conformations (Bessen and Marsh, 1992a; Bessen and Marsh, 1994). 
Such strain-specific differences in the physico-chemical properties of PrPSc were 
further demonstrated with the experimental transmission of two forms of familial 
CJD into a transgenic mouse model (Telling et al., 1996). In this study, inoculation 
of brain homogenate from a fatal familial insomnia (FFI) patient into transgenic mice 
expressing a chimeric human-mouse PrP gene (TgMHu2M) resulted in an incubation 
period of ~200 days with a ~19kDa PrPres fragment after Western blot analysis. In 
the same study, inoculation of brain homogenate from a familial CJD (fCJD) patient 
into the TgMHu2M mice also resulted in an incubation period of ~200 days; 
however, Western blot analysis resulted in a ~21kDa PrPres fragment. These findings 
demonstrated that the TgMHu2M PrPSc can exist in two different conformational 
states as determined by the size of the protease-resistant fragment (PrPres). 
Furthermore, the different PrPres fragments are associated with different human TSE 
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strains. Further evidence for strain-specific differences in PrPSc conformation have 
been provided by findings of studies showing differences among PrPSc aggregates in 
relation to the exposure of certain epitopes during guanidine induced denaturation 
(Safar et al., 1998), positions and intensities of infrared bands associated with β-sheet 
structure (Caughey et al., 1998) and sensitivity to protease digestion denaturation by 
guanidine HCL (Peretz et al., 2002). 
 
Strain-specific differences have also been observed in the glycosylation of 
asparagine residues at positions 181 and 197 (on the human PrP sequences).  Distinct 
TSE strains have consistent ratios of the di-, mono-, and unglycosylated forms of 
PrPres. These distinct glycosylation profiles are conserved on serial passage in 
animals, suggesting that different PrPSc aggregates can selectively recruit PrPC 
monomers in particular ratios according to glycosylation state (Prusiner, 1998; 
Collinge, 2001).  
 
Several distinct human PrPres types have been identified based on differences in the 
electrophoretic mobility (fragment size) of PrPres and glycosylation ratio after PK 
digestion and these have been associated with different disease phenotypes of CJD 
(Collinge et al., 1996; Parchi et al., 1996). These different PrPres types are proposed 
to be the molecular basis of strain typing. However, the relationship between PrPres 
types and agent strain remains unclear and has been recently questioned by the 
observation of mixed PrPres types within the brain of a proportion of sCJD cases 
(Parchi et al., 1999; Puoti et al., 1999; Schoch et al., 2006; Uro-Coste et al., 2008). 
Nevertheless, molecular typing continues to play an important role in the diagnosis 
of human TSE. For these different PrPres types to be considered as the biochemical 
basis of agent strain; the biological and biochemical characteristics of the agent must 
be retained after transmission to both the same species and that of other species. The 
relationship between PrPres type and disease phenotype in CJD will be fully 
discussed later in this Chapter (Chapter 1, section 1.10).  
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1.8 The species barrier 
Another important issue related to prion strains is the mechanism of the ‘species 
barrier’ (Pattison, 1965; Pattison and Jones, 1968). The ‘species barrier’ in TSEs is 
defined as the relative resistance to TSE disease by one species following infection 
with TSE agent of another species. In some instances the ‘species barrier’ provides 
complete resistance to disease. This is best illustrated with hamster scrapie strain 
263K, which does not transmit disease to mice despite the short incubation period of 
65 days when passaged in hamsters (Kimberlin and Marsh, 1975). More often the 
‘species barrier’ is reflected by longer more irregular incubation periods (Chandler, 
1961; Dickinson et al., 1975). For example, the Chandler strain of mouse scrapie can 
be transmitted to mice with an incubation period of around 120 days, while Syrian 
hamsters have an incubation period of up to 380 days with the same inoculum 
suggesting a substantial ‘species barrier’ between the two species (Kimberlin and 
Walker, 1978; Kimberlin et al., 1987). Changes in the disease characteristics of the 
recipient and a reduction in the number of animals that succumb to disease are also 
indicative of the ‘species barrier’. However, as the agent is serially passaged through 
the new host, adaptation occurs which usually sees a drop in incubation period and a 
more constant pattern of clinical and neuropathological signs, which stabilise after 
further passages (Dickinson, 1976; Bruce et al., 1994). 
 
The ‘species barrier’ is thought to be heavily influenced by the degree of homology 
in the primary PrP amino acid sequence between the PrPSc of the donor and PrPC of 
the recipient species. This is best illustrated through studies using transgenic mouse 
models.  In one such study, wild-type mice challenged intracerebrally with scrapie 
infected hamster tissue failed to show any signs of disease after around 500 days post 
injection, indicative of a ‘species barrier’. In the same study transgenic mice, which 
harbour the Syrian hamster prion gene and express hamster prion protein, challenged 
with the same scrapie infected hamster tissue all succumbed to disease with a 
relatively short incubation period of around 75 days (Scott et al., 1989). In human 
TSEs, transmission of sCJD into wild-type mice is notoriously difficult, with few if 
any mice developing clinical signs of disease. This is indicative of a substantial 
‘species barrier’ between mouse and human (Collinge et al., 1995b; Bruce et al., 
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1997; Hill et al., 1997). However, transgenic mice expressing only human PrP have 
been shown to be highly susceptible to sCJD, consistent with a lack of any ‘species 
barrier’ (Collinge et al., 1995b; Bishop et al., 2010).  
 
However, investigations on the transmission of human TSEs supports the proposal 
that ‘transmission barrier’ rather than ‘species barrier’ may be a more appropriate 
term in describing the differences observed the efficiency of transmission of different 
TSEs. As described, sCJD is notoriously difficult to transmit to wild-type mice, 
whereas human transgenic mice are highly susceptible. In contrast, vCJD readily 
transmits to wild-type mice with an almost 100% attack rate, whereas transmissions 
to humanised transgenic mice are relatively less efficient than those observed with 
sCJD (Hill et al., 1997; Bishop et al., 2006). As the PrP amino acid sequence is the 
same in the donor PrPSc and in the recipient mice in these experiments, the 
differences observed in the efficiency of transmission cannot be accounted for solely 
by differences in species.  
 
The experiments described above indicate that the ‘species barrier’ is also influenced 
by the TSE strain itself. This is further demonstrated with the BSE agent, which has 
successfully transmitted to a range of different species all with different PrP primary 
structures, either by natural transmission or experimentally (Bruce et al., 1994; 
Fraser et al., 1994; Bruce et al., 1997). Furthermore, the strain characteristics of the 
BSE agent are maintained on passage even through an intermediate species with a 





1.9 Human TSEs 
Human TSEs include CJD, kuru, Gerstmann-Sträusler-Scheinker (GSS) disease and 
fatal familial insomnia (FFI). Like scrapie, most human forms of TSEs have been 
shown to be transmissible to various animal species (Gajdusek et al., 1966; Gibbs, Jr. 
et al., 1968; Masters et al., 1981a; Collinge et al., 1995a; Bruce et al., 1997). Human 
TSEs are rare with an annual mortality rate of around 1- 1.5 cases per million of the 
population. As well as being rare, this group of diseases are unique in that they can 
occur in idiopathic, familial and acquired forms (Table 1.1). Kuru is a perfect 
example of the infectious, but non-contagious nature of TSEs. Kuru was spread 
through the Fore-speaking tribes of Papua New Guinea towards the end of the 1950s 
by ritualistic cannibalism, either through the ingestion of contaminated human tissues 
or transdermal infection through superficial wounds or skin scarification (Alpers 
1995). Since the practice of cannibalism stopped the incidence of kuru has dropped 
dramatically. Occasional cases still occur suggesting extremely long incubation 
period which can exceed 50 years (Collinge et al., 2006).  
 
GSS and FFI are examples of familial forms of human TSEs in which the cause of 
disease is attributed to the presence of an autosomal dominant mutation (including 
both point mutation and deletions and insertion mutations) of the PRNP gene.  
Familial forms of the disease are much less frequent and make up around 15% of 
human TSEs. The most common form of human TSE and the one which will be the 
main focus of this study is CJD. Specifically, this study focuses on the sporadic and 
variant forms of CJD. Therefore, the following sections will examine the clinical, 
neuropathological and biochemical features of CJD concentrating primarily on these 
two human TSEs 
 
1.9.1 Creutzfeldt-Jakob Disease 
CJD is the most frequently occurring form of human TSE. Spielmeyer introduced the 
term CJD in 1922 after combining the case reports of six patients reported by Hans-
Gerhard Creutzfeldt (Creutzfeldt, 1920) and Alfons Jakob (Jakob, 1921). 
Retrospective studies on these six cases have since revealed that only two out of the 
six cases would meet the modern day criteria for CJD.  CJD occurs worldwide and 
 32 
can be classified into four main forms with respect to aetiology, clinical symptoms, 
neuropathology and more recently genetic and biochemical characteristics. The four 
types of CJD are described below. 
 
1.9.1.1 Iatrogenic CJD  
Less than 5% of CJD cases are classified as iatrogenic. Iatrogenic CJD results from 
the inadvertent human-to-human transmission of TSE infectivity in the course of 
medical procedures; including, via neurosurgical instruments (Will and Matthews, 
1982), stereotactic electrodes (Bernoulli et al., 1977), tissue transmission such as 
corneal or dura mater grafts (Duffy et al., 1974; Heckmann et al., 1997; Brown et al., 
2000) and also through the administration of human growth hormone treatment 
(Koch et al., 1985; Powell-Jackson et al., 1985). In such cases the patient has had 
direct exposure to the TSE agent by contact with brain tissues or extracts 
contaminated by the sCJD agent. More recently, the observation of five instances of 
vCJD infection in individuals following transfusion with blood or treatment with 
blood products from vCJD patients who were asymptomatic at time of donation, 
highlights the risk of the iatrogenic spread of vCJD (Llewelyn et al., 2004; Peden et 
al., 2004; Wroe et al., 2006; Health Protection Agency., 2009; Peden et al., 2010). 
 
1.9.1.2 Familial CJD  
Like GSS and FFI, familial CJD (fCJD) is a genetic disorder in which the cause of 
disease is attributed to an underlying mutation of the human PRNP gene. It is 
speculated that many of these mutations occur around the α-helical regions of the 
prion protein possibly reducing the structural stability of the protein, predisposing the 
host to the disease. Familial CJD cases account for around 10-15% of human TSEs 
although this figure is variable between different countries according to the presence 







1.9.1.3 Sporadic CJD  
Sporadic CJD accounts for the majority of human TSE cases (~ 85% ) but still 
remains a relatively rare disorder with a world wide incidence of around 1 – 1.5 case 
per million of the population (Ladogana et al., 2005). Sporadic CJD is an idiopathic 
disorder in which cases occur in isolation with no evidence of an association with 
mutations in the human PrP gene or any epidemiological evidence for a direct 
exposure to the TSE agent as in the acquired forms. Current hypothesis regarding the 
aetiology of sCJD focuses on either an unidentified somatic mutation in the prion 
protein gene, the spontaneous conversion of PrPC to PrPSc or an as yet unidentified 
environmental exposure to a TSE.  Horizontal transmission from animals or humans 
has also been suggested, however no evidence has been put forward to support the 
hypothesis that this accounts for the vast majority of cases. A possible link between 
sCJD and general surgery has also been described; however, questions over recall 
bias in these findings can not be excluded  (Collins et al., 1999; Ward et al., 2009).  
 
Sporadic CJD has a median age at onset in the seventh decade and is rarely found in 
patients under 40 years old. However, several cases of sCJD have been reported 
world-wide in patients under the age of 20 (Monreal et al., 1981; Brown et al., 1985; 
Berman et al., 1988; Kulczycki et al., 1991; Murray et al., 2008). As has been 
discussed earlier in this chapter (section 1.3.1.1) there does appear to be a genetic 
susceptibility to sCJD. Analysis of the polymorphism at codon 129 on the PRNP 
gene has demonstrated that methionine homozygosity is a risk factor for the 
development of disease, with about 70% of cases having this genotype (Palmer et al., 
1991; Alperovitch et al., 1999).  
 
In sCJD, clinical manifestations can vary widely from case to case and are 
substantially affected by the genotype at codon 129 of the host prion protein gene 
(Table 1.4). Typically, sCJD presents with a rapidly progressive dementia often 
associated with cognitive disturbances such as confusion and memory loss. In 
addition, there is widespread neurological involvement including cerebellar ataxia 
and, most characteristically myoclonus.  As the disease progresses, mental 
disturbances become more prominent until the disease culminates in a terminal 
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akinetic mute state. In around 40-60% of cases visual disturbances are often noted 
and in around three quarters of patients there is also an abnormal electrocephalogram 
(EEG) in which periodic sharp-wave complexes are observed. Raised cerebrospinal 
(CSF) levels of 14-3-3 protein, S-100 and neuronal specific enolase (NSE), although 
not specific for sCJD may be helpful diagnostically (Jimi et al., 1992; Zerr et al., 
1995). Magnetic resonance imaging (MRI) can also be useful with some cases 
exhibiting a characteristic signal change in the putamen and caudate. The clinical 
duration in sCJD is usually short with around 70% of deaths usually within 6 months 
from first symptoms.  
 
As with the clinical features, sCJD shows a great diversity in the neuropathology, 
specifically in the nature, severity and location of spongiform change within the 
brain, the presence or absence of amyloid plaques and in the patterns of PrP 
accumulation. In the case of spongiform change this can vary from focal regions of 
microvacuolation (Figure 1.1) to more extensive areas of confluent spongiform 
change, whilst in the most extreme cases status spongiosis has been reported 
(Masters and Richardson, Jr., 1978; Gambetti et al., 2003).  The presence of amyloid 
plaques is only a feature of a small proportion of sCJD cases. In cases which do show 
amyloid plaque formation, these are generally confined to the cerebellar cortex 
(Figure 1.1). PrP deposition and immunoreactivity generally occurs in three main 
patterns in sCJD; plaque type, diffuse synaptic or granular and patchy/perivacuolar 
types in which much of the PrP labelling are found around vacuoles.  As with the 
clinical features, these variations in neuropathological change are thought to be 
influenced by the PRNP codon 129 genotype of the individual (Table 1.4). In 
addition, the different biochemical PrPres types identified in cases of sCJD are also 
thought to heavily influence the clinico-pathological phenotype of disease. The 
different PrPres types associated with sCJD are discussed in detail later in this 





















MM1/MV1  Myoclonic, 
Heidenhain 
variants  
70  3.9  Rapidly 
progressive 





unilateral signs at 
onset in 40% of 
cases 
“Classic CJD” distribution of 
pathology;  often prominent 
involvement of occipital cortex; 
“synaptic type” PrP staining; in 
addition, one-third of cases 
shows confluent vacuoles and 
perivacuolar PrP staining  
VV2  Ataxic variant  16  6.5  Ataxia at onset, late 
dementia, no 
typical EEG in 
most cases  
Prominent involvement of 
subcortical, including brain 
stem nuclei; in neocortex, 
spongiosis is often limited to 
deep layers; PrP staining shows 
plaque-like, focal deposits, as 
well as prominent perineuronal 
staining  
MV2  Kuru-plaques 
variant  
9  17.1  Ataxia in addition 
to progressive 
dementia, no 
typical EEG, long 
duration (>2 yr) in 
some cases  
Similar to VV2 but with 
presence of  amyloid-kuru 
plaques in the cerebellum, and 
more consistent plaque-like, 





2  15.6  Insomnia and 
psychomotor 
hyperactivity in 
most cases, in 
addition to ataxia 
and cognitive 
impairment, no 
typical EEG  
Prominent atrophy of the 
thalamus and inferior olive (no 
spongiosis) with little pathology 
in other areas; spongiosis may 
be absent or focal, and PrPSc is 
detected in lower amount than 
in the other variants  
MM2-
cortical  
Not established  2  15.7  Progressive 
dementia, no 
typical EEG  
Large confluent vacuoles with 
perivacuolar PrP staining in all 
cortical layers; cerebellum is 
relatively spared  
VV1  Not established  1  15.3  Progressive 
dementia, no 
typical EEG  
Severe pathology in the 
cerebral cortex and striatum 
with sparing of brain stem 
nuclei and cerebellum; no large 
confluent vacuoles, and very 
faint synaptic PrP staining  
 
PrP - prion protein 




Due to the clinico-pathological heterogeneity observed in sCJD, attempts have been 
made to correlate these phenotypic variations. This has resulted in a proposed sub-
classification system for sCJD describing six subtypes of sCJD, defined by their 
clinical and neuropathological phenotype (Table 1.4) (Parchi et al., 1999). These six 
phenotypic subtypes roughly correlated with the six possible combinations of PRNP 
codon 129 genotype and PrPres type (MM1/MV1, MM2 cortical, MM2 thalamic, 
MV2, VV1 and VV2) and have been suggested to represent distinct sCJD strains of 
agent.  
 
Since this study commenced, a novel form of human TSE has been identified. 
Initialy termed protease-sensitive prionopathy (PSPr), this human TSE was based on 
an original cohort of 11 patients all of which were homozygous for valine at codon 
129 on the human PrP gene (Gambetti et al., 2008). The defining feature of these 
PSPr cases was the unusual biochemical properties, in which the abnormal form of 
PrP was found to be much less resistant to protease digestion (Gambetti et al., 2008). 
Neuropathological features were also unusual, in particular the accumulation of 
microplaques in the brain which stained intensely on immunohistochemistry for the 
prion protein. Since the original description, a further 19 cases have been reported 
including patients who were homozygous for methionine and heterozygous for valine 
and methionine at codon 129 on the human PrP gene (Head et al., 2009; Jansen et al., 
2010; Rodrìguez-Martìnez et al., 2010). The condition has since been renamed as 
variably protease-sensitive prionopathy (VPSPr) to reflect the variable sensitivity in 
protease digestion reported between the three different codon 129 genotypes. VPSPr 
cases can be classified as sporadic TSEs as there are no identifiable risk factors for 
exposure to a TSE and no mutations in the coding sequence of the prion protein gene 










1.9.1.4 Variant CJD  
Variant CJD was first identified in the UK in 1996 (Will et al., 1996). Initially 
referred to as ‘new variant’ CJD (nvCJD) and since shortened to vCJD, this form of 
the disease was described in patients of an uncharacteristically young age with a 
much longer disease duration than that typically observed in sCJD. There is now 
convincing evidence to support the initial hypothesis that vCJD is caused by human 
infection with the BSE agent, most probably through the consumption of 
contaminated meat products (Collinge et al., 1996; Lasmezas et al., 1996; Bruce et 
al., 1997; Hill et al., 1997; Scott et al., 1999). Variant CJD therefore represents an 
acquired form of human TSE, caused by a cross-species transmission from cattle to 
human. To date, over 170 cases of vCJD have been identified in the UK. Currently, 
all confirmed vCJD cases who have undergone genetic analysis have been shown to 
be homozygote for methionine at codon 129 of PRNP which clearly indicates a 
genetic susceptibility in this genotype (Bishop et al., 2009). However, recent findings 
suggest that the other PRNP codon 129 genotypes are also susceptible to infection 
with the BSE agent (Peden et al., 2004; Hilton et al., 2004b; Ironside et al., 2006; 
Peden et al., 2010). The incubation period in infected MV and VV individuals may 
be longer than that observed in the MM population (Bishop et al., 2006). Annual 
mortality rates now suggest that the vCJD outbreak is in decline in the UK following 
a peak in 1999/2000 (http://www.cjd.ed.ac.uk/cjdq64jun10.pdf). However, as fears 
over a greater primary epidemic subside, public health concerns over the possible 
secondary transmission of vCJD have heightened due to recent reports of person-to-
person transmission of vCJD infectivity by blood transfusion and blood products 
(Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 2006; Health Protection 
Agency., 2009; Peden et al., 2010).  
 
The clinical phenotype of vCJD differs from that of sCJD and all other human TSEs. 
The unusually young age at which vCJD occurs is in contrast to all other forms of the 
disease (mean age at death of 29 years) and in comparison with sCJD, vCJD has a 
much longer disease duration (mean survival is 14 months). The clinical symptoms 
in vCJD are relatively uniform between cases. Patients present primarily with 
psychiatric and behavioural disturbances, anxiety, depression, and withdrawal are 
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often accompanied by sensory abnormalities. This is usually followed by ataxia, 
myoclonus, variable movement disorders and dementia. The later stages are similar 
to sCJD, with terminal akinetic mutism in many cases. Examination of MRI scans in 
vCJD has shown that there is often a high signal in the posterior thalamus the 
“pulvinar sign”, on T2 in around 90% of cases, more than likely a reflection of the 
extensive astocytic proliferation in this brain region in vCJD cases. The EEG shows 
no periodic complexes and CSF 14-3-3 assay is positive in only 50% of cases (Will 
et al., 1996; Will et al., 2000; Green et al., 2001; Knight and Will, 2004). 
 
In contrast to the marked heterogeneity in the neuropathological features of sCJD 
cases, vCJD have proved highly stereotypic. Variant CJD has a distinct pathology in 
terms of plaque accumulation. The presence of multiple ‘florid plaques’ within the 
cerebral cortex and cerebellum is the most striking feature of this disease (Will et al., 
1996; Ironside, 1996; Ironside et al., 2000). These plaques have the appearance of the 
classic kuru-type plaque and are surrounded by a halo of spongiform change. These 
plaques were first described in Icelandic scrapie and have also been describe in mice 
infected with the 11A scrapie strain (McBride et al., 1988) and have been reported in 
BSE-inoculated primates (Lasmezas et al., 1996). Florid plaques are rarely observed 
in human TSEs other than vCJD although occasional florid plaques have been 
reported in cases of iatrogenic CJD in patients who have received a dura mater graft 
(Takashima et al., 1997; Shimizu et al., 1999; Kretzschmar et al., 2003). In addition 
to florid plaques in vCJD there is also the accumulation of smaller plaque like 
aggregates usually found in clusters in the cerebral cortex. As well as plaques lighter, 
‘feathery’ deposits of PrP are found surrounding the neurons or blood vessels within 
the cerebellar and cerebral cortex. 
 
Variant CJD differs from other forms of human TSE in that there is a widespread, 
abundant and readily detectable accumulation of PrPres in lymphoid tissues 
throughout the body. This is best observed in spleen, tonsil, appendix and lymph 
nodes (Hill and Collinge, 2002; Joiner et al., 2002; Head et al., 2004a). The 
significance of PrPres within peripheral tissues in vCJD is demonstrated by the 
inclusion of a positive tonsil biopsy becoming part of the diagnostic criteria for 
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vCJD. More recently, with the increased sensitivity in detection assays, the detection 
of PrPres in tissues other than those of the lymphoreticular system indicates that the 
number of tissues and organs showing the presence of PrPSc in vCJD may be greater 
than first thought (Glatzel et al., 2003; Haik et al., 2003; Head et al., 2004b; Peden et 
al., 2006; Peden et al., 2007; Notari et al., 2010).  The detection of infectivity out 
side the CNS (Bruce et al., 2001) also has important consequences for the spread of 
vCJD by iatrogenic means, particularly in regard to the use of surgical instruments. 
Some of the important distinctions between vCJD and sCJD in terms of clinical and 
neuropathological features are listed in Table 1.5. 
 
 
Table 1.5: Clinical and neuropathological features of sporadic and variant CJD 
 
 sporadic CJD variant CJD 
Mean age at death 66years 29 years 
Median duration of illness 4 months 14 months 
Thalamic MRI high signal Caudate /putamen (60%) Pulvinar (90%) 
EEG ‘Typical’ 70% ‘Typical’ 0% 
Presence of plaques Kuru type 10% Florid plaques 100% 
PrPres distribution Diffuse/synaptic 
Patchy/peri-vacuolar 
Plaque like clusters 
Peri-neuronal 
 
PrPres in non CNS tissues reported in muscle 
(Glatzel et al., 2003; 
Peden et al., 2006), 
spleen (Glatzel et al., 
2003), pituitary gland 
(Peden et al., 2007) 
Reported in lymphoid 
tissue, peripheral nervous 
system (Haik et al., 2003; 
Head et al., 
2004b),pituitary gland 
(Peden et al., 2007),skeletal 
muscle (Peden et al., 2007), 
dura mater, liver, pancreas, 
kidney, ovary, uterus and 
skin (Notari et al., 2010) 
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1.10. Biochemical aspects of human TSEs 
The first demonstration that different PrPres types are associated with different 
disease phenotypes in human TSEs was in a study investigating the basis for the 
clinico-phenotypic heterogeneity observed in cases of FFI and fCJD, two familial 
TSEs which have an identical mutation at codon 178 on the human PRNP gene 
(Monari et al., 1994).  Biochemical analysis of CNS tissue by Western blotting 
showed differences in the extent of N-terminal truncation between these two TSEs 
resulting in two major size classes; one associated with FFI resulting in a ~19kDa 
unglycosylated fragment and a second associated with fCJD resulted in a ~21kDa 
fragment. FFI and fCJD differ in PRNP codon 129 genotype; the presence of 
methionine at codon 129 encodes FFI whereas the presence of valine encodes fCJD. 
Therefore, it was proposed that the combination of the mutation at codon 178 on the 
PRNP gene and the codon 129 PRNP genotype, determines the clinico-pathological 
phenotype by producing two different PrPres types (Monari et al., 1994). The 
suggestion that different PrPres types can have an influential role in determining 
disease phenotype has since been supported by studies of sCJD where an association 
between disease phenotype and PrPres type has been observed (Parchi et al., 1999). 
 
1.10.1 Molecular classification of CJD 
Two competing classification systems have been proposed for CJD as a result of 
differences found in the mobility of protease resistant PrP after Western blot and the 
relative abundance of the different glycosylated PrPres isoforms (referred to as the 
glycoform ratio). The two classification systems are those originally outlined by 
Collinge and co-workers (Collinge et al., 1996; Wadsworth et al., 1999a; Wadsworth 
et al., 1999b; Hill et al., 2003) and those of Parchi and Gambetti (Parchi et al., 1996; 
Parchi et al., 1997; Parchi et al., 1999). In addition to the mobility of PrPres and 
glycoform ratio (PrPres type), both systems include patient results from the PRNP 
genotype at codon 129 as an additional classification method, as the M/V 
polymorphism at this site has been implicated as playing an important role in the 
phenotypic variability in CJD (Alperovitch et al., 1999).  The following section will 
outline these two classification systems and show chronologically how the 
complexities in ‘molecular strain typing’ have arisen. 
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1.10.1.1 Collinge classification system 
(Collinge et al., 1996) 
In their first publication on molecular strain typing of human TSE, Collinge and co-
workers examined the physico-chemical properties of PrPSc in sporadic, iatrogenic 
and variant cases of CJD.  Western blot results identified four distinct patterns of 
PrPres that were termed types 1, 2, 3 and 4, associated with sporadic and acquired 
human TSEs (Figure 1.7a). Two distinct PrPres types were reported in sCJD cases. 
These two PrPres types, designated type 1 and type 2 resulted in PrP fragments of 
differing molecular mass. The PrPres glycoform ratio showed subtle differences 
between these two sCJD PrPSc types, with type 2 showing a greater abundance in the 
monoglycosylated fragment of the protein. By incorporating the codon 129 genotype 
of each case examined, Collinge and co-workers found that type 1 PrPres is uniquely 
associated with methionine homozygosity (MM) at PRNP codon 129 whereas, type 2 
PrPres is associated with a minority of MM patients as well as all the valine 
homozygotes (VV) and methionine/valine (MV) heterozygotes.  Type 3 PrPres was 
found in VV and MV cases of iatrogenic CJD, which had arisen from peripheral 
routes of exposure to TSEs, in particular patients who had received pituitary growth 
hormone. Type 3 was characterised by a downward shift in all three bands consistent 
with a decrease in the molecular mass of around 2-3kDa when compared to type 2 
(Figure 1.7a). The fourth pattern of PrPres, type 4, was associated with all vCJD 
cases. Type 4 resulted in a ~19kDa fragment size, similar to that observed in type 2 
and type 3 cases but were distinguished by the predominance of the diglycosylated 
fragment (Figure 1.7a). All type 4 cases were associated with methionine 
homozygosity at PRNP codon 129. The identification of this vCJD molecular 
signature was an important step in providing molecular evidence that vCJD 
represented a new and distinct human TSE strain.  
 
(Wadsworth et al., 1999a) 
The Collinge classification system was modified in 1999 with a publication by 
Wadsworth and co-workers demonstrating that strain-specific protein conformations 
in human TSE may be influenced by metal binding to PrPSc. Wadsworth examined 
sCJD (both type 1 and type 2) cases homozygous for methionine at codon 129. They 
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found that treatment of these cases with 20mM of the metal ion chelator EDTA prior 
to proteinase K treatment, changed the pattern of cleavage and instead of producing 
their own distinct patterns, produced an indistinguishable banding pattern. The 
resulting PrPres fragments had a smaller molecular mass than either type 1 or type 2 
and were termed type 2- (Figure 1.7c).  No modification of type 2 and type 4 was 
observed after treatment with EDTA.  
 
(Wadsworth et al., 1999b) 
In a slightly later publication, Wadsworth observed that type 3 PrPres, previously 
restricted to cases of iatrogenic CJD, was now found to include cases of sCJD with a 
codon 129 genotype of either MV or VV (Figure 1.7c). This now allowed for three 
possible PrPres types in sCJD as classified by the mobility of PrPres and glycoform 
ratio on Western blot as well as the genotype at codon 129 of PRNP. 
 
(Hill et al., 2003) 
In this large scale study, Hill et al., used a modified Western blotting technique to 
confirm that different PrPres types are associated with cases of sporadic, iatrogenic 
and variant CJD. However, in addition to the four types described previously 
(Collinge et al., 1996), a novel PrPres type, termed type 6, was reported in a single 
case of sCJD in a methionine homozygote patient. Type 6 is characterised on PrP 
fragment size alone, whereby the relative molecular mass of these fragments are 
larger than those observed in type 1 and type 2 cases (Figure 1.7d).  In addition, the 
classification of PrPres type 3 was modified with the addition of a single type 3 PrPres 
in an MM patient. Further analysis of the glycoform ratios in type 3 cases also 
showed that MV type 3 cases could be further distinguished by a more predominant 
unglycosylated fragment, a feature not previously reported (Figure 1.7d).  The 
modifications made in the Western blot protocol also identified consistent 
differences in the fragment size between PrPres type 3 and type 4 cases. Type 4 now 
showed a slightly larger molecular mass when compared with type 3 (Figure 1.7d).  
 
In his 1999 publication in Nature Cell Biology (Wadsworth et al., 1999a), 
Wadsworth observed that PrPres type 1 and type 2 (MM cases only) showed a slight 
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shift in fragment size following chelation of metal ions with EDTA prior to digestion 
with proteinase K resulting in indistinguishable pattern of digestion products 
designated type 2- (Figure 1.7c).  A similar finding was reported in this study in a 
single PrPres type 2 from an MV sCJD case and the single type 6 using the same 
protocol.  The shift in fragment size was also observed with type 3 cases but only in 
the valine homzygotes.  
 
A schematic representation summarising the results and the PrPres types described in 
the four publications above, representing the Collinge classification system for 
human TSEs are shown in Figure 1.7. 
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Figure 1.7: Collinge’s molecular classification of human TSEs 
 
Schematic representation of the development of the molecular classification system 
for human TSEs as reported by Collinge and co-workers. The illustrations show 
PrPres types 1-6 and their relationship with the PRNP codon 129 genotype.   
 
 






















(b) Hill et al., 1997 
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(d) Hill et al., 2003 
 









1.10.1.2 Parchi & Gambetti classification system 
Similar studies carried out by Piero Parchi and Pierluigi Gambetti reported only two 
PrPres types associated with sCJD cases. These two sCJD PrPres types differed in the 
migration of the unglycosylated fragment of the protein and in the ratio of the three 
PrP glycoforms. Type 1 was characterised by a relative molecular weight of the 
unglycosylated fragment of ~21kDa with type 2 characterised by a molecular weight 
of ~19kDa (Parchi et al., 1996; Parchi et al., 1997; Parchi et al., 1999). At further 
variance with Collinge’s classification system, Parchi and Gambetti reported that 
PrPres type 1 and type 2 were detected in sCJD patients from all three PRNP codon 
129 genotypes, resulting in six possible subgroups of sCJD as classified by PrPres 
type/PRNP codon 129 genotype combinations (Figure 1.8). These six subgroups of 
sCJD were found to show a close correlation to the six major subtypes of sCJD as 
classified according to the clinico-pathological phenotype of sCJD (Table 1.4) 
(Parchi et al., 1996; Parchi et al., 1999). This suggested that the PrPres type/PRNP 
codon 129 genotype combinations may underlie the phenotypic variation in sCJD 
and indeed represent the molecular basis of sCJD strains. The most common sCJD 
subtype and representing around 70% of all sCJD cases were found to have a type 1 
banding pattern and either a MM or MV PRNP codon 129 genotype.  Cases 
homozygous for valine, with a type 1 banding pattern were the least frequent subtype 
of sCJD representing only 1% of all cases (Parchi et al., 1999).  
 
In agreement with Collinge’s classification system, Parchi and Gambetti identified 
only a single PrPres type associated with vCJD cases. PrPres associated with vCJD had 
an indistinguishable migration of the unglycosylated to that observed in type 2 sCJD 
cases resulting in a ~19kDa fragment. However, vCJD PrPres could be distinguished 
from sCJD by the predominance in the diglycosylated form of the protein. Variant 
CJD PrPres was designated type 2B to distinguish it from sCJD type 2 cases (Figure 
1.8). Therefore, sCJD type 2 cases, where the monoglycosylated band predominates 
are often referred to as type 2A. 
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Figure 1.8: Parchi and Gambetti’s molecular classification of human TSEs 
 
Schematic representation of PrPres types 1-2 and their relationship with PRNP codon 















Comparisons drawn between these two studies argued that the type 1 PrPres reported 
by Parchi and Gambetti correspond to type 1 and type 2 described by Collinge and 
co-workers, with Collinge’s type 3 corresponding to Parchi and Gambetti’s type 2 
(Parchi et al., 1997). In their original study, Parchi and Gambetti identified a number 
of cases with a small variation in the molecular mass of PrPres type 1. They proposed 
that Collinge’ type 1 and type 2 represented artefactual separation of such cases.  
This proposal was disputed by Collinge and co-workers who proposed that the 
differences are more than likely due to methodological differences between the two 
studies, in particular treatment with the metal ion chelator EDTA prior to proteinase 
K treatment, which was found to modify the PrPSc conformation resulting in faster 
migration of PrPres (Wadsworth et al., 1999a). Further studies investigating the 
discrepancies between these two classifications suggest that the variation observed in 
N-terminal truncation may be due to the effects of pH variation during the 
preparations of tissues for analysis (Notari et al., 2004; Cali et al., 2006). Regardless 
of the differences between the Collinge classification and the Parchi and Gambetti 
sub-classification of sCJD, both are in agreement that the phenotypic heterogeneity 
observed within sCJD is dependant on the codon 129 PRNP genotype and the PrPres 
type of the patient. Nomenclature apart the only substantial difference between the 
two classification systems in terms of sCJD sub-classification is the existence of two 
different phenotypes associated with Parchi and Gambetti MM1, termed 1MM and 
2MM by Collinge. Whatever the basis of the difference between the two sets of 
results, a World Health Organisation  (WHO) unpublished ring trial concluded that 
the Parchi and Gambetti sub-classification system was a more reproducible and 
transferable system (Mark Head, personal communication). The investigations of 
human TSEs described in this thesis follow the Parchi and Gambetti classification 




1.10.2 Current concerns relating to molecular strain typing 
Biochemical characterisation of PrPres as a means of strain typing and diagnosing 
CJD has come under scrutiny recently following reports that regional variation in 
PrPres type occurs within cases of sCJD (Parchi et al., 1999; Puoti et al., 1999). This 
phenomenon was first reported in Parchi’s original analysis of 300 sCJD cases, in 
which around 5% of cases examined demonstrated both PrPres type 1 and type 2 
within the cerebral cortex of the same brain sample (Parchi et al., 1999). Recent 
studies have confirmed these findings and indicated that the existence of mixed PrPres 
types or ‘co-occurrence’ in the brain may be prevalent in a much higher proportion 
of cases (~ 30%) than first reported (Puoti et al., 1999; Schoch et al., 2006; Uro-
Coste et al., 2008). Correct identification of these cases may be limited by the extent 
of tissue sampling and the sensitivity of the assay in detecting minority PrPres 
components (Head et al., 2004a; Yull et al., 2006). It has also been suggested by two 
studies using antibodies raised to specifically recognise PrPres type 1, that all cases of 
sCJD type 2 contain a proportion of PrPres type 1 component (Polymenidou et al., 
2005; Yull et al., 2009).  The phenomenon of mixed PrPres types may be an 
indication that the different PrPSc types can either interconvert or occur 
spontaneously. In either case this challenges or at the very least complicates the 
relationship between disease phenotype, PrPres type, PRNP codon 129 genotype and 
agent strain. In addition to the extent of N-terminal truncation (electrophoretic 
mobility), glycosylation ratio is also proposed to show strain-specific variation. 
Recent reports that PrPres glycoform profile also shows regional variation in sCJD 
cases further highlights the difficulties associated with PrPres typing as a means of  
correctly identifying different human TSE and in providing a biochemical basis for 
agent strain (Levavasseur et al., 2008). 
 
The phenomenon of mixed PrPres types within sCJD cases has recently prompted the 
re-evaluation of the Parchi and Gambetti classification system for sCJD in which six 
sCJD subtypes have been proposed based on the correlation of clinical and 
pathological features of disease with variations in PRNP codon 129 and PrPres type 
(Parchi et al., 1999).  The main aim of this re-evaluation was to establish whether the 
presence of mixed PrPres types in the brain results in a further distinct clinico-
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pathological phenotype for inclusion in the current sub-classification system for 
sCJD. The first publication by Cali et al., re-analysed 34 cases of sCJD in patients 
homozygous for methionine at PRNP codon 129  (13 MM1, 9 MM2 and 12 MM1+2 
cases as previously classified based on Western blot analysis). Analysis of clinical, 
neuropathological and biochemical characteristics all indicated that sCJDMM1+2 do 
represent a unique sCJD subtype and should be included in the current sub-
classification system (Cali et al., 2009).  In a slightly later publication, further re-
analysis of all sCJD cases irrespective of genotype supported the inclusion of 
sCJDVV1+2 and sCJDMV1+2 as well sCJDMM1+2 as distinct subgroups within the 
classification system having shown unique neuropathological and biochemical 
phenotypes (Parchi et al., 2009). 
 
The publication of a case of CJD in a young Dutch patient also questioned the 
reliability of PrPres isotyping as a diagnostic tool for the sub-classification of sCJD 
and as a means of characterising agent strain (Head et al., 2001). The case in 
question focused on a 42 year old Dutch woman who was admitted to hospital with 
suspected CJD.  A brain biopsy (right frontal cortex) was taken from this patient due 
to the young age at onset and atypical clinical symptoms. Neuropathological 
examination of the biopsy material demonstrated classic signs of sCJD with 
spongiform change, astrocytosis and neuronal loss. Western blot analysis using 
Parchi and Gambetti’s classification system confirmed the diagnosis of sCJD and a 
type 1 PrPres type with genetic analysis confirming a valine homozygote at codon 129 
of PRNP.  The patient died 18 months after onset of clinical symptoms, unusually 
long disease duration for sCJD. Permission for examination of the brain was 
provided. Histological examination confirmed the previous diagnosis on the biopsy 
material of sCJD. However, Western blot analysis on a sample from the left frontal 
cortex showed contrasting results to those of the biopsy with unglycosylated PrPres 
type 2 mobility and a glycoform ratio that resembled vCJD not sCJD.  The final 
diagnosis of this patient was confirmed as an atypical case of sCJD. This case 
highlighted the difficulties in interpreting PrPres isotyping and the caution that must 
be taken when making a diagnosis. Again, the problems of strain typing in CJD were 
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raised with the question of conversion of PrPres types during disease progression and 
the possibility of regional variation in PrPres types.  
 
1.11 Experimental transmission of CJD  
If strain-specific information is enciphered within the different conformational 
variants of PrPSc, the biochemical properties of PrPSc would be expected to be 
conserved on transmission. Non-human primates have successfully been used in a 
number of experimental transmissions involving a wide range of human TSEs and 
were instrumental in the inclusion of kuru, sCJD and vCJD as human TSEs 
(Gajdusek et al., 1966; Gibbs, Jr. et al., 1968; Lasmezas et al., 1996). As primates are 
evolutionary closer to humans it is thought that they may represent the most accurate 
model for the pathogenesis of disease. In one of the largest TSE transmission studies, 
investigating the experimental transmission of brain homogenate from 300 human 
TSE cases in different primate species, the overall success rate for transmission was 
over 90 % for sCJD, iCJD and kuru with a lower rate of ~68% for the familial forms 
of the disease (Brown et al., 1994). Subsequently, comparison of the transmission 
characteristics of vCJD and BSE in macaques was to provide early support for the 
initial hypothesis that vCJD is BSE in humans (Lasmezas et al., 1996). Neither of 
these studies investigated the biochemical phenotype or the relationship of PRNP 
codon 129 genotype between the donor and the recipient. However, a later study 
investigating the experimental transmission of brain homogenate from sCJD and 
vCJD in the squirrel monkey, indicated that the biochemical phenotype is conserved 
on transmission to primates (Williams et al., 2007). However, in the case of sCJD, 
the findings of this study suggested that the resulting PrPres type may be attributed to 
variation in the PRNP codon 129 genotype of the host. In addition to primate models, 
the bank vole (Clethrionomys glareolus) has also proved to be highly susceptible to 
human TSEs (Nonno et al., 2006). Successful transmission of brain isolates from 
some sCJD subtypes in the bank vole confirmed that PrPres type is maintained on 
transmission in this animal model. These transmissions also suggest that the 
successful transmission from different sCJD subgroups may be influenced by the 
codon 129 genotype and PrPres type of the tissue donor.  
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1.11.1 Mouse models of human TSE 
Experimental transmission of human TSEs in wild-type mice has provided variable 
results. Sporadic CJD transmits inefficiently, often resulting in the absence of any 
clinical signs of disease, whereas vCJD transmission is highly efficient in wild-type 
mice, resulting in 100% of animals showing clinical signs of disease (Bruce et al., 
1997). In order to overcome the ‘transmission barrier’ observed with sCJD, the 
majority of transmission studies involving human TSEs now concentrate on the use 
of transgenic mice expressing human PrP. 
 
There are two main methods for the generation of transgenic mice; random genetic 
insertion (RGI) and gene targeting (GT). The most common transgenic mice 
associated with human TSE transmission are those generated by RGI which are 
produced by the injection of cloned PrP genes into fertilised mouse oocytes. Using 
this method of generation, there is no control over the insertion point or the number 
of copies of the PrP gene that have been generated. These mice often result in the 
over-expression of the PrP gene. There may also be a loss in function if the inserted 
PrP gene disrupts other genetic components. The second method of GT, involves the 
specific replacement of the Prn-p gene with the genetic material for insertion, in the 
case of human transgenic mice, insertion of the human PRNP gene. The benefits of 
these mice are that the inserted human PRNP gene remains under the correct 
transcriptional control in the mouse.  
 
Experimental transmission of human TSEs by Collinge and co-workers have 
provided experimental evidence to support the use of PrPres typing as a reliable and 
consistent method of strain typing. The use of transgenic mice expressing only 
human PrP has been an important step in transmission studies, allowing direct 
comparisons of the PrP protein.  In his first study on molecular strain typing of CJD, 
Collinge demonstrated the successful transmission of his type 2 and type 3 PrPres to 
Tg152 mice, RGI generated transgenic mice expressing human PrP not murine PrP 
and encoding for valine at codon 129 (designated HuPrP129V+/+ Prn-p0/0) (Collinge 
et al., 1996). This showed not only the lack of a ‘species barrier’ but importantly for 
the prion hypothesis and the proposal that strain variation is encoded by different PrP 
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conformations, that after transmission these two sporadic and iatrogenic types (type 
1-3) retained the biochemical characteristics of the individual inoculum (Collinge et 
al., 1996). However, transmission of type 1 CJD resulted consistently in a type 2 
banding pattern of human PrPres, perhaps a direct result of the mis-match of genotype 
at codon 129 on PRNP.  Transmission of types 1, 2 and 3 through wild type mice 
(FVB and C57BL) were less successful with only occasional transmissions with 
much longer incubation periods consistent with the presence of a ‘species barrier’. 
Crucially the glycoform ratios observed in these transmissions were identical to the 
three types of CJD. 
 
In a follow up study, transmission of vCJD to Tg152 mice proved less efficient when 
compared with sporadic and iatrogenic CJD and in the cases that did transmit, the 
incubation period was much longer (Hill et al., 1997). In FVB mice, transmission of 
vCJD proved much more efficient than sporadic and iatrogenic CJD although 
incubation period was more variable and longer. Transmission of BSE in FVB and 
Tg152 mice showed similar results to that of vCJD with efficient transmission into 
FVB mice but less efficient transmission in the transgenics. When glycoform 
patterns were examined, vCJD and BSE transmissions to FVB mice were 
indistinguishable, producing a type 4 pattern consistent with the inoculum. However, 
in the vCJD transmissions to Tg152 mice, a similar glycoform ratio to type 4 was 
observed but the fragment sizes differed to that of the inoculum. This pattern was 
given a new PrPres typing, designated type 5 (Figure 1.7b), and thought to represent a 
prion strain switch resulting from mis-match of the codon 129 polymorphism 
between inoculum and host human PrP (Hill et al., 1997). Western Blotting of the 
primary BSE transmissions in Tg152 mice did not demonstrate the presence of PrPres, 
possibly due to lower titres of the agent present in the BSE inoculum when compared 
to vCJD.  
 
In order to establish if the poor transmission of vCJD into Tg152 mice was indeed a 
result of the mis-match at codon 129 of PRNP, inoculum used in previous 
transmission studies (Collinge et al., 1996; Hill et al., 1997) was transmitted to Tg35 
mice, RGI generated transgenic mice expressing human PrP not murine PrP and 
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encoding methionine at codon 129 (HuPrP129M+/+, Prn-p0/0). Surprisingly, Tg35 
mice showed even more resistance to vCJD than had been found with Tg152 mice as 
judged by the development of clinical disease (Asante et al., 2002). However, 
investigation of the mice for subclinical infection provided very different results. 
Pathological examination of Tg35 mice challenged with vCJD provided evidence of 
prion infection in 100% of the challenged mice with the presence of PrP plaques 
many of which were of the ‘florid’ type. In terms of biochemical analysis, Western 
blotting showed a type 4 PrPres pattern characteristic of vCJD, consistent with the 
prion hypothesis that prion strain type is encoded by the biochemical properties of 
PrPres and, that the PRNP codon 129 polymorphism plays a key role. Re-examination 
of the vCJD transmissions in Tg152 mice (Collinge et al., 1996; Hill et al., 1997), 
which were negative on clinical assessment, showed no evidence of subclinical 
disease. In transmissions of sCJD to Tg35 mice the codon 129 genotype of the 
inoculum played an important role. Tg35 mice were highly susceptible to prions 
from sCJD PRNP 129 MM patients, but less susceptible to those from sCJD PRNP 
129 VV patients. Transmission of sCJD of the MV PRNP genotype was associated 
with either consistent short duration characteristics as with MM or long disease 
duration as observed with VV cases (Asante et al., 2002). 
 
Transmission of BSE into Tg35 mice also resulted in both clinical disease and 
subclinical infection (Asante et al., 2002). However, only a single mouse showed the 
characteristic PrPres type 4 after Western blotting with the neuropathological features 
characteristic of vCJD inoculated mice. In the remaining mice an alternative 
phenotype was observed, with a distinctive human PrPres type produced on Western 
blot showing a different fragment size of unglycosylated PrPres. The PrPres glycoform 
ratio of these mice was also very different from type 4 PrPres with the mono-
glycosylated portion the most abundant. Comparison with Collinge’s known human 
types indicated that this type corresponded to the type 2 PrPres observed in sCJD and 
iatrogenic cases. These cases also showed a shift in fragment size to type 2- PrPres 
after EDTA treatment prior to proteinase K digestion, a feature that had not been 
observed with type 4 PrPres cases. Neuropathological examination confirmed 
subclinical disease in these mice but showed no specific immunoreactivity; in 
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particular, there were no florid or other plaques. The authors raised the possibility 
that some humans infected with the BSE agent may develop a clinical disease 
indistinguishable from sCJD associated with type 2 PrPres. These transmissions were 
repeated in a second transgenic line expressing HuPrPM129, generated as described 
for Tg35 but which have a level of expression of human PrP four fold higher than a 
normal pooled human brain standard. Transmission of vCJD to these mice mirrored 
vCJD transmissions in Tg35 mice but showed no signs of the alternate type 2 PrPres 
pattern that was obtained with the Tg35 mice. Western blot and neuropathological 
examination of these mice showed a phenotype consistent with vCJD.  
 
More recently, a series of transmission experiments by the group lead by Jean 
Manson has provided valuable information on susceptibility to human TSEs and in 
characterising the agent strain in vCJD and sCJD. The transgenic models used in this 
series of experiments were produced using gene targeting in which the mouse PrP 
gene was directly replaced by the human PrP gene with the codon 129 MM, MV and 
VV genotypes. In their first series of experiments, successful transmission of vCJD, 
as determined by the appearance of clinical and pathological signs of a TSE was 
observed in all three transgenic mouse lines (HuMM, HuMV and HuVV), evidence 
that all PRNP codon 129 genotypes are susceptible to secondary transmission of 
vCJD (Bishop et al., 2006). However, differences in the appearance of clinical signs 
and in the progression of pathological features of TSE in the different transgenic 
lines indicated that there is a graduation of incubation period from MM to MV to 
VV. This was proposed to indicate that vCJD in an MV or VV genotype may be 
subject to a lengthy preclinical phase. Furthermore, differences observed in the 
pattern of PrP accumulation in the different mouse lines raised the possibility that 
vCJD in these other genotypes could result in a disease phenotype distinct from that 
recognised in vCJD in MM individuals (Bishop et al., 2006). 
 
In their follow up study, Bishop and co-workers further investigated the vCJD agent 
strain in transgenic and wild-type mice to determine whether there was any 
modification to the vCJD strain after secondary human transmission of vCJD. In this 
study, inoculation of brain homogenate from the first case of transfusion associated 
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vCJD showed only minor differences in biological properties from vCJD derived 
from BSE which was previously reported in these mouse lines (Bishop et al., 2008). 
Reassuringly, the similarities observed in the transmission properties of primary and 
secondary vCJD cases in transgenic and wild-type mice were consistent with the 
proposal that there are no major changes in the agent strain after secondary 
transmission via blood transfusion.  
 
In their most recent publication, all three transgenic mouse lines (HuMM, HuMV 
and HuVV) were challenged with the six different (Parchi and Gambetti) sCJD 
subgroups, as classified by PRNP codon 129 genotype and PrPres type, in order to 
define the agent strain in sCJD and the influence of codon 129 genotype on the 
transmission properties of sCJD (Bishop, 2008; Bishop et al., 2010). In summary, 
analysis of clinical, pathological and biochemical properties in the mice suggested 
that the six sCJD subgroups behave as four distinct strains of agent (MM1 and MV1; 
MV2 and VV2; VV1; MM2) on transmission in these transgenic mouse models. This 
study is closely related to the work presented in this thesis examining the agent strain 
of sCJD on transmission to wild-type mice. Therefore, the results of this study will 
be directly compared and discussed in Chapter 7 (section 7.2.1.1) in this thesis. 
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1.12 Thesis aims 
The working hypothesis of this thesis was that the different disease phenotypes of 
sCJD represented different strains of agent. However, there was no evidence to 
support this proposition and no rigorous studies had been reported. The aim of this 
thesis is to analyse existing mouse transmission studies to investigate the relationship 
between disease phenotype, PRNP codon 129 genotype, PrPres type and agent strain. 
In extending these mouse transmissions, this thesis also aims to investigate the 
presence of infectivity in tissues other than brain in CJD patients. In addressing these 
aims it will ask a number of specific questions. 
 
1. Do the six different sCJD subgroups, as classified by PRNP codon 129 
and PrP
res
 type, behave as different strains of agent on transmission to 
wild-type mice? This will consist of: 
i) Confirming the PrPres type of brain inocula used in the transmission 
series. 
ii) Characterising the sCJD agent using the classical strain typing parameters 
of incubation period and lesion profile to establish if the different sCJD 
subgroup show unique transmission properties in the mice. 
iii) Establishing whether the biochemical phenotype (PrPres type) is 
conserved on transmission consistent with that which would be predicted 
from the prion hypothesis. 
 
2. How do transmissions from sCJD, proposed to have more than one 
strain of agent compare with vCJD, believed to be a single strain of 
agent? This will consist of: 
i) Analysing the transmission properties of brain inocula from 10 vCJD 
patients in order to establish whether there are similarities, consistent with 
the proposal that vCJD is caused by a single strain of agent. 
ii) Comparing the transmission properties of vCJD with that of all six sCJD 
subgroups to determine whether there is any relationship between the 
vCJD agent and that of any sCJD subgroup.  
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3. Can the detection of infectivity in vCJD patients be extended to tissues 
other than brain, spleen and tonsil? Furthermore, can infectivity be 
detected outside the CNS in sCJD? This will consist of: 
i) Establishing any evidence of positive transmission of a TSE (as 
determined by clinical signs of disease, lesion profile and PrP deposition) 
from a wide-range of lymphoid and peripheral neural tissues from vCJD 
patients on transmission to wild-type mice, extending the evidence of 
peripheral infectivity in vCJD. 
ii) Determining evidence of positive transmission from sCJD spleen in order 
to establish evidence of a peripheral involvement in sCJD.  
iii) To establish whether infectivity can be detected in different vCJD and 
sCJD blood fractions in wild-type mice. 
 
4. Is agent strain subject to any tissue specific modifications? This will 
consist of: 
i) Characterising the agent strain in lymphoid tissues, peripheral neural 
tissues and biological fluids showing positive transmission to mice.  
ii) Comparison of the transmission properties of vCJD/sCJD brain inocula 
with those of other tissues and fluids from vCJD/sCJD patients to 





Chapter 2: Materials and Methods 
 
The series of experiments described in this thesis involves a large scale study 
investigating the transmission properties of sCJD and vCJD in wild-type mice. This 
is part of an on-going collaboration between the National CJD Research & 
Surveillance Unit (NCJDRSU), Edinburgh University and the Neuropathogenesis 
Division (NPD), Roslin Institute (formerly part of the Neuropathogenesis Unit 
(NPU) of the Institute for Animal Health). Experimental challenge of mice with 
tissue homogenates from CJD patients were carried out from 1995 and 2002 and did 
not directly involve the author of this thesis in either the planning or the animal 
husbandry aspects of this study. The period of PhD study began in October 2002. 
The author of this study has carried out all the laboratory tests on collected fixed and 
frozen tissue and performed all of the data analysis as described below unless 
otherwise stated. 
 
2.1 Experimental mice 
Experimental transmission of brain tissue obtained from patients diagnosed with CJD 
was carried out in mice from the colony maintained in the Category 3 containment 
facilities of the NPU/NPD. Three inbred mouse lines and one genetic cross were 
selected; these were RIII, C57BL, VM, and the F1 cross between C57BL and VM 
mice (C57BL x VM).  These mouse lines were selected because they are routinely 
included in TSE strain typing experiments at the NPU/NPD and have been well 
characterised after experimental challenge with many different TSE agents. These 
mouse lines differ in their prion protein genotype. RIII and C57BL mice are both of 
the Prn-pa genotype; VM mice are of the Prn-pb genotype and C57BL x VM mice 
are Prn-pab. The effect of the PrP gene on disease progression is described in full in 
Chapter 1, section 1.3.2.  Mice within the Category 3 facility of the animal unit are 
all housed in individual ventilated cages (IVC). In this series of experiments, each 
cage held six mice. Strains and sexes of mice were kept separate and mice challenged 
with different TSE inocula were not mixed within cages. Individual mice were 
identified by an ear punch and a unique code for blind clinical assessment. 
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Information on each mouse was collated and stored in a purposely designed database 
(NPU/NPD e-mouse database). 
 
2.2 Selection of CJD cases and tissues for transmission to mice  
2.2.1 Human TSE case selection 
All human tissues used in this series of transmission experiments were taken from 
the brain bank of the NCJDRSU. Forty cases of CJD (referred to in this thesis as CJD 
1 – CJD 40) were selected for transmission. These comprised 27 sCJD and 13 vCJD 
cases. The patients were initially diagnosed on the basis of the clinical features of the 
disease and the diagnosis confirmed by neuropathological and Western blot 
examination of post-mortem CNS tissue. Inclusion criteria for cases were: the 
availability of frozen brain and peripheral tissues taken at post-mortem, appropriate 
consent and ethical approval for retention and research use (Lothian Research Ethics 
Committee (LREC) reference number LREC/2000/4/157), and a full range of clinical 
and genetic data on each CJD case. In addition, cases having a relatively short 
autopsy interval to minimise the effects of autolysis were preferred. Patient data for 
the forty CJD cases including age, gender, date of disease onset, disease duration, 
PRNP codon 129 genotype and PrPres type are detailed in Table 2.1. 
 
2.2.1.1 Brain tissue 
Transmission experiments were carried out with brain tissue sampled from 27 sCJD 
patients with clinical onset ranging between 1980 and 1999. Therefore, this series of 
transmissions experiments included sCJD patients who had died both before and 
after the start of the BSE outbreak. Two of the sCJD cases (patients CJD 2 and CJD 
4) were specifically selected as they had been dairy farmers from different UK farms 
who had potentially been exposed to BSE-infected cattle and BSE-contaminated 
animal feed because of BSE within their herds. The remaining 25 sCJD cases 
included all six possible combinations of PRNP codon 129 genotype and PrPres type, 
as set out in the Parchi and Gambetti classification system for human TSEs (Parchi et 
al., 1999) and were selected as having clinical and pathological features that were 
typical for sCJD. In addition, transmission experiments were carried out with brain
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CJD 1 57 M Sept 1990 1 sCJD MM 1 
CJD 2 61 M Feb 1992 7 sCJD MM 1 
CJD 3 55 F Sept 1992 1 sCJD MM 1 
  CJD 4 64 M Apr 1993 3 sCJD MM 1 
CJD 5 82 F 1983 4 sCJD MM 1 
CJD 6 57 F 1981 5.5 sCJD MM 1 
CJD 7 59 M Jul 1995 3 sCJD MM 1 
CJD 8 78 M 1980 8 sCJD MM 1 
CJD 9 78 M Dec 1995 4 sCJD MM 1 
CJD 10 86 F Mar 1998 4 sCJD MM 1 
CJD 11 65 F Dec 1997 9 sCJD MM 1(+2A) 
CJD 12 46 F Dec 1996 17 sCJD MM 2A 
CJD 13 20 F May 1993 54 sCJD MV 1 
CJD 14 78 M Apr 1998 8 sCJD MV 1 
CJD 15 76 M Jan 1999 5 sCJD MV 1 
CJD 16 54 M Dec 1994 52 sCJD MV 2A 
CJD 17 66 F Oct 1990 13 sCJD MV 2A 
CJD 18 64 F Nov 1996 21 sCJD MV 2A 
CJD 19 54 M Jul 1994 5 sCJD VV 1 
CJD 20 38 M 1984 15 sCJD VV 1 
CJD 21 28 M Feb 1997 29 sCJD VV 1 
CJD 22 42 M May 1995 10 sCJD VV 1 
CJD 23 53 M 1982 5 sCJD VV 2A 
CJD 24 69 M 1983 8 sCJD VV 2A 
CJD 25 77 M 1983 3.5 sCJD VV 2A 
CJD 26 53 M Aug 1995 6 sCJD VV 2A 
CJD 27 47 M Sept 1995 11 sCJD VV 2A 
CJD 28 29 F Feb 1994 23 vCJD MM 2B 
CJD 29 30 F Aug 1994 18 vCJD MM 2B 
CJD 30 31 M Aug 1995 9 vCJD MM 2B 
CJD 31 35 F Jul 1995 14 vCJD MM 2B 
CJD 32 41 F July 1994 18 vCJD MM 2B 
CJD 33 25 M Dec 1995 14 vCJD MM 2B 
CJD 34 36 M Oct 1996 12 vCJD MM 2B 
CJD 35 23 F Mar 1996 14 vCJD MM 2B 
CJD 36 33 F Sept 1995 30 vCJD MM 2B 
CJD 37 36 F Jul 1997 15 vCJD MM 2B 
CJD 38 39 M May 1998 14 vCJD MM 2B 
CJD 39 26 M Sept 2000 10 vCJD MM 2B 
CJD 40 30 F Oct 2000 10 vCJD MM 2B 
 
* The identification reference (ID) for each case relates to this thesis only. Separate ID’s were given to 
the same CJD cases analysed in previous publications. CJD 1 – CJD 6 and CJD 28 – CJD 30 
corresponds to the CJD cases investigated in the original vCJD strain typing paper described by Bruce 
et al (2007). CJD 28 – CJD 37 correspond to the 10 vCJD cases investigated in Ritchie et al (2009). 
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tissue sampled from ten typical examples of vCJD from an early part of the vCJD 
epidemic (onsets between 1994 and 1997).   
 
2.2.1.2 Peripheral lymphoid and neural tissues 
In general, cases with a wide range of peripheral tissues available were selected for 
transmission. In the selection of vCJD lymphoid tissues (spleen, tonsil, lymph node 
and appendix), cases having the presence of PrPSc confirmed after 
immunhistochemical analysis were selected. In the sampling of tissues, trigeminal 
ganglia (TRG) were sampled from the left side. Dorsal root ganglia (DRG) were 
sampled from the lower thoracic/upper lumbar region. Bone for bone marrow 
extraction was sampled from the vertebral column. Peripheral nerves were sampled 
from the vagus nerve because of its potential involvement in disease pathogenesis.  
 
2.2.1.3 Biological fluids 
In addition to the experimental transmission of brain and peripheral tissues, mice 
were experimentally challenged with biological fluids and associated cells (buffy 
coat, plasma, and cerebrospinal fluid) taken from sCJD and vCJD patients. Buffy 
coat and plasma had been previously separated from whole blood samples by 
centrifugation. In the case of CSF, buffy coat and plasma, these samples were taken 
from patients during the clinical stage of disease and not at post-mortem. Differences 
in the time point at which these samples were taken may be important in the analysis 
of the results. Therefore, details of the time at which the biological fluids were taken, 
calculated as a percentage of the disease duration are detailed in Table 2.2. 
 
2.2.2 Sampling of human TSE tissues 
All human tissue sampling was carried out in the Class 1 microbiological safety 
cabinet in the Category 3* high-risk laboratory at the NCJDRSU by Professor James 
Ironside. For the experimental challenge of CJD brain tissue, a small piece of frozen 
grey matter (approximately 2 grams) from the frontal cortex or cerebellum of each 
CJD case was removed by aseptic technique, using sterilised single use disposable 
instruments. The size and weight of sample taken from peripheral tissues was 
dependent upon the availability of tissue for each case. Each sample was individually 
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labelled with the corresponding laboratory accession (RU) number assigned by the 
NCJDRSU to each CJD case and full and detailed records of the source and 
destination of the tissue taken.  Tissues were transported to the NPU/NPD and stored 
at -80oC until required. Details of the individual tissues sampled from each CJD case 





Table 2.2: Time points for the collection of biological fluids from CJD patients 
 
Diagnosis Case Biological fluid 
Time point extracted 
 (% of the disease duration) 
CJD 10 Blood 76 
CJD 11 Blood 88 
CJD 15 Blood 69 
sCJD 
CJD 18 Blood 56 
CJD 31 Blood 87 
CJD 35 Blood 85 
CJD 36 Blood 81 
CJD 37 Blood 76 
CJD 38 Cerebrospinal fluid 43 
vCJD 




















Table 2.3: Primary transmission of TSE infected tissues into panels of mice 
 
 
Case Tissue type 
Inoculation 
route 
Inoculated mouse lines 
*CJD 1 FC IC/IP RIII, C57BL, VM, C57BL x VM 
*CJD 2 CB IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 3 FC IC/IP RIII, C57BL, VM, C57BL x VM 
CJD 4 FC IC/IP RIII, C57BL, VM, C57BL x VM   
*CJD 5 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 6 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 7 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 8 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 9 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 10 FC, BC, SPL IC RIII, VM 
CJD 11 FC, BC, PL IC RIII, VM 
CJD 12 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 13 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 14 CB IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 15 FC, BC IC RIII, VM 
CJD 16 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 17 FC IC/IP  RIII, C57BL, VM, C57BL x VM  
CJD 18 FC, BC, PL IC RIII, VM 
CJD 19 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 20 FC IC RIII, C57BL, VM, C57BL x VM  
CJD 21 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 22 FC IC/IP  C57BL 
CJD 23 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 24 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 25 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 26 FC IC/IP RIII, C57BL, VM, C57BL x VM  
sCJD 
CJD 27 FC IC/IP RIII, C57BL, VM, C57BL x VM  
*CJD 28 CB IC/IP RIII, C57BL, VM, C57BL x VM  
*CJD 29 CB IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 30 CB IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 31 FC IC/IP RIII, C57BL, VM, C57BL x VM  
 FC, BC, PL, SPL, TONS IC RIII, VM 
CJD 32 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 33 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 34 FC IC/IP RIII, C57BL, VM, C57BL x VM  
CJD 35 FC, BC, PL, TONS IC RIII, VM 
CJD 36 FC, BC, PL IC RIII, VM 
CJD 37 FC, BC, PL IC RIII, VM 
CJD 38 APP, BM, CSF, DRG, LN, PN, SC, 
TRG 
IC RIII 
CJD 39 APP, BM, DRG, LN, PN, SC, TRG IC RIII 
vCJD 





APP – appendix,  BC – buffy coat,  BM – bone marrow,  CB - cerebellar cortex,   CSF – cerebrospinal fluid,  
DRG – dorsal root ganglia,  FC – frontal cortex,  LN – lymph node,  PL – plasma,  PN – peripheral nerve, 
SC – spinal cord,  SPL – spleen,  TONS – tonsil,  TRG – trigeminal ganglia 
 
* subsequent  mouse-to-mouse passages of brain isolates was carried out from these cases 
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2.3 Preparation of inocula and inoculations  
All inoculations were carried out at the NPU/NPD under an appropriate Home Office 
project licence (PPL 60/3132 and PPL 60/3380). Inoculum preparation and injections 
were carried out in a Class II safety cabinet within the category 3 containment 
facility. Injections were carried out by Professor Moira Bruce, Mrs Irene McConnell, 
Mrs Val Thomson and Miss Dawn Drummond. 
 
2.3.1 Primary transmission 
In the inoculation of tissue or biological fluids from CJD patients into mice, a 
‘species barrier’ exists between the donor and recipient species. Previous 
transmission experiments suggest that the attack rate (number of mice that develop 
clinical signs within a defined period) in such primary transmission is often low with 
extended incubation periods. In order to maximise the chance of transmission in this 
series of experiments: 
 
 Wherever possible, a large number of mice (20-24 mice of each strain) were 
inoculated with each CJD inoculum to compensate for losses due to 
intercurrent death during an extended incubation period.   
 Inoculation by a combination of intracerebral (IC) and intraperitoneal (IP) 
routes was carried out in 29 of the 38 primary transmissions from CJD brain 
homogenates. 
 Inoculations were carried out with a relatively concentrated 10% 
weight/volume (w/v) tissue homogenate.  
 
Inocula were prepared using the standard methods employed at the NPU/NPD 
(Dickinson et al., 1968; Bruce et al., 2004). Tissue samples were thawed, re-weighed 
and transferred to a sterile tissue grinder. Tissues were homogenised in a 0.9% sterile 
physiological saline solution (TPS medical, UK; product SC005) to give a 10% wet 
weight concentration and transferred into sterilised, sealable glass containers and 
stored at -20oC until required. Due to the extreme resistance of the TSE agent to 
conventional decontamination methods, all glassware was disposed of after single 
use. Cerebrospinal fluid, buffy coat and plasma, were inoculated into mice undiluted. 
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Bone marrow was prepared by flushing the bone through with 1ml physiological 
saline. Therefore the dilution of the bone marrow inoculum was unknown. Prior to 
injection, homogenates were thawed and re-suspended by being drawn repeatedly 
through a series of graded needles. Mice were inoculated via a single IC injection or 
by a combination of IC and IP routes using procedures described below.  
 
2.3.2 Intracerebral inoculation of mice 
Mice were injected intracerebrally with 20µl volume of inoculum under halothane 
anaesthesia (fluothane). Injections were made to the right of the midline of the skull 
through the parietal bone. A 26G needle was used for the injections with a needle 
guard attached preventing the needle penetrating more than 2mm into the brain.  
 
2.3.3 Intraperitoneal inoculation of mice 
Mice were injected via the IP route with 100µl volume of inoculum while under 
halothane anaesthesia. Injections were made into the ventral abdominal cavity using 
a 26G needle. 
 
The mouse lines inoculated with each CJD brain homogenate and the routes of 
inoculation are detailed in Table 2.3. In the majority of experiments, control animals 
were included, with six mice of each mouse line injected with 0.9% sterile 
physiological saline via the same inoculation route. After inoculation, the general 
health of the mice was monitored daily. All remaining unused inoculum and residual 











2.3.4 Secondary and serial passages in mice 
Secondary mouse-to-mouse passage of isolates derived from brain samples of three 
sCJD cases (CJD 1, CJD 2 and CJD 5) and two vCJD cases (CJD 28 and CJD 29) 
were carried out in RIII, C57BL and VM mice. All three sCJD cases selected for 
sub-passage were of the MM1 subtype, the most common subtype of sCJD, 
accounting for approximately 70% of all sCJD cases (Alperovitch et al., 1999).  
 
For secondary mouse passage, inoculum was prepared as previously described for 
primary transmissions (chapter 2, section 2.3.1), from the brain of a single RIII, 
C57BL or VM mouse which, where possible, had received a positive score for both 
clinical and neuropathological signs of TSE disease following primary transmission. 
In the absence of mice with a positive score for clinical disease, mice that had 
received a positive score for TSE-specific vacuolar pathology were selected. With 
the removal of the ‘species barrier’ on secondary passage (Dickinson, 1976; Bruce et 
al., 1994) and the expectation that transmission would now be more efficient, 
inoculum was prepared at a lower concentration of 1% (w/v) in physiological saline 
and injected via a single IC injection. For each inoculum, smaller groups of 10-12 
mice were inoculated. A further serial mouse-to-mouse passage was carried out from 
each secondary passage using the same protocol. 
 
2.4 Clinical monitoring of mice experimentally challenged with TSEs  
In all primary transmissions, formal clinical scoring of mice for signs of clinical TSE 
disease was carried out weekly from 250 days post injection (dpi) until the end of the 
natural life span of the mice, by suitably qualified NPU/NPD animal facility staff.  
This time-point is approximately 50 days before the clinical end-point of the shortest 
incubation periods observed in non-transgenic mice after primary challenge with a 
TSE. Clinical scoring for sub-passage experiments was started earlier, at 50dpi 
because incubation periods generally shorten with the removal of the ‘species 
barrier’.  
 
Clinical signs of TSE disease in mice are variable and often begin with subtle 
changes in behaviour prior to definite neurological disease. Some of the clinical signs 
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included lethargy, hyperactivity, changes in gait, aggression, weight loss or gain and 
scratching of the skin. Each week inoculated mice were given a score of 
“unaffected”, “possibly affected” or “definitely affected”. Mice were sacrificed at 
either clinical end-point for TSE disease and allocated a positive clinical score; or the 
full life span of the mice if they do not develop clinical TSE disease and allocated a 
negative clinical score. In some experiments, a termination date was set in which all 
remaining animals in the experiment were culled. Clinical end-point was determined 
in the following ways: 
 
 The day on which the mouse received two consecutive “definitely affected” 
scores.  
 The day on which the mouse received a second “definitely affected” rating in 
three consecutive weeks.  
  The animal had been found dead in the cage having received a “definitely 
affected” score at the previous week’s scoring.  
 
2.4.1 Incubation period 
Incubation period in mice challenged with individual TSE isolates is a major 
transmission characteristic that helps define agent strain (Dickinson and Meikle, 
1971; Bruce et al., 1991). Incubation periods were calculated as the period in days 
between initial infection (date of injection) and the date at which mice were 
sacrificed at clinical end-point of TSE disease (date of death).  Mean incubation 
periods were then calculated for individual groups within an experiment. Survival 
times were calculated for mice sacrificed due to intercurrent disease or at the end of 
their natural life span where no clinical signs were observed. In primary 
transmissions, mice sacrificed as a result of intercurrent disease before 250dpi, the 
start of formal clinical scoring, were excluded from the analyses. This time-point was 




2.5 Harvesting of mouse CNS tissues at post-mortem 
At post-mortem, brains were removed aseptically and assigned a unique brain 
pathology (BP) number for identification purposes and for blind histological 
analysis.  For the majority of mice, brains taken at post-mortem were immersed in 
10% formal saline for histological analysis.  However in a proportion of mice a 
lateral third of the brain was sliced and frozen and stored at –80oC for either 
biochemical analysis of PrPres type or for further passage in mice as shown in Figure 





Figure 2.1: Trimming levels for fixed mouse brain.  
 
The dashed line shows the lateral portion of the brain that is routinely sliced away 
and frozen for biochemical analysis of PrPres or for further passage in mice. Solid 
lines show the trimming levels providing four section levels for histological analysis 

















2.6 Histological Analysis 
Neuropathological examination of CNS tissue remains the definitive method for the 
diagnosis TSEs. In experimental mouse models, analysis of spongiform vacuolation 
and PrP deposition within the mouse brain not only confirms the successful 
transmission of a TSE, but also plays an important role in defining agent strain.  
 
2.6.1 Fixation, embedding and sectioning of mouse brain for histological 
techniques 
Mouse brains for histological analysis were fixed in 10% formal saline for at least 48 
hours, before immersing in 98% formic acid for 1 hour, a step introduced to reduce 
the titre of the infectious agent (Brown et al., 1990). Tissues were then re-immersed 
in 10% formal saline for a further 48 hours. Brains were trimmed coronally at four 
standard rostro-caudal levels to give five brain slices (Figure 2.1). These levels are 
precise in order to expose the nine grey matter regions and three white matter regions 
required for lesion profiling (see section 2.6.3). Tissues were then processed into 
paraffin wax and embedded exposing the cut surface of the tissue. Serial sections 
(approximately 10) were cut at a thickness of 5µm. Sections were placed onto electro 
statically charged microscope slides (VWR international, UK; product 631-0108) 












2.6.2 Haematoxylin and eosin staining  
To confirm the presence of TSE-specific vacuolation and undertake lesion profiling, 
haematoxylin and eosin (H&E) staining was performed on a single formalin fixed 
paraffin brain section of all inoculated mice as follows: 
 
Paraffin embedded brain sections were de-paraffinised in xylene for 5 minutes 
followed by stepwise re-hydration (5 minute incubations) in absolute alcohol, 74% 
industrial methylated spirits (IMS) and 70% IMS. Sections were immersed in 
haematoxylin solution (Surgipath Europe Ltd, UK; product 01542E) for 3 minutes 
before a thorough wash in water. After a single dip in a 1% acid alcohol solution 
[99mls 70% alcohol; 1ml concentrated HCL], sections were dipped three times in 
lithium carbonate solution [300ml tap water; 5-10ml saturated aqueous lithium 
carbonate (Fisher Scientific, UK; product L/2100/50)] and stained in eosin solution 
(Surgipath Europe Ltd, UK; product 01600E) for 3 minutes. Following a final rinse 
in water, sections were de-hydrated by immersing (approximately 10 seconds) in 
70% IMS, 74% IMS and absolute alcohol. Sections were cleared in xylene, cover 
slipped with pertex mountant (Leica Microsystems, UK; product 08707E) and left to 
harden overnight. In order to analyse the slides outside the laboratory, sections were 
immersed in 96% formic acid for 5 minutes and washed well in water. 
 
2.6.3 Assessment of TSE-specific vacuolation – The lesion profile 
Along with incubation period, the targeting and severity of TSE-specific vacuolation 
provide a “signature” for the biological properties of the agent. Lesion profiling is a 
semi-quantitative assessment of the severity of TSE-specific vacuolar pathology in 
nine specified grey matter regions and three white matter regions of the mouse brain 
(Fraser and Dickinson, 1968) (Figure 2.2). In each of the nine grey matter scoring 
regions, the severity of vacuolation is scored on a scale of 0-5. The definition of 
vacuolation scores in the grey matter is shown in Table 2.4. Vacuolation scores from 
a minimum of five mice in a single experimental group were required in order to 
construct a reliable lesion profile. All mice in this transmission series, regardless of 
clinical status were scored for the presence of TSE-specific vacuolation. To ensure 
consistency of results all scoring was carried out by Aileen Boyle at the NPU/NPD. 
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Figure 2.2: Lesion profiling scoring regions.  
 
The nine grey matter scoring regions (numbers 1-9) and three white matter scoring 
region (WM1-WM3) are indicated. Grey matter scoring regions are: (1) dorsal 
medulla, (2) cerebellar cortex of folia adjacent to forth ventricle, (3) superior 
colliculus, (4) hypothalamus, (5) medial thalamus, (6) hippocampus, (7) septum, (8) 
and (9) medial areas of the cerebral cortex at levels shown. White matter areas are: 
(1) inferior and middle cerebral peduncles, (2) decussation of superior cerebellar 
peduncles, (3) cerebral peduncles. The dashed lines show the lateral portion of the 





Table 2.4: Definition of vacuolation scores 
(From Bruce et al., 2004)  
 





A few vacuoles widely and unevenly scattered, not 
convincingly TSE specific pathology 
2 
A few vacuoles evenly scattered, more than for score 1 and 
convincingly diagnostic for TSE 
3 
Moderate numbers of vacuoles, evenly scattered 
 
4 
Many vacuoles with some confluence 
 
5 
Dense vacuolation with most of microscopic field confluent,  
lace like appearance 
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2.6.4 Immunohistochemical detection of PrP
 
in CNS tissues from mice 
experimentally challenged with TSE 
Detection of PrP in formalin fixed tissue sections was carried out using the anti-PrP 
antibody 6H4 (Prionics, Switzerland; product 01-010) in combination with the highly 
sensitive catalyzed signal amplification (CSA) (DAKO, UK; product K1500) system 
which is used at the NCJDRSU in the detection of PrP in human tissue sections. In 
each immunohistochemical run, a paraffin embedded section from a VM mouse 
experimentally challenged with the 87V strain of scrapie was included as a positive 
control for the antibody.  
 
Paraffin embedded tissue sections were de-paraffinised in xylene for 5 minutes 
followed by stepwise re-hydration in absolute alcohol, 74% IMS and 70% IMS (5 
minute incubations). Endogenous peroxidase activity was blocked by immersing 
sections in 1% hydrogen peroxidise (Fisher Scientific, UK; product BP2633-500) in 
methanol (Fisher Scientific, UK; product M/3950/17) for 30 minutes. In order to 
retrieve PrP antigen binding sites from the formalin fixed tissues, sections were 
autoclaved in distilled water (dH2O) at 121
oC for 10 minutes followed by immersion 
in 96% formic acid (Fisher Scientific, UK; product F/1850/PB17) for 5 minutes. 
Sections were washed in Tris-buffered saline (TBS) [50mM Tris; 150mM NaCL; 
pH7.6] before blocking with normal rabbit serum (NRS) (Vector laboratories, UK; 
product S-5000) diluted 1:5 in TBS for 20 minutes. Blocking of any non-specific 
binding of avidin-biotin was carried out with an avidin-biotin blocking kit (Vector 
laboratories, UK; product SP-2001). Sections were incubated for 15 minutes in the 
avidin solution followed by a 15 minute incubation in biotin solution. Sections were 
then incubated in the primary antibody 6H4, diluted 1:8000 in TBS for 1 hour. After 
a wash in TBS, immunolabelling was completed using the CSA kit with 15-minute 
incubations in biotinylated link, streptavidin biotin complex reagent [Prepare at least 
30 minutes prior to use: 1 drop streptavidin-biotin complex reagent A; 1 drop of 
streptavidin-biotin reagent B; 1 ml of streptavidin-biotin complex diluent], 
amplification reagent and streptavidin-HRP. Washes in TBS were carried out 
between each reagent. After a final wash, staining was visualised with 3, 3’ 
diaminobenzidine (DAB). The DAB was prepared immediately before use from the 
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CSA kit [10 drops of substrate buffer concentrate; 10 ml of dH2O; 1 DAB 
chromagen tablet. The DAB was activated immediately before use by adding 1 drop 
of substrate hydrogen peroxide per 2 ml of DAB solution (DAKO, UK: product 
K1500)]. Sections were washed well in water before lightly counterstained (immerse 
in haematoxylin solution for 20 seconds, wash in water, dip once in a 1% acid 
alcohol solution, rinse in water and dip 4 times in saturated aqueous lithium 
carbonate solution). After a wash in water sections were dehydrated by immersing 
(approximately 10 seconds) in 70% IMS, 74% IMS and absolute alcohol. After 
clearing in xylene, sections were cover slipped with pertex and left to harden 
overnight. In order to analyse the slides outside the laboratory, sections were 
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2.6.5 Immunohistochemical detection of astrocytes
 
in CNS tissue from mice 
experimentally challenged with TSE  
Astrocytic proliferation, a common pathological feature of TSEs, is marked by 
increased glial fibrillary acidic protein (GFAP) immunostaining. Mice were 
immunolabelled with the anti-GFAP antibody, GFAP (Dako, UK; product Z0334) in 
combination with a Vectastain rabbit elite ABC kit (Vector laboratories, UK; product 
PK-6101) in order to visualise astrocytosis within the mouse brain after experimental 
challenge with the different TSE inocula. Immunolabelling was carried out on vCJD 
challenged mice as follows: 
 
Paraffin embedded tissue sections were de-paraffinised in xylene for 5 minutes 
followed by stepwise re-hydration in absolute alcohol, 74% IMS and 70% IMS (5 
minute incubations). Endogenous peroxidase activity was blocked by immersing 
sections in 1% hydrogen peroxidise in methanol for 30 minutes. Sections were 
washed in TBS before blocking in normal goat serum (NGS) [1 drop of NGS in 
10mls TBS]. Excess NGS was drained off and sections incubated in the primary 
antibody GFAP diluted 1:800 in TBS for 45 minutes at room temperature. After a 
wash in TBS, sections were incubated in anti-rabbit biotinylated secondary for 30 
minutes [1 drop of biotinylated anti-rabbit to 10mls of NGS] before a further wash in 
TBS. Immunolabelling was completed by incubating sections in ABC elite reagent 
for 30 minutes [prepared at least 30 minutes prior to: add 5mls TBS/BSA; 1 drop 
reagent A; 1 drop reagent B]. Staining was then visualised with DAB and sections 
counterstained and cover slipped for analysis as described in the CSA detection 
method of PrP in section 2.6.4. 
 
2.6.6 Microscopy and image capture. 
Staining of paraffin embedded tissue sections was analysed with a Leica DMR 
microscope and image capture carried out with a Leica DFC 500 camera in 
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2.7 Biochemical typing of PrPres in frozen tissues 
PrPres typing of brain inocula and frozen brain tissue was carried out using the 
standard diagnostic Western blot protocol carried out at the NCJDRSU for the 
detection and classification of PrPres in human CNS tissue (Head et al., 2004a). As 
discussed in Chapter 1, section 1.10.1.2, investigations of PrPres types in sCJD 
described in this thesis follow the Parchi and Gambetti classification system for 
human TSEs. In this classification system, two PrPres types are associated with sCJD 
differing in the migration of the unglycosylated fragment of the protein; type 1 where 
the unglycosylated PrPres has a molecular weight of around 21 kDa and type 2, where 
the unglycosylated PrPres fragment is slightly smaller with a mobility of around 
19kDa (Parchi et al. 1996). The migration pattern of the unglycosylated fragment of 
the protein in sCJD type 2 cases is indistinguishable to that of vCJD. However, vCJD 
is distinguished from sCJD type 2 cases by the predominance in the diglycosylated 
form of the protein. To indicate this difference in glycoform ratio the type 2 PrPres 
associated with sCJD is termed type 2A and the type 2 PrPres associated with vCJD is 
termed type 2B. Therefore in all Western blot runs performed in this thesis analysing 
both human and murine samples, diagnostic reference standards from a sCJD MM1 
patient and a vCJD (MM2B) patient were included with every Western blot run 
serving as an appropriate reference control for both fragment mobility and glycoform 
ratio. 
 
2.7.1 Sample preparation for Western blot analysis 
Preparation of tissue for Western blot analysis was carried out in the Class 1 
Microbiological Safety Cabinet within the High Risk Laboratory of the NCJDRSU as 
follows: 
 
2.7.1.1 Preparation of PrP
res
 from tissue inocula 
Residual inocula from the transmission series were vortexed and a 0.45ml sample 
removed and supplemented with 0.05ml of 10X extraction buffer [200mM Tris 
pH7.4; 5% Nonident P40; 5% Sodium deoxycholate]. After a brief vortex, insoluble 
material was pelleted by spinning samples at 2000rpm for 5 minutes at 4oC using a 
microcentrifuge (Eppendorf AG, UK; product 5417R) with a fixed angle motor 
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(Eppendorf AG, UK; product F-45-30-11). The supernatant was then aspirated using 
an aerosol resistant tip into a fresh eppendorf tube and the remaining pellet frozen at 
-20oC. A 0.2ml volume of the supernatant was then aspirated into a fresh eppendorf 
and proteinase K (PK) (VWR, UK; product 395092L) added to a final concentration 
of 50µg/ml. PK treated samples were then incubated at 37oC for 1 hour before 
stopping the reaction with the addition of Pefabloc™ (Roche, UK; product 
11429868001) to a final concentration of 1mM. The PK treated sample along with 
any residual supernatant were frozen at -20oC until required.  
 
2.7.1.2 Preparation of PrP
res
 from frozen brain tissue 
A small piece (approximately 100mg) of frozen grey matter enriched brain tissue 
(human or mouse) was sampled and placed in a sterile eppendorf. The precise weight 
of each brain sample was calculated and sufficient 1X extraction buffer [20mM Tris 
pH7.4; 0.5% Nonident P-40; 0.5% Sodium deoxycholate] added to give a 10% 
(wt/vol) brain homogenate. Tissues were then homogenised in the 1X extraction 
buffer using a disposable micropestle. Insoluble material was pelleted by spinning at 
2000rpm for 5 minutes as 4oC. The supernatant was aspirated using an aerosol 
resistant tip into a fresh eppendorf tube and the remaining pellet frozen at -20oC. A 
0.2ml volume of the supernatant was then removed and PK treated as described in 
the preparation of PrPres from tissue inocula (section 2.7.1.1). After stopping the 
reaction with Pefabloc™, the PK treated sample was frozen at -20oC until required. 
 
2.7.1.3 Centrifugal concentration of PrP
res 
Centrifugal concentration is an optional step used for increased sensitivity in the 
Western blot detection of PrPres. After PK treatment, 100µl of the PK treated sample 
was given a brief vortex before centrifugation at 14,000rpm for 1 hour at 4oC. The 
supernatant was removed and the pellet re-suspended in 5µl of 4X NuPAGE LDS 
sample buffer (Invitrogen, UK; product NP007) supplemented with 15µl of 1X 
extraction buffer (20mM Tris pH7.4; 0.5%NP-40; 0.5% Sodium deoxycholate). After 
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2.7.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
PK treated samples were thawed and given a short vortex before removing a 5µl 
volume and adding to 5µl of 4X NuPAGE LDS sample buffer, supplemented with 
10µl of 1X Extraction buffer. After a brief vortex, samples were denatured by boiling 
at 100oC for 10 minutes before a brief spin at 14,000rpm. In addition to the human 
diagnostic reference standards, protein molecular weight markers were included in 
each run [1µl Magic MarkerTM XP (Invitrogen, UK; product LC5602); 5µl 
Benchmark (Invitrogen, UK; product 10748-010); 9µl of 1X Extraction buffer; 5µl 
of NuPAGE LDS sample buffer]. Molecular weight markers were not boiled. 
Proteins were then separated by running at 200V (constant current) for 55 minutes in 
1X NuPAGE MES running buffer [50mls 20X running buffer (Invitrogen, UK; 
product NP0002-02); 950mls dH2O] within a Western blot running tank.  
 
 
2.7.3 Western blot transfer 
Proteins separated by Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) were transferred onto polyvinylidene difluoride (PVDF) membrane 
(Bio-rad, UK; product 162-0177) at 30V (constant current) for 1 hour using the 
NuPAGE transfer system. Transfers were carried out in 1X NuPAGE transfer buffer 
[25ml 20X NuPAGE transfer buffer (Invitrogen, UK; product NP0006-1); 375ml 
dH2O, 100ml methanol]. 
 
2.7.4 Detection of PrP bound to PDVF membrane 
Membranes were rinsed in TBST [100mls 10X TBS (Sigma-Aldrich, UK; product 
T5912); 900mls dH2O; 0.1% Tween 20 (Sigma-Aldrich, UK; product P9416)] before 
incubating in 5% powdered milk/TBST for 45 minutes at room temperature or 
overnight at 4oC. Membranes were then washed (3 x 5 minutes) in TBST prior to 
incubating in the primary anti-PrP antibody 6H4 diluted 1:25 000 in TBST for 1 hour 
at room temperature. After a further wash, immunolabelling was completed by 
incubating the membrane in the anti-mouse IgG linked horseradish peroxidise-
conjugated secondary antibody (GE Healthcare, UK; product NA9310) diluted 
1:40,000 in TBST for 1 hour at room temperature. Immunodetection was carried out 
                                                                                   
 79 
by incubating the membrane with the chemiluminescent substrate ECL plus [50µl of 
reagent B per 2 mls of reagent A (GE Healthcare, UK; product RPN2132)]. After 
draining off the excess ECL plus, membranes were exposed to Hyperfilm ECL (GE 
Healthcare, UK; product 28-9068-37) for 30 seconds, 3 minutes and 30 minutes 
before the films were developed in an automatic film hyperprocessor (Konica 
Minolta SRX-101A medical film processor). 
 
2.7.5 Densitometry and PrP
res
 typing 
Once developed, X-ray films were scanned using a GS-700 or 800 Densitometer 
(Biorad, UK; product 170-7980) and densitometry performed using the Biorad 
Quantity One Analysis software (version 4.4.1). The glycoform ratio and mobility of 
the unglycosylated band of samples under investigation were directly compared to 
the diagnostic reference standards (sCJD MM1 and vCJD MM2B).  
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Chapter 3: Characterisation of the inocula used in wild-type 
mouse transmission study 
 
3.1 Objective 
1. To confirm the presence of PrPres within inocula used in the experimental 
transmission of CJD to wild-type mice. 
2. To confirm the original brain PrPres isotyping result using the actual inocula 
used for transmission studies. 
 
3.2 Introduction  
The existence of individual TSE strains raises the question of how a single misfolded 
protein can encode all of the information required for the demonstrable phenotypic 
diversity of TSEs (Farquhar et al., 1998). The ‘protein only’ hypothesis proposes that 
strain-specific biological properties are enciphered in the different conformations and 
glycosylation states of PrPSc (Collinge et al., 1996; Telling et al., 1996). These 
different conformers and glycotypes are usually distinguished by the analysis of the 
proteinase resistant core of PrPSc (referred to as PrPres) after limited digestion with 
PK and analysis by Western blotting in an approach commonly referred to as 
‘molecular strain typing’ (Collinge et al., 1996; Parchi et al., 1996; Parchi et al., 
1999). In the classification system of human TSEs described by Parchi and Gambetti, 
two major PrPres types have been reported among cases of sCJD:  type 1 where the 
unglycosylated PrPres has a molecular weight of around 21 kDa and type 2A, where 
the unglycosylated PrPres is slightly smaller with a mobility of around 19kDa (Parchi 
et al. 1996). A representative Western blot showing the fragment mobility and 
glycoform ratio of PrPres from a diagnostic reference standard from a sCJD MM1 
patient and a sCJD VV2 patient is shown in Figure 3.1 These two biochemically 
distinct PrPres types have been associated with different sCJD phenotypes (Parchi et 
al. 1999). In order for these biochemical types to be considered as being properties of 
separate strains of the agent causing sCJD, the biochemical properties must be 
maintained on serial passage in mice.  
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Recently the significance of biochemical typing in CJD has been questioned with the 
observation of type 1 and type 2A co-occurring within the same brain in up to a third 
of sCJD patients examined (Puoti et al., 1999; Schoch et al., 2006; Uro-Coste et al., 
2008). These studies examined multiple small samples from different regions of the 
brain from individual sCJD patients, and it has been suggested that regional variation 
of PrPres types may be the rule rather than the exception in CJD. This has been 
further supported with reports of regional variation in PrPres types within cases of 
iCJD (Head et al., 2004b; Uro-Coste et al., 2008) and fCJD (Haik et al., 2004). In 
contrast to sCJD, only a single PrPres type (type 2B) has been detected within the 
brain of vCJD patients, defined by a characteristic predominance of the 
diglycosylated form of PrPres and an apparent molecular weight of around 19kDa for 
the unglycosylated form of PrPres (Figure 3.1) (Collinge et al. 1996; Head et al 
2004a). A similar glycosylation pattern has been found in cases of natural BSE and 
other BSE related conditions (Collinge et al., 1996). This BSE “glycoform signature” 
supports the hypothesis that vCJD and BSE are linked by a common agent. In recent 
studies using PrPres “type 1 selective” antibodies some researchers have claimed to 
detect low levels of type 1 PrPres in vCJD and BSE brain (Yull et al., 2006), but the 





 in sCJD and vCJD diagnostic reference standards 
 
Western blot analysis of PrPres in frontal cortex samples of a sCJD MM type 1, a 
sCJD VV type 2 and a vCJD (MM) type 2B diagnostic reference standard. Tissues 
are analysed after digestion with proteinase K and blots probed with the anti-PrP 
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If strain-specific properties are enciphered in the different conformations and 
glycosylation states of PrP as outlined in the ‘protein only’ hypothesis, establishing 
the actual PrPres type of inocula used in formal strain typing experiments is of 
fundamental importance to the interpretation of the results. In the series of 
experiments described in this study, CJD cases for transmission were selected 
according to the PrPres type identified in brain tissue taken at post-mortem. However, 
in the preparation of inocula for transmission, the brain from each CJD case was re-
sampled, raising the possibility that the PrPres type of the specimen for transmission 
may be different from the specimen used for diagnosis as a result of regional 
variation in the brain. In order to accurately interpret results from this study, it was 
therefore necessary to carry out Western blotting on inocula from each sCJD source 
as a means of establishing the actual PrPres type in the homogenate used to inoculate 
the mice. Although only a single PrPres type has been reported in the brain of vCJD 
patients, when analysed by conventional Western blotting, inocula from the vCJD 
transmissions were also analysed by Western blotting.  
 
In addition to the experimental transmission of brain tissue, this study investigated 
attempted transmissions from a wide range of lymphoid tissues, peripheral neural 
tissues and biological fluids, to establish whether TSE infectivity can be detected in 
tissues other than brain in both sCJD and vCJD. Accumulation of PrPSc has been 
described in a wide range of lymphoid and peripheral neural tissues in vCJD and to a 
much lesser extent in certain sCJD cases (Glatzel et al., 2003; Haik et al., 2003; Head 
et al., 2004b; Peden et al., 2006; Peden et al., 2007; Notari et al., 2010). However, 
studies showing the correlation between PrPSc accumulation and infectivity are 
limited.  Infection of spleen and tonsil tissue in vCJD patients has been previously 
confirmed by bioassay in RIII mice and has indicated that infectivity levels are a 
hundred to a thousand times lower than those demonstrated in brain (Bruce et al., 
2001). Furthermore, immunohistochemistry and Western blot studies have shown 
that the distribution of PrPSc within peripheral tissues of vCJD is much more 
heterogeneous than those found in the brain (Joiner et al., 2002; Hilton et al., 2004a; 
Head et al., 2004b). Immunohistochemical analysis of PrPSc in lymphoid tissues from 
vCJD patients at the end-stage of disease showed positively stained germinal centres 
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in a patchy distribution (Head et al., 2004b). This finding mirrors the irregular 
presence of PrPSc in the appendix in vCJD patients as detected by Western blot 
analysis (Joiner et al., 2002), with positivity detected in one out of two specimens at 
levels around 0.5% of that in the brain. These findings suggest that there may be 
sampling issues associated with the transmission of CJD infected peripheral tissues, 
in that PrPSc (and infectivity) may be present in the tissues but that the small samples 
taken for inoculation might not include areas where foci are most frequent. 
Consequently, even in those CJD tissues which were confirmed as having PrP by 
immunohistochemistry, establishing the presence of PrPres within inocula prepared 
from these tissues is crucial to the interpretation of results. Therefore Western 
blotting was carried out on residual inocula as a means of establishing whether PrPres 
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3.3 Experimental results 
 
3.3.1 Confirmation of PrP
res
 type of human brain tissue homogenates inoculated 
into mice  
In this investigation of agent strain in CJD, 38 primary transmission experiments 
were carried out from brain homogenates prepared from 37 patients diagnosed with 
CJD (27 sCJD patients and 10 vCJD patients). Three inbred mouse lines (RIII, 
C57BL and VM) and one cross C57BL X VM were challenged with individual brain 
homogenates as described in Chapter 2, section 2.3. Not all inocula were available 
for analysis; so Western blot analysis was carried out using the following order of 
preference; 
 
1. Human brain inoculum. Homogenate used in the inoculation of mice was 
the preferred and was considered to be the definitive method of determining 
the PrPres type of the brain homogenate. 
 
2. Residual frozen brain tissue used for the preparation of inoculum. In the 
absence of inoculum, Western blotting was carried out on a sample prepared 
from any unused frozen brain tissue sent to the NPU/NPD for transmission.  
 
3. CJD brain bank. In the absence of any residual inoculum or frozen brain 
sample, the original brain held at the NCJDRSU was re-sampled. The sample 
for Western blot was taken from the same brain region as that previously 
sampled for transmission. 
                                                                                   
 85 
Inoculum was available from 30 of the 38 primary transmissions for PrPres isotyping. 
Residual tissue from the brain sample sent to NPU/NPD was analysed for four 
experiments with the original brain held at the NCJDRSU brain bank re-sampled for 
the remaining four experiments. The tissue type analysed from each CJD case and 
the resulting PrPres type after Western blotting is detailed in Table 3.1.  
 
PrPres was readily detected in all brain extracts analysed. A similar intensity in the 
PrPres banding pattern was observed between the different brain extracts analysed. 
Thirty-seven of the 38 brain extracts analysed confirmed the PrPres type determined 
at diagnosis (Table 3.1). Crucially for this study, these results confirmed the 
transmission of brain tissue from all six possible combinations of PRNP codon 129 
genotype and PrPres type used in the classification of sCJD (Parchi et al., 2009). The 
number of individual sCJD cases of each PRNP codon 129 genotype/PrPres type 
combination used in a primary transmission is summarised in Table 3.2. A 
representative Western blot from the analysis of inoculum from each of these six 
possible CJD subgroups is shown in Figure 3.2.   
 
The single contradictory result from the Western blot analysis was from a sCJD 
patient (CJD 11) who was originally characterised as having PrPres type 1 in the 
extract of frontal cortex tissue tested during diagnosis, but who was subsequently 
found to have both PrPres type 1 and 2A in the brain when a large cortical specimen 
was taken to prepare sCJD reference standards by the National Institute of Biological 
Standards and Control (Minor et al., 2004). Neuropathological examination of post-
mortem frontal cortex tissue from this case, the brain region used in the preparation 
of inoculum, showed pathological changes consistent with those found in both sCJD 
MM1 and MM2 cases (Figure 3.3). This case has since been re-classified as sCJD 
MM1 + 2 as a result of the subsequent Western blot findings.  In this study, re-
analysis of the original diagnostic specimen homogenate showed that although it is 
predominantly type 1, it also contains some type 2 PrPres (Figure 3.4). Western blot 
analysis of the actual inoculum from this case detected PrPres solely with an 
electrophoretic mobility and glycosylation pattern of sCJD type 2A (Figure 3.4).    
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Table 3.1: Confirmation of PrP
res
















 type in 
inoculum 
Tissue type tested 
†CJD 1 MM 1 1 human brain inoculum 
†CJD 2 MM 1 1 human brain inoculum  
CJD 3 MM 1 1 human brain inoculum  
CJD 4 MM 1 1 human brain inoculum  
†CJD 5 MM 1 1 human brain inoculum  
CJD 6 MM 1 1 human brain inoculum  
CJD 7 MM 1 1 human brain inoculum  
CJD 8 MM 1 1 CJD brain bank 
CJD 9 MM 1 1  human brain inoculum 
CJD 10 MM 1 1 residual brain sample 
CJD 11 MM 1(+2A) 2A   human brain inoculum 
CJD 12 MM 2A 2A CJD brain bank 
CJD 13 MV 1 1 human brain inoculum  
CJD 14 MV 1 1 human brain inoculum  
CJD 15 MV 1 1 human brain inoculum  
CJD 16 MV 2A 2A human brain inoculum  
CJD 17 MV 2A 2A human brain inoculum  
CJD 18 MV 2A 2A residual brain sample 
CJD 19 VV 1 1 human brain inoculum 
CJD 20 VV 1 1 CJD brain bank 
CJD 21 VV 1 1 human brain inoculum  
CJD 22 VV 1 1 human brain inoculum  
CJD 23 VV 2A 2A human brain inoculum  
CJD 24 VV 2A 2A human brain inoculum  
CJD 25 VV 2A 2A CJD brain bank 
CJD 26 VV 2A 2A human brain inoculum  
sCJD 
CJD 27 VV 2A 2A human brain inoculum  
†CJD 28 MM 2B 2B residual brain sample 
†CJD 29 MM 2B 2B human brain inoculum  
CJD 30 MM 2B 2B human brain inoculum  
*CJD 31 MM 2B 2B human brain inoculum  
CJD 32 MM 2B 2B human brain inoculum  
CJD 33 MM 2B 2B human brain inoculum  
CJD 34 MM 2B 2B human brain inoculum  
CJD 35 MM 2B 2B human brain inoculum  
CJD 36 MM 2B 2B human brain inoculum  
vCJD 
CJD 37 MM 2B 2B residual brain sample 
 
  * Two separate transmission experiments were carried out from this CJD case.  
† Further serial mouse-to-mouse passages carried out from the primary transmissions. 
 
Table 3.2: CJD cases used in the brain tissue transmission series 
 
PRNP codon 129 genotype       
PrP
res  
type MM MV VV 
1 10 3 4 
2A 2 3 5 
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Figure 3.2: Western blot analysis of human brain inocula transmitted to mice.  
 
Brain inocula are shown in the middle lane and were run between sCJD MM1 (T1) 
and vCJD (T2B) diagnostic reference standards. Tissue extracts were PK digested 
and blots probed with the anti-PrP antibody 6H4. (a) Representative blots of inocula 
from all six subtypes of sCJD as classified according to PRNP codon 129 genotype 
and PrPres type (Parchi et al., 1999). (b) Representative Western blots of inoculum 
from a single vCJD (CJD 31) case. All vCJD brain tissue showed the characteristic 
predominance of the diglycosylated form of PrPres after Western blotting. 
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Figure 3.3: Neuropathology in frontal cortex tissue from patient CJD 11 
 
(a) Haematoxylin and eosin labelling showing confluent spongiform most commonly 
associated with the MM2 subtype of sCJD. In addition, the presence of 
microvacuolar spongiform lesions most commonly associated with sCJD MM1 
patients, are also evident. (b) PrP labelling with the anti-PrP antibody KG9 in the 
frontal cortex showing intense peri-vacuolar deposits of PrP most commonly 
associated with sCJD MM2 patients. A background of synaptic PrP labelling, a 





Figure 3.4: Western blot analyses of PrP
res
 types in brain extracts from CJD 11  
 
Analysis of aliquots of the original frontal cortex sample analysed at diagnosis (*) 
showing the presence of PrPres types 1 and a small amount of type 2. In contrast, an 
extract of inoculum (†) transmitted in the wild-type mouse panel, shows only PrPres 
with a type 2 mobility.  Samples shown are run between a sCJD MM1 (T1) and a 
vCJD (T2B) diagnostic reference standard. Tissue extracts were PK digested and 
blots probed with the anti-PrP antibody 6H4. Molecular weight markers (MW) are 
shown in kDa.     
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3.3.2 Detection of PrP
res
 in inoculum prepared from CJD lymphoid tissues, 
peripheral neural tissues and biological fluids 
In order to determine the presence of infectivity within tissues other than brain, 41 
transmission experiments were carried out on a number of lymphoid tissues 
(appendix, lymph node, spleen and tonsil), peripheral nervous system tissues (DRG, 
TRG and peripheral nerve), bone marrow and biological fluids and their constituent 
cells (buffy coat, plasma and cerebrospinal fluid) from four sCJD cases and seven 
vCJD cases (Table 3.3). Western blot analysis of peripheral tissues of CJD patients 
have demonstrated that the biochemical profile of PrPres is subject to tissue-specific 
modifications (Glatzel et al. 2003; Head et al. 2004b; Peden et al. 2006; Peden et al. 
2007). However, in the Western blot analysis of inocula used in this series of 
transmissions from peripheral tissues of CJD patients, the objective was not to carry 
out PrPres isotyping but simply to establish whether PrPres was present at detectable 
levels in the samples inoculated into the mice. Due to the heterogeneous distribution 
of PrPSc in peripheral tissues and the valuable nature of these tissues, in the absence 
of any residual inocula, tissues were not re-sampled for further Western blot analysis.  
 
Residual inoculum was available from six of the 41 transmission experiments (Table 
3.3).  These six different inocula were homogenates of lymphoid tissues and a single 
TRG. Previous bioassay studies have shown that infectivity levels in vCJD spleen 
and tonsil are significantly lower than those observed in brain (Bruce et al., 2001). In 
order to increase the sensitivity of the Western blot assay, an additional centrifugal 
concentration step was carried using the residual volume of each inoculum (Head et 
al., 2004b). Samples were run alongside an extract of tonsil from a non TSE-related 
neurodegenerative disorder and the same control tonsil sample spiked with a 1µl 
volume of the vCJD diagnostic reference standard. These samples were included as a 
positive control to confirm that PrPres can be recovered from tonsil tissue using the 
centrifugation procedure. The volume of inocula analysed from each source and the 


















CJD 10 sCJD SPL 200 -ve 
  BC n/t - 
CJD 11 sCJD BC n/t - 
  PL n/t - 
CJD 15 sCJD BC n/t - 
CJD 18 sCJD BC n/t - 
  PL n/t - 
CJD 31 vCJD SPL n/a - 
  TONS 50 -ve 
  BC n/t - 
  PL n/t - 
CJD 35 vCJD TONS 200 +ve 
  BC n/t - 
  PL n/t - 
CJD 36 vCJD BC n/t - 
  PL n/t - 
CJD 37 vCJD BC n/t - 
  PL n/t - 
CJD 38 vCJD APP 200 -ve 
  BM n/t - 
  CSF n/t - 
  DRG n/a - 
  LN n/a - 
  PN n/a - 
  SC n/a - 
  TRG 100 -ve 
CJD 39 vCJD APP n/a - 
  BM n/t - 
  DRG n/a - 
  LN n/a - 
  PN n/a - 
  SC n/a - 
  TRG n/a - 
CJD 40 vCJD APP 200 -ve 
  BM n/a - 
  CSF n/a - 
  DRG n/a - 
  LN n/a - 
  PN n/a - 
  SC n/a - 
  TRG n/a - 
 
APP – appendix,  BC – buffy coat,  BM – bone marrow,  CSF – cerebrospinal fluid,  DRG – dorsal 
root ganglia, LN – lymph node,  PL – plasma,  PN – peripheral nerve, SC – spinal cord,  SPL – 
spleen,  TONS – tonsil,  TRG – trigeminal ganglia  
 
n/a – not available for analysis 
n/t – not tested 
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PrPres was detected in only a single inoculum tested. This single extract originated 
from a 200µl sample of tonsil homogenate from a vCJD case (CJD 35). The resulting 
PrPres banding pattern of this tonsil extract was less intense than that of the 5µl vCJD 
brain standard (Figure 3.5), indicating that PrPres levels were more than 40 times 
lower in this vCJD tonsil tissue than those found in vCJD brain. Although the PrPres 
banding on the tonsil inocula extract was faint, the dominance of the diglycosylated 
fragment, which is characteristic of vCJD PrPres, was clearly observed. No detectable 
levels of PrPres were found following Western blot analysis of a 50µl tonsil extract 
from a second vCJD case (CJD 31). The remaining four inocula (sCJD spleen, vCJD 
appendix and vCJD TRG) analysed showed no detectable levels of PrPres by Western 
blot analysis under these conditions (Table 3.3)  
 
 
Figure 3.5: Western blot analyses of PrP
res
 in vCJD tonsil inocula  
 
Blot shows PrPres in an extract of inoculum (CJD 35) used in the experimental 
transmission to mice. This inoculum sample was prepared from tonsil tissue sampled 
from patient CJD 35. The inoculum was run alongside a vCJD (T2B) diagnostic 
reference standard, an extract of tonsil tissue taken from a patient with a non-TSE 
diagnosis (TC) and an extract of the same tonsil extract spiked with a 1µl vCJD of 
the vCJD diagnostic standard (TC*). Tissue extracts were PK digested and blots 
probed with the anti PrP antibody 6H4. Molecular weight markers (MW) are shown 
in kDa.     
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3.4 Results summary 
Determining the PrPres type of CJD brain inocula is fundamental to the interpretation 
of results from any transmission series. This study has confirmed; 
 
 PrPres was readily detected in all inocula prepared from sCJD and vCJD brain 
tissue 
 Western blot analysis confirmed the inoculation of brain inocula from all six 
subgroups of sCJD as classified according to PRNP codon 129 and PrPres type 
 Re-analysis of one of the sCJD inocula corrected the predominant PrP type 
from type 1 to predominantly type 2A. The brain in this case is now recognised 
as containing both PrPres types and has been sub-classified as MM1+2A  
 PrPres was detected in only one out of seven peripheral tissue homogenates 
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3.5 Discussion  
This chapter had two specific aims. Firstly, to confirm the presence of PrPres within 
tissue homogenates used in the inoculation of mice and secondly, to carry out PrPres 
isotyping on brain homogenates used in the experimental transmission series. Using 
conventional Western blot analysis techniques, PrPres was readily detected in all CJD 
brain homogenate analysed. Furthermore, PrPres typing of individual brain inocula 
confirmed the transmission of brain homogenate from all six possible subgroups of 
sCJD as classified according to the PRNP codon 129 genotype and PrPres type 
(Parchi et al., 1999). However, Western blot analysis on a limited number of 
peripheral neural and lymphoid tissue homogenates produced more variable results 
with only a single vCJD tonsil homogenate demonstrating detectable levels of PrPres. 
PrPres was not detected in three other vCJD lymphoid tissue homogenates or a single 
vCJD TRG homogenate, even though PrPSc deposition in these tissues had been 
confirmed after immunohistochemical analysis of paraffin fixed tissue sections. 
Furthermore, PrPres was not detected in any inocula prepared from sCJD spleen 
tissue. 
 
3.5.1 Infectivity levels within peripheral tissues 
Western blotting on extracts of CJD brain inocula used in the transmission series 
(Figure 3.2) demonstrated a more intense PrPres banding pattern when compared to 
that of the vCJD tonsil inocula (Figure 3.5), even though volumes of brain inocula 
tested were 40 times lower than that analysed in the tonsil extract. These 
observations are consistent with bioassay experiments which have indicated that 
infectivity levels in vCJD spleen and tonsil tissue are significantly lower than those 
demonstrated in vCJD brain (Bruce et al., 2001). 
 
The presence of readily detectable levels of PrPSc in peripheral tissues is not a 
general feature of sCJD (Head et al., 2004b). In this study, the sCJD spleen tissue 
sampled for transmission to mice had shown no evidence of PrPSc by 
immunohistochemical analysis for the prion protein. Therefore, the lack of any 
detectable PrPres in these tissue homogenates after Western blotting was not 
unexpected. In contrast, PrPSc had been demonstrated by immunohistochemistry in 
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all vCJD lymphoid tissues and peripheral neural tissues selected for transmission and 
so the lack of any detectable PrPres in four of the five tissue homogenates tested was 
somewhat surprising.  One possible explanation may be simply a sampling problem. 
In the preparation of inocula for transmission, all tissues were re-sampled, raising the 
possibility that infectivity was present in these tissues, but that the small samples 
taken had missed the major sites of PrPSc deposition, perhaps due to the 
heterogeneous distribution of PrPSc in these tissues. Another possible explanation for 
the lack of any detectable PrPres in the vCJD homogenate could lie with the 
sensitivity of the Western blot assay. It may be that PrPSc was present within the four 
tissue homogenates but at levels which are below the sensitivity of conventional 
Western blotting techniques, even after centrifugal concentration. This appears to be 
the most likely explanation as experimental challenge with the vCJD tonsil (CJD 31), 
TRG (CJD 38) and appendix (CJD 38) homogenates that had shown no detectable 
levels of PrPres after Western blotting; all produced either clinical and/or pathological 
evidence of a TSE in a proportion of mice challenged. This confirms the presence of 
infectivity in these tissue homogenates. However, a further explanation which cannot 
be discounted is that the long term storage of these tissue homogenates has resulted 
in the degradation or insolubility of PrPSc present in the inoculum samples. The 
results for the experimental challenge of different CJD tissue types are discussed in 
detail in chapter 6.   
 
3.5.2 Detection of PrP
Sc 
in peripheral tissues in CJD 
Conventional Western blotting on the different tissue inocula has demonstrated that 
this method is sufficiently sensitive to detect PrPres in post-mortem brain tissue from 
CJD patients at the end stage of disease. However, Western blotting is insufficiently 
sensitive for the reliable detection of PrPSc in lymphoid tissues and peripheral neural 
tissues when compared to bioassay in mice. Although sensitive, bioassay 
experiments are long and expensive and do not provide a practical solution for the 
routine detection of PrPSc in suspected cases of CJD or in the development of a 
diagnostic test for the presence of PrPSc in biological solutions such as blood and 
urine.  The recent development of techniques such as conformation dependant 
immunoassay (CDI) (Safar et al., 1998), sodium phosphotungstate (NaPTA) 
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precipitation (Safar et al., 1998; Wadsworth et al., 2001) and protein misfolding 
cyclic amplification (PMCA) (Saborio et al., 2001; Castilla et al., 2005) address 
these issues and have been developed specifically to increase the sensitivity of the 
assay. It would be interesting to see whether PrPSc can be detected in the vCJD tissue 
homogenates using any of these methods, thus allowing a direct comparison between 
these new innovative methods with that of traditional bioassay in mice.  
  
3.6 Chapter conclusion 
The characterisation of inocula used in the transmission study has demonstrated that 
Western blot analysis is a reliable and sensitive method for the detection and typing 
of PrPres in extracts of CJD brain homogenate and has largely confirmed the 
biochemical type of PrPres involved. However, the sensitivity of the Western blot 
assay may be below the limits for the detection of PrPres in lymphoid and peripheral 
neural tissues or the samples may no longer be suitable for this form of analysis. 
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Chapter 4: Characterisation of the sporadic Creutzfeldt-Jakob 
disease agent by transmission to wild-type mice 
 
4.1 Objective 
1. To characterise the sCJD agent strain after primary transmission of brain 
tissue in panels of wild-type type mice using the standard strain typing 
properties of incubation period and lesion profiling, plus a full analysis of PrP 
in the mouse brain and analysis of the PrPres molecular subtypes present. 




A number of distinct strains of scrapie in sheep have been identified following 
experimental transmission to inbred lines of mice. These strains are distinguished by 
the observation of simple disease characteristics, specifically incubation period and 
patterns of TSE-specific vacuolar pathology (“lesion profile”) in the brain after serial 
passage through inbred lines of mice. These same strain typing methods were 
instrumental in providing early evidence for the close similarity between the BSE 
agent and that of vCJD, while confirming that the vCJD agent represented a new 
human TSE distinct from that which causes sCJD (Bruce et al., 1997). However, it 
has yet to be established whether there are distinct strains of agent which are 
responsible for the phenotypic heterogeneity that is observed sCJD.  
 
According to the prion hypothesis, strain-specific biological properties are 
enciphered in the different conformations and glycosylation states of PrPSc (Collinge 
et al., 1996; Telling et al., 1996).  Molecular typing of PrPres in the brain of sCJD 
patients by Western blot analysis has shown that the abnormal protein can exist in 
different conformational states distinguished by differences in the extent of their N-
terminal truncation following partial protease digestion (Parchi et al., 1996; Hill et 
al., 2003). These different conformational states or PrPres types, in combination with 
the M/V polymorphism at codon 129 on the PRNP gene, have been proposed as the 
major determinants of the different clinico-pathological phenotypes in sCJD and 
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form the basis of two different classification systems for sCJD; that outlined by 
Collinge and co-workers (Collinge et al., 1996; Wadsworth et al., 1999a; Wadsworth 
et al., 1999b; Hill et al., 2003) and that of Parchi and Gambetti (Parchi et al., 1996; 
Parchi et al., 1997; Parchi et al., 1999; Hill et al., 2003). Both proposed classification 
systems are described in detail in Chapter 1, section 1.10.  
 
This thesis follows the classification system described by Parchi and Gambetti, in 
which two major PrPres types are identified in sCJD; type 1 where the molecular 
weight of the unglycosylated fragment is approximately 21kDa and type 2 with a 
molecular weight of the unglycosylated fragment of approximately 19kDa (Parchi et 
al., 1996; Parchi et al., 1999; Hill et al., 2003).  In this proposed classification 
system, six different subtypes of sCJD have been described based on differing 
clinico-pathological phenotypes (Parchi et al., 1999).  Each of these six phenotypic 
subtypes closely correlates with the different combinations of PRNP codon 129 
genotype and PrPres type. However, the question of whether these different sCJD 
subtypes relate to different TSE strains remains an unsubstantiated assumption.  
 
Molecular isotyping of PrPres is increasingly used as a surrogate marker for agent 
strain. In human TSEs, differences in PrPres type have been used as a diagnostic tool 
to distinguish sCJD from vCJD (Collinge et al., 1996).  In their original study on the 
classification of sCJD, Parchi and Gambetti reported the co-occurrence of PrPres 
types 1 and type 2 in the brain in around 5% of  sCJD cases examined (Parchi et al., 
1999). Several studies have since concurred with Parchi and Gambetti’s findings and 
estimate that co-occurrence of PrPres types is a feature of between 5% and 30% of 
sCJD cases (Collinge et al., 1996; Puoti et al., 1999; Kovacs et al., 2002a; Hill et al., 
2003; Haik et al., 2004; Head et al., 2004a; Schoch et al., 2006; Uro-Coste et al., 
2008). In contrast, two studies using monoclonal antibodies specifically raised 
against PrPres type 1 suggest that the co-occurrence of PrPres types in sCJD cases is 
underestimated and is much higher than initially thought (Polymenidou et al., 2005; 
Yull et al., 2006; Yull et al., 2009). Regardless of the percentage of sCJD in which 
there is the co-occurrence of PrPres types, this feature of sCJD has cast some doubt 
over the validity of molecular classification of sCJD and the relationship between 
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PrPres types and molecular strain. More recently the question of whether the co-
occurrence of PrPres type 1 and type 2 in the brain of sCJD cases results in a distinct 
phenotype has caused the original classification system for sCJD to be re-addressed 
creating additional sCJD clinico-pathological subtypes in the 30-40% of cases that 
show some degree of co-occurrence (Parchi et al., 2009; Cali et al., 2009). This thesis 
predates this proposed re-classification of sCJD and has addressed the co-occurrence 
issue in the form of direct testing of inocula for their PrPres type rather than relying 
on homogeneity throughout the brain (see chapter 3)      
 
This particular chapter addresses the question of whether distinct isolates or TSE 
strains are present within sCJD. The vast majority of information on the sCJD agent 
has come from the transmission of sCJD in numerous transgenic mouse lines over 
expressing human PrP or in chimeric human-mouse PrP mice  (Telling et al., 1994; 
Korth et al., 2003; Taguchi et al., 2003; Asante et al., 2006; Kobayashi et al., 2007; 
Wadsworth et al., 2008; Bishop et al., 2010). Transmission of sCJD into bank voles 
has also provided a valuable insight into the existence of different sCJD strains 
(Nonno et al., 2006). However, at present it remains that strain typing is most highly 
developed using transmission into panels of non-transgenic (wild-type) mice. 
Previous studies examining the transmission properties of sCJD to wild-type mice 
suggested that a full characterisation of the sCJD agent is hampered by the ‘species 
barrier’ effect between the donor and recipient (Brown et al., 1994; Bruce et al., 
1997). A limitation of these studies is that a full and direct comparison of the strain 
typing properties of the sCJD agent present in each of the six sCJD subtypes as 
classified according to Parchi’s 1999 classification system has not been examined. In 
response to this, this chapter provides a full and direct characterisation of the sCJD 
agent following inoculation of panels of wild-type mice with brain homogenates 
from sCJD cases of all six possible combinations of PRNP codon 129 genotype and 
PrPres type. As a result of the findings from studies on the co-occurrence of PrPres 
types in sCJD, an important aspect in the accurate interpretation of results from this 
transmission series was to establish the actual PrPres type in the homogenate used to 
inoculate the mice. Therefore, Western blot analysis on inocula from each sCJD 
source was carried out as described in detail in chapter 3. 
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Results from these primary transmissions will directly test the relationship between 
the biochemical properties of the prion protein (PrPres type) and M/V polymorphism 
at codon 129 with the biological properties of the agent (i.e. strain). Consequently, 
the results can be used to question whether the clinico-pathological phenotypes in 
sCJD as described by Parchi and Gambetti do indeed correlate with distinct strains of 
TSE agent.  
 
4.3 Experimental results: Primary transmissions 
Brain homogenates from 27 cases of clinically and neuropathologically confirmed 
sCJD (Chapter 2, Table 2.1; CJD 1 – CJD 27) were experimentally inoculated into 
panels of wild-type mice (RIII, C57BL, VM and C57BL x VM). Brain homogenates 
were prepared from all six possible combinations of PRNP codon 129 genotype and 
PrPres type (type 1 or type 2A). Throughout this thesis, the term “subgroup” is used in 
reference to sCJD cases classified according to their PRNP codon 129 
genotype/PrPres type combination. The term “subtype” refers to the classification of 
sCJD cases according to their clinical and pathological features as described by 
Parchi and Gambetti (Parchi et al., 1999).  Brain homogenates from 25 of the sCJD 
cases were prepared from grey matter tissue of the frontal cortex, with the remaining 
two brain homogenates prepared from tissue taken from the cerebellar hemisphere.  
Inoculations were carried out either via a single IC injection or a combination of the 
IC and IP routes. Brain region used in inoculum preparation, inoculation routes and 
mouse lines challenged for each sCJD brain isolate are detailed in Chapter 2, Table 
2.3. 
 
4.3.1 Incubation periods and incidence of disease 
In any transmission experiment, intercurrent illness and death reduces the numbers of 
mice available for strain typing analysis. In this transmission series, only mice 
surviving over 250dpi were included in the analysis. Mean incubation periods were 
drawn from experimental groups with at least five mice that had received a positive 
score for clinical signs of disease, with disease confirmed histologically having 
received a positive score for the presence of TSE-associated vacuolar degeneration in 
the brain.  
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4.3.1.1 sCJD MM1 subgroup 
Ten transmission experiments were carried out with brain tissue from 10 patients 
who were homozygous for methionine at codon 129 of the PRNP gene and who were 
confirmed as a having a PrPres type 1 after Western blot analysis of the inocula. Table 
4.1 details the incidence of clinical signs of disease and vacuolar pathology in each 
experimental group. Clinical signs of a neurological disease in mice challenged with 
brain homogenate from sCJD MM1 cases were rare. Only 12 mice (eight C57BL 
mice and four VM mice) from the 580 surviving over 250dpi received a positive 
score for clinical signs of TSE disease, with disease confirmed by the presence of 
vacuolar degeneration typical of TSE infection seen in the brains of the mice at post-
mortem (Table 4.1). All mice that developed clinical signs of a TSE had lengthy 
incubation periods of over 650 days. A few mice (4/580) received a positive score for 
clinical signs of TSE disease but had a negative score for vacuolar pathology after 
histological analysis (Table 4.1). Assessing clinical signs of a TSE in mice is 
challenging and involves a great deal of training. Nevertheless in such an extensive 
transmission series as this it is not unexpected to encounter a small number of mice 
scored as positive for clinical signs of disease but which are then found to be 
negative for TSE pathology. This is, particularly true for very old mice. While the 
reason for the discordance between clinical signs and pathological confirmation 
cannot be known with certainty, it is the working assumption of this thesis that the 
neuropathological assessment is definitive and that in these few examples the 
positive clinical signs are either in doubt or indicative of an unrelated illness or 
ageing.    
  
The lack of any clinical signs of neurological disease in the majority of mice does not 
however indicate a failure to transmit sCJD from the MM1 brain homogenates, as 
vacuolar degeneration was observed in the brains of 424 out of 580 mice of mice 
dying with intercurrent disease (Table 4.1). A full analysis of the vacuolation in the 
mouse brain will be discussed in detail in section 4.3.2. No clinical signs of disease 
or vacuolar degeneration were found in the control mice of any age in this series of 
transmissions (data not shown). 
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Table 4.1: Primary transmission of sCJD MM1 brain homogenate 
 
Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice challenged 
with brain tissue from ten sporadic CJD cases, homozygous for methionine at codon 129 of 
the PRNP gene with a PrPres type 1. Mice sacrificed with intercurrent disease before 250 dpi 
were excluded from the analysis.  In mice with a positive score for clinical signs of a TSE 
and a negative score for vacuolar pathology, the neuropathological assessment is considered 
definitive. 
 
                                                          Mouse line 
 
C57BL RIII VM C57BL x VM 
















    
5/9 0/13 11/13 0/16 14/16 0/17 12/17 
*CJD 3  
 
0/12 
   
4/12 0/9 5/9 0/16 15/16 0/15 13/15 
*CJD 4 
 
1/9 (path –ve) 
   









    
8/15 0/14 9/14 0/14 11/14 0/15 10/15 
 
*CJD 7  
 
4/24 (833, 834, 
 864, path –ve) 




    
12/12 0/15 15/15 0/22 22/22 0/16 15/16 
*CJD 9 
 































* Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from frontal cortex tissue 
† Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from cerebellar cortex tissue 
‡ Intracerebral injection with 10% brain inoculum prepared from frontal cortex tissue 
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4.3.1.2 sCJD MV1 subgroup 
Three transmission experiments were carried out with brain tissue from three patients 
who were heterozygous for methionine and valine at codon 129 of the PRNP gene 
and who were confirmed as having a PrPres type 1 after Western blot analysis of the 
inocula. Table 4.2 details the incidence of clinical signs of disease and vacuolar 
pathology in each experimental group. No clinical signs of neurological disease 
related to a TSE were confirmed in the mice (clinical signs were observed in a single 
RIII mouse but histological analysis of the brain failed to show the presence of 
vacuolar degeneration).  Therefore, incubation period was not a relevant parameter in 
the strain typing analyses of sCJD MV1 brain homogenate.  As found with sCJD 
MM1 brain homogenate, the absence of clinical signs in the sCJD MV1 inoculated 
mice does not indicate a failure to transmit disease, as vacuolar degeneration was 
observed in the brains of 109 out of 166 inoculated mice (Table 4.2). No clinical 
signs of disease or vacuolar degeneration were found in the control mice of any age 
in this series of transmissions (data not shown). 
 
4.3.1.3 sCJD VV1 subgroup 
Inoculation of brain homogenate from four patients who were homozygous for valine 
at codon 129 of the PRNP gene and who were confirmed as having a PrPres type 1 
after Western blot analysis of the residual inocula was carried out in the mouse panel. 
Table 4.3 details the incidence of clinical signs of disease and vacuolar pathology in 
each experimental group. No clinical signs of neurological disease related to a TSE 
were confirmed in the mice (clinical signs were observed in a single RIII mouse but 
histological analysis failed to show the presence of vacuolar degeneration).  
Therefore, incubation period was not a relevant parameter in the strain typing 
analyses of sCJD VV1 brain homogenates.   In contrast to transmissions from sCJD 
MM1 and sCJD MV1 brain homogenate, histological examination of the mouse 
brain showed vacuolar degeneration associated with TSE infection was rare, even in 
mice surviving over 800 days after challenge. Only a single C57BL x VM mouse 
produced vacuolar pathology (survival time 915 days after challenge) (Table 4.3). 
This clinical and histological data suggests that transmission of sCJD from the VV1 
subgroup is rare in wild-type mice. 
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Table 4.2: Primary transmission of sCJD MV1 brain homogenate 
 
Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice challenged 
with brain tissue from three sporadic CJD cases, heterozygous for methionine and valine at 
codon 129 of the PRNP gene with a PrPres type 1. Mice sacrificed with intercurrent disease 
before 250 dpi were excluded from the analysis. In mice with a positive score for clinical 
signs of a TSE and a negative score for vacuolar pathology, the neuropathological 




C57BL RIII VM C57BL x VM 









*CJD 13  0/11 6/11 0/15 10/15 0/21 19/21 0/17 15/17 




    
nd 0/15 11/15 0/17 12/17 nd nd 
*  Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from frontal cortex tissue 
†  Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from cerebellar cortex tissue 




Table 4.3: Primary transmission of sCJD VV1 brain homogenate 
 
Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice challenged 
with brain tissue from four sporadic CJD cases, homozygous for valine at codon 129 of the 
PRNP gene with a PrPres type 1. Mice sacrificed with intercurrent disease before 250 dpi 
were excluded from the analysis. In mice with a positive score for clinical signs of a TSE 





C57BL RIII VM C57BL x VM 









Clin Vac path 
*CJD 19  0/18 0/18 
1/22 (path –
ve) 
0/22 0/26 0/26 0/30 0/30 
‡CJD 20 0/17 0/17 0/23 0/23 0/22 0/22 0/19 0/19 




    
0/14 nd nd nd nd nd nd 
*  Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from frontal cortex tissue 
‡  Intracerebral  injection with 10% brain inoculum prepared from frontal cortex tissue 
nd Not done 
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4.3.1.4 sCJD MM2A subgroup 
Inoculation of brain homogenate from two sCJD patients who were homozygous for 
methionine at codon 129 of the PRNP gene and who were confirmed as having a 
PrPres type 2 after Western blot analysis of inocula was carried out in the mouse 
panel. Table 4.4 details the incidence of clinical and pathological signs in each 
experimental group. In contrast to all other sCJD subgroups investigated, seven out 
of 19 RIII mice inoculated with brain homogenate from one MM2 case (patient CJD 
12) were sacrificed with clinical TSE disease, allowing a mean incubation period of 
736 ± 9 days to be calculated for this experimental group. The development of 
clinical TSE disease in this RIII group distinguishes this sCJD MM2 case from the 
other 26 sCJD cases examined. Clinical TSE disease was not observed in any other 
mouse line following inoculation with the same CJD isolate. In contrast, inoculation 
of brain homogenate from a second sCJD MM2 case (patient CJD 11) showed no 
clinical TSE disease in any of the mice inoculated (clinical signs were observed in a 
single RIII mouse but histological analysis showed no evidence of vacuolar 
pathology). Such differences in the efficiency of transmission between these two 
sCJD MM2 brain homogenates may be indicative of differences in infectious titres 
between the two inocula. Alternatively, it may also be that in the primary 
transmission of brain homogenate from sCJD MM2, the IP route is more efficient 
that the IC route. Although somewhat surprising, this has been shown previously in 
the primary transmission of BSE (Bruce et al., 1994). Regardless of the differences 
between the inoculum, these experiments have shown that transmission of a TSE 
from sCJD MM2 brain homogenate, as judged by clinical and vacuolar pathology 
does occur. These findings also suggest that there may be subtle differences in the 
transmission properties of the sCJD MM2 subgroups compared to the other sCJD 
subgroups which can be distinguished after transmission in the RIII mouse line. 
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Table 4.4: Primary transmission of sCJD MM2A brain homogenate 
 
Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice challenged 
with brain tissue from two sporadic CJD cases, homozygous for methionine at codon 129 of 
the PRNP gene with a PrPres type 2. Mice sacrificed with intercurrent disease before 250 dpi 
were excluded from the analysis. Mean incubation periods in days are shown in brackets ± 
S.E.M. In mice with a positive score for clinical signs of a TSE and a negative score for 























nd 7/19 (736 ± 9) 12/19 0/20 2/20 0/14 4/14 
 
*  Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from frontal cortex tissue 
‡  Intracerebral injection with 10% brain inoculum prepared from  frontal cortex tissue 
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4.3.1.5 sCJD MV2A subgroup 
Inoculations were carried out with brain tissue from three patients who were 
heterozygous for methionine and valine at codon 129 of the PRNP gene and who 
were confirmed as having a PrPres type 2A after Western blot analysis of the brain 
homogenate. Table 4.5 details the incidence of clinical and pathological signs in each 
experimental group. No clinical signs of neurological disease related to a TSE were 
observed in the mice (clinical signs were observed in two RIII mice but histological 
analysis showed no evidence of vacuolar pathology). Therefore incubation period is 
not a relevant parameter in the strain typing analyses of sCJD from MV2 cases.   As 
found with inoculations from sCJD VV1 brain homogenates, TSE associated 
vacuolar degeneration in the brain was rare, with only a single RIII mouse producing 
vacuolar pathology with a survival time of 711 days after challenge (Table 4.5). This 
data suggests that transmission of sCJD from the MV2 subgroup is a rare occurrence. 
No clinical signs of disease or vacuolar degeneration were found in the control mice 
of any age in this series of transmissions. 
 
4.3.1.6 sCJD VV2A subgroup 
Transmission of brain homogenate from five sCJD cases in which patients were 
homozygous for valine at codon 129 of the PRNP gene and who were confirmed as 
having a PrPres type 2A after Western blot analysis of the inocula were carried out in 
the mouse panel. Table 4.6 details the incidence of clinical and pathological signs in 
each experimental group. No clinical signs of neurological disease related to a TSE 
were observed in the mice; therefore, incubation period is not a relevant parameter in 
the strain typing analyses of sCJD from the VV2 subgroup (clinical signs were 
observed in four mice; however, histological analysis failed to confirm a TSE).  
Vacuolar pathology in the mice was rare with only a single C57BL mouse showing 
vacuolar pathology with a survival time of 845 days after challenge (Table 4.6). 
These results suggest that successful transmission of TSE disease from the sCJD 
VV2 subgroup is rare.  
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Table 4.5: Primary transmission of sCJD MV2A brain homogenate 
 
Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice challenged 
with brain tissue from three sporadic CJD cases, heterozygous for methionine and valine at 
codon 129 of the PRNP gene with a PrPres type 2. Mice sacrificed with intercurrent disease 
before 250 dpi were excluded from the analysis. In mice with a positive score for clinical 
signs of a TSE and a negative score for vacuolar pathology, the neuropathological 




C57BL RIII VM C57BL x VM 
Source      Clin 
Vac 
path 






*CJD 16  0/20 0/20 0/21 1/21 0/20 0/20 0/19 0/19 





nd 2/7 (path –ve) 0/7 nd nd nd nd 
*  Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from frontal cortex tissue 
‡  Intracerebral injection with 10% brain inoculum prepared from frontal cortex tissue 




Table 4.6: Primary transmission of sCJD VV2A brain homogenate 
 
Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice challenged 
with brain tissue from five sporadic CJD cases, homozygous for valine at codon 129 of the 
PRNP gene with a PrPres type 2. Mice sacrificed with intercurrent disease before 250 dpi 
were excluded from the analysis. In mice with a positive score for clinical signs of a TSE 





C57BL RIII VM C57BL x VM 









Clin Vac path 
*CJD 23  0/18 1/18 0/21 0/21 2/23 (path –ve) 0/23 0/23 0/23 
*CJD 24 0/5 0/5 0/14 0/14 0/2 0/2 0/6 0/6 
*CJD 25 2/22 (path –ve) 0/22 0/24 0/24 0/23 0/23 0/20 0/20 
*CJD 26 0/22 0/22 0/24 0/24 0/23 0/23 0/19 0/19 
*CJD 27 0/16 0/16 0/8 0/8 0/18 0/18 0/10 0/10 
* Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from frontal cortex tissue 
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4.3.2 Patterns of vacuolar pathology- lesion profiles 
The presence of vacuolar degeneration, typical of TSE infection within the mouse 
brain is required for the positive confirmation of the successful transmission of TSE 
isolates in mice, even in mice which have received a positive score for clinical signs 
of disease.  When combined with incubation period patterns in different mouse 
genotypes, the lesion profile produces a “signature” of the biological agent, which 
can be used to characterise the TSE strain present in an isolate from a naturally 
infected host. The lesion profiling and its contribution as a strain typing parameter in 
TSE disease is described in detail in Chapter 1.  
 
In the transmission of brain homogenate from all six sCJD subgroups into the mouse 
panel, clinical signs of a neurological disease consistent with a TSE in mice were 
rare (Table 4.1 – 4.6). However, this did not indicate a failure to transmit sCJD, as 
vacuolar degeneration typical of TSE disease was seen in the brains of a proportion 
of the mice dying with intercurrent illness (Table 4.1 – 4.6). Histological 
examination of the brains of all inoculated mice was carried out blind to the 
experimental details, the mouse line and the sCJD subgroup from which the 
inoculum was prepared. Scoring of vacuolar changes in the mouse brain and 
construction of the lesion profiles were carried out as described in chapter 2, section 
2.6.3. Traditionally, lesion profiles are constructed from mice sacrificed at the 
clinical end-point of disease in which mice have received a positive score for clinical 
signs of a TSE and where disease was confirmed histologically. In these 
investigations on the transmission of sCJD, in the lack of mice sacrificed with signs 
of clinical TSE disease, lesion profiles were constructed from animals which had 
received a positive score for vacuolar degeneration in the brain and sacrificed with 
either intercurrent illness or at the full life span of the mouse. 
 
TSE-specific vacuolation was most prominent in mice inoculated with brain 
homogenate from the sCJD MM1 (Table 4.1), MV1 (Table 4.2) and MM2 (Table 
4.4) subgroups (Figure 4.1), with sufficient mice having receiving a positive score 
for vacuolar pathology for the construction of a lesion profile.  In contrast, as only a 
single mouse challenged with brain homogenate from the sCJD MV2 (Table 4.5), 
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VV1 (Table 4.3) and VV2 (Table 4.6) subgroups received a positive score for TSE-
specific vacuolation; there were insufficient mice available for the construction of a 
lesion profile. Lesion profiling is therefore not a relevant parameter in the strain 
typing of sCJD from MV2, VV1 and VV2 cases. Although it is not possible to 
compare the single mouse profiles from the sCJD MV2, VV1 and VV2 challenged 
mice, it is worth noting that analysis of these single mouse profiles showed a pattern 
and intensity of vacuolation consistent to that observed in mice inoculated with sCJD 
MM1 and MV1 brain homogenate.  In particular this is characterised by a peak in the 
intensity of vacuolation in the superior colliculus (G3). Lesion profile data for the 
MM1, MV1 and MM2 subgroups of sCJD are detailed in the following sections.  
                                                                                   
 111 
 
Figure 4.1: TSE-specific vacuolar pathology in sCJD inoculated mice 
 
Bar graph showing the percentage of mice receiving a positive score for TSE-
specific vacuolar pathology following histological analysis of the brain. Results 
shown are the combined results from the individual brain homogenate from each 
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4.3.2.1 sCJD MM1 subgroup 
All but three experimental groups (C57BL mice inoculated with CJD 3, C57BL mice 
inoculated with CJD 5, RIII mice inoculated with CJD 10) had sufficient mice 
scoring positive for TSE-specific vacuolation in the brain for the construction of a 
lesion profile. Mean lesion profiles in each mouse line are shown in Figure 4.2.  
Overall, patterns of vacuolar pathology were remarkably similar between individual 
sCJD cases and between the different mouse Prn-p genotypes, regardless of brain 
region used in the inoculation or route of injection. There was some variability in the 
severity of vacuolation between individual sCJD brain homogenates, most notable in 
the VM mouse line; however the general pattern of vacuolation was similar. Lesion 
profiles are characterised by a distinct and consistent peak of mild-to-moderate 
vacuolation targeting the superior colliculus (brain scoring region G3).  Vacuolation, 
although less severe, is also prominent in the thalamus (scoring region G5) and the 
cerebral cortex (scoring region G8 and G9). Although these profiles are not based on 
mice at clinical end-point of disease, they clearly show a similarity in the lesion 
profile between the 10 sCJD MM1 brain homogenates and between the different 
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Figure 4.2: Lesion profiles for sCJD MM1 inoculated mice 
 
Lesion profiles are constructed for groups in which there was a minimum of five 
mice with a positive score for TSE associated vacuolar pathology. Vacuolation was 
scored at nine specified grey (G) matter regions and three white (W) matter regions 
of the mouse brain. Lesion profiles are shown with standard error bars (± S.E.M). 
Each line represents a different sCJD MM1 case. (black line) brain homogenate 
prepared from frontal cortex tissue, (red line) brain homogenate prepared from the 
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4.3.2.2 sCJD MV1 subgroup 
Sufficient mice receiving a positive score for the presence of TSE-specific 
vacuolation in the brain were available in all experimental groups inoculated with 
sCJD MV1 brain homogenate for the construction of a lesion profile (Figure 4.3).  
As observed in sCJD MM1 inoculated mice, there was a consistent targeting of mild-
moderate vacuolation in the superior colliculus (brain scoring region G3) in all four 
mouse lines. Differences in the severity of vacuolation were observed between the 
RIII, C57BL and C57BL x VM mouse lines between scoring regions G5 (thalamus) 
and G9 (cerebral cortex); however, the general pattern of vacuolation was similar in 
these three mouse lines. Subtle differences in the pattern of vacuolar pathology were 
observed in the VM mice, most obviously in the thalamus region (brain scoring 
region G5) where there was no obvious peak in vacuolar degeneration compared to 
the other mouse lines.  The brain region used in inoculation and route of inoculation 
had no observable effect on the targeting of vacuolar pathology. These lesion profiles 
are not based on mice at the clinical end-point of disease; therefore, some variation in 
vacuolar degeneration would be expected from mice sacrificed at different stages in 
the disease progression. However, they clearly show a similarity in lesion 
distribution between the three MV1 brain homogenates and show that minor 
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Figure 4.3: Lesion profiles for sCJD MV1 inoculated mice 
 
Lesion profiles are constructed for groups in which there was a minimum of five 
mice with a positive score for TSE associated vacuolar pathology. Vacuolation was 
scored at nine specified grey (G) matter regions and three white (W) matter regions 
of the mouse brain. Lesion profiles are shown with standard error bars (± S.E.M). 
Each line represents a different sCJD MV1 case. (black line) brain homogenate 
prepared from frontal cortex tissue, (red line) brain homogenate prepared from the 
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4.3.2.3 sCJD MM2A subgroup 
In mice inoculated with brain homogenate from two sCJD MM2 cases, only a single 
experimental group (RIII mice inoculated with CJD 12) produced sufficient mice 
with a positive score for TSE-specific vacuolation for the construction of a reliable 
lesion profile (Table 4.4). Furthermore, the development of clinical TSE disease in a 
proportion of RIII mice has allowed a lesion profile to be constructed from the seven 
mice displaying both clinical and pathological signs of a TSE (Figure 4.4a). 
However, it is difficult to draw any conclusions regarding the agent strain in sCJD 
when comparing lesion profiles constructed from mice at clinical end-point with 
those of mice sacrificed for other reasons. Therefore, a lesion profile was also 
constructed from the five RIII mice which had received a positive score for TSE-
specific vacuolar pathology, but had a negative score for clinical signs of disease 
(Figure 4.4a). This allows a direct comparison between lesion profiles in RIII mice 
challenged with brain homogenate from the sCJD MM1, MV1 and MM2 subgroups. 
Patterns of vacuolar pathology were remarkably similar between RIII mice sacrificed 
at the clinical end-point of disease and those sacrificed with intercurrent illness or at 
their full life span (Figure 4.4a). Unsurprisingly, severity of vacuolation appeared 
higher in mice sacrificed with clinical TSE disease. Both lesion profiles showed 
subtle differences from those of RIII mice inoculated with sCJD MM1 (Figure 4.2) 
and MV1 brain homogenates (Figure 4.2), with a more widespread grey matter 
vacuolation involvement of the hippocampal region (G6) and the septum (G7). 
Although based on a single lesion profile, this may be indicative of subtle differences 
in the transmission properties of this sCJD MM2 case and other sCJD subgroups. 
 
Differences were found in the clinical signs and in the proportion of mice showing 
vacuolar pathology between the two sCJD MM2 brain homogenates in the RIII 
mouse line. To determine whether these differences were reflected in the pattern of 
vacuolar degeneration in this mouse line, a lesion profile was constructed from the 
three RIII mice showing vacuolar degeneration following inoculation with brain 
homogenate from CJD 11 (Figure 4.4b). Although based on only three mice, pattern 
of vacuolar degeneration was similar to that observed with the MM1/MV1 brain 
isolates; however, the severity of vacuolar degeneration was lower. This is further 
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evidence that there are differences in the transmission properties of these two sCJD 
MM2 brain homogenates. 
 
Figure 4.4: Lesion profiles for sCJD MM2A inoculated mice 
 
(a) Lesion profile constructed from seven RIII mice with a positive score for clinical 
TSE disease and TSE-specific vacuolar pathology following challenge with brain 
homogenate from patient CJD 12 (solid line). Lesion profile constructed from five 
RIII mice with a positive score for TSE-specific vacuolar pathology with no signs of 
clinical disease following challenge with brain homogenate from patient CJD 12 
(dotted line). (b) Lesion profile constructed from three RIII mice with a positive 
score for TSE-specific vacuolar pathology with no signs of clinical disease following 
challenge with brain homogenate from patient CJD 11. Lesion profiles are shown 
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4.3.3 Deposition of PrP in the mouse brain 
Different TSE isolates often show different patterns of PrP deposition in the brain 
following transmission to mice of the same Prn-p genotype.  When combined with 
incubation period data and lesion profile analysis, patterns of PrP deposition in the 
mouse brain can provide valuable information on agent strain (Bruce et al., 1989; 
Hecker et al., 1992; DeArmond et al., 1993).  In these investigations, histological 
analysis of the mouse brain confirmed that all sCJD subgroups can transmit to wild-
type mice, but with varying degrees of success. In the sCJD MM1, MV1 and MM2 
subgroups, which transmit disease most successfully, not all inoculated mice showed 
TSE-associated vacuolar degeneration in the brain. Therefore, when selecting an 
immunohistochemical method for the detection of PrP in the brains of mice, the 
highly sensitive Catalyzed Signal Amplification System (CSA) was chosen in order 
to maximise the assay (Chapter 2, section 2.6.4.).  Due to the similarity in the lesion 
profiles between different mouse lines, only two mouse lines were examined by 
immunohistochemistry; RIII from the Prn-pa genotype and VM from the Prn-pb 
genotype. Immunohistochemistry was carried out on 5µm formalin fixed, formic acid 
treated, brain sections from mice challenged with a minimum of two different brain 
homogenates from each sCJD subgroup. In each experiment, seven mice of each 
mouse line were analysed; five inoculated with CJD brain homogenate and two 
saline injected controls (where available). In the selection of CJD inoculated mice for 
immunohistochemical analysis, mice which had received a positive score for 
vacuolar pathology or if these were not available, mice which had the longest 
survival time were analysed.  In addition, the C57BL mouse and C57BL x VM 
mouse which had shown evidence of vacuolar degeneration in the brain following 
inoculation with a sCJD VV2 (CJD 23) and VV1 (CJD 21) isolate were also 
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Table 4.7: Deposition of PrP in sCJD inoculated mice 
 
 
* Groups of mice all scoring positive for TSE vacuolar degeneration 
† Groups of mice all with a negative score for TSE vacuolar degeneration 
‡ 2 mice scored positive for PrP deposition in the absence of vacuolar degeneration  
§ 2 mice scored positive for vacuolar degeneration 
 
                                                                                      Mouse line 
        CJD inoculated 
 
    Saline inoculated 
Source of  brain inocula Case RIII VM RIII VM 
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PrP deposition was observed in both the RIII and VM mice after inoculation of brain 
homogenate from the sCJD MM1, MV1 and MM2 cases, further confirming the 
successful transmission of a TSE from these subgroups. In contrast, PrP deposition 
was not detected in any mouse following challenge with brain homogenate from 
sCJD VV1, MV2 or VV2 cases. This includes the three mice which had shown a 
positive score for vacuolar pathology in the brain. The patterns of PrP accumulation 
in the sCJD MM1, MM2 and MV1 challenged mice are detailed below. Coronal 
sections of the mouse brain at the four levels analysed as a reference to the major 
anatomical regions of the brain associated with the deposition of PrP following 
challenge with sCJD subgroups are shown in Figure 4.5. All saline injected controls 
were negative for the presence of PrP. 
 
 
Figure 4.5: Diagrammatic representation of the mouse brain 
 
Diagrammatic representation of the four coronal levels used in the histological and 
immunohistological examination for TSE-related pathology in the mouse brain. 
Brain regions associated with the targeting of PrP pathology following experimental 
challenge with sCJD brain homogenate are highlighted in green and labelled. 
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4.3.3.1 sCJD MM1 subgroup 
All mice analysed by immunohistochemistry following inoculation with sCJD MM1 
brain homogenate had received a positive score for the presence of vacuolar 
degeneration in the brain. Immunohistochemistry showed PrP deposition in almost 
all mice tested (Table 4.7). Overall, PrP pathology was limited in the mice analysed. 
Faint granular deposits of PrP were consistently found targeting the dorsal lateral 
geniculate nucleus (dLGN), the medial habenular nucleus (MHb), the vestibular 
nucleus of the medulla and to a lesser extent the  arcuate hypothalamic nucleus 
(ArcH) (Figure 4.6a -h). The deposition of PrP in the brains did not always correlate 
with the areas of most intense vacuolar pathology; however, PrP accumulation was 
observed in the superior colliculus and the cerebral cortex, regions of the brain 
associated with the most severe vacuolar pathology, in a few mice (Figure 4.7a and 
b). Amyloid plaques, a characteristic feature of certain sCJD subtypes, were 
observed in a single VM mouse analysed (Figure 4.7c and d).  Although PrP 
pathology was limited in the mice, targeting of PrP accumulation was remarkably 
similar between the different mouse Prn-p genotypes and between mice inoculated 
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Figure 4.6: PrP deposition in sCJD MM1 inoculated mice 
 
Fine granular deposits of PrP targeting the dorsal lateral geniculate nucleus (dLGN) 
in (a) RIII and (b) VM mice. Faint granular deposits of PrP within the medial 
habenular nucleus (MHb) in (c) RIII and (d) VM mice. Small focal deposits of PrP 
targeting the arcuate hypothalamic nucleus (ArcH) in (e) RIII and (f) VM mice. 
Granular accumulation of PrP accumulation in the vestibular nucleus of the medulla 
in (g) RIII and (h) VM mice. Sections shown were labelled with the monoclonal anti-
PrP antibody 6H4 in combination with the CSA detection method, visualised with 
DAB and counterstained with haematoxylin. Original magnification; x200 (a, b, e, f, 
g, h), x400 (c, d). 
                                                                                   
 123 
Figure 4.7: Further accumulations of PrP in sCJD MM1 inoculated mice 
 
Fine granular deposits of PrP in (a) the superior colliculus and (b) the cerebral cortex 
in RIII mice. (c) Haematoxylin and eosin staining showing the presence of an 
amyloid plaque (arrow) within the corpus callosum of a VM mouse. (d) serial section 
from the same mouse immunolabelled for PrP. Sections shown were labelled with 
the anti-PrP antibody 6H4 in combination with the CSA detection method, visualised 
with DAB and counterstained with haematoxylin. Original magnification; x200 (a, 
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4.3.3.2 sCJD MV1 subgroup 
All mice examined following challenge with MV1 brain homogenate had received a 
positive score for the presence of vacuolar degeneration in the brain. 
Immunohistochemical staining showed PrP deposition in the majority of mice tested 
(Table 4.7). The general targeting of PrP pathology was remarkably similar to that 
found in mice inoculated with sCJD MM1 brain homogenate, with localised deposits 
of faint granular PrP staining in the dLGN, MHb, ArcH and the vestibular nucleus of 
the medulla (Figure 4.8a-h). Occasional deposits of PrP were also observed in the 
superior colliculus, the cerebral cortex and the thalamus (Figure 4.9a-c). Staining 
patterns in the mouse brain were similar between the different mouse Prn-p 
genotypes (Figure 4.8) and between brain homogenate from different MV1 cases.  
Amyloid plaques were a common feature in the mice following challenge with sCJD 
MV1 brain isolates. This differs from the pattern in the MM1 transmissions where 
amyloid plaques were only observed in the VM mice (Figure 4.7d). Although 
observed in both the RIII and VM mice, these plaques were a more prominent feature 
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Figure 4.8: PrP deposition in sCJD MV1 inoculated mice 
 
Granular deposits of PrP targeting the dorsal lateral geniculate nucleus (dLGN) in (a) 
RIII and (b) VM mice. Faint granular deposits of PrP within the medial habenular 
nucleus (MHb) in (c) RIII and (d) VM mice. Small focal deposits of PrP targeting 
the arcuate hypothalamic nucleus (ArcH) in (e) RIII and (f) VM mice. Granular 
deposition of PrP in the reticular nucleus of the medulla in (g) RIII and (h) VM mice. 
Sections shown were labelled with the anti-PrP antibody 6H4 in combination with 
the CSA detection method, visualised with DAB and counterstained with 
haematoxylin. Original magnification; x100(c, d), x200 (a, e, f, g, h), x400 (b). 
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Figure 4.9: Further accumulations of PrP in sCJD MV1 inoculated mice 
 
Fine granular deposits of PrP throughout the (a) superior colliculus and (b) cerebral 
cortex in RIII mice. (c) Granular deposition of PrP throughout the thalamus in a VM 
mouse. (d) Section of a VM mouse brain immunolabelled for PrP showing the 
presence of amyloid plaques within the corpus callosum. Sections shown were 
labelled with the anti-PrP antibody 6H4 in combination with the CSA detection 
method, visualised with DAB and counterstained with haematoxylin. Original 










                                                                                   
 127 
4.3.3.3 sCJD MM2A subgroup 
Consistent with other strain typing parameters, subtle differences were found in the 
deposition of PrP between the two sCJD MM2 cases under investigation. 
Immunohistochemistry for the prion protein showed the deposition of PrP in almost 
all mice inoculated with brain homogenate from CJD 11, even in two RIII mice 
which showed no evidence of vacuolar pathology. In contrast, only two RIII mice 
showed evidence of PrP accumulation in the brain after challenge with brain 
homogenate from CJD 12 (Table 4.7). Mice challenged with brain homogenate from 
CJD 11, showed a widespread distribution of small granular deposits of PrP in brain 
regions (vestibular nucleus of the medulla, MHb and dLGN) consistently targeted 
following challenge with brain homogenate from sCJD MM1 and MV1 subgroups 
(Figure 4.10 a-c). In addition, peri-neuronal deposits of PrP were consistently found 
targeting the pons in the RIII mice, a region of the brain not commonly associated 
with mice challenged with sCJD MM1 and MV1 brain homogenates (Figure 5.10d). 
In the two mice showing PrP pathology following challenge with CJD 12, small 
intense granular deposits of PrP were restricted to the pons and the thalamus (Figure 
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Figure 4.10: PrP deposition in sCJD MM2A inoculated mice 
Immunohistochemical labelling of the abnormal prion protein in mice following 
inoculation of brain homogenate from CJD 11 (a, b, c, d) and CJD 12 (e and f). 
Granular deposition of PrP in the (a) medial habenular nucleus and (b) dorsal lateral 
geniculate nucleus of an RIII mouse. (c) Intense focal deposits of PrP targeting the 
vestibular nucleus of the medulla in a VM mouse. Peri-neuronal and granular 
deposition of PrP in the pons of an RIII mouse after challenge with brain 
homogenate from (d) CJD 11 and (e) CJD 12.  (f) Small intense deposits of PrP 
located in the thalamus of an RIII mouse. Sections shown were labelled with the anti-
PrP antibody 6H4 in combination with the CSA detection method, visualised with 
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4.3.4 Biochemical isotyping of PK resistant PrP
Sc
 
Characterisation of the PrPres type in the mouse brain following inoculation with 
brain homogenate from all sCJD subgroups was carried out using a standard Western 
blot protocol used in the diagnostic typing of human TSEs (Chapter 2, section 2.7). 
Western blotting was carried out on extracts of frozen CNS tissue from mice (n ≥ 2) 
of all Prn-p genotypes inoculated with brain homogenate from a minimum of two 
sCJD cases from each sCJD subgroup. Mice preferentially selected for analysis had 
received a positive score for vacuolar pathology in the brain. In the absence of any 
mice with a positive vacuolar score, mice with the longest survival time were 
selected. Western blot analysis was carried out on 5µl extracts of a 10% brain tissue 
weight to buffer volume (w/v) in mice that had received a positive score for vacuolar 
degeneration unless otherwise stated. In mice showing no evidence of vacuolar 
pathology, Western blotting was carried out on 100µl of a 10% w/v extract 
concentrated by centrifugation prior to analysis.  Mouse extracts were run alongside 
a sCJD MM1 and a vCJD MM2B diagnostic brain sample as reference controls for 
both fragment mobility and glycoform ratio.  
 
4.3.4.1 sCJD MM1 subgroup 
All mice analysed had evidence of vacuolar degeneration in the brain. PrPres was 
readily detected in CNS extracts of all mice analysed, further evidence for the 
successful transmission of disease from MM1 brain homogenate.  PrPres in mouse 
brain extracts showed a glycosylation pattern closely resembling that of the sCJD 
MM1 diagnostic brain extract (Figure 4.11). A subtle difference in the 
electrophoretic mobility of the unglycosylated form of the protein was found 
between the mouse and human brain samples. This suggests some variation in the 
size of the protease-resistant core of the mouse and human protein, either because of 
differences in the exact truncation point for PK or because of sequence differences 
between human and murine PrP. PrPres type was similar between mice of different 
Prn-p genotypes (Figure 4.11) and between mice of the same Prn-p genotype after 
inoculation with brain homogenate from different sCJD MM1 cases. These results 
indicate that the biochemical phenotype of sCJD in MM1 individuals is maintained 
on primary transmission to wild-type mice. 
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Figure 4.11: Western blot analysis of PrP
res
 in sCJD MM1 inoculated mice 
 
Western blot analysis of PrPres in CNS samples of RIII, C57BL, VM and C57BL x 
VM (CV) mice after experimental transmission of sCJD MM1 brain homogenate. 
Tissues are analysed after digestion with proteinase K. Mouse samples (M) are run 
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4.3.4.2 sCJD MV1 subgroup 
All mice analysed for the presence of PrPres in CNS tissue extracts had received a 
positive score for TSE-specific vacuolar degeneration in the brain. As seen in sCJD 
MM1 inoculated mice, PrPres was readily detected in all brain extracts analysed 
following experimental challenge with MV1 brain homogenate. This further 
confirms transmission of a TSE to mice from sCJD MV1 brain homogenate. The 
glycosylation pattern and electrophoretic mobility of the recipient mouse PrPres was 
consistent with those of the sCJD MM1 diagnostic standard (Figure 4.12) and the 
PrPres type 1 detected in the sCJD MV brain homogenate used in the inoculation of 
the mice (Figure 3.2).  Furthermore, the PrPres type detected in the brains of the MV1 
inoculated mice was closely similar to that observed in MM1 inoculated mice 
(Figure 4.11). Again, a similar PrPres type was observed in mice from the different 
Prn-p genotypes (Figure 4.12) and between different MV1 brain homogenates. These 
results confirm that the biochemical phenotype of MV1 sCJD cases is conserved 
following primary transmission to wild-type mice. 
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Figure 4.12: Western blot analysis of PrP
res
 in sCJD MV1 inoculated mice 
 
Western blot analysis of PrPres in CNS samples of RIII, C57BL, VM and C57BL x 
VM (CV) mice after experimental transmission of sCJD MV1 brain homogenate. 
Tissues are analysed after digestion with proteinase K. Mouse samples (M) are run 









































                                                                                   
 133 
4.3.4.3 sCJD VV1 subgroup 
Only one mouse (a C57BL x VM mouse) showed vacuolar evidence of a TSE 
following experimental challenge with brain homogenate from a sCJD VV1 patient 
(Table 4.3). Western blot analysis of a 10µl CNS extract from this mouse further 
confirmed the diagnosis of a TSE with the detection of PrPres. The resulting PrPres 
banding pattern had a glycosylation pattern and molecular weight of the 
unglycosylated fragment closely resembling that of the type 1 sCJD MM diagnostic 
standard (Figure 4.13) and the type 1 sCJD VV brain homogenate used in the 
inoculation of the mouse (Figure 3.2). Western blotting on a 100µl CNS extract from 
mice of all Prn-p genotypes which had shown no pathological evidence of a TSE, 
also showed no detectable levels of PrPres in the mouse brain (Figure 4.14). Western 
blotting on these CNS extracts without proteinase K treatment, confirmed the 
presence of PrP in the mouse brains (Figure 4.15). Although based on a single mouse 
showing detectable levels of PrPres in the brain, this result suggests that in mice 
which do show positive transmission from sCJD VV1 cases, the biochemical 
phenotype of the donor tissue is maintained. Furthermore, these results confirm that 
of previous strain typing parameters which indicate that transmission of sCJD from 
VV1 cases does occur but is rare. 
 
 
Figure 4.13: Detection of PrP
res
 in a sCJD VV1 inoculated mouse 
 
Western blot analysis of PrPres in a 10µl CNS extract from a C57BL x VM (CV) 
mouse which had shown positive TSE vacuolar pathology after inoculation with a 
sCJD VV1 (CJD 21) brain homogenate. Tissues are analysed after digestion with 
proteinase K. Mouse sample (M) is run alongside a human (H) sCJD MM1 type 1 
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Figure 4.14: Western blot analysis of PrP
res 
in sCJD VV1 inoculated mice 
 
Western blot analysis of PrPres in 100µl centrifugal concentrated CNS samples of 
RIII, C57BL, VM and C57BL x VM (CV) mice after experimental transmission of 
sCJD VV1 brain homogenate. Tissues are analysed after digestion with proteinase K. 
Mouse samples (M) are run alongside a human (H) sCJD MM1 type 1 (T1) and a 
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Figure 4.15: Confirmation of PrP in sCJD VV1 inoculated mice 
 
Western blot analysis of a Prn-pa (RIII) and Prn-pb (VM) mouse CNS extract 
analysed with (+) and without (-) proteinase K treatment. Mouse samples (M) were 
run alongside a human (H) sCJD MM1 type 1 (T1) diagnostic standard. Molecular 
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4.3.4.4 sCJD MM2A subgroup 
Frozen mouse CNS tissue for Western blot analyses was only available from a single 
sCJD MM2 experiment (CJD 12). All mice investigated from this experiment had 
received a positive score for TSE-specific vacuolar pathology in the brain. PrPres was 
readily detected in all RIII, VM and C57BL x VM CNS extracts examined. C57BL 
mice were not challenged with this brain homogenate and were therefore not 
available for testing. The PrPres banding pattern in CNS extracts of mice of all Prn-p 
genotypes (the two homozygotes and the heterozygote F1 cross) showed a molecular 
weight of the unglycosylated fragment of approximately 19kDa, similar to that seen 
in the vCJD diagnostic standard (Figure 4.16). However, the glycosylation pattern 
more closely resembled that of the sCJD MM2 brain homogenate used in the 
inoculations (Figure 3.2). Crucially, this banding pattern differed from sCJD MM1 
diagnostic standard in terms of the molecular weight of the unglycosylated fragment 
(Figure 4.16). These results further confirm the successful transmission of a TSE 
from sCJD MM2 cases and show that the biochemical phenotype of this MM2 sCJD 
brain homogenate was maintained on transmission to mice. Furthermore, the 
detection of PrPres in the VM challenged mice suggests that Western blot analysis is a 
more sensitive assay in the detection of PrP in the sCJD inoculated mice when 
compared to immunohistochemistry, as immunohistochemistry showed no evidence 
of PrP in the brains of VM inoculated mice. 
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Figure 4.16: Western blot analysis of PrP
res
 in sCJD MM2 inoculated mice 
 
Western blot analysis of PrPres in CNS samples of RIII, VM and C57BL x VM (CV) 
mice after experimental transmission of sCJD MM2 brain homogenate. Tissues are 
analysed after digestion with proteinase K. Mouse samples (M) are run alongside a 
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4.3.4.5 sCJD MV2A subgroup 
Western blot analyses of frozen mouse CNS tissue after primary challenge with brain 
homogenate from sCJD MV2 cases showed detectable levels of PrPres in a single RIII 
mouse examined. This same RIII mouse had also provided the only positive score for 
the presence of TSE-specific vacuolar pathology in the brain following histological 
examination. Surprisingly, the PrPres type of this RIII mouse had an unglycosylated 
fragment with a molecular weight of approximately 21kDa. This molecular weight 
closely resembles that of the sCJD MM1 diagnostic standard and differs from that of 
the vCJD type 2B diagnostic standard (Figure 4.17) and that of the type 2 PrPres 
detected in the inoculum (Figure 3.2)..  All other extracts from RIII, C57BL, VM and 
the C57BL x VM mice showed no evidence of PrPres in the brain, even after analysis 
of 100µl concentrated samples (Figure 4.18). However, PrP was confirmed in these 
mouse CNS extracts in the absence of PK digestion (Figure 4.19) This result 
supports observations made from the previous strain typing parameters, that 
transmission of a TSE from sCJD MV2 cases is rare. However, the PrPres type 
detected in the brain of the one RIII mouse suggests that the biochemical phenotype 
of the donor MV2 sCJD case was not maintained on primary transmission but 
resulted in a PrPres type more reminiscent of that detected in a sCJD MM1 and MV1 
inoculated mouse. It is interesting that the vacuolar pathology of this single mouse 
also resembled that seen in sCJD MM1 challenged RIII mice. 
 
 
Figure 4.17: Detection of PrP
res
 in a sCJD MV2 inoculated mouse 
 
Western blot analysis of PrPres in a 10µl CNS extract from an RIII mouse which had 
shown positive TSE vacuolar pathology after inoculation with a sCJD MV2 (CJD 
16) brain homogenate. Tissues are analysed after digestion with proteinase K. Mouse 
sample (M) is run alongside a human (H) sCJD MM1 type 1 (T1) and a vCJD 
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Figure 4.18: Western blot analysis of PrP
res
 in sCJD MV2 inoculated mice 
 
Western blot analysis of PrPres in CNS samples of RIII, C57BL, VM and C57BL x 
VM (CV) mice after experimental transmission of sCJD MV2 brain homogenate. 
Tissues are analysed after digestion with proteinase K. Mouse samples (M) are run 
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Figure 4.19: Confirmation of PrP in sCJD MV2 inoculated mice 
  
Western blot analysis of a Prn-pa (RIII) and Prn-pb (VM) mouse CNS extract 
analysed with (+) and without (-) proteinase K treatment. Mouse samples (M) were 
run alongside a human (H) sCJD MM1 type 1 (T1) diagnostic standard. Molecular 
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4.3.4.6 sCJD VV2A subgroup 
PrPres was detected after experimental challenge with sCJD from a single VV2 
source (CJD 23) but only in one C57BL mouse. This same C57BL mouse had also 
received a positive score for vacuolar degeneration.  The PrPres type in this mouse 
showed a mobility of the unglycosylated fragment resembling that of the vCJD 
diagnostic standard (Figure 4.20) and consistent with that detected in the sCJD VV2 
inoculum used in the transmission (Figure 3.2). A feature of the experimentally 
infected mouse that was not observed in the human vCJD MM2B standard or the 
inoculum was the appearance of the unglycosylated fragment as a doublet composed 
of a distinct upper and lower band (Figure 4.20). All other mice tested showed no 
evidence of PrPres in the brain, even after analysis of 100µl concentrated samples 
(Figure 4.21).  Again, Western blot analysis of these mouse CNS samples without 
any PK digestion had confirmed the presence of PrP (Figure 4.22). This result 
confirms the previous observations from the other strain typing parameters that 
transmission from sCJD VV2 cases does occur but is rare. In addition, this result also 
indicates that the biochemical phenotype of sCJD VV2 cases showing positive 




A representative Western blot comparing PrPres type in recipient mice after primary 
challenge with brain homogenate from sCJD MM1, MV1 and MM2 cases is shown 



















Figure 4.20: Detection of PrP
res
 in a sCJD VV2 inoculated mouse 
 
Western blot analysis of PrPres in a 40µl CNS extract from a C57BL mouse which 
had shown positive TSE vacuolar pathology after inoculation with a sCJD VV2 (CJD 
23) brain homogenate. Tissues are analysed after digestion with proteinase K. Mouse 
sample (M) is run alongside a human (H) sCJD MM1 type 1 (T1) and a vCJD 
diagnostic standard (T2B). (U) Upper band of the unglycosylated fragment, (L) 
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Figure 4.21: Western blot analysis of PrP
res
 in sCJD VV2 inoculated mice 
 
Western blot analysis of PrPres in CNS samples of RIII, C57BL, VM and C57BL x 
VM (CV) mice after experimental transmission of sCJD VV2 brain homogenate. 
Tissues are analysed after digestion with proteinase K. Mouse samples (M) are run 





























                                                                                   
 144 
 
Figure 4.22: Confirmation of PrP in sCJD VV2 inoculated mice 
 
Western blot analysis of a Prn-pa (RIII) and Prn-pb (VM) mouse CNS extract 
analysed with (+) and without (-) proteinase K treatment. Mouse samples (M) were 
run alongside a human (H) sCJD MM1 type 1 (T1) diagnostic standard. Molecular 
















 in RIII mice after challenge with different sCJD subgroups 
 
All mouse CNS extracts are analysed after (+) digestion with proteinase K. Mouse 
samples (M) are run alongside a human (H) sCJD MM1 type 1 (T1) diagnostic 
standard. Molecular weight makers (MW) are shown in kDa 
 
 
                                                                                   
 145 
4.4 Experimental results: mouse-to-mouse passage 
Different TSE strains are often isolated from a single source by serial passage 
through mice of different Prn-p genotypes, so a full characterisation of a source 
includes strain typing following primary transmission to mice and on subsequent 
mouse-to-mouse transmission of the TSE isolate.  In this thesis, further 
characterisation of the agent strain in sCJD was carried out by conducting two serial 
mouse-to-mouse passages of brain isolates derived from two different sCJD MM1 
frontal cortex samples (CJD 1 and CJD 5) and a single sCJD cerebellar sample (CJD 
2). The sCJD MM1 subtype was selected for further sub-passage because primary 
transmissions indicated that this sCJD subgroup transmits most successfully in the 
wild-type mouse panel, with the largest numbers of mice having had a positive score 
for the presence of TSE-specific vacuolar pathology (Figure 4.1). In addition, 
methionine homozygosity at PRNP codon 129 is a recognised risk factor in the 
development of sCJD with the presence of type 1 PrPres in the brain comprising the 
largest proportion of sCJD cases. Brain homogenates were prepared as previously 
described (Chapter 2, section 2.3.4.) from the brain of a single RIII, VM and C57BL 
mouse showing TSE-specific vacuolation in the brain after primary challenge with 
sCJD MM1 brain homogenate. Groups of approximately 12 mice from each mouse 
Prn-p genotype were inoculated via a single IC injection. As in the primary 
transmission of sCJD into wild-type mice, only mice surviving over 250dpi were 
included in the analysis. Saline inoculated controls were not carried out in the sub-
passage experiments. Figure 4.24 shows a diagrammatic representation of the sub-
passages carried out in this thesis. 
                                                                                   
 146 








                                                                                   
 147 
4.4.1 Incubation periods and incidence of disease 
Each sCJD brain isolate produced similar results in all mouse lines challenged, 
regardless of the brain region used in the original primary transmission. The 
incidence of clinical and vacuolar pathology in mice after serial passage of sCJD 
brain isolates in Prn-pa and Prn-pb mice are detailed in Table 4.8a and Table 4.8b 
respectively. 
 
The numbers of mice sacrificed as a result of clinical TSE disease was more frequent 
than was observed on primary transmission (Table 4.1), a feature indicative of a 
removal of the ‘species barrier’ which was present during the original human to 
mouse transmission. The most striking difference was found in the VM mouse line in 
which almost 100% of mice challenged with brain isolates passaged through Prn-pb 
mice developed clinical signs of disease with TSE-specific vacuolar pathology 
confirmed at post-mortem (Table 4.8b). In contrast, only a small proportion of VM 
mice challenged with brain isolates passaged through Prn-pa (RIII and C57BL) mice 
resulted in clinical signs of a TSE (Table 4.8a). In the RIII-passage of brain isolates 
from CJD 2, no clinical or histological evidence of a TSE disease was found in any 
of the mice inoculated (Table 4.8a). This was not the case in the RIII-passage of 
brain isolates from CJD 1 or CJD 5. Although titres of infectivity in the inoculum are 
not known, these contrasting results may reflect low levels of infectivity within the 
RIII mouse brain selected from the primary transmission of CJD 2 for further 
passage in mice. In support of this proposal, immunohistochemical analysis failed to 
show any evidence of PrP in the RIII mouse selected as inocula for the subsequent 
mouse passage. A further explanation is that infectivity levels may be lower in sCJD 
cerebellar tissue compared to frontal cortex. However, results from the primary 
transmission of sCJD MM1 brain isolates show no evidence of this regional 
difference in levels of infectivity. 




Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice after two serial mouse-to-mouse passages of isolates derived from 
brain homogenates from three sCJD MM1 cases. Mice sacrificed with intercurrent disease before 250 dpi were excluded from the analysis. Incubation 
periods in days are shown in brackets (mean ± S.E.M. for groups with >5 clinical cases. In mice with a positive score for clinical signs of a TSE and a 
negative score for vacuolar pathology, the neuropathological assessment is considered definitive. 
 
 
* frontal cortex isolates † cerebellar cortex isolates  
 










C57BL x VM 
             







Clin Vac path Clin Vac path 
 
*CJD 1  RIII       1st  pass 
 
3/10 (820, 834, 944) 
 
4/10 3/8 (939, path -ve, path -ve) 1/8 3/10 (562, 649,734) 9/10 0/10 7/10 
   





0/4 0/4 0/9 5/9 0/9 4/9 
 
             C57BL    1st pass 
 
3/12 (780, 806, 862) 
 
8/12 
2/9 (885, path –ve) 6/9 2/7 (776, 875) 7/7 0/10 6/10 
 





2/7 (894, path –ve) 3/7 0/11 9/11 0/10 8/10 
 
†CJD  2  RIII      1st  pass 
1/9 (path –ve) 0/9 0/7 0/7 2/8 (path –ve) 0/8 0/8 0/8 
 
             C57BL    1st pass 
 
5/15 (898 ± 28) 
 
9/15 1/12 (path –ve) 7/12 1/11 (820) 11/11 0/9 6/9 
 
                            2nd pass 
0/11 7/11 1/9 (path –ve) 5/9 1/8 (path –ve) 5/8 0/10 9/10 
 
*CJD 5   RIII      1st  pass 
 
5/10 (847 ± 17) 
 
8/10 
4/10 (485, 698, 835, path –ve) 5/10  3/11 (625, 716, path –ve) 8/11 0/10 6/10 
  
                            2nd pass 
 
2/11 (855, 889) 
 
9/11 
1/7 (887) 4/7 2/10 (701, 764) 10/10 0/7 7/7 
 
              C57BL   1st pass 
 
4/10 (521, 797, 883, path –ve) 
 
6/10 
2/12 (856, 883) 6/12 1/12 (751) 12/12 1/12 (881) 11/12 
                                                                                            
2nd pass 
 
1/7 (path –ve) 
 
0/7 
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Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice after two serial mouse-to-mouse passages of isolates derived from 
brain homogenates from three sCJD MM1 cases. Mice sacrificed with intercurrent disease before 250 dpi were excluded from the analysis. Incubation 
periods in days are shown in brackets (mean ± S.E.M. for groups with >5 clinical cases).  In mice with a positive score for clinical signs of a TSE and 




* frontal cortex isolates 













C57BL x VM 
             







Clin Vac path Clin Vac path 
 
*CJD 1    VM          1st  pass 
 
6/12 (856 ± 36) 
 
6/12 
4/9 (729, 764, 868, path –ve) 6/9 9/11 (563 ± 8) 11/11 0/9 7/9 
  
                           2nd pass 
 
2/10 (864, path –ve) 
 
7/10 
1/7 (path –ve) 3/7 11/11 (542 ± 8) 11/11 0/8 6/8 
 
†CJD 2   VM           1st pass 
6/16 (791 ± 12) 7/16 3/9 (776, 820, 844) 7/9 11/11 (548 ± 9) 11/11 1/7 (545) 6/7 
  
                            2nd pass 
1/11(path –ve) 6/11 0/6 5/6 11/12 ( 493 ± 2) 12/12 0/10 10/10 
 
*CJD 5   VM           1st pass 
 















     
                            2nd pass 
 
0/10 10/10 0/7 3/7 9/10 (514 ± 6) 10/10 0/8 8/8 
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The development of a progressive clinical disease in a proportion of the inoculated 
mice has provided mean incubation period data in some experimental groups. Mean 
incubation periods were drawn from groups with a minimum of five mice that had 
recieved a positive score for both clinical signs of disease and for the presence of 
TSE-specific vacuolation in the brain. Incubation periods are shown in Figure 4.25.  
All VM mice challenged with isolates passaged through Prn-pb (VM) mice 
developed disease with mean incubation periods up to a standard clinical endpoint of 
563 ± 8, 558 ± 6 and 548 ± 9 days (± S.E.M) on first mouse-to-mouse passage with a 
slight shortening on a further passage (Table 4.8b). In contrast, incubation periods 
were not observed in any VM group after passage in Prn-pa mice. This suggests the 
isolation of two distinct mouse-passaged strains of agent recognised in VM mice by 
passage in the different mouse Prn-p genotypes. Incubation period data was not a 
common feature of the other mouse lines after passage in either mouse Prn-p 
genotype. Interestingly, with the exception of the VM mice injected with VM-
passaged isolates, groups with incubation period data on first mouse-to-mouse 
passage, failed to show an incubation period on further passage. This is in contrast to 
the sub-passage of other TSE isolates where incubation periods generally shorten 
after further mouse-to-mouse passages.  
 
As observed in the primary transmission of sCJD MM1 brain homogenate, the failure 
to show clinical signs of disease does not indicate a failure to transmit disease, as 
vacuolar degeneration typical of TSE infection was seen in the brains of a proportion 
of the mice dying with intercurrent disease in almost all experimental groups (Table 
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Figure 4.25: Incubation times in mice after sub-passage of sCJD MM1  
 
Mean incubation periods in RIII, C57BL and VM mice after first and second mouse 
passage of sCJD MM1 brain isolates through (a) Prn-pa and (b) Prn-pb mice. Data 
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4.4.2 Patterns of vacuolar pathology- lesion profiles 
In the primary transmission of sCJD brain homogenates, the lack of any clinical TSE 
disease in inoculated mice meant that lesion profiling was predominantly carried out 
using mice showing only positive vacuolar pathology. Profiles from the primary 
challenge of sCJD MM2 brain homogenate in RIII mice indicate that patterns of 
vacuolar pathology are closely similar between mice dying with clinical TSE disease 
and those dying with intercurrent illness or at full life span, although unsurprisingly 
the pathology is less severe in non-clinical mice (Figure 4.4). In the sub-passage of 
sCJD brain isolates, numbers of mice showing both clinical and vacuolar pathology 
were low in most groups. Therefore, in the construction of lesion profiles after sub-
passage of sCJD, mice that had received a positive score for TSE specific 
vacuolation and which were sacrificed with either intercurrent disease or at clinical 
end-point of disease were included in the same lesion profile. Vacuolar degeneration 
was seen in all four mouse lines injected with sCJD MM1 brain homogenates 
passaged in the different mouse Prn-p genotypes; however, not all experimental 
groups had sufficient mice (≥ 5 mice) with a positive score for TSE-specific 
vacuolation for the construction of a lesion profile.  Lesion profiles were remarkably 
similar for the three sCJD MM1 brain isolates and are shown in Figure 4.26.   
 
In general, there was little difference in the pattern or severity of vacuolar pathology 
between first and second mouse-to mouse passages. Overall, the pattern of vacuolar 
pathology in each mouse line was consistent with that observed on primary 
transmission to the same mouse line. However, VM mice with MM1 homogenate 
passaged in Prn-pa mice showed a lesion profile more reminiscent of primary 
transmission from sCJD MV1 brain tissue to VM mice (Figure 4.3). Vacuolar 
pathology was characterised by a distinct and consistent targeting of mild-moderate 
vacuolation in the superior colliculus (brain scoring region G3) in all groups.  There 
was also a widespread involvement of the thalamus (scoring region G5) and the 
cerebral cortex (scoring region G8 and G9). In VM mice challenged with isolates 
passaged in Prn-pb mice, most of which died with clinical disease, vacuolation scores 
were consistently higher than in all other experimental groups, with widespread 
moderate vacuolation throughout the scoring regions of the brain. Although not all 
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profiles were based on mice at clinical end-point of disease, they clearly show a 
similarity in lesion distribution between the three sCJD MM1 brain homogenates and 
confirm that lesion profiles were similar irrespective of the Prn-p genotype of the 
mice through which the sCJD brain homogenate was passaged. 
Figure 4.26: Lesion profiles for mice following sub-passage of sCJD MM1  
 
Lesion profiles are constructed from a minimum of five mice with a positive score for TSE associated vacuolar pathology. Vacuolation was scored at 
nine specified grey (G) matter regions and three white (W) matter regions of the mouse brain. Lesion profiles shown are for all mouse lines in the (a) 
the primary transmission of brain homogenate from three sCJD MM1 cases (CJD 1, CJD 2 and CJD 5) and the subsequent first and second mouse-to-
mouse passage of the same three brain isolates in (b) Prn-pa and (c) Prn-pb mice. Lesion profiles are shown with standard error bars (± S.E.M). (Solid 
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4.4.3 Deposition of PrP in the mouse brain 
Patterns of PrP deposition in the mouse brain were investigated following the first 
and second mouse-to-mouse passage of isolates derived from a single sCJD MM1 
(CJD 1) frontal cortex sample. Immunohistochemistry was carried out on 5µm 
formalin fixed, formic acid treated, brain sections from all three recipient mouse 
lines (RIII, VM and C57BL) and the C57BL x VM cross using the anti-PrP antibody 
6H4 in combination with the CSA detection method as previously described (Chapter 
2, section 2.6.4). In each experiment, three mice from each mouse line were 
analysed. In the selection of mice for immunohistochemical analysis, mice which had 
received a positive score for both clinical signs of disease and vacuolar pathology 
were preferentially selected. In the absence of clinically positive mice, mice which 
had received a positive score for vacuolar pathology with the longest survival time 
were selected. Results from the immunohistochemical analysis of PrP deposition in 
the brains of mice after sub-passage are shown in Table 4.9. Not all experimental 
groups showed the deposition of PrP within the mouse brain after the first passage in 
mice. However, PrP was detected in all mouse lines after a further passage in the 
mice. The patterns of PrP accumulation in the mice are detailed below.  
 
Table 4.9: Deposition of PrP in mice following sub-passage of sCJD MM1  
 
                                                                              Recipient mouse line 
Donor tissue 
source 
Passage RIII C57BL VM C57BL x VM 
CJD 1   RIII 1st  *2/3 ‡0/3 *1/3 †3/3 
 2nd  §2/3 †2/3 †3/3 †3/3 
CJD 1   C57BL 1st  *1/3 ‡0/3 §0/3 †3/3 
 2nd  ‡3/3 ‡3/3 †3/3 †3/3 
CJD 1   VM 1st  *0/3 *0/3 *2/3 †3/3 
 2nd  ‡2/3 †3/3 *3/3 †3/3 
 
* mice with a positive score for vacuolar pathology sacrificed with clinical disease 
† mice with a positive score for vacuolar pathology in the absence of clinical signs of a TSE 
‡ all mice positive for vacuolar pathology, one mouse showing clinical TSE disease 
§ all mice positive for vacuolar pathology, two mice showing clinical TSE disease 
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4.4.3.1 Sub-passage in Prn-p
a
 mice 
Immunohistochemical labelling for the prion protein showed PrP deposition in the 
brains of all C57BL x VM mice examined after the first mouse-to-mouse passage, 
but in only a proportion of the brains of the RIII and VM mice. No evidence of PrP 
deposition was found in the brain of any C57BL mouse examined after first passage 
through either of the Prn-pa mouse line (Table 4.9). In contrast, 
immunohistochemical analysis of the mice after a further serial passage in the Prn-pa 
mice showed PrP deposition in the brain of almost all mice examined.  The detection 
of PrP in the brains of C57BL mice after the second serial passage indicates the 
presence of infectivity in the C57BL mice after the first passage in the absence of 
any detectable levels of PrP by immunohistochemical analysis. The deposition and 
targeting of PrP pathology in the mice was closely similar to that observed in the 
primary transmission of sCJD MM1, with a restricted pathology of small granular 
deposits of PrP consistently targeting the vestibular nucleus of the medulla (Figure 
4.27a and b) and the dLGN (Figure 4.27c and d) in all mouse lines. Deposition in the 
medial habenular nucleus (MHb), an area consistently targeted in the primary 
transmissions, was observed only in the VM mouse line (Figure 4.27e and f). In 
general, PrP showed a more widespread and intense pattern of deposition after 
second passage in mice (Figure 4.28a – d) with further PrP deposits found within the 
thalamus, pons and superior colliculus in a proportion of the mice examined (Figure 
4.28e and f). There was no evidence of amyloid plaques in any of the mice 
examined. 
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Faint granular deposits of PrP targeting the vestibular nucleus of the medulla in (a) 
RIII and (b) VM mice after the first passage in RIII mice. Granular deposition of PrP 
in the dorsal lateral geniculate nucleus (dLGN) of C57BL x VM mice following the 
first passage in (c) RIII and (d) C57BL mice. Granular deposits of PrP within the 
medial habenular nucleus (MHb) in VM mouse following the (e) first and (f) second 
mouse passage in RIII mice. Sections shown were labelled with the monoclonal anti-
PrP antibody 6H4 in combination with the CSA detection method, visualised with 
DAB and counterstained with haematoxylin. Original magnification x400. 
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Immunohistochemistry for the prion protein in mice following second mouse-to-
mouse passage of sCJD MM1 brain isolates in Prn-pa mice. Strong peri-neuronal 
labelling for PrP in the vestibular nucleus of the medulla in (a) a VM mouse after 
passage in the RIII mouse line and (b) a C57BL x VM mice after passage through 
C57BL mice. (c) Strong punctate labelling in the dorsal lateral geniculate nucleus 
(dLGN) in a VM mouse after passage in the RIII mouse line. (d) Widespread 
synaptic labelling in the dLGN in a C57BL after passage through C57BL mice. (e) 
Peri-neuronal staining for PrP throughout the pons of an RIII mouse after passage 
through RIII mice. (f) Faint granular deposition of PrP around vacuolation in the 
superior colliculus in a C57BL mouse after passage through the C57BL mouse line. 
Sections shown were labelled with the monoclonal anti-PrP antibody 6H4 in 
combination with the CSA detection method, visualised with DAB and 
counterstained with haematoxylin. Original magnification; x100 (d), x200 (a, b, c, e, 
f). 
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4.4.3.2 Sub-passage in Prn-p
b
 mice  
Immunohistochemical staining showed no evidence of PrP deposition in the brain of 
any Prn-pa (RIII and C57BL) mouse examined after the first passage of sCJD brain 
isolates through VM mice. However, examination of the brains of RIII and C57BL 
mice following a further VM-passage showed PrP deposition in the brain of almost 
all mice tested (Table 4.9). These results support findings from the serial passage of 
sCJD in Prn-pa mice which indicated that infectivity may be present in the absence 
of any PrP accumulation in the mice as judged by immunohistochemical analysis. In 
contrast, PrP deposition was observed in almost all Prn-pb (VM) and Prn-pab 
(C57BL x VM) mice after the first and second passage in VM mice (Table 4.9). The 
deposition and targeting of PrP pathology in the mice was closely similar to that 
observed in the same mouse lines in the primary transmission of sCJD MM1 and 
after serial passage in Prn-pa mice, with a restricted pathology of small granular 
deposits of PrP consistently targeting the vestibular nucleus of the medulla (Figure 
4.29a and b) and the dLGN (Figure 4.29c and d). Overall, PrP pathology was more 
widespread following a further mouse-to-mouse passage with further PrP deposits 
found within the thalamus, pons and superior colliculus in a proportion of the mice 
examined (Figure 4.29e and f).   In contrast to primary transmissions and passage 
through Prn-pa mice, deposition of PrPSc in the MHb was not a feature in the mice 
challenged. There was no evidence of amyloid plaques in any of the mice examined. 
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Immunohistochemistry for the prion protein in mice after a first (a-d) and second (e-
h) mouse passage in Prn-pb (VM) mice. Small granular deposits of PrP around 
neurons in the vestibular nucleus of the medulla in a (a) VM and (b) C57BL x VM 
mouse. Granular deposits of PrP in the dorsal lateral geniculate nucleus (dLGN) of a 
(c) VM and (d) C57BL x VM mouse. (e) Strong granular deposits of PrP in the 
vestibular nucleus of an RIII mouse. (f) Intense deposits of PrPSc staining the dLGN 
of a VM mouse. (g) Peri-neuronal staining for PrP throughout the pons of C57BL x 
VM mouse. (h) Faint granular deposition of PrP in the superior collicullus in a 
C57BL x VM mouse. Sections shown were labelled with the monoclonal anti-PrP 
antibody 6H4 in combination with the CSA detection method, visualised with DAB 
and counterstained with haematoxylin. Original magnification; x200 (d, e, f, g), x400 
(a, b, c, h) 
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4.4.4 Biochemical isotyping of PK resistant PrP
Sc 
This thesis has confirmed the conservation of PrPres type in mice following the 
primary transmission of sCJD MM1 from human brain homogenate. To determine 
whether the PrPres type observed in sCJD MM1 brain homogenate is maintained on 
subsequent mouse-to-mouse passage, characterisation of PrPres was carried out on all 
three mouse lines (RIII, C57BL and VM) and the C57BL x VM mice following 
serial passage in Prn-pa (C57BL) and Prn-pb (VM) mice. PrPres types were analysed 
from the first and second mouse-to-mouse passage of the isolates derived from a 
single sCJD MM1 cerebellar (CJD 2) sample. Western blot analysis was performed 
on a minimum of two mice from each experimental group, using the standard 
Western blot protocol used in the diagnostic typing of human TSEs and in the 
detection and typing of PrPres in mice following primary transmission of brain 
homogenate from sCJD subgroups (Chapter 2, section 2.7).  All mice analysed had 
shown evidence of TSE-associated vacuolar pathology. Western blot analysis was 
carried out on 5µl samples of a 10% brain tissue weight to buffer volume (w/v) 
unless otherwise stated.  As described previously, mouse samples were run alongside 
a sCJD MM1 diagnostic brain reference standard and a vCJD diagnostic brain 
reference standard serving as controls for both fragment mobility and glycoform 
ratio.  
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4.4.4.1 Sub-passage in Prn-p
a
 mice 
PrPres was readily detected in CNS extracts from all mice analysed following passage 
in C57BL mice.  The PrPres detected in the mouse extracts showed a glycosylation 
pattern and elecrophoretic mobility of the unglycosylated form of the protein closely 
resembling that detected in the primary transmission of sCJD MM1 to the same 
mouse lines and that seen in sCJD MM1 patients (Figure 4.30). The PrPres banding 
pattern was similar in mice of all Prn-p genotypes and showed no observable 
difference in glycosylation pattern or in the mobility at the unglycosylated band 
between the first and second mouse-to-mouse passage (Figure 4.30). These results 
confirm the findings from the primary transmission of sCJD MM1 brain 
homogenate, which demonstrated that the biochemical properties of PrPres from this 
subgroup are maintained on primary transmission and on subsequent passage in 
mice. 
 
4.4.4.2 Sub-passage in Prn-p
b
 mice  
PrPres was readily detected in all mouse CNS extracts examined after passage in VM 
mice. Consistent with the primary transmission data and that of serial passage in Prn-
p
a mice, Western blotting of CNS extracts demonstrated a PrPres banding pattern 
closely resembling that seen in sCJD MM1 cases and in mice following experimental 
challenge with sCJD MM1 brain homogenate, with a molecular weight at the 
unglycosylated fragment of approximately 21kDa (Figure 4.31). Furthermore, the 
PrPres type in the mice was closely similar to that observed in the same mouse lines 
after serial passage in Prn-pa mice (Figure 4.30). The similarity in the PrPres type in 
VM mice infected with isolates passaged in Prn-pa and Prn-pb mice shows no 
evidence of the two distinct mouse-passaged strains that were inferred from the 
incubation period data. Again there were no observable differences in the PrPres type 
between the first and second mouse-to-mouse passage (Figure 4.31). These results 
confirm that the type 1 PrPres seen in the original sCJD inoculum is maintained on 
primary transmission and on subsequent serial passage in VM mice. 
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Figure 4.30: Western blot analysis of PrP
res





Western blot analysis of PrPres in CNS samples of RIII, C57BL, VM and C57BL x 
VM (CV) mice after the 1st and 2nd mouse-to-mouse passage of brain isolates in 
C57BL (Prn-pa) mice.  Tissues are analysed after digestion with proteinase K. 
Mouse samples (M) are run alongside a human (H) sCJD MM1 type 1 (T1) and a 
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Figure 4.31: Western blot analysis of PrP
res





Western blot analysis of PrPres in CNS samples of RIII, C57BL, VM and C57BL x 
VM (CV) mice after the 1st and 2nd mouse-to-mouse passage of brain isolates in VM 
mice.  Tissues are analysed after digestion with proteinase K. Mouse samples (M) are 
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4.5 Results Summary  
In addressing the question of whether different strains of agent are present within 
sCJD, this chapter examined the transmission characteristics of all six sCJD 
subgroups, as classified according to PrPres type and codon 129 PRNP genotype, 
after inoculation into panels of wild-type mice. Results from the primary 
transmission and the subsequent mouse-to-mouse passages have shown that all three 
mouse lines (RIII, C57BL and VM) and the C57BL x VM mice are susceptible to 
infection with sCJD; however, not all subgroups of sCJD examined transmit 
efficiently in the mouse panel. Transmission was most efficient from the sCJD MM1, 
MV1 and MM2 brain homogenate. In contrast, transmission of disease from sCJD 
MV2, VV1 and VV2 brain homogenates was rarely observed. Sporadic CJD in wild-
type mice is characterised by the following features; 
 
 Clinical signs of a neurological disease are rare in wild-type mice after primary 
challenge with sCJD subgroups.  
 Histological and biochemical analysis, confirms a TSE in mice dying with 
intercurrent illness after challenge with all six sCJD subgroups. 
 Transmission as determined by the presence of vacuolar pathology in the 
mouse brain and the detection of PrP deposition in the brain by 
immunohistochemistry and Western blotting is most efficient in mice 
inoculated with sCJD MM1, MV1 and MM2 brain homogenates. 
 Lesion profiles show a similar pattern of vacuolar pathology between mouse 
lines of different Prn-p genotypes inoculated with different sCJD MM1 and 
MV1 isolates. This pattern of vacuolar pathology showed subtle differences 
from mice inoculated with a single sCJD MM2 isolate. 
 Immunohistochemistry shows a precise targeting of PrP pathology in the 
brains of infected mice. However, PrP pathology is not a major feature of 
sCJD in wild-type mice.  
 sCJD cases with a PrPres type 1 in the brain show conservation of PrPres type 
on primary transmission and after serial passage in mice. 
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 PrPres typing indicates that sCJD with type 2 PrPres detected in the brain 
inoculum do not always show conservation in PrPres type when experimentally 
transmitted to mice. 
 Serial passage of the sCJD MM1 agent in Prn-pa and Prn-pb mice results in the 
isolation of two distinct mouse-passaged strains, distinguishable by whether or 
not they produce clinical disease in VM mice. 
 
4.6 Discussion of experimental results 
The aim of this chapter was to characterise the agent strain in sCJD by transmissions 
to wild-type mice. Using incubation times, patterns of TSE associated vacuolar 
pathology and detection of PrP by immunohistochemistry and Western blot in mice, 
similarities and differences between the six sCJD subgroups have emerged. Overall, 
the data presented in this thesis implies the existence of at least two distinct strains of 
sCJD, which can be distinguished by subtle differences in their transmission 
properties following inoculation in panels of wild-type mice. The lack of 
transmission for other sCJD subgroups suggests that they could represent a further 
third strain of agent. 
 
4.6.1 Preclinical TSE disease in sCJD inoculated wild-type mice 
In previous studies examining the transmission properties of sCJD in wild-type mice, 
clinical signs of disease were rarely observed, suggesting that a substantial ‘species 
barrier’ exists between the donor (human) and recipient species (mouse) (Bruce et 
al., 1997; Hill et al., 1997; Asante et al., 2002; Wadsworth et al., 2008). In support of 
these findings, this thesis confirms that the development of clinical TSE disease in 
wild-type mice is rare following inoculation of brain homogenate from sCJD MM1, 
MV1, MV2, VV1 and VV2 cases, consistent with the existence of a ‘transmission 
barrier’. Therefore, in the experimental challenge of sCJD brain homogenate to wild-
type mice, incubation period data is not able to distinguish between sCJD MM1, 
MV1, MV2, VV1 and VV2 cases and is therefore not a relevant strain typing 
parameter for these five sCJD subgroups. In contrast, clinical TSE disease was 
observed in seven out of 19 RIII mice inoculated with a single sCJD MM2 brain 
homogenate, suggesting that the sCJD MM2 subgroup may be distinguished from 
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other sCJD subgroups on the basis of development of clinical disease in a proportion 
of RIII mice challenged. Inoculations from the sCJD MM2 subgroup are discussed in 
detail later in this discussion (Chapter 4, section 4.6.3)  
 
The lack of clinical TSE disease in mice inoculated with sCJD MM1, MV1, MV2, 
VV1 and VV2 brain homogenate, does not necessarily indicate a failure to transmit 
disease from these five subgroups. Examination of the brain for TSE associated 
vacuolar pathology, PrP deposition and biochemical analysis of PrPres provided 
evidence of TSE disease in a proportion of mice dying with intercurrent disease. This 
confirms the successful transmission of TSE infectivity from these five sCJD 
subgroups in the wild-type mouse panel. However, it is difficult to determine 
whether these mice are at a preclinical stage in which clinical signs would develop 
had the mice survived long enough, or whether these mice have a subclinical disease 
in which clinical signs do not develop but the mice would remain asymptomatic 
carriers of TSE infection however long they lived. The observations of clinical 
disease in 12 mice (from the 580 surviving over 250dpi) inoculated with sCJD MM1 
homogenates and also in seven (from the 91 surviving over 250dpi) inoculated with 
sCJD MM2 homogenate shows that, although rare, wild-type mice are capable of 
developing clinical TSE disease within their life spans. This suggests that preclinical 
disease in the sCJD inoculated mice is a more likely explanation.  
  
The presence of TSE-specific vacuolar pathology and the detection of PrPres in the 
brains of mice, confirmed the successful transmission of a TSE from all sCJD 
subgroups; however, the efficiency of transmission, as assessed by the numbers of 
mice showing pathological or biochemical evidence of a TSE varied according to the 
individual brain homogenate and was used to further distinguish between the 
different sCJD subgroups. Such differences in the transmission efficiency in the 
different sCJD subgroups are not likely to be a result of species mis-matching, as the 
donor and recipient species are consistent throughout this series of experiments. 
Therefore, these findings, support recent proposals that ‘transmission barrier’ rather 
that ‘species barrier’ may be a better term to describe the variation in the 
transmission efficiency between different TSE inocula and different species (Hill et 
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al., 2003). It is more likely that the differences found were a result of differences in 
the individual inocula from the same donor species. Furthermore, the ‘species 
barrier’ effect is comparative based on the difference observed in the incubation 
period between the primary transmission of an isolate and its subsequent passage in 
the new host species. Usually, but not always, the efficiency of transmission 
increases on subsequent serial passage, which is represented by a decrease in the 
incubation period. This incubation period difference is thought partly to be a result of 
increased efficiency of replication in the new host and partly a result of agent strain 
selection. Surprisingly there does not appear to be any observable increase in the 
efficiency of sCJD agent transmission, at least for the Prn-pa passages, where they 
resemble the primaries, indicating that there is little or no adaption to the new 
species. This is further evidence that the difficulties in sCJD transmission may be 
determined by agent strain rather than by a mis-match between species. It may 
simply be that sCJD strains are not replicated efficiently in these wild-type mice.  
 
4.6.2 sCJD MM1/MV1 agent strain 
Few if any differences were observed in transmission properties between brain 
homogenates from sCJD MM1 and MV1 cases. This suggests that the MM1 and 
MV1 subgroups represent a distinct strain of agent within sCJD. This finding is 
consistent with the current clinical and pathological classification of sCJD in which 
the MM1 and MV1 subtypes are grouped together as the ‘classical’ forms of sCJD 
(Parchi et al., 1999). Vacuolar degeneration typical of TSE infection was seen in a 
high percentage of mice following inoculation with both MM1 and MV1 
homogenate, indicating that transmission of sCJD is most efficient from these two 
subgroups.  Lesion profiles showed a similar pattern of TSE-specific vacuolation 
between with the 10 sCJD MM1 cases and the three sCJD MV1 cases, consistent 
with the proposal that these two subgroups share similar strain properties. PrP 
pathology, as judged by immunohistochemistry was limited in mice following 
inoculation with sCJD MM1 and sCJD MV1 isolates. This may be an indication that 
PrP accumulation in the mice occurs at a later stage in the progression of the disease, 
after the appearance of vacuolar degeneration. Alternatively, PrP pathology (as 
detectable by imunohistochemistry) may not a major pathological feature of sCJD in 
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wild-type mice. As mice were not sacrificed as a result of clinical TSE disease this is 
difficult to determine in the primary transmission series. However, 
immunohistochemical analysis of PrP deposition in mice sacrificed with clinical TSE 
following sub-passage of sCJD MM1, showed a restricted pattern of PrP deposition 
in the brain, supporting the proposal that PrP pathology may not be a major feature 
of sCJD in wild-type mice. Western blot analysis of CNS tissue from mice of all 
Prn-p genotypes after inoculation with sCJD MM1 and MV1 homogenates produced 
a PrPres type that was similar to the type 1 documented in the sCJD inocula. No 
observable difference was found in the molecular weight at the unglycosylated PrPres 
or the PrPres glycosylation ratio in mice inoculated with either sCJD MM1 or MV1 
brain homogenate. This is further supporting evidence indicating a single strain of 
agent associated with the sCJD MM1 and MV1 subgroups.  
 
4.6.3 sCJD MM2A agent strain 
Certain differences were seen in the transmission properties of the two sCJD MM2 
cases. In one of the MM2 cases, patient CJD 12, transmission properties showed 
subtle differences from those of the other five sCJD subgroups suggesting that the 
sCJD MM2 subgroup may represent a second strain of sCJD. In contrast to the 
MM1, MV1, MV2, VV1 and VV2 subgroups, clinical TSE disease was evident in a 
proportion of RIII mice following inoculation with inoculum from patient CJD 12. 
The resulting incubation period was 736 ± 9 days.  Although titres of infectivity in 
the primary inocula used in this series of transmissions are not known, one possible 
explanation for the appearance of clinical disease in this experimental group may 
simply be that titres of infectivity were higher in this inoculum compared to the other 
sCJD inocula or that the sCJD MM2 subtype is associated with high titres of 
infectivity. However, there was no evidence of this when comparing the intensity of 
the Western blot banding pattern from this MM2A case with that of the other 26 
sCJD inocula. Lesion profiling and PrPres typing of CNS tissue of the mice 
inoculated with this sCJD brain inoculum, provided further evidence that the sCJD 
MM2 subtype represents a distinct strain of sCJD.  Lesion profile from RIII mice 
produced a subtly different profile to that observed in RIII mice following challenge 
with inocula from the MM1 and MV1 brain isolates. Furthermore, the lack of any 
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vacuolar pathology and lesion profile in the VM and C57BL x VM mice also 
distinguished the sCJD MM2 subtype from the sCJD MM1 and MV1 subgroups. 
Western blot analysis of CNS tissue from RIII, VM and C57BL x VM mice showed 
conservation in the electrophoretic mobility and glycosylation pattern of the PrPres 
type 2A as detected in the inoculum from this CJD case, further distinguishing this 
sCJD MM2 brain isolate from the sCJD MM1 and MV1 subgroups. 
 
Experimental data from a second sCJD MM2 (patient CJD 11) inoculation was 
limited to two mouse lines (RIII and VM). Mice inoculated with this brain 
homogenate showed no evidence of the clinical TSE disease that developed in the 
RIII mice following challenge with inoculum from CJD 12. In this respect, this sCJD 
MM2 isolate resembled the sCJD MM1 and MV1 brain isolates. Furthermore, lesion 
profiling carried out with three RIII mice showing vacuolar pathology showed a 
pattern more consistent to that found with MM1 and MV1 isolates. Although frozen 
mouse tissue was unavailable in this experiment, this suggests that this sCJD MM2 
subtype transmits to the mice with a phenotype more commonly associated with 
sCJD MM1 and MV1 cases rather than that of the other sCJD MM2 inoculum. One 
explanation could that this sCJD MM2 brain isolate contained a minority type 1 
component that was undetected by PrPres typing of the inoculum. It may be that the 
minority type 1 is preferably selected by the recipient mice over the more abundant 
type 2 detected in the inoculum. In support of this explanation, this particular sCJD 
brain is known to contain both PrPres type 1 and type 2, as judged by analysis of a 
large cortical specimen used to prepare a sCJD reference standards by the National 
Institute of Biological Standards and Control (Minor et al., 2004). Therefore in this 
thesis, the results from CJD 12 may be more representative of transmission from a 
‘pure’ sCJD MM2 isolate in mice than those obtained from CJD 11 in which a 
mixture of PrPres types are likely. It would be interesting to re-examine these 
inoculum with an antibody specifically raised against PrPres type 1, to determine 
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4.6.4 sCJD MV2A, VV1 and VV2A agent strain  
Evidence of a TSE in mice following challenge with sCJD MV2, VV1 and VV2 
brain isolates was rare, in any of the Prn-p genotypes investigated. Inoculation of 
three sCJD MV2 isolates resulted in one mouse (from the 157 surviving over 250dpi) 
producing evidence for transmission of disease, with vacuolar degeneration and 
PrPres detected in the brain. Inoculation of four sCJD VV1 isolates similarly resulted 
in only a single mouse (from the 235 surviving over 250dpi) showing evidence of 
transmission with TSE associated vacuolar degeneration and PrPres detected in the 
brain. In the case of the sCJD VV2 subgroup, inoculation with five different VV2 
sources gave evidence of transmission in one mouse (from the 341 surviving over 
250dpi), again with vacuolar pathology and PrPres detected in the brain. This lack of 
transmission distinguished the brain inocula from these three sCJD subgroups from 
that of sCJD MM1, MV1 and MV2. One possibility for the lack of transmission in 
these sCJD subgroups is that lower levels of infectivity are associated with the 
frontal cortex tissue sampled from the MV2, VV1 and VV2 cases. However, this is 
unlikely, as Western blotting on extracts of these inocula showed comparable levels 
of PrPres to those observed in extracts of the sCJD MM1, MV1 and MM2 inocula 
(chapter 3). If PrPres does correspond to infectivity levels as has been suggested 
(Prusiner, 1998; Weissmann, 2004; Aguzzi et al., 2008), this implies that similar 
levels of infectivity were present in the different inocula tested and that the differing 
transmission characteristics most likely derive from strain-related properties.  
 
In any experimental transmission, a failure to transmit disease is often an indication 
of a ‘species barrier’ between the donor tissue and the recipient species. However, 
this thesis has confirmed that some sCJD subtypes do successfully transmit disease. 
Furthermore, findings from the subsequent mouse passage of sCJD MM1 brain 
isolates suggest that there may be no ‘species barrier’ present between the wild-type 
mice and the sCJD brain isolates. Therefore, it is possible, as has been discussed 
earlier (Section 4.6.1), that the sCJD MV2, VV1 and VV2 subgroups are associated 
with different ‘transmission barriers’ to that of the sCJD MM1, MV1 and MM2. 
Results would also suggest that the ‘transmission barrier’ to the development of 
disease from sCJD MV2, VV1 and VV2 subgroups is more difficult to overcome 
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than that of sCJD MM1, MV1 and MM2.  Further evidence for the existence of 
different ‘transmission barriers’ in the experimental transmission of CJD is provided 
in Chapter 5 where, the efficient transmission of vCJD with the development of 
clinical disease in the same mouse panel is distinct from all sCJD subgroups.  
 
The lack of transmission from these sCJD subgroups may also be evidence that these 
sCJD subgroups (MV2, VV1, and VV2) represent a further sCJD strain. This was 
also suggested in a comparable investigation on the transmission of the different 
sCJD subgroups in the bank vole (Nonno et al., 2006). A comparison of the findings 
from this thesis and the study in bank voles is discussed in Chapter 7, section 7.2.1. 
However, the possibility that these three sCJD subgroups could represent more that 
one strain of agent which can not be distinguished in this mouse model can not be 
discounted. Evidence that there are further strains of agent within these three sCJD 
subgroups has been supported through recent findings from a comparative study 
analysing the transmission properties of all six sCJD subgroups in humanised 
transgenic mice (Bishop, 2008; Bishop et al., 2010). Analysis of the transmission 
properties in this transgenic mouse model are examined in detail in Chapter 7 and 
indicate that two strains of agent are propagated in these transgenic mice following 
experimental challenge with sCJD MV2, VV2 and VV1; one associated with the 
MV2 and VV2 subgroups and a further strain associated with the sCJD VV1 
subgroup.  
  
4.6.4.1 Role of codon 129 genotype and PrP
res
 type in the transmission of sCJD in 
wild-type mice 
A further explanation for the lack of transmission from sCJD MV2, VV1 and VV2 
subgroups may reside in the mis-match between the PRNP codon 129 genotype of 
the donor inoculum and the corresponding Prn-p codon 128 in the recipient host   
(wild-type mice strains are all homozygous for methionine at the corresponding Prn-
p codon 128). Although this may explain the ‘transmission barrier’ between the mice 
and the human sCJD VV cases, it does not provide an explanation for the difference 
in transmission properties found between sCJD MV1 and MV2 cases. Isolates 
prepared from MV1 sources transmit successfully in the mice whereas the MV2 
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isolates do not appear to. It is reasonable to suggest that such differences in the 
transmission properties may be related to agent strain. As both subgroups are 
heterozygous at PRNP codon 129, one possibility is that the strain-specific 
differences between sCJD subgroups may in part be attributed to the differences in 
the PrPSc conformation between these two sCJD subtypes. This is further supported 
by differences observed in the transmission properties between mice inoculated with 
sCJD MM1 and sCJD MM2 brain homogenate (Chapter 4, section 4.6.).  This is 
consistent with the proposal that distinct TSE strains are associated with differences 
in PrPSc conformation and (Bessen and Marsh, 1992a; Bessen and Marsh, 1994; 
Collinge et al., 1996; Telling et al., 1996) and glycosylation  (Collinge et al., 1996, 
Lasmezas et al., 1996, Hill et al. 1997). However, the question of whether the 
different PrPres types alone could encode agent strain is still unclear.  
 
Another possible explanation for the lack of transmission in these three sCJD 
subgroups (which would be difficult to determine within the bounds of this 
transmission series) is that there are differential allelic contributions in the formation 
of PrPSc in the heterozygotes. This proposal has been made in a recent study by Jones 
and co-workers using the cell-free PMCA method. The study examined the 
efficiency of sCJD PrPSc, from all six sCJD subgroups, as seeds in the conversion of 
PrPC to PrPSc in substrates prepared from humanised transgenic mouse brain tissue of 
each of the PRNP codon 129 genotypes (Jones et al., 2008). Results from the PMCA 
conversion process confirmed that a complex relationship exists between the sCJD 
patients codon 129 genotype and the PrPres type in the brain. In agreement with the 
findings of this thesis, efficiency in the conversion of PrPC to PrPSc by PMCA was 
determined in part by compatibility in the seed/substrate PRNP codon 129 genotype. 
In this thesis the seed corresponds to the donor human tissue with the recipient 
mouse corresponding to the MM substrate. Jones and co-workers found that seeds 
from sCJD MM1, MV1 and MM2 amplified PrPSc in the MM substrate, whereas no 
amplification of PrPSc was observed from seeds of sCJD MV2, VV1 and VV2 cases 
in the MM substrate. By extending the investigations to include MV and VV 
substrates Jones provided evidence that seeds of sCJD VV can efficiently amplify 
PrPSc but only in VV substrate. This supports the proposition that the lack of 
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transmission in the sCJD VV cases in this thesis may be in part a result of mis-match 
in the PRNP/Prn-p genotypes. Furthermore, differences were found in the 
amplification of seeds from sCJD in MV patients. As described, sCJD MV1 cases 
behaved similarly to MM cases and amplify PrPSc in MM substrates. However, seeds 
from MV2 cases behaved similarly to VV cases, showing evidence of amplification 
only in VV substrates. This would suggest the PrPSc in sCJD MV1 cases is 
predominantly composed of PrPSc containing methionine at PRNP codon 129, 
whereas the PrPSc in MV2 cases consist predominantly of PrPSc containing valine at 
PRNP codon 129. These results are consistent with the findings of this thesis and 
might explain the differences observed in the transmission properties between the 
MV1 and MV2 cases.   
 
4.6.4.2 Alteration in PrP
res
 type following experimental challenge of sCJD in wild-
type mice  
Biochemical typing of PrPres in CNS tissue from the one RIII mouse showing 
positive transmission after inoculation with a sCJD MV2 brain homogenate, showed 
an electrophoretic mobility and glycosylation pattern resembling that seen in sCJD 
type 1 cases as well as  that seen in RIII mice after inoculation with sCJD MM1, 
MV1 and VV1 (one positive mouse) inocula. Therefore, the PrPres type associated 
with transmitted infection in this mouse is different in conformation to the PrPres 
detected in the inoculum. Although caution is advisable in interpreting data based on 
a single mouse, such changes in the fragment size of unglycosylated PrPres have also 
been reported in studies investigating the transmission properties of vCJD in 
transgenic mice expressing human PrP (Collinge et al., 1996; Hill et al., 1996; 
Asante et al., 2002; Beringue et al., 2008; Bishop et al., 2008; Bishop et al., 2010).  
 
The detection of a different PrPres type in one mouse following transmission of a 
single MV2 inoculum may be an indication of the existence of agent strain variation 
within some sCJD subtypes. Strain variation has been widely reported in TSEs and is 
best documented following transmission of TSE isolates in mice (Bruce, 2003). It is 
proposed that a change in species or even in the mouse line allows the selection of 
minor variant strains that replicate more efficiently in the host.  In the case of the 
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sCJD MV2 transmission, it is possible that mouse transmission of sCJD has 
produced a strain associated with a different PrPres conformation, one more 
commonly found with transmitted infection of cases of sCJD MM and MV type 1 
and that detected in a single mouse following challenge with a VV1 isolate. 
 
A further possibility for the detection of a different PrPres type on  sCJD transmission 
is outlined in the  “conformational selection model” for cross-species transmission 
(Collinge, 1999). This model of TSE transmission proposes that within the 
mammalian PrP sequence there are a number of possible PrPres conformations. The 
extent of any given ‘species’ or ‘transmission barrier’ is determined by the 
compatibility between the favoured or allowed conformations for PrPres derived from 
the donor and recipient species. Substantial overlap between these possible PrPres 
conformations between donor and recipient species would result in a low 
‘transmission barrier’ compared to a high ‘transmission barrier’ between two species 
with fewer preferred PrPSc conformations in common. Overall, the lack of any 
clinical disease in the mice suggest a substantial ‘transmission barrier’ across the 
whole sCJD series; however, transmission of disease across all mouse lines is more 
readily achieved from sCJD cases with a PrPres type 1 and in which there is a match 
at codon 129 on the PrP gene between the human inoculum and the recipient mouse. 
Therefore, in the transmission of sCJD from MV2 and VV2 cases there is an even 
greater ‘transmission barrier’ to overcome for the development of disease. The 
detection of a PrPres type 1 in the single RIII mouse following challenge with an 
MV2 isolate may reflect the presence of a minority PrPres type 1 component within 
the inocula that was undetected by conventional Western blotting using the anti-PrP 
antibody 3F4, an antibody shown to have quantitative limitations in the co-detection 
of type 1 and type 2 (Yull et al., 2006).  Although, type 2 was the dominant PrP 
conformation detected within the inoculum, the presence of a minority component of 
type 1 within the inoculum would increase the compatibility between this preferred 
PrPres type of the mouse and the incoming PrPres type of the inoculu. This would 
result in transmission in the one mouse showing a different PrPres type from that 
detected in the original inocula. However, this ‘conformational selection model’ does 
not hold true with the transmission of vCJD (Chapter 5), and to a much lesser degree 
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sCJD MM2 isolates, where infectivity is readily and efficiently transmitted in the 
mice from a human TSE with a type 2 PrPres. 
 
4.6.5 Confirmation of TSE infectivity in the absence of clinical TSE disease 
The development of a TSE in a proportion of mice following subsequent mouse-to-
mouse passage of three sCJD MM1 isolates confirmed the presence of infectivity 
within clinically asymptomatic mice after primary transmission. The presence of 
TSE infectivity in asymptomatic carriers is not a feature unique to sCJD 
transmissions in wild-type mice. Infectivity has been reported in the transmission of 
hamster scrapie in wild-type mice (Race and Chesebro, 1998; Race et al., 2001; Race 
et al., 2002) and in the transmission of vCJD and BSE in humanised transgenic mice 
(Asante et al., 2002; Hill and Collinge, 2002).   
  
4.6.5.1 Isolation of distinct sCJD mouse-passaged strains following serial passage 
in different mouse Prn-p genotypes 
Mean incubation period data was available for all VM experimental groups following 
passage of brain isolates in Prn-pb mice. The development of clinical TSE disease in 
these VM groups is indicative of a reduction in the ‘transmission barrier’ which was 
present on primary transmission, and is a characteristic feature of subsequent sub-
passage of TSE isolates within the same host species. In contrast, Prn-pb-passaged 
isolates produced very little evidence of clinical disease in Prn-pa mice. In fact, 
evidence of transmission as determined by clinical disease actually reduces after a 
further VM-passage. This suggests that the Prn-pa mice may not necessarily be 
infected with the same strain of agent that is causing a clinical disease in the VM 
mice and whatever strain is infecting them is gradually being lost. Sub-passage of 
brain isolates in Prn-pa lines showed very little evidence of a reduction of the 
‘transmission barrier’ which was evident on primary transmission. In fact, sub-
pssage of brain isolates in Prn-pa mice suggests that there may be no transmission 
barrier between sCJD and wild-type mice. Incubation periods, if present were long, 
and evidence of transmission reduced following a further Prn-pa passage. These 
findings may be a reflection of lower levels of infectivity present in the mouse brain 
when compared to the original human sCJD since the majority of sCJD inoculated 
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mice, including those selected for serial passage were sacrificed before the 
development of a clinical TSE disease. Alternatively it may be that the sCJD isolates 
may not have adapted in the mouse lines.  
 
The differences found in the clinical disease in VM mice following passage of brain 
isolates in either Prn-pa and Prn-pb mice, implies the isolation of two distinct mouse-
passaged strains of sCJD MM1, selected according to the Prn-p genotype of host 
used for passage. Such a divergence of strains has been seen for a large number of 
TSE isolates from a range of different species. Importantly, transmission properties 
in the two strains isolated by VM mice in this investigation are unlike any previously 
isolated from any other source including vCJD (Moira Bruce, personal 
communication).  
 
4.6 Chapter conclusion 
This study has identified two distinct strains of sCJD by comparison of their 
transmission properties in wild-type mice; one associated with the MM1/MV1 
subgroups and another associated with the sCJD MM2 subgroup. The lack of 
transmission from the sCJD MV2, VV1 and VV2 inocula in the same mouse panel 
implies that these three subgroups may represent a further sCJD strain or sCJD 
strains. The identification of these distinct sCJD strains are in agreement with that of 
previous studies investigating the transmission properties of sCJD in humanised 
transgenic models (Asante et al., 2002; Korth et al., 2003; Taguchi et al., 2003; 
Bishop, 2008; Bishop et al., 2010) and bank voles (Nonno et al., 2006) and appear to 
largely concur with the current clinico-pathological classification of sCJD (Parchi et 
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Chapter 5: Characterisation of the variant Creutzfeldt-Jakob 
agent by transmission to wild-type mice 
 
5.1 Objective  
1. To characterise the vCJD agent strain after primary transmission of human 
brain tissue in panels of wild-type type mice using the standard strain typing 
properties of incubation period and lesion profiles, plus a full 
immunohistochemical analysis of PrP in the infected mouse brain and 
analysis of the PrPres molecular subtypes present. 
2. To further extend the analysis of the vCJD agent strain by similar analysis 
after subsequent mouse-to-mouse passage. 
 
5.2 Introduction 
Variant CJD was first identified as a new form of human TSE in 1996 on the basis of 
a series of ten patients with a clinico-pathological phenotype that was distinct from 
other previously recognised forms of human TSE (Will et al., 1996). In contrast to 
the phenotypic heterogeneity observed in sCJD, these patients all showed a 
remarkably uniform clinical presentation, beginning with neuropsychiatric 
symptoms, such as anxiety or depression, dysaethesia and ataxia. In addition, the 
neuropathological features were remarkably similar between cases, with the 
appearance of the distinctive “florid plaques” (Ironside et al., 1996). Subsequent 
biochemical analysis of brain tissue by Western blotting demonstrated a single PrPres 
type associated with vCJD cases, characterised by a glycoform profile dominated by 
the diglycosylated fragment of PrPres (Collinge et al., 1996; Head et al., 2004a). 
Crucially, the PrPres type found in vCJD cases differed from that of the two major 
PrPres types (type 1 and type 2A) associated with sCJD cases (Parchi et al., 1996). 
The prion hypothesis proposes that strain-specific information is enciphered in the 
different biochemical conformations of PrP. In accordance with this hypothesis, the 
unique PrPres type associated with vCJD cases was used to argue that vCJD 
represents the result of infection with a single strain of agent which is distinct from 
other human TSEs.   
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The identification of vCJD so soon after the BSE epidemic in the UK raised concerns 
that vCJD was causally linked to the BSE agent. Now, almost twenty years on from 
the peak of the BSE epidemic, a wealth of experimental data supports the initial 
hypothesis that vCJD emerged as a result of human infection with the BSE agent, 
most probably through the consumption of contaminated meat products (Collinge et 
al., 1996; Lasmezas et al., 1996; Bruce et al., 1997; Hill et al., 1997; Scott et al., 
1999).  
 
As of December 2011, 176 cases of vCJD have been identified in the UK 
(http:www.cjd.ed.ac.uk/figures.htm). Although case numbers remain relatively low, 
having reached a peak incidence in 2000, a number of important concerns still 
surround vCJD. To date, all pathologically and biochemically confirmed clinical 
cases of vCJD for which codon 129 is known have occurred in patients who are 
homozygous for methionine at codon 129 of PRNP. The susceptibility of the other 
codon 129 subgroups to infection with the BSE agent and the development of clinical 
vCJD remain uncertain, although it appears that MV and VV individuals may also be 
susceptible to infection. In a retrospective study investigating the prevalence of vCJD 
in approximately 13,000 tonsil and appendix specimens, three specimens stained 
positive for the disease-associated prion protein (Hilton et al., 2004a). Further 
investigations confirmed two of these specimens were homozygous for valine at 
PRNP codon 129 (Ironside et al., 2006). This was the first indications that the VV 
subgroup was susceptible to vCJD infection. In addition, the recent observations that 
vCJD appears to be transmissible by blood transfusion and by blood components 
highlighted two cases of peripheral infection in patients heterozygous at codon 129 
(Peden et al., 2004; Peden et al., 2010). More recently, a case of clinical vCJD was 
also reported in a heterozygous individual (Kaski et al., 2009). However, as an 
autopsy was not carried out on this patient, the diagnosis was based on clinical 
criteria and has not been confirmed by neuropathological examination or by Western 
blot analysis of PrPres type. These cases and the retrospective tonsil/appendix study 
suggest that all PRNP codon 129 subgroups may be susceptible to vCJD infection. 
This has been supported by animal models in which experimental transmission of 
vCJD in transgenic mice expressing human PrP with the codon 129 MM, MV and 
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VV genotypes showed all genetic groups may be susceptible to vCJD but that 
patients with the MV and VV genotype may have a lengthy preclinical disease 
(Bishop et al., 2006). The PRNP codon 129 genotype has been shown to influence 
the phenotype of other human TSEs (Parchi et al., 1999) and it is not known if any 
future cases of BSE transmission in these other genetic subtypes may show an altered 
clinical and pathological phenotype to that of vCJD in methionine homozygous 
individuals. The continued surveillance of vCJD and characterisation of the agent 
strain in these other genetic subgroups will play an important role in the 
identification of these cases. 
 
The detection of infectivity and PrP deposition in peripheral tissues in vCJD (Bruce 
et al., 2001; Glatzel et al., 2003; Haik et al., 2003; Peden et al., 2004; Head et al., 
2004b; Peden et al., 2006; Peden et al., 2007; Notari et al., 2010) and now the 
apparent transmission of vCJD via infectivity in blood and blood products (Llewelyn 
et al., 2004; Peden et al., 2004; Wroe et al., 2006; Health Protection Agency, 2009b; 
Peden et al., 2010), highlight the risk of possible secondary transmission of vCJD. 
An additional concern is the theoretical possibility of alterations in agent strain on 
secondary transmission, which may result in a modified disease phenotype and 
biochemical profile.  
 
Experimental strain typing in mice and biochemical characterisation of PrPres has 
produced convincing evidence that vCJD is caused by the same strain of agent that 
caused BSE (Collinge et al., 1996; Bruce et al., 1997; Hill et al., 1997). However the 
existence of more than one BSE strain, which may have already infected humans, has 
been suggested in a publication examining the transmission of BSE into transgenic 
mice expressing human PrP with methionine at codon 129 (Asante et al., 2002). In 
this study, Western blot analysis of the PrPres type in the mouse brain after challenge 
with BSE resulted in more than one biochemical phenotype, one with a BSE/vCJD-
like profile and a second that was indistinguishable from that of sCJD. This raises 
concerns that patients with a phenotype consistent with sCJD may have actually 
acquired the disease from infection with the BSE agent. A similar finding has been 
reported in a different humanised transgenic mouse line expressing methionine 
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homozygosity following inoculation with vCJD (Beringue et al., 2008). However, in 
this study the vCJD/BSE biochemical profile was retained in the spleen. 
 
In response to these and other concerns surrounding the vCJD agent, this chapter 
aims to provide a full characterisation of the vCJD agent on primary transmission in 
panels of wild-type mice. Extensive studies of the transmission of vCJD in numerous 
transgenic mouse models have provided valuable information on the vCJD agent. 
However, at present the characterisation of different TSE strains is most highly 
developed using transmission into non-transgenic (wild-type) mice. The original 
vCJD strain typing paper by Bruce and co-workers (Bruce et al., 1997) remains one 
of the most compelling pieces of evidence that vCJD resulted from the same major 
strain of agent that caused BSE and that the BSE/vCJD agent is distinct from the 
causing sCJD. A limitation to this paper is that the characterisation of the vCJD agent 
was based on the incubation period and lesion profiles produced on primary 
transmission from three vCJD cases to a single wild-type mouse line (RIII). The data 
presented in this chapter significantly extends these studies by increasing the number 
of cases transmitted to ten and providing the complete incubation period and lesion 
profile data in a larger panel of mouse lines. In addition the analysis is extended to 
include the biochemical and immunohistochemical analysis of the abnormal prion 
protein accumulation in the mice. During the transmission of different TSE isolates 
to mice, different strains are often isolated from a single source by serial passage 
through mice of different Prn-p genotypes, so for a full characterisation of vCJD it 
was necessary to do strain typing both on primary transmission to mice and on 
subsequent mouse-to-mouse passage of the isolate.  
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5.3 Experimental results: Primary transmissions 
Eleven primary transmission experiments were carried out in panels of wild-type 
mice from brain homogenate prepared from ten neuropathologically confirmed cases 
of vCJD (two separate transmission experiments were carried out with different 
frontal cortex samples taken from one of the vCJD patient). Patient details for these 
ten cases (CJD 28 – CJD 37) are provided in Chapter 2, Table 2.1. Brain homogenate 
was prepared from either grey matter tissue from the cerebellar cortex or the frontal 
cortex, with inoculations either via a single IC injection or a combination of the IC 
and IP routes (Chapter 2, Table 2.3).  
 
5.3.1 Incubation periods and incidence of disease 
All eleven vCJD brain homogenates transmitted successfully to all three mouse lines 
(RIII, C57BL and VM) and the C57BL x VM cross, with the appearance of a 
progressive clinical disease and/or the presence of TSE-specific vacuolar 
degeneration in the brains of mice after histological analysis. The incidence of 
clinical disease and vacuolar pathology in each experimental group, with results 
grouped according to brain region inoculated and route of injection are detailed in 
Table 5.1. Mean incubation periods were calculated for experimental groups with a 
minimum of five mice receiving a positive score for both clinical signs of disease 
and the presence of vacuolar pathology in the brain. Mean incubation period data for 
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Table 5.1: Primary transmission from vCJD brain homogenate 
 
Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice 
challenged with brain homogenate from vCJD cases. Mice sacrificed with 
intercurrent disease before 250 dpi were excluded from the analysis. Incubation 





RIII C57BL VM C57BL x VM 












vCJD 28*  14/14 (307 ± 4) 14/14 10/10 (428 ± 4) 10/10 13/13 (464 ± 7) 13/13 6/9 (673 ± 10) 9/9 
vCJD 29* 17/18 (309 ± 8) 18/18 15/16 (422 ± 8) 15/16 16/21 (492 ± 12) 16/21 11/14 (699 ± 3) 14/14 
vCJD 30*  
 
17/17 (306 ± 3) 
 
16/17 13/15 (426 ± 9) 15/15 22/22 (444 ± 6) 21/22 14/19 (685 ± 6) 19/19 
vCJD 31† 
 
13/20 (402 ± 4) 
 






17/25 (383 ± 7) 
 
24/25 9/18 (524 ± 8) 12/18 8/23 (586 ± 12) 20/23 2/24 (783,621) 16/24 
vCJD 33† 20/23 (362 ± 8) 20/23 
 












vCJD 34† 21/22 (342± 6) 22/22 12/17 (466 ± 16) 16/17 
 
15/20 (531 ± 14) 
 





10/13 nd nd 9/13 (556 ± 13) 12/13 nd nd 
vCJD 35‡ 
 
17/18 (353± 9) 
 





17/20 nd nd 
 
21/22 (523± 12) 
 
21/22 nd nd 
vCJD 37‡ 
 
17/21 (382± 6) 
 
16/21 nd nd 
 
11/18 (536± 9) 
 
16/18 nd nd 
 
*  Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from vCJD cerebellar tissue 
†  Intracerebral and intraperitoneal injection with 10% brain inoculum prepared from vCJD frontal cortex tissue 
‡   Intracerebral injection with 10% brain inoculum prepared from vCJD frontal cortex tissue 
nd  Nnot done 
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Figure 5.1: Incubation times in vCJD challenged mice  
 
Mean incubation periods in RIII, C57BL, VM and C57BL x VM mice after 
experimental challenge with brain homogenate from ten vCJD cases. Data are mean 
± S.E.M. (FC) frontal cortex, (CB) cerebellar cortex, (IC) intracerebral inoculation 
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Each vCJD brain homogenate gave the same order of appearance of clinical signs in 
the mouse lines inoculated. The shortest incubation periods were consistently 
observed in the two Prn-pa mouse lines (RIII and C57BL) with the longest in the 
C57BL x VM cross. The RIII and C57BL mice, although of the same Prn-p 
genotype, consistently showed incubation period differences of around 100 days, 
with mean incubation periods up to a standard clinical endpoint ranging from 306 ± 3 
to 402 ± 4 days (± S.E.M) in the RIII mouse line compared to 422 ±8 to 524 ± 1 days 
(± S.E.M) in the C57BL line.  Incubation periods were broadly similar irrespective of 
the brain region (frontal cortex or cerebellum) inoculated or the route of injection. 
However, the exact timing of the appearance of clinical symptoms showed some 
variability between individual brain homogenates, most noticeably with homogenate 
prepared from the frontal cortex of the brain.  Shorter incubation periods were 
observed with homogenate prepared from cerebellar cortex, independent of the route 
of injection. In RIII mice, inoculation via a combination of the IC and IP routes with 
homogenate prepared from frontal cortex produced means of between 342 ± 6 and 
402 ± 4 days (± S.E.M.) compared to means of between 306 ± 3 and 309 ± 8 days (± 
S.E.M.) with homogenate from the cerebellar hemisphere inoculated via the same 
route. These results imply that levels of infectivity may be higher in the cerebellum 
region than in the frontal cortex.   
 
5.3.2 Patterns of vacuolar pathology- lesion profiles 
Vacuolar pathology typical of TSE infection was observed in the majority of mice 
challenged with each vCJD brain homogenate (601/678 mice analysed) (Table 5.1). 
This confirmed the diagnosis of a TSE for all clinically affected mice. All but three 
experimental groups (C57BL x VM mice inoculated with brain homogenate from 
patients CJD 31, CJD 32 and CJD 33) had sufficient mice with a positive score for 
clinical signs of disease and vacuolar degeneration in the brain for the construction of 
a lesion profile. The lesion profiles for all three mouse lines and the C57BL x VM 
cross following inoculation with brain homogenate from all ten vCJD cases are 
shown in Figure 5.2.  A remarkably similar pattern of mild-to-moderate vacuolation 
was observed with each vCJD homogenate regardless of the brain region used in the 
inoculation or the route of injection.  There was some variability in the intensity of 
the vacuolation between individual homogenates, most noticeably in the VM and 
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C57BL x VM cross. In the C57BL x VM mice, the profile was much lower in the 
one group inoculated with frontal cortex tissue compared to the profiles of the three 
groups inoculated with cerebellar tissue. This was also found to a lesser extent in VM 
mice, where profiles were also slightly higher in those groups inoculated with 
cerebellar tissue. However, in general the pattern of vacuolation was similar.  
 
In contrast to transmission of sCJD from brain homogenates (Chapter 4), patterns of 
vacuolar degeneration in vCJD-inoculated mice differed between the different mouse 
Prn-p genotypes. The RIII and C57BL mice, both of the Prn-pa genotype, produced 
a distinct pattern of mild-to-moderate vacuolation, consistently targeting the 
hypothalamus (scoring region G4) with some prominent vacuolation in the medulla 
(scoring region G1) and the septum (scoring region G7). This pattern differed from 
those in the VM (Prn-pb) mice and the C57BL x VM cross which show a more 
widespread targeting of moderate vacuolation throughout the scoring regions of the 
mouse brain. In general, vacuolar pathology was more severe in the C57BL x VM 
cross, perhaps reflecting the longer incubation period in this mouse line. These 
vacuolation profiles clearly show a similarity in lesion distribution between the ten 
vCJD cases. 
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Figure 5.2: Lesion profiles for vCJD inoculated mice 
 
Lesion profiles are constructed for groups in which there was a minimum of five 
mice with a positive score for both clinical signs of TSE and TSE-specific vacuolar 
pathology. Vacuolation was scored at nine specified grey (G) matter regions and 
three white (W) matter regions of the mouse brain. Lesion profiles are shown with 
standard error bars (± S.E.M). Each line represents a different vCJD transmission. 
(Black line) brain homogenate prepared from frontal cortex tissue; (red line) brain 
homogenate prepared from the cerebellar cortex. No distinction is made between 
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5.3.3 Deposition of PrP in the mouse brain  
Lesion profiles in vCJD-infected mice differed between mouse lines of different PrP 
genotypes. Therefore, in investigating the patterns of PrP deposition in the brain of 
vCJD-infected mice, all four mouse lines were analysed. Immunohistochemistry was 
carried out on 5µm formalin fixed, formic acid treated paraffin sections of brain from 
mice challenged with five different vCJD sources. In each experiment, seven mice of 
each mouse line were analysed; five inoculated with CJD brain homogenate and two 
saline injected controls. All vCJD-infected mice selected for analysis had received a 
positive score for both clinical disease and vacuolar pathology. 
Immunohistochemistry was carried using the highly sensitive Catalyzed Signal 
Amplification System (CSA) as described in chapter 2, section 2.6.4. 
 
Deposition of the abnormal prion protein was observed in all vCJD challenged mice 
examined, further confirming the successful transmission of a TSE from vCJD brain 
homogenate. Patterns of PrP accumulation in the mouse brain were remarkably 
similar between mice inoculated with the different vCJD homogenate. Overall, 
immunohistochemistry showed an intense, widespread deposition of granular and 
peri-cellular PrP staining throughout the brains of infected mice at clinical endpoint. 
Representative examples of brain sections, from each mouse line, immunolabelled 
for PrP using the anti-PrP antibody 6H4 are shown in Figure 5.3. In contrast to lesion 
profile data, patterns of PrP deposition were similar in the different mouse PrP 
genotypes, with the most prominent depositions of PrP in the medial habenular 
nucleus (MHb), the medulla, the thalamus and around areas of intense vacuolation 
(Figure 5.3).  Granular PrP deposits were also observed in the molecular and granular 
layer of the cerebellum. Subtle differences in PrP staining patterns were observed in 
the hippocampal region between the different Prn-p genotypes; Prn-pa mice (RIII 
and C57BL) showed a faint granular deposition of PrP within the CA2 region of the 
hippocampus (Figure 5.3b and d) while the Prn-pb (VM) and the C57BL x VM cross 
showed a more intense deposition of PrP targeting the dentate gyrus (Figure 5.3f and 
h). Amyloid plaques, a common and characteristic feature of vCJD, were not a 
prominent feature in the mice, and were observed only in the VM mice and the 
C57BL x VM mice, mainly restricted to the corpus callosum (Figure 5.4a and b). 
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Intensity of PrP staining was consistently higher in the Prn-pb mice and the C57BL x 
VM cross when compared to the Prn-pa mice, perhaps a reflection of the longer 
incubation periods occurring in these two mouse Prn-p genotypes. No evidence of 
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Figure 5.3: PrP  deposition in vCJD inoculated mice 
 
The deposition of PrP in the mice was examined at five defined brain levels of which 
two are shown here (a, c, e, f) the medulla and cerebellum, (b, d, f, h), hippocampus, 
habenula, thalamus, corpus callosum and cerebral cortex. Sections shown were 
labelled with the anti-PrP antibody 6H4 in combination with the CSA detection 
method, visualised with DAB and counterstained with haematoxylin. Corpus 
callosum (CC), CA2 region of the hippocampus (CA2), dentate gyrus (DG), medial 
habenular nucleus (MHb), thalamus (Th). Original magnification; x25 (a, c, e, g), 
x50 (b, d, f, h). 
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Figure 5.4: Amyloid plaques in vCJD inoculated mice 
 
Amyloid plaques in a VM mouse challenged with vCJD brain homogenate. (a) 
Haematoxylin and eosin staining showing the presence of amyloid plaques (arrows) 
within the corpus callosum. (b) Serial section labelled with the monoclonal anti-PrP 
antibody 6H4 in combination with the CSA detection method, visualised with DAB 
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5.3.4 Astrocytic proliferation in vCJD challenged mice 
Astrocytosis within the brain is a characteristic feature of TSEs. Immunolabeling for 
GFAP was carried out in the mice to determine if there was an upregulation in GFAP 
in the mouse brain that would indicate the development of astrocytosis. All mice 
examined showed a widespread and marked upregulation in GFAP staining when 
compared to saline injected controls, indicative of astrocytosis within vCJD-infected 
mice (Figure 5.5). This upregulation in GFAP was observed in mice of all PrP 
genotypes examined. Staining for GFAP was most extensive around areas of PrP 
accumulation; specifically in the medulla, thalamus and hippocampus region and 
throughout the mid-brain. As was observed with the deposition of PrP, astrocytosis 
appeared more extensive in the Prn-pb mice and Prn-Pab cross when compared to the 
Prn-p
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Figure 5.5: GFAP labelling in vCJD inoculated mice 
 
Extensive astrocytosis within the brains of vCJD challenged mice (a, c, e) when 
compared to saline injected controls (b, d, f). GFAP staining was most extensive 
within the (a) midbrain and the (c) medulla of infected mice compared to (b, d) 
saline inoculated controls. The dentate gyrus showing an upregulation of GFAP in 
(e) infected mice when compared to (f) uninfected controls. All sections shown are 
from VM mice and are labelled with the anti-GFAP antibody in combination with the 
ABC detection method, visualised with DAB and counterstained with haematoxylin. 
Original magnification; x50 (a, b), x100 (c, d), x200 (e, f). 
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5.3.5 Biochemical isotyping of PK resistant PrP
Sc
 
To investigate whether the vCJD biochemical phenotype is maintained on 
transmission to mice, Western blot analysis of the PrPres type was carried out on 
vCJD-infected mice from all mouse PrP genotypes using standard Western blotting 
methods as described in Chapter 2, section 2.7. All mice examined were scored 
positive for the appearance of clinical signs of disease and vacuolar pathology. 
 
PrPres was readily detected in the brain in all vCJD-infected mice examined. Results 
showed that important aspects of the biochemical phenotype of vCJD brain PrPres 
were maintained after primary transmission to the mice. Western blot analysis of 
PrPres in CNS tissue from infected mice of all four mouse lines produced a 
glycosylation pattern closely resembling that of vCJD brain tissue, characterised by 
the predominance in the diglycosylated form of the protein (Figure 5.6). A subtle 
difference in the electrophoretic mobility of the unglycosylated form of the protein 
was found between the mouse and human brain samples, suggesting some variation 
in the size of the protease-resistant core of the mouse and human protein, either 
because of differences in the exact truncation point for PK or because of sequence 
differences between human and murine PrP. A feature of the experimentally infected 
mice, not observed in vCJD in humans, was the appearance of the unglycosylated 
form of the protein as a doublet composed of distinct upper and lower bands (Figure 
5.7). The relative amounts of the two bands in the doublet varied and appeared to 
correlate with the different Prn-p genotypes; the Prn-pa mice appeared to show 
predominance of the lower band of the doublet, whereas Prn-pb mice had 
predominance in the upper band. Both the upper and lower band of the doublet was 
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Figure 5.6: Western blot analysis of PrP
res
 in vCJD inoculated mice 
 
Western blot analysis of PrPres in CNS samples of RIII, C57BL, VM and C57BL x 
VM (CV) mice after experimental transmission of vCJD brain homogenate. Tissues 
are analysed after digestion with proteinase K and probed with the anti-PrP antibody 
6H4. Mouse samples (M) are run alongside a human (H) sCJD MM1 type 1 (T1) and 
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Figure 5.7: Further Western blot analysis of PrP
res
 in vCJD inoculated mice 
 
Western blot analysis of PrPres in CNS samples of RIII, C57BL (C57), VM and 
C57BL x VM (CV) mice after experimental transmission of vCJD brain homogenate. 
Tissues are analysed after digestion with proteinase K and probed with the anti-PrP 
antibody 6H4. Mouse samples (M) are run alongside a human (H) sCJD MM1 type 1 
diagnostic standard (T1) and a human vCJD diagnostic standard (T2B). Molecular 
weight makers (MW) are shown in kDa. (U) Upper band of the unglycosylated 
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5.4 Experimental results: mouse-to-mouse passage 
Further characterisation of the agent strain in vCJD was carried out by conducting 
analysis of two serial mouse-to-mouse passages of brain isolates derived from two 
different vCJD cerebellar samples (patients CJD 28 and CJD 29).  Homogenates 
were prepared from the brains of a single RIII, VM or C57BL mouse which had 
shown both clinical and pathological signs of a TSE after primary challenge of 
vCJD. Homogenates were inoculated via a single IC injection into all three mouse 
lines and the C57BL x VM cross. In each case, this was repeated for a further mouse-
to-mouse passage. A diagrammatic representation of the sub-passage experiments is 
shown in chapter 4, Figure 4.24. 
 
5.4.1 Incubation periods and incidence of disease 
Each brain isolate transmitted successfully in mice of all Prn-p genotypes. Details of 
the incidence of clinical disease and vacuolar degeneration after passage in Prn-pa 
and Prn-pb mice are provided in Tables 5.2a and 5.2b, respectively.  The two 
cerebellar sources provided similar results, with the incidence of clinical and 
pathological disease 100% in most groups and close to 100% in the others. Mean 
incubation periods shortened dramatically on the first mouse-to-mouse passage for 
all experimental groups, consistent with the removal of the ‘species barrier’ between 
the donor and recipient which was present in the primary transmission (Figure 5.8).  
Incubation periods were broadly similar between the first and second mouse-to-
mouse passages, suggesting that the vCJD agent stabilises almost immediately on 
passage in mice. Sub-passage in Prn-pa mice (RIII or C57BL) resulted in an identical 
ranking of incubation periods in the mouse genotypes to that seen in primary 
transmissions (Figure 5.8a and b), whereas a change in order was found on sub-
passage in Prn-pb mice (VM) (Figure 5.8c). Furthermore, sub-passage in Prn-pb mice 
produced the shortest incubation period observed in this transmission series, with 
mean incubation periods as low as 106 days in VM recipients (Figure 5.8c). These 
distinct rankings of incubation period indicate that serial mouse passage of these two 
vCJD brain isolates has resulted in the isolation of two variant strains of agent, 
selected according to which has the shorter incubation period in the Prn-p genotype 
of host used for passage. 
   
 199 




Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice after two serial mouse-to-mouse passages of isolates 
derived from cerebellar homogenates from two vCJD patients. Mice sacrificed with intercurrent disease before 250 dpi were excluded 




Recipient mouse lines  
 
 RIII C57BL VM C57BL x VM 
   Donor  tissue source 
Clin Vac path Clin Vac path Clin Vac path Clin Vac path 
 
vCJD 28  RIII         1st  pass 
 
12/12 (180 ± 1) 
 
12/12 8/9 (208 ± 3) 9/9 11/11 (365 ± 6) 11/11 10/10 (560 ± 7) 10/10 
   
                                2nd pass 
 
9/10 (171± 1) 
 
10/10 12/12(194 ± 3) 12/12 10/12 (326 ± 7) 12/12 10/10 (527 ± 2) 10/10 
 
                C57BL     1st pass 
 
10/10 (169 ± 2) 
 
10/10 4/4 (199 ± 2) 4/4 10/11 (336 ± 9) 11/11 10/10 (548 ± 4) 10/10 
 
                                2nd pass 
 
9/9 (165 ± 2) 
 
9/9 8/9 (199 ± 2) 9/9 12/12 (332 ± 9) 12/12 10/10 (546 ± 13) 10/10 
 
vCJD 29   RIII        1st  pass 
 
10/10 (175 ± 1) 
 
10/10 12/12(204 ± 2) 12/12 12/12 (316 ± 8) 12/12 9/10(547 ± 4) 10/10 
  
                                2nd pass 
 
12/12 (164 ± 1) 
 
12/12 12/12(198 ± 1) 12/12 11/11 (304±10) 11/11 9/9 (527 ± 5) 9/9 
 
                C57BL     1st pass 
 
12/12 (176 ± 3) 
 
12/12 11/11(208 ± 1) 11/11 11/11 (341 ± 9) 11/11 8/9 (546 ± 7) 9/9 
        
                                2nd pass 
 
    11/11 (164 ± 1) 
 















Incidence of clinical signs (Clin) and vacuolar degeneration (Vac path) in mice after two serial mouse-to-mouse passages of isolates 
derived from cerebellar tissue from two vCJD patients. Mice sacrificed with intercurrent disease before 250 dpi were excluded from the 
analysis. Incubation periods in days are shown in brackets (mean ± S.E.M. for groups).  
 
 
Recipient mouse lines  
 
 RIII C57BL VM C57BL x VM 
   Donor tissue source 
Clin Vac path Clin Vac path Clin Vac path Clin Vac path 
 
vCJD 28   VM        1st pass 
 
10/10 (251 ± 1) 
 
10/10 8/8 (285 ± 6) 8/8 12/12 (116 ± 1) 12/12 10/10 (255 ± 1) 10/10 
  
                               2nd pass 
 
7/7 (228 ± 1) 
 
7/7 7/8 (282 ± 1) 7/8 11/11 (106 ± 3) 11/11 9/9 (241 ± 2) 9/9 
 
vCJD 29   VM       1st pass 
 
8/9 (242 ± 7) 
 
9/9 6/9 (290 ± 7) 9/9 11/11 (110 ±1) 11/11 9/9 (255 ± 1) 9/9 
     
                               2nd pass 
 
 
8/9 (231 ± 4) 
 
9/9 7/7 (278 ± 7) 7/7 10/10 (110 ±2) 10/10 9/10 (240 ± 1) 10/10 
 
200 
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Figure 5.8: Incubation times in mice after sub-passage of vCJD MM1  
 
Mean incubation periods in RIII, C57BL, VM and C57BL x VM mice after (a) 
primary transmission of two vCJD cerebellar homogenates and following first and 
second mouse passage of the same cerebellar isolates in (b) Prn-pa and (c) Prn-pb 
mice. Data are mean ± S.E.M 
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5.4.2 Patterns of vacuolar pathology- lesion profiles 
Lesion profiles comparing the primary transmissions of vCJD from patients CJD 28 
and CJD 29 with lesion profiles after subsequent serial passage of these isolates in 
different mouse Prn-p genotypes are presented in Figure 5.9. Both brain isolates 
showed a remarkably similar pattern of vacuolar pathology in the mouse brain 
indicating the same strain of agent within each brain isolate. Lesion profiles from the 
serial passages showed a modified pattern of vacuolar pathology when compared to 
the primary transmissions (Figure 5.9). In the RIII mouse line, vacuolar pathology 
was observably more severe after serial passage of brain isolates in both mouse 
genotypes when compared to the primary transmissions particularly in the thalamus 
(G5), hippocampus (G6) and septum (G7).  Although incubation period data 
indicated the isolation of two different agent strains following passage in the 
different mouse Prn-p genotypes, this was not clearly reflected in the lesion profiles, 
except in the case of C57BL x VM mice, in which the VM-passaged profile showed 
a less severe vacuolar pathology in the brain. No significant differences were 
observed in the lesion profiles between first and second mouse passages, thus 
providing no evidence of strain selection or host modification beyond the primary 
transmission stage. As was observed in the primary passage of vCJD brain 
homogenate, slight, but consistent differences did occur between the different 
recipient mouse lines showing the influence that host genetic factors have on lesion 
profiles.  
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Figure 5.9:  Lesion profiles for mice following sub-passage of vCJD  
 
Lesion profiles are constructed from groups in which a minimum of five mice had clinical signs of a TSE and a positive score for TSE 
associated vacuolar pathology. Vacuolation was scored at nine specified grey (G) matter regions and three white (W) matter regions of the 
mouse brain. Lesion profiles shown are from mice following the (a) primary transmission from cerebellar tissue from two vCJD cases and 
subsequent passage in (b) Prn-pa and (c) Prn-pb mice. Lesion profiles are shown without standard error bars (± S.E.M). (Solid lines) 
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5.4.3 Deposition of PrP in the mouse brain  
Patterns of PrP deposition in the mouse brain were investigated following the first 
and second mouse-to-mouse passage of both brain isolates. Immunohistochemistry 
was carried out on 5µm formalin fixed, formic acid treated, brain sections from all 
three recipient mouse lines (RIII, VM and C57BL) and the C57BL x VM cross using 
the anti-PrP antibody 6H4 in combination with the CSA detection method as 
previously described (Chapter 2, section 2.6.4). All mice examined had received a 
positive score for the presence of clinical disease and vacuolar pathology.  
 
Results confirmed the deposition of PrP in the brain of all mice examined. Overall, 
immunohistochemistry showed a consistently more intense deposition of PrP on 
serial passage when compared to the primary transmissions (Figure 5.10).  The 
general distribution of PrP deposition in the mice following sub-passage was similar 
to that found in the same mouse lines after primary transmission of vCJD, with a 
widespread and intense granular and peri-cellular deposition of PrP within the MHb, 
medulla, hippocampus and the thalamus (Figure 5.10).  The subtle differences 
observed in the distribution of PrP within the hippocampus region of the mouse brain 
between the different Prn-p genotypes were conserved on serial passage. This was 
most obvious in the VM and C57BL x VM mouse lines with intense PrP 
accumulation targeting the dentate gyrus (Figure 5.10g-l). However, with a generally 
more intensive staining and distribution of PrP, the whole hippocampal region of the 
brain showed PrP pathology. In addition to the intense PrP positivity observed in the 
mice, there were numerous plaque-like deposits observed in the corpus callosum in 
Prn-p
a (RIII and C57BL) mice on serial passage in both mouse PrP genotypes 
(Figure 5.10b, c, e and f). Furthermore, in contrast to the primary transmissions in 
which amyloid plaques were observed only in VM mice and the C57BL x VM cross, 
all four mouse lines showed the presence of amyloid plaques following the serial 
passage of brain isolates in Prn-pa and Prn-pb mice. The distribution of these 
amyloid plaques was also more widespread than those in the primary transmissions, 
with plaques observed in the hippocampus, thalamus and in the cerebral cortex 
(Figure 5.11).  No significant differences in patterns of PrP accumulation were 
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observed between first and second passage (data not shown) or between Prn-pa 
passaged and Prn-pb passaged isolates (Figure 5.10). 
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Figure 5.10: PrP deposition after serial passage of vCJD brain isolates 
 
Deposition of PrP in wild-type mice following the primary transmission of vCJD 
brain homogenate (a, d, g, j) and after subsequent first serial passage of vCJD brain 
isolates in Prn-pa (b, e, h, k) and Prn-pb (c, f, i, l) mice. Brain regions shown are 
hippocampus, medial habenular nucleus, thalamus and corpus callosum. Sections 
shown were labelled with the anti-PrP antibody 6H4 in combination with the CSA 
detection method, visualised with DAB and counterstained with haematoxylin. 
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Figure 5.11: Amyloid plaques in mice after serial passage of vCJD brain isolates  
 
Amyloid plaques in all four mouse lines after the passage of vCJD brain isolates in 
Prn-p
a and Prn-pb mice. (a) Haematoxylin and eosin staining showing amyloid 
plaques (arrows) within the corpus callosum of an RIII mouse and a (b) serial section 
immunolabelled for the prion protein. (c) Haematoxylin and eosin staining in the 
thalamus of a C57BL mouse showing the presence of  a single amyloid plaque 
(arrow) and a (d) serial section immunolabelled for the prion protein. (e) PrP 
deposition in the hippocampus of a VM mouse showing the presence of an amyloid 
plaque. (f) Amyloid plaques throughout the cerebral cortex of a C57BL x VM 
mouse. Sections showing PrP immunohistochemistry were labelled with the anti-PrP 
antibody 6H4 in combination with the CSA detection method, visualised with DAB 
and counterstained with haematoxylin. Original magnification; x100 (e, f), x200 (a, 
b, c, d) 
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5.4.4 Biochemical isotyping of PK resistant PrP
Sc
  
Results have confirmed that the biochemical phenotype of vCJD is maintained on 
primary transmission to wild-type mice. To establish whether PrPres type is further 
conserved on subsequent mouse-to-mouse passage, Western blot analysis was carried 
out as previously described (Chapter 2, section 2.7) on a minimum of two frozen 
CNS samples of all mouse lines after two serial passages of a single vCJD brain 
isolate (CJD 28) in Prn-pa and Prn-pb mice. Western blot analysis was carried out on 
5µl extracts of a 10% brain tissue weight to buffer volume (w/v) unless otherwise 
stated.  Mouse samples were run alongside a sCJD MM1 diagnostic brain reference 
standard and a vCJD diagnostic brain reference standard.  
 
PrPres was readily detected in all mouse CNS extracts analysed. The intensity of the 
PrPres signal with 5µl mouse CNS extracts was observably higher than those seen in 
the human CJD reference standard (Figure 5.12) and that of the primary passages 
(Figure 5.6). If PrPres correlates with infectivity, as has been proposed, this may be an 
indication of higher levels of infectivity associated with mouse CNS tissue following 
serial passage of the vCJD brain isolates. All mouse samples were re-analysed with 
1µl PrPres extracts. The resulting PrPres banding pattern showed predominance in the 
diglycosylated form of the protein, typical of vCJD in human CNS tissue (Figure 
5.13 and Figure 5.14) and in the mice after primary mouse passage (Figure 5.6). In 
addition, the appearance of the unglycosylated form as a doublet, composed of 
distinct upper and lower bands, was also maintained on mouse-to-mouse passage. No 
significant differences were observed in the PrPres banding pattern between Prn-pa 
and Prn-pb-passaged isolates or between the first and second passage; however, there 
was notable variation in the relative abundance of the upper and lower 
unglycosylated bands (Figure 5.13 and Figure 5.14). Unlike the primary mouse 
passages, where the lower band of the doublet was found to predominate in Prn-pa 
mice and the upper band predominated in Prn-pb mice, there appeared to be no 
simple correlation between the composition of the doublet and the Prn-p genotype of 
the mouse on secondary passage. Regardless of the variation in the unglycosylated 
doublet, PrPres typing in the mice has provided strong evidence that the biochemical 
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phenotype of vCJD is conserved in mice after serial mouse passage of vCJD brain 
isolates. 
Figure 5.12: Western blot analysis of PrP
res
 in vCJD brain isolates  
 
Western blot analysis of PrPres in 5µl CNS extracts of an RIII and VM mouse after 
the 1st mouse-to-mouse passage of brain isolates in C57BL (Prn-pa) mice.  Tissues 
are analysed after digestion with proteinase K. Mouse samples (M) are run alongside 
































Figure 5.13: Western blot analysis of PrP
res





Western blot analysis of PrPres in CNS samples of RIII, C57BL, VM and C57BL x 
VM (CV) mice after the 1st and 2nd mouse-to-mouse passage of brain isolates in 
C57BL (Prn-pa) mice.  Tissues are analysed after digestion with proteinase K. 
Mouse samples (M) are run alongside a human (H) sCJD MM1 type 1 (T1) and a 











































Figure 5.14: Western blot analysis of PrP
res





Western blot analysis of PrPres in CNS samples of RIII, C57BL, VM and C57BL x 
VM (CV) mice after the 1st and 2nd mouse-to-mouse passage of brain isolates in VM 
(Prn-pb) mice.  Tissues are analysed after digestion with proteinase K. Mouse 
samples (M) are run alongside a human (H) sCJD MM1 type 1 (T1) and a vCJD 



















NT- no frozen tissue available for Western blot analysis 
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5.5 Results Summary  
Variant CJD is characterised by a number of unique and highly reproducible 
biological and biochemical features after transmission into panels of wild-type mice. 
The consistency in the transmission properties shown by each vCJD brain 
homogenate supports previous reports that vCJD results from infection with a single 
major strain of agent. Variant CJD in wild-type mice is characterised by the 
following features; 
 
 Variant CJD-infected mice develop a progressive clinical disease. 
 Clinical signs occur in a consistent order of appearance in the wild-type panel, 
with the shortest incubation periods in the RIII mouse line with the longest in 
the C57BL x VM cross.  
 Incubation periods differences of over 100 days are observed in mouse lines of 
the same Prn-p genotype.  
 The lesion profile in vCJD-infected mice differs between mouse lines of 
different Prn-p genotypes, but within each mouse line there are few 
differences between isolates derived from different vCJD patients. 
 Amyloid plaques are observed in VM mice and C57BL x VM cross after 
primary transmission and in all mouse lines on subsequent serial mouse 
passage.   
 Molecular PrPres typing in the infected mouse shows conservation in the vCJD 
type on primary transmission and on further serial passage in mice, which is 
dominated by the diglycosylated form of the protein.  
 Serial mouse passage of vCJD results in the isolation of two distinct mouse-
passaged strains, recognised by incubation period in VM mice; a VM-passaged 
strain and an RIII/C57BL-passaged strain.   
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5.6 Discussion of experimental results 
The aim of this chapter was to complete and further extend the work described in the 
original vCJD strain typing paper by Bruce and co-workers (Bruce et al., 1997). In 
the original study, characterisation of the vCJD agent strain was based solely on 
incubation period data and lesion profiling in RIII mice after the experimental 
transmission of vCJD from brain homogenate from three vCJD patients (vCJD cases 
analysed in Bruce et al (1997) correspond to patients CJD 28, CJD 29 and CJD 30 
analysed in this thesis). These early observations were instrumental in providing 
evidence that the transmission characteristics of vCJD were indistinguishable from 
those of BSE, FSE and TSEs in exotic ruminants but differed from the transmission 
characteristics of sCJD (Bruce et al., 1997).  The series of transmissions described in 
this chapter has confirmed the original observations and extended them in a number 
of important aspects. Firstly, this study increases the number of transmitted cases in 
the wild-type mouse panel to 10 and included cases with disease onsets two years 
after those analysed in the study by Bruce et al (1997). Secondly, characterisation of 
the vCJD agent was extended to include the immunohistochemical and biochemical 
analysis of the abnormal PrP in the vCJD inoculated mice. Finally, further 
characterisation of the vCJD agent in the wild-type mouse panel was carried out after 
two subsequent mouse-to-mouse passages. 
 
5.6.1 Variant CJD cases are associated with a single strain of agent 
Primary transmission from each vCJD brain homogenate showed strikingly similar 
transmission properties for all strain typing parameters considered, consistent with 
previous studies (Bruce et al., 1997) and indicating that all 10 cases had resulted 
from infection with the same major strain of agent. In the preliminary studies 
described by Bruce et al (1997), vCJD cases used in the transmissions to wild-type 
mice were limited to those early on in the epidemic (onsets between 1994 and 1995). 
In this thesis, analysis of transmissions from a larger number of UK vCJD cases and 
from cases occurring later in the epidemic (onsets between 1994 and 1997), has 
shown that the transmission properties of vCJD in mice remain constant, showing no 
evidence for alterations in the agent strain as the epidemic progressed. It will be 
interesting to establish whether more recent cases of vCJD or those cases which have 
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since occurred in other countries share these exact features. These studies are 
underway as part of the continuing collaboration between the NCJDRSU and the 
NPU/NPD in the investigations of human TSEs.  
 
As part of this on-going collaboration, a recent study in human transgenic mice, in 
which the vCJD agent was characterised in patients who were infected as a result of 
secondary human transmission by blood transfusion, suggests that there is no 
significant alteration in agent strain following secondary infection via this route 
(Bishop et al., 2008). Although this study using humanised transgenic mice provides 
valuable evidence on the vCJD agent acquired through human-to-human 
transmission, it remains true that agent strain in TSEs is best defined by passage in 
non-transgenic (wild-type) mice panels. The full characterisation of the vCJD agent 
described in this chapter will provide a valuable baseline to which data from further 
vCJD transmissions can be compared.  
 
5.6.2 Regional difference in levels of infectivity in vCJD 
Incubation periods in mice are determined by agent strain in combination with host 
genetic factors, but titre of infectivity can also play an important role. This study 
found consistently shorter incubation periods in mice following inoculation with 
vCJD cerebellar tissue when compared to those obtained with inoculations from 
frontal cortex tissue (Figure 5.1). Although tissues were sampled from different 
vCJD cases, this outcome suggests that levels of infectivity are consistently higher in 
the cerebellar cortex than in the frontal cortex. Furthermore, in contrast to 
homogenate prepared from the frontal cortex tissue, levels of infectivity in the 
cerebellar homogenate were sufficiently high as to produce incubation period data in 
all C57BL x VM groups challenged. This may be a further indication that there are 
regional differences in levels of infectivity in the brain. Although the incubation 
period data indicates differences in the levels of infectivity between frontal cortex 
and cerebellum this was not reflected in gross differences in the levels of PrPres, as 
determined by Western blotting (chapter 3). Furthermore, pathological changes in 
these different brain regions in vCJD patients also appear to be quantitatively similar; 
however, deposition of PrP in the cerebellum is often more pronounced compared to 
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the frontal cortex. In addition, amyloid plaques, a characteristic pathological feature 
of vCJD, are more frequently observed in the cerebellum compared to the cortical 
regions of the brain in vCJD (Ironside et al., 2000), perhaps corresponding to the 
apparent relatively higher levels of infectivity in the cerebellum.  
 
5.6.3 Isolation of distinct mouse-passaged vCJD strains 
Incubation period differences of over 100 days were observed between the RIII and 
C57BL strains of mice, both of which are from the same Prn-p genotype (Figure 
5.1). This incubation period difference was seen in all seven vCJD transmissions in 
which both mouse lines were included. This difference in incubation period of vCJD-
infected mice of the same Prn-p genotype is unusual and has not been observed in 
transmissions of different strains of scrapie, but is a characteristic feature of BSE in 
the same mice (Bruce et al., 2002; Ritchie et al., 2009). The possibility that this 
difference in incubation period may be due to the presence of another minor strain of 
agent can be excluded, as no differences were found in the agent strain after the 
serial passage of vCJD brain isolates in RIII and C57BL mice. It is more likely that 
the differences are due to the direct control on incubation period from a gene or 
genes other than prn-p.  
 
However, further characterisation of the vCJD agent by sub-passage in Prn-pa and 
Prn-p
b mice did result in the isolation of two apparently distinct mouse-passaged 
strains. Although the evidence indicates that each of the human vCJD brain samples 
tested contained the same major strain of agent, this does not rule out the presence of 
other minor strains in these samples.   Previous studies of mouse-passaged scrapie 
have shown that, like viruses, these agents can generate variant “mutant” strains 
(Bruce and Dickinson, 1987), and it is likely that isolates always contain mixtures of 
variants.  In the case of sheep scrapie and some other TSEs, initial transmission to 
mice is very inefficient and the biological properties of the isolates only gradually 
stabilize over several serial mouse passages (Moira Bruce, personal communication).  
This might suggest that the scrapie strains isolated in mice are derived from minor 
variant strains present in the sheep, and that there may be further stepwise generation 
of variants in mice in the process of adaptation.  In contrast, vCJD transmits 
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efficiently to wild-type mice and analysis of incubation period data (Figure 5.8) 
indicates that the properties stabilize almost immediately on mouse-to-mouse 
passage, suggesting that the mouse-passaged strains isolated are identical or closely 
related to strains that were actually present in the human source brains.  The ranking 
of incubation periods in the mouse panel in the primary transmission of vCJD is 
conserved in the Prn-pa mouse-passaged isolates, but not in the Prn-pb mouse-
passaged isolates, further suggesting that the Prn-pa mouse-passaged strain is more 
representative of the major strain present in humans. 
 
Interestingly, the biological properties of these two mouse-passged vCJD-related 
strains were not reflected in differences in the PrPres type found in the brains of the 
mice replicating these two strains of agent (Figure 5.13 and Figure 5.14). No obvious 
differences were found in the glycosylation pattern, with the diglycosylated form 
predominating in all vCJD-passaged mice examined. However, certain differences 
were observed in the unglycosylated form which, like the primary transmissions, was 
seen as a doublet. In the primary transmission of vCJD, the upper and lower bands of 
this doublet appeared to be associated with the different Prn-p genotypes in that the 
lower band is predominant in Prn-pa mice whereas the upper band predominates in 
Prn-p
b mice.  These apparent differences in the biochemical profile of PrPres could 
perhaps be attributed to differences in the polymorphic residues between Prn-pa and 
Prn-p
b that result in different conformation or aggregation states of the misfolded 
form of the protein. However, this simple relationship did not hold on serial passage 
of vCJD brain isolates in the mice and so the biochemical basis of this phenomenon 
and its biological significance remain unclear.  
 
Comparison of the strain typing parameters in the mice showed clear differences 
between the transmission properties of vCJD and sCJD inoculated mice (chapter 4). 
The most striking differences were in the development of clinical TSE disease. 
Almost 100% of mice inoculated with vCJD developed a progressive neurological 
disease-associated with a TSE, whereas clinical disease in the sCJD inoculated mice 
was rare. It is interesting that the only evidence of clinical disease in the sCJD 
inoculated mice resulted from experimental challenge of brain homogenate from the 
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sCJD MM2 subgroup. This sCJD subgroup shares the most similarities with vCJD. 
Both diseases occur in the same PRNP codon 129 genotype and both have a similar 
protein conformation, as inferred from the electrophoretic mobility of the 
unglycosylated fragment (approximately 19kDa) after PK digestion. This may be an 
indication that strain-specific properties in TSEs may be associated with differences 
in the glycosylation states of the protein rather than differences in conformation. The 
relationship between vCJD and sCJD will be addressed in greater detail in the 
discussion (Chapter 7, section 7.2.4).  
 
In addition to confirming that the agent strain in vCJD differs from that of sCJD, this 
series of transmissions has confirmed that the transmission properties of vCJD in this 
mouse panel are indistinguishable from those previously described for BSE, 
confirming that a BSE-related strain of agent is involved in vCJD. The close 
relationship between the BSE agent and that of vCJD is addressed in detail in the 
discussion (Chapter 7, section 7.2.3).  
 
5.7 Chapter conclusion 
In conclusion, results from this extensive series of vCJD transmissions to wild-type 
mice have provided further evidence that vCJD is the result of infection with a single 
major strain of agent.  The data described in this chapter will provide a valuable 
standard on which to compare future vCJD transmissions experiments, including any 
future cases of vCJD in the other PRNP codon 129 genotypes, in order to determine 
any changes in agent strain in these different genotypes. 
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Chapter 6: Detection of infectivity in peripheral neural and 
lymphoid tissues and biological fluids of sporadic and 
variant CJD patients by transmission to wild-type mice 
 
6.1 Objective  
1. To determine the presence of infectivity within a range of lymphoid and 
neural tissues from sCJD and vCJD patients. 
2. To determine the presence of infectivity within bone marrow, buffy coat, 
plasma and cerebrospinal fluid from vCJD patients. In addition, the presence 
of infectivity in buffy coat and plasma from sCJD patients will be 
investigated. 
3. To characterise the agent strain in lymphoid and neural tissues of CJD 
patients and to determine whether agent strain characteristics are subject to 
any tissue specific alterations. 
 
6.2 Introduction 
TSEs are characterised by vacuolar degeneration in CNS tissues and the 
accumulation in the brain of the abnormal and disease-associated form of the prion 
protein. Results from previous chapters have confirmed that TSE infectivity in brain 
tissue of vCJD (chapter 5) and to a lesser extent sCJD (chapter 4) patients can be 
transmitted successfully to wild-type mice.  However, tissue involvement, as judged 
by the deposition of the abnormal form of the prion protein in TSEs is not confined 
to the CNS.  Abnormal accumulations of the prion protein have been described in 
peripheral tissues in scrapie in sheep (van Keulen et al., 1996; van Keulen et al., 
1999), chronic wasting disease in deer (Sigurdson et al., 1999; Sigurdson et al., 
2001), as well as a number of animal models of TSEs (Kimberlin and Walker, 1979; 
Maignien et al., 1999; Beekes and McBride, 2000) .  In human TSEs, the deposition 
of PrPSc in peripheral lymphoid tissues is a characteristic and diagnostic feature of 
vCJD and has indicated a widespread involvement of lymphoid tissues in vCJD at 
the end-stage of disease (Head et al., 2004b). Furthermore, infectivity in vCJD spleen 
and tonsil tissue has been confirmed by bioassays in RIII mice, which have indicated 
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infectivity levels in these tissues a hundred to a thousand times lower than those 
demonstrated in brain (Bruce et al., 2001). In addition to lymphoreticular tissues, 
immunohistochemistry for PrP has demonstrated abnormal PrP positivity in a variety 
of peripheral nervous tissues including trigeminal, dorsal root and autonomic ganglia 
(Haik et al., 2004; Head et al., 2004b). Further investigations using highly sensitive 
immunohistochemical and Western blotting techniques have also identified PrPSc 
within the pituitary gland (Peden et al., 2007), peripheral motor nerve fibres in 
skeletal muscle (Glatzel et al., 2003; Peden et al., 2006) and more recently for the 
first time in dura mater, liver, pancreas, kidney, ovary, uterus and skin in vCJD 
(Notari et al., 2010). Thus, the number of tissues and organs showing the presence of 
the abnormal prion protein may be greater than previously thought.  In contrast, the 
distribution of PrPSc pathology is thought to be largely restricted to the CNS system 
in cases of sCJD (Head et al., 2004b). However, findings from studies using a highly 
sensitive Western blot technique have shown detectable levels of PrPres in the 
pituitary gland (Peden et al., 2007), spleen and intramuscular nerve fibres (Glatzel et 
al., 2003; Peden et al., 2006) in a proportion of sCJD patients suggesting that there 
may also be a more limited peripheral involvement in some cases of sCJD.  
 
Reports of PrPSc in tissues other than brain are generally described in vCJD patients 
who had died following the development of clinical symptoms of disease. However, 
in a retrospective review of tissues removed from vCJD patients prior to the onset of 
clinical disease, PrP positivity was detected in appendix samples surgically removed 
from two patients that went on to develop clinical vCJD eight months and two years 
after their appendectomies (Hilton et al., 1998). The detection of PrPSc in lymphoid 
tissues prior to the onset of clinical disease has been widely reported in both natural 
and experimental models of scrapie and confirms earlier findings from bioassay in 
mice which demonstrated that replication of the TSE agent occurs in the 
lymphoreticular system before detection in the CNS (Dickinson and Fraser, 1969; 
Kimberlin and Walker, 1979; Kimberlin and Walker, 1989a). The demonstration of 
PrPSc in the appendix taken from individuals who went on to develop vCJD suggests 
that there may be a similar pathogenesis in vCJD. More recently, the apparent 
transmission of vCJD infectivity to four individuals by blood transfusion, associated 
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with transfusions of blood collected from vCJD patients during the asymptomatic 
phase of the disease (Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 2006; 
Health Protection Agency., 2009) and the detection of infectivity in a haemophiliac 
patient after treatment with UK-sourced plasma products prepared from “vCJD-
implicated batches” (Peden et al., 2010), further supports the proposal that infectivity 
is present in peripheral tissues and biological fluids much earlier than in the brain. 
 
The accumulation of the abnormal prion protein out side the brain has raised 
concerns about iatrogenic transmission risks associated with contamination of 
surgical instruments, tissue transplantation and treatment with pharmaceuticals 
prepared from human tissue. Furthermore, the cases of vCJD infection, associated 
with contaminated blood products collected from vCJD patients during the 
asymptomatic phase of the disease (Llewelyn et al., 2004; Peden et al., 2004; Wroe 
et al., 2006; Health Protection Agency., 2009; Peden et al., 2010), highlights the risks 
and concerns over the secondary human transmission of vCJD. An additional 
concern is the theoretical possibility of alterations in agent strain on secondary 
transmission from human-to-human which may result in a modified disease 
phenotype and biochemical profile which may have implications for the diagnosis of 
such cases.  
  
To date, PrPSc has been reported in a wide range of peripheral tissues and organs in 
vCJD; however, it remains that the published demonstration of infectivity in tissues 
other than brain has been limited spleen and tonsil. This chapter aims to extend the 
evidence for infectivity in other vCJD lymphoid (lymph node and appendix) and 
neural tissues (spinal cord, DRG, TRG and peripheral nerve) in which the presence 
of the pathological prion protein has been confirmed by immunohistochemistry and 
Western blot assays. In addition, this study extends the investigation to include blood 
fractions (buffy coat and plasma), CSF and bone marrow, in which the presence of 
PrPSc has not been demonstrated by such conventional methods but in which the 
demonstration of infectivity could play an important role in the risk assessment for 
certain medical procedures such as blood transfusion and bone marrow 
transplantation. Furthermore, this chapter aims to investigate whether a similar 
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involvement of the lymphoid system occurs at the end stage of disease in sCJD, by 
extending the analysis to include transmissions from sCJD spleen.  Finally, this 
chapter also provides the complete incubation period data, lesion profiles and 
immunohistochemical analysis of the abnormal prion protein accumulation in mice 
following transmission from these tissue homogenates to establish whether the agent 
strain is subject to any tissue specific alterations. 
 
6.3 Experimental results 
Forty-one transmission experiments were carried out with tissue inocula prepared 
from specified peripheral tissues, neural tissues and biological fluids from four sCJD 
cases (CJD 10, CJD 11, CJD 15 and CJD 18) and seven vCJD cases (CJD 31, CJD 
35, CJD 36, CJD 37, CJD 38, CJD 39 and CJD 40), as summarised in Table 6.1. 
Tissue homogenates were prepared and inoculated intracerebrally into RIII (Prn-pa) 
and VM (Prn-pb) mice as described in Chapter 2, section 2.3. Frozen CNS samples 
were collected from a small number of mice inoculated with vCJD spleen and tonsil 
homogenate.  
 
Transmission of a TSE, as judged by the development of neurological signs 
associated with TSE and the presence of vacuolar pathology was seen in some mice 
inoculated with vCJD spleen, tonsil, lymph node, peripheral nerve, DRG, TRG and 
spinal cord samples, but with varying degrees of efficiency between the different 
tissue homogenates. Subsequent immunohistochemical detection for PrP also showed 
evidence of positive transmission in mice challenged with vCJD appendix. In 
contrast, mice inoculated with vCJD bone marrow, buffy coat, plasma and CSF 
showed no evidence of a TSE.  All sCJD transmissions were negative with the 
exception of one mouse which showed TSE type pathology after challenged with a 
sCJD buffy coat sample. Results from the experimental challenge of the different 
tissue types are detailed below. 
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Table 6.1: Tissues/fluids experimentally inoculated into wild-type mice 
 
Case Diagnosis Tissues used as inoculum Mouse lines challenged 
CJD 10 sCJD MM1 BC, SPL RIII, VM 
CJD 11 sCJD MM1+2A BC, PL RIII, VM 
CJD 15 sCJD MV1 BC RIII, VM 
CJD 18 sCJD MV2A BC, PL RIII, VM 
CJD 31 vCJD  BC, PL, SPL, TONS RIII, VM 
CJD 35 vCJD BC, PL, TONS RIII, VM 
CJD 36 vCJD BC, PL RIII, VM 
CJD 37 vCJD BC, PL RIII, VM 
CJD 38 vCJD APP, BM, CSF, DRG, LN,  PN, SC, TRG  RIII 
CJD 39 vCJD APP, BM, DRG, LN, PN, SC, TRG RIII 
CJD 40 vCJD APP, BM, CSF, DRG, LN, PN, SC, TRG RIII 
APP – appendix,  BC – buffy coat,  BM – bone marrow, CSF – cerebrospinal fluid, DRG – dorsal root 
ganglia,  LN – lymph node,  PL –  plasma, PN – peripheral nerve, SC – spinal cord, SPL – spleen,  
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6.3.1 Spleen tissue 
Two transmission experiments were carried out with inoculum prepared from spleen 
tissue from one sCJD (CJD 10) case and one vCJD case (CJD 31).  The incidence of 
clinical signs of disease and TSE-specific vacuolar pathology in the inoculated mice, 
and results from the analysis of PrP accumulation in some mice from each 
experimental group are shown in Table 6.2.  
 
Clinical TSE disease was observed in a proportion of the RIII and VM mice 
following experimental challenge with vCJD spleen homogenate, resulting in 
incubation periods of 490 ± 18 and 659 ± 11 respectively (Table 6.2). These 
incubation periods were longer than those observed for vCJD brain homogenate in 
the same mouse lines, as detailed in chapter 5. In contrast, no evidence of a 
neurological disease indicative of a TSE was observed in any RIII or VM mouse 
challenged with the sCJD spleen homogenate. Further histological examination also 
failed to show any evidence of TSE-specific vacuolar pathology in the sCJD 
inoculated mice (Table 6.2).  
 
In general, vacuolar degeneration was observed in RIII and VM mice that had 
developed clinical TSE disease, confirming the successful transmission of TSE 
infectivity from vCJD spleen. Only a single VM mouse produced vacuolar pathology 
in the absence of any clinical signs of disease (Table 6.2). Patterns of vacuolar 
pathology in the clinically affected mice differed between the two mouse PrP 
genotypes (Figure 6.1). The lesion profile in the RIII mouse line was characterised 
by the targeting of a mild-moderate vacuolar pathology in the medulla oblongata 
(G1) and the hypothalamus (G4) whereas, the pattern of vacuolar degeneration in the 
VM mouse line resulted in a more widespread distribution of mild-moderate vacuolar 
pathology throughout the grey matter scoring regions of the brain. The patterns of 
vacuolar pathology in the clinically affected RIII and VM mice were closely similar 
to those seen in the same mouse lines inoculated with vCJD brain homogenate as 
described in chapter 5. 
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Table 6.2: Primary transmission from vCJD and sCJD spleen homogenates 
 
Clinical signs (Clin), vacuolar degeneration (Vac path) and PrP deposition (PrP path) 
in mice intracerebrally inoculated with spleen homogenate from a sporadic CJD and 
variant CJD patient. Mice sacrificed with intercurrent disease before 250 dpi were 
excluded from the analysis. Mean incubation periods in days are shown in brackets ± 
S.E.M. 
 
Mouse line  
 


































Figure 6.1: Lesion profiles for mice inoculated with vCJD spleen homogenate 
 
Mean lesion profiles are constructed from a minimum of five RIII mice (solid line) 
and five VM mice (dashed line) scoring positive for both clinical TSE disease and 
TSE-specific vacuolar pathology. (G) grey matter scoring regions, (W) white matter 
scoring regions of the mouse brain. Mean lesion profiles are shown with standard 
error bars (± S.E.M).  
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Immunohistochemistry for PrP was carried out on 5µm formalin fixed, formic acid 
treated brain sections from seven RIII and seven VM mice that had received a 
positive score for both clinical and vacuolar signs of TSE following challenge with 
the vCJD spleen homogenate. Immunolabelling was carried out using the CSA 
detection method in combination with the monoclonal anti-PrP antibody 6H4 as 
described in Chapter 2, section 2.6.4. All mice analysed showed an intense and 
widespread accumulation of PrP in the mouse brain, further confirming the 
successful transmission of a TSE from the vCJD spleen homogenate. Pattern of PrP 
accumulation in the mouse brain was similar in both mouse lines, with a peri-cellular 
pattern of PrP staining, most prominent throughout the thalamus (Figure 6.2a and b), 
medulla (Figure 6.2c and d) and around areas of intense vacuolation.   PrP deposition 
was also observed in the granular layer and to a lesser extent the molecular layer of 
the cerebellum (Figure 6.2e and f). Subtle differences in staining pattern were 
observed in the hippocampal region between the RIII and VM inoculated mice, a 
feature also observed in the experimental transmission of vCJD brain homogenates in 
the same mouse lines. The RIII mice showed a granular deposition of PrP targeting 
the CA2 region of the hippocampus, whereas the VM mice showed a more intense 
deposition of PrP targeting the dentate gyrus (Figure 6.2g and h). In general, levels of 
PrP immunostaining appeared higher in the RIII (Prn-pa) mice compared to the VM 
(Prn-pb) mice. Amyloid plaques were not observed in the mice. 
Immunohistochemistry on five RIII and five VM mice inoculated with sCJD spleen 
homogenate with survival times over 750dpi showed no detectable PrP accumulation 
in the brain. 
   
 227 
Figure 6.2: PrP deposition in mice inoculated with vCJD spleen homogenate 
 
Heavy granular deposits of PrP targeting the thalamus and medulla in (a, c) RIII and 
(b, d) VM mice. (e) Small granular deposits of PrP targeting the granular layer of the 
cerebellum in RIII mice with a more intense labelling pattern observed in the 
granular layer of (f) VM mice. (g) Granular deposition of PrP targeting the CA2 
region of the hippocampus of RIII mice. (h) Heavy peri-cellular labelling of PrP in 
the dentate gyrus region of the hippocampus in a VM mouse. Sections shown were 
labelled with the anti-PrP antibody 6H4 in combination with the CSA detection 
method, visualised with DAB and counterstained with haematoxylin. Original 
magnification; x50 (c, d), x100 (g, h), x200 (a, b, e, f).  
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6.3.2 Tonsil tissue 
Two transmission experiments were carried out with homogenate prepared from 
tonsil tissue sampled from two vCJD cases (CJD 31 and CJD 35). The incidence of 
clinical signs of disease and TSE-specific vacuolar pathology in the inoculated mice, 
and results from the analysis of PrP accumulation in some mice from each 
experimental group are shown in Table 6.3.  
 
Clinical TSE disease was observed in some RIII and VM mice inoculated with both 
tonsil homogenates (Table 6.3). Mean incubation periods differed between the two 
homogenates, suggesting that titres of infectivity may be subject to case-to-case or 
sample-to-sample variation. One tonsil homogenate (CJD 35) produced mean 
incubation periods that were comparable to those observed in spleen, suggesting 
similar levels of infectivity present in these different lymphoid inocula.   
 
Only one tonsil homogenate (CJD 35) produced sufficient mice with both clinical 
and histological evidence of a TSE for the construction of a lesion profile. Vacuolar 
degeneration in RIII mice showed a consistent pattern to that of vCJD spleen in the 
same mouse line, characterised by the targeting of a mild-moderate vacuolar 
pathology in the medulla (G1), hypothalamus (G4) and septum (G7) (Figure 6.3). A 
different pattern was observed in the VM mouse line with a more widespread 
distribution of vacuolar pathology throughout the grey matter scoring regions of the 
brain (Figure 6.3), mirroring the transmission properties of vCJD spleen tissue in the 
same mouse line.  
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Table 6.3: Primary transmission from vCJD tonsil homogenates 
 
Clinical signs (Clin), vacuolar degeneration (Vac path) and PrP deposition (PrP path) 
in mice intracerebrally inoculated with vCJD tonsil homogenates. Mice sacrificed 
with intercurrent disease before 250 dpi were excluded from the analysis. Mean 
incubation periods in days are shown in brackets ± S.E.M. 
 
 





























* mice analysed had a positive score for vacuolar pathology sacrificed with clinical disease 
‡ Incubation period calculated from only four animals in this group which showed a positive 




Figure 6.3: Lesion profiles for mice inoculated with vCJD tonsil homogenate  
 
Lesion profiles are constructed from a minimum of five RIII mice (solid line) and 
five VM mice (dashed line) scoring positive for both clinical TSE disease and TSE-
specific vacuolar pathology following inoculation with homogenate from patient 
CJD 35. (G) grey matter scoring regions, (W) white matter scoring regions of the 
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All mice analysed with a positive score for both clinical and vacuolar signs of a TSE 
showed an intense and widespread deposition of PrP in the brains of the mice, further 
confirming the transmission of infectivity from vCJD tonsil tissue. Patterns of 
deposition were similar between the different mouse genotypes and closely 
resembled that produced by vCJD spleen in the same mouse lines. Intense peri-
cellular deposits of PrP were observed throughout the thalamus (Figure 6.4a and b), 
hypothalamus and medulla (Figure 6.4c and d) as well as around areas of severe 
vacuolation. PrP deposition was also observed in the cerebral cortex and in the 
granular layer and to a lesser extent the molecular layer of the cerebellum (Figure 
6.4e and f). The subtle differences in staining pattern within the hippocampal region 
between the RIII and VM inoculated mice, a feature also observed in the 
experimental transmission of vCJD spleen and brain isolates in the same mouse lines, 
were also observed following challenge with vCJD tonsil isolates (Figure 6.4g and 
h). As described with vCJD spleen, levels of PrP immunostaining appeared higher in 
the RIII (Prn-pa) mice compared to the VM (Prn-pb) mice. Amyloid plaques, a 
characteristic feature in the brain of vCJD patients, were not observed in the mice. 
The two mice analysed with no evidence of clinical disease or vacuolar pathology 
also showed no evidence of PrP accumulation. 
   
 231 
Figure 6.4: PrP deposition in mice inoculated with vCJD tonsil homogenate 
 
Heavy granular deposits of PrP within the thalamus of a (a) RIII and (b) VM mouse. 
Similar PrP deposition within the medulla in an (c) RIII and (d) VM mouse. Small 
granular deposits of PrP targeting the granular layer of the cerebellum in an (e) RIII 
mouse with a more intense labelling pattern observed in the granular layer of a (f) 
VM mouse. (g) Granular deposition of PrP targeting the CA2 region of the 
hippocampus of an RIII mouse. (h) Heavy peri-cellular labelling of PrP in the 
dentate gyrus region of the hippocampus in a VM mouse. Sections shown were 
labelled with the anti-PrP antibody 6H4 in combination with the CSA detection 
method, visualised with DAB and counterstained with haematoxylin. Original 
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6.3.3 Lymph node tissue 
Experimental transmission of homogenates prepared from tissue samples from a 
cervical lymph node from three vCJD cases (CJD 38, CJD 39 and CJD 40) were 
carried out in RIII mice.  The incidence of clinical signs of disease and TSE-specific 
vacuolar pathology in inoculated mice, and results from the accumulation of PrP in 
mice from each experimental group are shown in Table 6.4.  
 
Clinical TSE disease was observed in some mice challenged with two of the vCJD 
lymph node inocula (CJD 38 and CJD 39), with one producing a mean incubation 
period of 702 days in the mice, much longer than the incubation periods reported 
with vCJD spleen and tonsil in the same mouse line. This indicates that infectivity 
levels in the cervical lymph node are lower than those found in spleen and tonsil.  No 
evidence of clinical TSE disease, vacuolar pathology or PrP accumululation was 
observed in mice inoculated with the third lymph node homogenate (CJD 40). The 
variation observed in the efficiency of transmission between the three vCJD lymph 
node inocula suggests that titres of infectivity differed between these three tissue 
homogenates. 
 
Vacuolar pathology was observed in only a small proportion of the RIII mice (eight 
out of 64) surrviving over 250dpi; however, the presence of vacuolar pathology in 
these mice confirms the presence of infectivity in vCJD cervical lymph node. Inocula 
from CJD 38 produced sufficient mice showing clinical TSE disease and vacuolar 
degeneration in the brain for the construction of a lesion profile. Pattern of vacuolar 
pathology in the clinically affected RIII mice showed similarities to that of vCJD 
spleen and tonsil in the same mouse line, in particular the peak in vacuolar intensity 
in the hypothalamus (G4) of the mice (Figure 6.5). The similarity in the targeting and 
severity of vacuolar pathology in RIII mice inoculated with vCJD spleen, tonsil and 
lymph node isolates indicates close similarities in the transmission properties in these 
three lymphoid tissues. 
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Table 6.4: Primary transmission from vCJD cervical lymph node homogenates 
 
Clinical signs (Clin), vacuolar degeneration (Vac path) and PrP deposition (PrP path) 
in RIII mice intracerebrally inoculated with vCJD lymph node homogenates. Mice 
sacrificed with intercurrent disease before 250 dpi were excluded from the analysis. 
Mean incubation periods in days are shown in brackets ± S.E.M. 
 
 







Clin Vac path PrP path 
CJD 38 
 





















Figure 6.5: Lesion profiles for mice inoculated with vCJD lymph node 
homogenate  
 
Lesion profiles are constructed from six RIII mice scoring positive for both clinical 
TSE disease and TSE-specific vacuolar pathology following inoculation with 
homogenate from CJD 38. (G) grey matter scoring regions, (W) white matter scoring 
regions of the mouse brain. Mean lesion profiles are shown with standard error bars 










All mice examined by immunohistochemistry which had received both a positive 
score for clinical and vacuolar signs of a TSE also showed the deposition of PrP in 
the brain, further confirming the transmission of infectivity from vCJD cervical 
lymphoid tissue. In addition, PrP deposits were detected in four mice that showed no 
evidence of vacuolar pathology (Table 6.4, patient CJD 39). The targeting of PrP 
pathology mirrored that produced by other lymphoid tissues in the same recipient 
mice with intense peri-cellular deposits of PrP throughout the thalamus, (Figure 
6.6a), medulla (Figure 6.6b) and around areas of severe vacuolation. PrP deposition 
was also observed in the cerebral cortex (Figure 6.6c) and in the granular and 
molecular layers of the cerebellum. PrP deposition targeting the CA2 region of the 
hippocampus, a characteristic feature of transmission from the other lymphoid tissues 
was also observed in the mice (Figure 6.9d).  
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Figure 6.6: PrP deposition in mice challenged with vCJD lymph node 
homogenate 
 
Deposition of PrP in RIII mice which showed clinical and histological evidence of a 
TSE following inoculation with homogenate prepared from a vCJD cervical lymph 
node. Intense granular and peri-cellular deposits of PrP throughout the (a) thalamus 
and (b) medulla. (c) Fine granular deposits of PrP in the cerebral cortex. (d) PrP 
deposition targeting the CA2 region of the hippocampus. Sections shown were 
labelled with the anti-PrP antibody 6H4 in combination with the CSA detection 
method, visualised with DAB and counterstained with haematoxylin. Original 
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6.3.4 Appendix tissue 
Inoculation of homogenate prepared from appendix tissue sampled from three vCJD 
patients (CJD 38, CJD 39 and CJD 40) was carried out in RIII mice. Table 6.5 details 
the incidence of clinical signs of disease, TSE-specific vacuolar pathology and 
deposition of PrP in each experimental group.  
 
No clinical signs of a neurological disease related to a TSE were observed in any of 
the RIII mice following inoculation with appendix homogenate (clinical signs were 
observed in a single RIII mouse but histological analysis failed to confirm a TSE 
disease). In addition, no TSE-specific vacuolar pathology was observed in any mouse 
following challenge with appendix homogenate (Table 6.5). 
 
The lack of any vacuolar pathology in the mice could indicate that there is no 
transmission of infectivity from vCJD appendix tissue. However, 
immunohistochemical analysis for the prion protein in all mice inoculated, confirmed 
the presence of PrP accumulation in 6 out of the 31 mice challenged with 
homogenate prepared from appendix tissue sampled from patient CJD 38 and CJD 
39 (Table 6.5). This provided the first direct evidence for the successful transmission 
of infectivity from vCJD appendix. One mouse showed PrP deposition with a closely 
similar distribution and level of intensity to that described for mice infected with 
other vCJD tissue homogenates (Figure 6.7a-c). The remaining five RIII mice 
showed a more restricted pattern of PrP pathology, mainly targeting the medulla 
(Figure 6.7d) and thalamus of the mouse brain. No evidence of PrP accumulation 
was seen in mice challenged with appendix homogenate from patient CJD 40. 
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Table 6.5: Primary transmission from vCJD appendix homogenates 
 
Incidence of clinical signs (Clin), vacuolar degeneration (Vac path) and PrP 
deposition (PrP path) in RIII mice intracerebrally inoculated with vCJD appendix. 
Mice sacrificed with intercurrent disease before 250 dpi were excluded from the 
analysis. In mice with a positive score for clinical signs of a TSE and a negative score for 
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Figure 6.7: PrP deposition in RIII mice inoculated with vCJD appendix 
homogenate 
 
Deposition of PrP in RIII mice following inoculation with homogenate prepared 
from a vCJD appendix tissue. Intense granular and peri-cellular deposits of PrP 
throughout the (a) medulla and (b) thalamus. (c) PrP deposition targeting the CA2 
region of the hippocampus. (d) Small intense deposits of PrP targeting the medulla in 
the presence of aging vacuolation. Sections shown were labelled with the anti-PrP 
antibody 6H4 in combination with the CSA detection method, visualised with DAB 
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6.3.5 Peripheral nerve tissue 
Inoculation of peripheral nerve homogenates prepared from three vCJD patients 
(CJD 38, CJD 39 and CJD 40) was carried out in RIII mice. Table 6.6 details the 
incidence of clinical signs of disease, TSE-specific vacuolar pathology and 
deposition of PrP in each experimental group.  
 
Clinical TSE disease was observed in one RIII mouse following inoculation of three 
vCJD peripheral nerve homogenates. The presence of TSE-specific vacuolar 
degeneration in this mouse confirmed the diagnosis of a TSE (Table 6.6). No 
evidence of vacuolar pathology was observed in any other RIII mouse challenged 
with the three peripheral nerve inocula. With insufficient mice available for the 
construction of a lesion profile, it was not possible to compare the single mouse 
profile from the vCJD peripheral nerve with lesion profiles from other peripheral and 
neural tissues. The lesion profile is therefore not a relevant parameter in the strain 
typing of vCJD in peripheral nerve tissue investigated in this study. 
 
Immunohistochemistry on all mice inoculated confirmed the transmission of 
infectivity from all three vCJD peripheral nerve homogenates, with the 
demonstration of PrP accumulation in a small number of the mice tested (Table 6.6). 
The intensity of the PrP labelling varied between the individual mice; however, the 
general pattern of labelling closely resembled that of vCJD lymphoid homogenates 
inoculated in RIII mice (Figure 6.8). This suggests that in those mice which do show 
positive transmission after challenge with vCJD peripheral nerve, the transmission 
properties are consistent with those found in mice challenged with other vCJD tissue 
homogenates. These challenges indicate that transmission of infectivity from 
peripheral nerve can occur but it is rare or inefficient. 
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Table 6.6: Primary transmission from vCJD peripheral nerve homogenates 
 
Incidence of clinical signs (Clin), vacuolar degeneration (Vac path) and PrP 
deposition (PrP path) in RIII mice intracerebrally inoculated with vCJD peripheral 
nerve homogenates. Mice sacrificed with intercurrent disease before 250 dpi were 
excluded from the analysis. Incubation periods in days are shown in brackets. 
 
 




























Figure 6.8: PrP deposition in an RIII mouse inoculated with vCJD peripheral 
nerve homogenate 
 
Intense granular and peri-cellular deposits of PrP throughout the (a) medulla and (b) 
thalamus, hypothalamus, hippocampus, cerebral cortex of an RIII mouse challenged 
with a vCJD peripheral nerve homogenate. Sections shown were labelled with the 
anti-PrP antibody 6H4 in combination with the CSA detection method, visualised 
with DAB and counterstained with haematoxylin. Original magnification x25 
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6.3.6 Dorsal root ganglia tissue 
Three transmission experiments were carried out in RIII mice with homogenate 
prepared from dorsal root ganglia (DRG) tissue sampled from three vCJD patients 
(CJD 38, CJD 39 and CJD 40). The incidence of clinical signs of disease, TSE-
specific vacuolar pathology and deposition of PrP in each experimental group are 
detailed in Table 6.7.  
 
One of the vCJD DRG (CJD 38) transmitted disease readily to RIII mice resulting in 
a mean incubation period of 528 days. This was similar to the incubation period for 
vCJD spleen and tonsil tissue using the same mouse line, suggesting similar levels of 
infectivity in this DRG homogenate to that found in the vCJD lymphoid tissues. The 
other two DRG homogenates gave evidence of transmission in only a small number 
of mice, indicating lower levels of infectivity in these homogenates.  
 
Transmission of infectivity from DRG was confirmed by the presence of vacuolar 
pathology in some RIII mice following experimental challenge with each DRG 
inoculum (Table 6.7). In general, the appearance of vacuolar pathology in the mouse 
brain corresponded to the development of clinical TSE in the mice. Sufficient mice 
showing both clinical and vacuolar signs of TSE disease were available from the 
experimental challenge of DRG inoculum from CJD 38 for the construction of a 
lesion profile. The pattern of vacuolar degeneration closely resembles that seen in 
RIII mice challenged with vCJD lymphoid tissues, specifically with the targeting of 
vacuolar pathology in the medulla (G1), hypothalamus (G4) and the septum (G7) 
(Figure 6.9). This suggests that the vCJD agent, present in DRG is similar to that 
found in lymphoid tissues.  
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Table 6.7: Primary transmission from vCJD DRG homogenates 
 
Incidence of clinical signs (Clin) of disease and vacuolar degeneration (Vac path) 
and the accumulation of PrP (PrP path) in RIII mice intracerebrally inoculated with 
vCJD DRG homogenate. Mice sacrificed with intercurrent disease before 250 dpi 
were excluded from the analysis. Mean incubation periods in days are shown in 
brackets ± S.E.M. 
 
 







Clin Vac path PrP path 
CJD 38 
 



















Figure 6.9: Lesion profiles for mice inoculated with vCJD DRG homogenate 
 
Lesion profiles are constructed from 17 RIII mice scoring positive for both clinical 
TSE disease and TSE-specific vacuolar pathology following inoculation with DRG 
homogenate from CJD 38. (G) grey matter scoring regions, (W) white matter scoring 
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Further confirmation of the successful transmission of infectivity from DRG was the 
observation of PrP in the brains of RIII mice examined immunohistochemically 
(Table 6.7). Patterns of PrP accumulation in the brain were closely similar in RIII 
mice inoculated with the different DRG homogenates. Furthermore, the pattern of 
PrP accumulation was similar to that of mice inoculated with vCJD lymphoid 
homogenates with a peri-cellular staining pattern for PrP throughout the medulla, the 
thalamus and hypothalamus regions of the brain (Figure 6.10a and b). PrP 
accumulation was also observed to a lesser extent in the granular and molecular layer 
of the cerebellum (Figure 6.10c). In the hippocampal region, PrP staining pattern 
mirrored that of other vCJD tissue types experimentally inoculated into RIII mice, in 
which PrP deposition was found to target the CA2 region of the hippocampus (Figure 
6.10d).  
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Figure 6.10: PrP deposition in RIII mice inoculated with vCJD DRG 
homogenate 
 
Intense granular and peri-cellular deposits of PrP throughout the (a) medulla, (b) 
thalamus and hypothalamus in an RIII mouse following experimental challenge with 
a vCJD DRG homogenate. (c) Small granular deposits of PrP within the granular and 
molecular layer of the cerebellum. (d) Targeting of PrP in the CA2 region of the 
hippocampus. Sections shown were labelled with the anti-PrP antibody 6H4 in 
combination with the CSA detection method, visualised with DAB and 
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6.3.7 Trigeminal ganglia tissue 
Three transmission experiments were carried out in RIII mice with homogenate 
prepared from trigeminal ganglia tissue (TRG) sampled from three vCJD patients 
(CJD 38, CJD 39 and CJD 40). Details of the incidence of clinical signs of disease, 
TSE-specific vacuolar pathology and PrP accumulation in each experimental group 
are shown in Table 6.8. 
 
Two TRG homogenates (CJD 38 and CJD 40) transmitted disease readily in RIII 
mice with mean incubation periods of 536 and 579 days (Table 6.8). No clinical 
evidence of TSE disease was seen in the mice inoculated with the remaining TRG 
homogenate. However, further histological analysis of the brains at post-mortem 
showed vacuolar pathology in one RIII mouse. This confirmed transmission of 
disease from this TRG but indicates lower infectivity levels compared to the other 
two TRG tissue samples. Mean incubation periods for mice inoculated with TRG 
homogenates were comparable to that seen in transmissions from DRG, suggesting 
similar levels of infectivity in these two peripheral neural tissues.   
 
The presence of vacuolar pathology in the brain of a proportion of the mice 
experimentally challenged with all three TRG inocula, confirmed the transmission of 
a TSE in a proportion of the inoculated mice. Sufficient mice were available from the 
experimental challenge of DRG homogenate from patients CJD 38 and CJD 40 for 
the construction of a lesion profile (Figure 6.11). Patterns of vacuolar pathology as 
represented by the lesion profile were closely similar between the two TRG 
homogenates, indicating that the mice were infected with the same strain of agent. In 
addition, the targeting of vacuolar pathology was closely similar to that observed in 
transmissions from vCJD spleen, tonsil, lymph node and DRG in the same mouse 
line.  
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Table 6.8: Primary transmission from vCJD TRG homogenates 
 
Incidence of clinical signs (Clin), vacuolar degeneration (Vac path) and PrP 
deposition (PrP path) in RIII mice intracerebrally inoculated with vCJD TRG 
homogenates. Mice sacrificed with intercurrent disease before 250 dpi were excluded 
from the analysis. Mean incubation periods in days are shown in brackets ± S.E.M. 
 
 







Clin Vac path PrP path 
CJD 38 
 




















Figure 6.11: Lesion profiles for mice inoculated with vCJD TRG homogenates 
 
Lesion profiles are constructed from a minimum of five RIII mice scoring positive 
for both clinical TSE disease and TSE-specific vacuolar pathology. (G) grey matter 
scoring regions, (W) white matter scoring regions of the mouse brain. Mean lesion 
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All inoculated mice with a positive score for clinical signs of disease and vacuolar 
degeneration in the brain showed PrP accumulation in the brain following 
immunohistochemical analysis. In addition, PrP accumulation was demonstrated in a 
proportion of mice that had shown no evidence of any clinical or vacuolar signs of a 
TSE (Table 6.8). Patterns of PrP accumulation in the brain were closely similar 
between individual RIII mice with heavy deposits of PrP in the medulla (Figure 
6.12a) and throughout the thalamus and hypothalamus (Figure 6.12b) as well as 
around areas of intense vacuolation. The targeting of PrP in the CA2 region of the 
hippocampus, a characteristic feature of the different vCJD lymphoid and peripheral 
neural tissues in RIII mice was also seen following experimental challenge of TRG 
homogenate (Figure 6.12c).  This similarity in the PrP accumulation in the mouse 
brain is indicative of a similarity in the agent strain between these different tissue 
types. 
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Figure 6.12: PrP deposition in RIII mice inoculated with vCJD TRG 
homogenate 
 
(a) Peri-cellular and granular deposition of PrP in the medulla and cerebellum.  (b) 
Widespread intense PrP deposition in the thalamus, hypothalamus and hippocampus 
following experimental challenge with a vCJD TRG homogenate. (c) Targeting of 
granular PrP deposits in the CA2 region of the hippocampus. Sections shown were 
labelled with the anti-PrP antibody 6H4 in combination with the CSA detection 
method, visualised with DAB and counterstained with haematoxylin. Original 
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6.3.8 Spinal cord tissue 
Tissue homogenates prepared from spinal cord tissue sampled from three vCJD 
patients (CJD 38, CJD 39 and CJD 40) were experimentally inoculated into RIII 
mice. Details of the incidence of clinical signs of disease and TSE-specific vacuolar 
pathology in the inoculated mice, and results from the investigation of PrP 
accumulation in each experimental group are shown in Table 6.9. 
 
Clinical TSE disease was observed in the majority of mice inoculated with each 
spinal cord homogenate, with mean incubation periods of 458, 587 and 568 days 
(Table 6.9). Experimental challenge of the spinal cord sample from CJD 38 provided 
the shortest incubation period of any of the vCJD lymphoid and peripheral neural 
tissues examined, indicating the highest levels of infectivity in this homogenate. 
However, with an incubation period of 458 days, this was still longer than previous 
transmissions from vCJD brain tissue (Chapter 5, section 5.3.1), indicating that levels 
of infectivity are lower than those found in brain tissue. The 100-day incubation 
period difference found between the spinal cord inoculum from CJD 38 and CJD 39 
and CJD 40 is more likely to be attributed to variations in levels of infectivity 
between the different spinal cord homogenates  
 
TSE-specific vacuolar pathology in the majority of the inoculated mice confirmed 
the clinical diagnosis of a TSE. Furthermore, sufficient mice were available from all 
experimental groups for the construction of a lesion profile. Patterns of vacuolar 
pathology were remarkably similar for each spinal cord homogenate, evidence that 
the same strain of agent is present in each vCJD spinal cord (Figure 6.13) and further 
evidence that incubation period differences are due to variations in levels of 
infectivity. The targeting of vacuolar pathology in the RIII mice was similar to that 
described in the previous transmissions from vCJD lymphoid tissues and peripheral 
neural tissues with the most severe vacuolar pathology being found in the medulla, 
hypothalamus and the septum (Figure 6.13).  
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Table 6.9: Primary transmission from vCJD spinal cord homogenates 
 
Clinical signs (Clin), vacuolar degeneration (Vac path) and PrP deposition (PrP path) 
in RIII mice intracerebrally inoculated with vCJD spinal cord homogenates. Mice 
sacrificed with intercurrent disease before 250 dpi were excluded from the analysis. 
Mean incubation periods in days are shown in brackets ± S.E.M 
 







Clin Vac path PrP path 
CJD 38 
 





















Figure 6.13: Lesion profiles for mice inoculated with vCJD spinal cord 
homogenates 
 
Lesion profiles are constructed from RIII mice scoring positive for both clinical TSE 
disease and TSE-specific vacuolar pathology. (G) grey matter scoring regions, (W) 
white matter scoring regions of the mouse brain. Mean lesion profiles are shown with 
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As expected, inoculation of spinal cord homogenate produced an intense pattern of 
PrP deposition in the brain. The pattern of PrP accumulation was similar between 
mice inoculated with the different spinal cord homogenates and closely resembled 
those of all other vCJD tissue homogenates in the same mouse line. A widespread 
distribution of peri-cellular and granular PrP deposits throughout the mouse brain 
was observed (Figure 6.14). As described with other vCJD tissue homogenates, the 
most intense deposition of PrP was found in the medulla oblongata (Figure 6.14a), 
the thalamus and hypothalamus and around areas of extensive vacuolar pathology 
(Figure 6.14b). The targeting of PrP in the CA2 region of the hippocampus in the 
mice (Figure 6.14c) further confirms the similarity in the transmission properties of 
RIII mice inoculated with spinal cord tissue to that described from challenge with 
other lymphoid and peripheral neural tissues. 
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Figure 6.14: PrP deposition in RIII mice inoculated with vCJD spinal cord 
homogenate 
 
 (a) Heavy peri-cellular and granular deposition of PrP in the medulla and cerebellum 
of an RIII mouse.  (b) Widespread intense PrP deposition in the thalamus, 
hypothalamus, hippocampus and cerebral cortex following experimental challenge 
with a vCJD spinal cord homogenate. (c) Targeting of granular PrP deposits in the 
CA2 region of the hippocampus. Sections shown were labelled with the anti-PrP 
antibody 6H4 in combination with the CSA detection method, visualised with DAB 
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6.3.9 Bone Marrow 
Experimental transmission of bone marrow sampled from three vCJD patients (CJD 
38, CJD 39 and CJD 40) was carried out in RIII mice. Details of the incidence of 
clinical signs of disease, TSE-specific vacuolar pathology and deposition of PrP in 
the mouse brain in each experimental group are shown in Table 6.10. 
 
Only one RIII mouse inoculated with vCJD bone marrow received a positive score 
for the development of clinical signs of a TSE (Table 6.10); however, histological 
analysis failed to confirm a TSE in this mouse with no evidence of vacuolar 
degeneration in the brain. In the absence of any TSE-specific vacuolar pathology in 
these mice, lesion profiling was not a relevant strain typing parameter in the 
experimental challenge of vCJD bone marrow. The lack of any vacuolar pathology in 
the mice therefore provides no evidence for the transmission of TSE infectivity from 
vCJD bone marrow. Furthermore, immunohistochemical examination for the prion 
protein on all inoculated mice also failed to show any evidence of transmission from 
vCJD bone marrow (Table 6.10).  
 
Table 6.10: Primary transmission from vCJD bone marrow samples 
 
Incidence of clinical signs (Clin), vacuolar degeneration (Vac path) and PrP 
deposition (PrP path) in RIII mice intracerebrally inoculated with vCJD bone marrow 
samples. Mice sacrificed with intercurrent disease before 250 dpi were excluded 
from the analysis. In mice with a positive score for clinical signs of a TSE and a negative 
score for vacuolar pathology, the neuropathological assessment is considered definitive. 
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6.3.10 Blood components 
Inoculation of buffy coat and plasma separated from blood samples taken from four 
sCJD and four vCJD patients were carried out in RIII and VM mice.  Details of the 
incidence of clinical signs of disease, TSE-specific vacuolar pathology and results 
from the deposition of PrP in the mouse brain in experimental groups are shown in 
Table 6.11. 
 
Clinical signs of disease were observed in a proportion of VM and RIII mice 
following inoculation with plasma (15/245 mice) and buffy coat (3/276 mice) 
samples from sCJD and vCJD patients (Table 6.11). Histological analysis failed to 
confirm a TSE in any of these mice, with no evidence of vacuolar degeneration in the 
brain.  As discussed in Chapter 4, section 4.3.1.1, it is the working assumption of this 
thesis that the neuropathological assessment of these 18 mice that is definitive and 
the positive clinical signs are either in doubt or indicative of an unrelated illness or 
ageing. 
 
However, TSE-specific vacuolar pathology was observed in one VM mouse from the 
group experimentally challenged with a sCJD buffy coat sample from a patient who 
was homozygous for methionine at codon 129 and known to have a mixed PrPres type 
in the brain (patient CJD 11). No evidence of transmission, as judged by the 
development of vacuolar pathology, was observed in any mouse (RIII or VM) after 
challenge with vCJD buffy coat (Table 6.11). In the absence of sufficient mice 
available for the construction of a lesion profile it was not possible to compare the 
single VM mouse profile with the lesion profiles from other peripheral neural and 
lymphoid tissues. In contrast, no evidence of vacuolar pathology was found in any 
mouse after challenge with CJD (sCJD or vCJD) plasma samples. This suggests that 
either transmission of a TSE does not occur from this blood fraction or that the titres 
of infectivity are lower than that associated with the buffy coat fraction. In summary 
the lesion profile is not a relevant parameter in the strain typing of buffy coat or 
plasma from CJD patients in this study.  
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Immunohistochemical analysis for the prion protein was carried out on all mice (VM 
and RIII) inoculated with buffy coat and plasma components from each sCJD and 
vCJD patient. Only one mouse showed any evidence of PrP deposition in the brain 
(Table 6.11). This same VM mouse had shown TSE-specific vacuolar degeneration 
in the brain, thus confirming that this mouse was positive for TSE pathology after 
inoculation with this probable sCJD MM 1+2 sCJD buffy coat fraction.  The pattern 
of PrP deposition in this mouse was consistent with that observed in VM mice 
challenged with sCJD brain homogenate described in chapter 4, characterised by a 
restricted PrP pathology targeting the MHb (Figure 6.15a). In addition, some light 
granular deposition of PrP was observed in the superior colliculus (Figure 6.15b) in 
which vacuolar pathology is a consistent feature of mice following inoculation with 
sCJD brain homogenates (chapter 4) and in the pons (Figure 6.15c), a region of the 
brain particularly targeted in mice challenged with the MM2 subtype of sCJD.  
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Table 6.11: Primary transmission from vCJD blood components 
 
Incidence of clinical signs (Clin), vacuolar degeneration (Vac path) and PrP 
deposition (PrP path) in RIII and VM mice intracerebrally inoculated with buffy coat 
and plasma fractions taken vCJD and sCJD patients. Mice sacrificed with 
intercurrent disease before 250 dpi were excluded from the analysis. In mice with a 
positive score for clinical signs of a TSE and a negative score for vacuolar pathology, the 
neuropathological assessment is considered definitive. 
 
 
Mouse line  
 










































0/17 0/17 0/17 0/14 0/14 0/14 
Buffy 
coat 








Plasma 0/20 0/20 0/20 1/20 0/20 0/20 
Buffy 
coat 






Plasma 0/23 0/23 0/23 0/21 0/21 0/21 
Buffy 
coat 






Plasma 0/18 0/18 0/18 0/23 0/23 0/23 
Buffy 
coat 






Plasma 8/27 0/27 0/27 2/19 0/19 0/19 
Buffy 
coat 








Plasma 4/14 0/14 0/14 0/17 0/17 0/17 
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Figure 6.15: PrP deposition in a VM mouse challenged with sCJD buffy coat 
 
Faint granular deposition of PrP in the (a) medial habenular nucleus (MHb) and (b) 
superior colliculus following inoculation with a sCJD buffy coat sample. (c) 
Targeting of faint peri-cellular PrP deposits around in pons in the same mouse brain. 
Sections shown were labelled with the anti-PrP antibody 6H4 in combination with 
the CSA detection method, visualised with DAB and counterstained with 




   
 258 
6.3.11 Cerebrospinal Fluid 
Inoculation of CSF samples from two vCJD patients was carried out in RIII mice. 
Details of the incidence of clinical signs of disease, TSE-specific vacuolar pathology 
and deposition of PrP in the mouse brain in each experimental group are shown in 
Table 6.12. 
 
Clinical signs were observed in six mice inoculated with CSF from a single vCJD 
patient (Table 6.12). However, histological analysis of all inoculated mice, failed to 
confirm a TSE in any mouse challenged, with no evidence of vacuolar degeneration 
in the brain. As described previously (Chapter 4, section 4.3.1.1), the 
neuropathological assessment is considered definitive in such cases. Furthermore, 
immunohistochemical analysis for the prion protein showed no evidence of PrP 
accumulation within the brain of inoculated mice. Therefore, there is no evidence of 




Table 6.12: Primary transmission from vCJD CSF samples 
 
Incidence of clinical signs (Clin), vacuolar degeneration (Vac path) and PrP 
deposition (PrP path) in RIII intracerebrally inoculated with vCJD CSF samples. 
Mice sacrificed with intercurrent disease before 250 dpi were excluded from the 
analysis. In mice with a positive score for clinical signs of a TSE and a negative score for 
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6.3.12 Biochemical isotyping of PK resistant PrP
Sc
  
Frozen tissues available for the investigation of PrPres type in mice following 
inoculation with non-CNS tissue homogenates were limited. Only three RIII mice 
(two inoculated with vCJD tonsil tissue; one inoculated with vCJD spleen tissue) and 
two VM mice (one inoculated with vCJD tonsil tissue; one inoculated with vCJD 
spleen tissue) had frozen CNS tissue available for testing. Each mouse had received a 
positive score for clinical signs of disease and vacuolar pathology in the brain 
following inoculation with the different tissue types. Characterisation of the PrPres 
type in the mouse brain was carried out using a standard Western blot analysis 
method used in the diagnostic typing of human TSEs (Chapter 2, section 2.7). 
Western blot analysis was carried out on 5µl extracts of a 10% brain tissue weight to 
buffer volume (w/v).  
 
Overall, transmission from vCJD spleen and tonsil in RIII and VM mice 
demonstrated a glycoform pattern and electrophoretic mobility closely resembling 
that observed in the same mouse lines following transmission from vCJD brain tissue 
(Figure 6.16). However, the one RIII mouse inoculated with vCJD spleen 
homogenate that was available for analysis had a substantially modified glycoform 
ratio with an observable loss of the predominance of the diglycosylated fragment of 
the protein (Figure 6.16a). The appearance of the unglycosylated fragment as a 
doublet composed of distinct upper and lower bands, a feature observed in the mice 
experimentally infected with vCJD brain homogenate (Chapter 5, section 5.3.5), was 
also a feature of these five mice. There did not appear to be a correlation between the 
different mouse Prn-p genotypes and the relative abundance of the upper and lower 
bands comprising the unglycosylated doublet. 
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Figure 6.16: Western blot analysis of PrP
res
 in mice inoculated with vCJD tonsil 
and spleen 
 
Western blot analysis of PrPres in CNS samples of RIII and VM mice after 
experimental transmission of vCJD (a) spleen and tonsil homogenate and (b) brain 
homogenate. Tissues are analysed after digestion with proteinase K. Molecular 
weight markers are shown in kDa. (T2) human vCJD diagnostic standard; (U) upper 
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6.4 Results summary 
A full summary of the results examined in this Chapter is presented in Table 6.13. 
Infectivity was detectable to some extent in vCJD spleen, tonsil, cervical lymph 
node, appendix, spinal cord, peripheral nerve, DRG and TRG. No evidence of a TSE 
was observed in mice inoculated with vCJD bone marrow, plasma or CSF samples. 
In addition, no evidence of infectivity was found in sCJD spleen and plasma samples. 
However, infectivity was demonstrated to some degree in a sCJD buffy coat sample.  
Differences and similarities were observed in the transmission properties of the 
various vCJD peripheral in wild-type mice and were characterised by the following 
features; 
 
 In general, vCJD-infected mice develop a progressive clinical disease. 
However, preclinical infection was detected in mice inoculated with vCJD 
appendix and peripheral nerve isolates. 
 Mean incubation periods are extended in mice inoculated with lymphoid and 
peripheral neural tissues compared to those observed in the same mouse line 
challenged with vCJD brain homogenate (Figure 6.17). 
 Incubation periods in mice vary between different tissue inocula and also 
between the same tissue inocula from different vCJD cases. This suggests 
variation in the levels of infectivity between different tissue types and between 
the same tissue types sampled from different vCJD patients (Figure 6.17). 
 Lesion profiles show a remarkable similarity (most obvious in the RIII line) 
between different tissue types with a pattern which is closely similar to that 
observed in the same mouse lines following challenge with vCJD brain 
homogenate. (Figure 6.18). 
 Lesion profiles demonstrate a different pattern of vacuolar degeneration 
between RIII and VM mice (Figure 6.18). 
 Patterns of PrP deposition in vCJD-infected mice are remarkably similar 
following inoculation with different tissue types and a pattern that mirrors that 
observed in mice following challenge with vCJD brain homogenate. 
 Amyloid plaques are not a feature of vCJD in wild-type mice following 
inoculation with peripheral tissues. 
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Overall, results indicate similar transmission properties in mice challenged with 
different vCJD tissue types. These transmission properties are similar to those found 
with vCJD brain homogenate described in chapter 5. This indicates that the same 




Table 6.13: Summary of experimental transmissions 
 
Positive (+) and negative (-) scores for the presence of clinical disease (Clin), 
vacuolar pathology (Vac path) and PrP deposition (PrP path) in mice following 
inoculation with different tissue homogenates. Positive scores are based on results 





Tissue Clin Vac path PrP path 
spleen +ve +ve +ve 
tonsil +ve +ve +ve 
lymph node +ve +ve +ve 
appendix -ve -ve +ve 
peripheral 
nerve 
*+ve *+ve +ve 
spinal cord +ve +ve +ve 
DRG +ve +ve +ve 
TRG +ve +ve +ve 
bone marrow -ve -ve -ve 
buffy coat -ve -ve -ve 
plasma -ve -ve           -ve 
vCJD 
CSF -ve -ve -ve 
spleen -ve -ve -ve 
buffy coat -ve *+ve *+ve 
sCJD 
plasma -ve -ve -ve 
 
* Evidence for transmission based on one mouse 
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Figure 6.17: Mean incubation times in vCJD challenged mice  
 
Mean incubation periods in RIII and VM mice after experimental challenge with 
brain homogenate and different tissue homogenates from vCJD patients. Data are 
mean ± S.E.M. (FC) frontal cortex, (CB) cerebellar cortex, (IC) intracerebral 
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Figure 6.18: Lesion profiles for vCJD inoculated mice 
 
Comparison of lesion profiles in RIII (a, b) and VM mice (c, d) after experimental 
challenge with vCJD brain homogenate (a, c) and lymphoid and neural tissue 
homogenates (b, d). Lesion profiles are constructed from a minimum of five mice 
scoring positive for both clinical TSE disease and TSE-specific vacuolar pathology. 
(G) grey matter scoring regions, (W) white matter scoring regions of the mouse 
brain. Mean lesion profiles are shown with standard error bars (± S.E.M). 
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6.5 Discussion of experimental results 
This chapter had two specific aims. Firstly to assess whether infectivity is present 
within specified peripheral neural and lymphoid tissues of patients with vCJD and 
sCJD; and secondly to characterise the agent strain present within these peripheral 
tissues. Data presented in this chapter confirms the original demonstration of 
infectivity in spleen and tonsil (Bruce et al., 2001) and extends the evidence of 
infectivity to other tissues of CJD patients in a number of important respects. Firstly, 
this study extends the evidence for a widespread infection of the lymphoid system at 
the end-stage of disease with infectivity demonstrated in vCJD appendix and cervical 
lymph node. Secondly, the data provides the first direct demonstration of infectivity 
in the peripheral nervous system of vCJD patients. Thirdly, the identification of TSE 
pathology in a single mouse after challenge with a sCJD buffy coat sample suggests 
the possibility of infection in sCJD blood, and finally, this study confirms the same 
strain of agent within vCJD lymphoid and neural tissues. 
 
6.5.1 Infectivity levels within vCJD peripheral neural and lymphoid tissues 
In general, infectivity was detected in tissues from CJD patients in which the 
presence of the abnormal prion protein has been previously reported. Clinical and 
pathological signs associated with a TSE were observed to some extent from vCJD 
spleen, tonsil, lymph node, appendix, DRG, TRG, peripheral nerve, spinal cord and 
sCJD buffy coat.  Previous transmission experiments have shown that titres of 
infectivity in vCJD spleen and tonsil are lower than in brain resulting in extended 
incubation periods (Bruce et al., 2001). Overall, analysis of incubation period data in 
this study confirms these findings and indicates that levels of infectivity in other 
vCJD lymphoid tissues and neural tissues are also lower than those demonstrated in 
brain (Figure 6.17).  In tissue homogenates that transmitted disease readily to mice 
resulting in clinical disease (vCJD spleen, tonsil, lymph node, DRG, TRG and spinal 
cord), incubation periods were broadly similar irrespective of the tissue type used in 
the inoculation (Figure 6.17). This suggests that levels of infectivity are similar 
within these different inocula and are comparable to those infectivity titres 
previously demonstrated in vCJD spleen and tonsil (Bruce et al., 2001). However, 
efficiency of transmission from each tissue type varied between vCJD patients. In the 
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transmission of peripheral neural tissue, one vCJD DRG and two TRG transmitted 
disease readily to mice with incubations comparable to those seen in spleen and 
tonsil. However the other DRG and TRG homogenates gave evidence of 
transmission in only a small number of the mice. The results from the lymphoid 
tissues also varied between patients. One of the vCJD lymph nodes gave definite 
transmission to mice; although the long incubation periods and partial take suggest 
only low infectivity levels. Another vCJD lymph node sample showed only trace 
infectivity levels and the third was completely negative (based on clinical and 
pathological assessment).  This suggests there may be patient-to-patient variation in 
levels of infectivity.  
 
However, is variation in infectious titre the only possible explanation for the 
differences found in the efficiency of transmission between the different lymphoid 
tissues?  Accumulations of pathological PrP have been detected in appendix samples 
surgically removed from patients that went on to develop clinical vCJD eight months 
or two years later (Hilton et al., 2004a), suggesting a long-term lymphoid tissue 
involvement. However, data from this study demonstrates that transmission from 
appendix tissue is relatively inefficient compared to spleen, tonsil and lymph node. 
Furthermore, immunohistochemistry confirmed the deposition of PrP in these 
appendix tissues, so it is important to ask why were there so few mice showing 
evidence of transmission compared to the other lymphoid tissues. This could simply 
be a sampling problem, as was discussed earlier in Chapter 3. It may be that 
infectivity was present in the appendix tissue, but that the small tissue samples 
prepared as inoculum had missed the major infectivity foci in the lymphoid follicles, 
perhaps because of fibrosis or previous inflammation and scarring in the appendixes. 
Lymphoid follicles containing germinal centres are irregularly distributed in the adult 
appendix; this was confirmed on immunohistochemistry for PrP in the three 
appendixes sampled in this study, which showed positively staining germinal centres 
in a patchy distribution, consistent with an earlier study (Head et al., 2004b). 
Furthermore, Western blot analysis of 200µl extracts of residual inoculum from two 
of the inoculations (CJD 38 and CJD 40) failed to show any detectable levels of 
PrPres, supporting evidence that the appendix tissue sampled for these inoculations 
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may have missed the major foci of infectivity.  It could be that the differences 
observed in the efficiency of transmission between other tissue types in this study 
may also reflect sampling difficulties in tissues in which the deposition of PrPSc is 
known to be much more heterogeneous that those found in brain, (Joiner et al., 2002; 
Hilton et al., 2004a; Head et al., 2004b), rather that a reflection of differences in 
levels of infectivity in the tissues as a whole. 
 
6.5.2 The same agent strain is present within different vCJD peripheral 
lymphoid and neural tissues 
Comparison of the transmission properties from the inoculation of tissue samples 
from vCJD spleen, tonsil, cervical lymph node, appendix, peripheral nerve, DRG, 
TRG and spinal cord has provided convincing evidence that the same strain of agent 
is present within these different tissues. Overall, lesion profiling in RIII mice showed 
a remarkably similar pattern for each vCJD inoculation, regardless of the tissue type 
used to prepare the inoculum (Figure 6.18). In addition, the different vCJD tissues 
produced a consistent pattern and targeting of PrP pathology in the RIII mouse brain. 
These findings confirm those of previous studies which report that the strain 
properties of the agent are not substantially altered by the tissue in which it replicates 
(Beringue et al., 2008). This is interesting because minor differences in the PrPres 
glycosylation and fragment size, factors proposed to be important in enciphering 
strain-specific information, have been described in vCJD lymphoreticular and 
peripheral neural tissues compared to brain although they all retain a resemblance to 
PrPres in vCJD brain (Head et al., 2004b).  The lack of any frozen CNS tissue in the 
majority of the inoculations has meant that establishing whether these tissue or cell-
specific influences on the conformation or glycosylation of PrP are conserved on 
transmission to mice is largely unanswered in this study. However, analysis of a 
limited number of RIII and VM mice following inoculation with vCJD spleen and 
tonsil tissue generally produced a glycoform pattern closely resembling that of vCJD 
brain and in murine CNS after experimental challenge with vCJD brain homogenate 
(chapter 5). This provides further evidence that the same strain of agent is present in 
vCJD tissues examined in this study and that the differences seen in PrPres type 
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between brain and other tissue types in vCJD are not fundamental properties of the 
agent and may be tissue specific epiphenomena.   
 
 
6.5.3 Comparison of infectivity levels in sCJD and vCJD tissues 
Direct comparison of infectivity in vCJD and sCJD tissues was limited to spleen and 
blood fractions (buffy coat and plasma) in this study. The absence of any evidence of 
transmission from sCJD spleen homogenate supports previous findings that there is a 
more limited involvement of lymphoid tissues in sCJD in comparison to vCJD (Head 
et al., 2004b) and suggests a greater potential for iatrogenic spread for vCJD than for 
sCJD. However this did not appear to hold true when infectivity in different blood 
components from CJD patients was examined.  
 
The successful transmission of a TSE in sheep after receiving a transfusion of either 
whole blood or buffy coat fractions from sheep incubating scrapie and experimental 
BSE demonstrated that infectivity was present in blood (Hunter et al., 2002).  
Furthermore, the probable transmission of vCJD infectivity in five individuals who 
received a blood transfusion or blood products from blood donated from 
asymptomatic vCJD patients confirmed that infectivity was also present within blood 
in vCJD patients. These findings suggest that blood transfusion may be a highly 
efficient route of transmission. However, this thesis has shown no evidence of 
transmission from either vCJD blood fractions (buffy coat and plasma). This may not 
be a surprising result: it may be that the infectious titres in the blood components, 
combined with the relatively low volumes inoculated (20µl) were insufficient to 
cause disease in these mice. It could also be an indication that the intravenous route 
is more efficient in the transmission of infectivity from blood. Somewhat 
surprisingly, this study suggests the possibility of infectivity in sCJD blood.  With 
such an anomalous result there are two possible explanations. Firstly, that this is a 
true result and provides evidence of infectivity in sCJD blood; or that this results 
from an artefact or some laboratory error. The theoretical considerations of these two 
possibilities are discussed in full in Chapter 7, section 7.2.9.   
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It is obviously not possible in humans to trace the accumulation of vCJD infectivity 
in peripheral tissues through the long incubation period. However, experimental 
animal studies of other TSEs have shown that infectivity may accumulate rapidly in 
lymphoid tissues soon after exposure (Kimberlin and Walker, 1979; Kimberlin and 
Walker, 1989b) and may remain at plateau levels for long periods before the animal 
develops clinical signs of disease (Dickinson and Fraser, 1969; Dickinson, 1976). 
Similarly there is evidence of an early involvement of the peripheral nervous system 
in experimental animal models (Groschup et al., 1999; Beekes and McBride, 2000). 
If the pathogenesis of disease in vCJD is similar to that seen in these models, an 
infected asymptomatic individual could represent a transmission risk over a period of 
years. The data presented in this chapter provides further valuable evidence pertinent 
to the ongoing risk assessment of the dangers associated with the different neural and 
peripheral tissues from patients with variant and sporadic CJD.  
 
6.6 Chapter conclusion 
This study has extended the evidence for widespread lymphoid tissue infection in 
vCJD. In addition, inoculations from neural tissues provide the first direct 
demonstration of infectivity in the peripheral nervous system. Characterisation of the 
agent strain confirms a single agent strain associated with different vCJD tissues 
which is closely similar to that observed in vCJD brain. These results provide 
valuable information for assessing risks of iatrogenic transmission associated with 
different surgical and medical procedures. 
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 Chapter 7: Discussion 
 
7.1 Overview of the aims of the thesis 
The aims of this thesis were to characterise the sCJD and vCJD agent strain by 
primary transmission and following the subsequent mouse-to-mouse passage of CNS 
tissue in wild-type mice. In addition, inoculation of the same mouse lines with tissue 
homogenates prepared from a wide range of peripheral tissues and biological fluids 
from CJD patients were carried out to investigate the distribution of infectivity and 
characterise the agent present in tissues other than brain. The principal findings from 
the data generated in this thesis are itemised below and then discussed in relation to 
each other and to issues which have arisen within the TSE field during the course of 
this work.  
 
7.2 Principle findings 
 Data from this thesis provides evidence of at least three distinct strains of 
agent associated with sCJD cases. Two sCJD strains were distinguished by 
subtle differences in their biological and biochemical properties on 
transmission to wild-type mice and a third is proposed based on the lack of 
transmission in the mice. 
 Experimental transmission of vCJD in wild-type mice confirms that vCJD 
appears as a single strain of agent on primary transmission and is distinct 
from sCJD. 
 Data from this thesis extends the evidence for a widespread peripheral 
lymphoid tissue involvement in vCJD and provides the first direct 
demonstration of the presence of vCJD infectivity in the peripheral nervous 
system and evidence of sCJD infectivity in blood. 
 Furthermore, data generated shows that there are no tissue-specific 
adaptations of the vCJD agent. 
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7.2.1 The relationship between disease phenotype, PRNP codon 129 genotype, 
PrP
res
 type and agent strain in sporadic CJD 
The different phenotypic subtypes identified in cases of sCJD (Parchi et al., 1999) 
are proposed to relate to the propagation of unique strains of sCJD; however, this 
proposal remains unconfirmed. This thesis represents the first systematic analysis of 
each of the major sCJD subgroups (classified according to PRNP codon 129 
genotype and PrPres type combination) based on the “gold standard” strain typing of 
TSEs in panels of wild-type mice. Three major groupings of sCJD have been 
distinguished by this method (MM1 and MV1; MM2; MV2, VV1 and VV2), defined 
by similarities and differences in their transmission properties in the mice. Evidence 
in support of these three major groups of sCJD was reported in a comparable study 
examining the survival times and disease phenotype in bank voles experimentally 
challenged with sCJD subgroups (Nonno et al., 2006). In agreement with the findings 
in the wild-type mice, voles were most susceptible to infection with brain 
homogenate from sCJD MM1, MV1 and MM2 cases. The authors inferred the 
existence of two sCJD strains; one associated with the sCJD MM1 and MV1 
subgroups and a second associated with the sCJD MM2 subgroup, based on 
differences in the clinical disease, neuropathology and biochemical phenotypes 
observed after primary and secondary transmission. Furthermore, the lack of any 
evidence of transmission in the voles following inoculation with tissue from sCJD 
MV2 and VV2 cases was used as evidence that these could represent a further sCJD 
strain. This is consistent with the findings in the wild-type mice described in this 
thesis. The sCJD VV1 subgroups was not investigated by the inoculation of bank 
voles (Nonno et al., 2006).  
 
Both in the bank vole study and in the mouse study described in this thesis, 
susceptibility to disease appears to be attributable in part to the effect of methionine, 
rather than valine at PRNP codon 129 in the sCJD donor. Only in exceptional cases 
was transmission observed from VV donors. The numbers of comparative studies in 
wild-type mice is surprisingly limited; however, in one study examining the 
transmission properties of Japanese sCJD cases from each of the codon 129 
genotypes, a similar ranking of susceptibility of the mice to sCJD cases of each 
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codon 129 genotype was reported (Tateishi et al., 1996); further evidence that the 
presence of at least one methionine allele at codon 129 appears to facilitate the 
transmission of sCJD in wild-type mice. However, it is worth noting that the lack of 
transmission from the sCJD MV2 inocula in this thesis suggests that susceptibility to 
disease is not solely a consequence of PRNP codon 129 genotype. This will be 
discussed in detail later in this Chapter.  
 
A potential limitation to the use of wild-type mice in the investigation of human 
TSEs is the effect of host codon 129 genotype on disease susceptibility. Wild-type 
mouse lines are all homozygous for methionine at the corresponding Prn-p codon 
128.  So the question of whether the different sCJD transmission properties described 
in this thesis are a direct result of the presence of the methionine allele at codon 129 
in the sCJD donor or merely a consequence of the compatibility between the 
corresponding PrP genotype of the donor and host species can not be determined.  
The same question is also relevant in the interpretation of data from the sCJD 
transmissions to bank voles discussed earlier in this section (Nonno et al., 2006). As 
in mice, the vole prion protein gene encodes for methionine at the equivalent position 
to human codon 129; therefore, the question of whether the transmission properties 
observed in this animal model are a reflection of the compatibility between the donor 
PrPSc and recipient PrPC is also unresolved. Nevertheless, bioassay in wild-type mice 
distinguishes the MM1, MV1, MM2 cases from the MV2, VV1 and VV2 cases based 
on the manifestation of clinical disease, neuropathology and the demonstration of 
PrPSc in the brain.  
 
In principle it is possible that differences in the efficiency of transmission between 
sCJD subgroups may simply be due to differences in infectious titres between the 
different groups rather than a reflection of any strain-specific properties. The lack of 
transmission from the MV2, VV1 and VV2 subgroups might therefore be taken to 
mean that these subgroups have a consistently lower titre than the MM1, MV1 and 
MM2 subgroups. However, there is much evidence in this study to suggest that such 
differences are not related to infectious titre, but are indeed a true reflection of strain-
specific properties.  The detection of PrPres in different CJD tissues is proposed to 
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correspond to the presence of infectivity. Western blot analysis of the different sCJD 
brain inocula showed that PrPres was readily detected in all brain extracts and that the 
intensity of the PrPres signal was comparable between the different inocula (Chapter 
3). If PrPres correlates with infectivity, this would suggest that infectivity levels were 
broadly similar in the different sCJD brain inocula. Furthermore, in the challenges 
from other CJD tissue types, the successful transmission of infectivity occurred from 
vCJD tonsil, appendix and TRG tissue, tissues in which levels of PrPres were lower 
than could be detected by conventional Western blot analysis. Although vCJD is a 
different agent strain from sCJD and transmits more readily in wild-type mice, this 
may be supporting evidence evidence that titres of infectivity are likely not to be 
responsible for the differences in the transmission efficiency.  
 
7.2.1.1 Comparison of transmission properties between wild-type mice and human 
transgenic mice after experimental transmission with brain homogenate from 
sporadic CJD subgroups 
To further understand the role that host PRNP codon 129 genotype has in defining 
transmission and propagation of sCJD strains, three transgenic mouse lines were 
produced by gene targeting with the direct replacement of the mouse prion protein 
open reading frame with the three different human PRNP sequences (129MM, MV, 
VV).  These mice designated HuMM, HuMV and HuVV were inoculated with brain 
homogenate from each sCJD subgroup in a directly comparable study to that 
undertaken in this thesis (Bishop, 2008; Bishop et al., 2010). In fact, five of the six 
sCJD cases selected for experimental challenge to the human transgenic mice were 
those that had previously been used for the inoculation of wild-type mice reported in 
this thesis.  Therefore in the discussion of some of the data generated in this study, it 
is useful to draw a comparison with data from the human transgenic mice.  
 
Similarities and differences emerge when comparing the two studies. By employing 
the identical strain typing parameters to those used in this thesis, inoculations of the 
transgenic mice demonstrated that the six sCJD subgroups behave as four distinct 
strains of agent (MM1 and MV1; MM2; MV2 and VV2; VV1) (Bishop, 2008; 
Bishop et al., 2010). These identical groupings have also been reported using two 
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different in vitro assays, one examining the protease sensitivity and conformational 
stability of PrPSc in different sCJD subgroups  (Uro-Coste et al., 2008) and a second 
using the recently described PMCA method to investigate the efficiency of the 
different sCJD subgroups in the conversion of PrPC to PrPSc (Jones et al., 2008). The 
grouping of these sCJD subgroups as distinct strains is closely similar to that 
reported in this thesis, supporting evidence that wild-type mice can be used to 
distinguish some sCJD strains. Where differences occur between the challenge of 
wild-type mice and the transgenic mice described by Bishop and co-workers, the 
differences may be explained by the resistence of the wild-type mice to infection 
with certain forms of sCJD agent. As a consequence, wild-type mice are not able to 
further distinguish between sCJD MV2, VV2 and VV1 inocula. In the transgenic 
mouse study, Bishop and co-workers showed that the HuMM and HuMV mice had 
similar levels of clinical disease and mean incubation periods for four of the six 
sCJD brain inocula (MM1, MV1, MV2 and VV2). These levels of clinical disease 
and incubation periods differed from those found in the HuVV mice challenged with 
the same four brain inocula.  Few animals showed clinical disease following 
inoculation with the VV1 subtype in any of the three transgenic lines (Bishop, 2008; 
Bishop et al., 2010). This implies that transmission properties in the mice are 
influenced by the presence of methionine at codon 129 in the host. Therefore, the 
strain-related properties observed in the sCJD inoculated mice in this thesis may in 
part be a reflection the mice having the methionine allele at the corresponding mouse 
Prn-p codon 128.  
 
However, data generated from the experimental challenge of sCJD MV2 inocula to 
wild-type mice in this thesis and in the experimental challenge of sCJD MM2 inocula 
in the corresponding human transgenic mouse model (Bishop, 2008; Bishop et al., 
2010) have demonstrated that sCJD transmission properties are not solely defined by 
the codon 129 genotype of the donor and host. A complex relationship with the PrPres 
type of the sCJD donor has also been demonstrated. In general, the presence of type 
1 PrPres in sCJD MM and MV donors appears to facilitate transmission across all 
four mouse lines examined in this thesis. With the exception of sCJD MM2 in RIII 
mice, cases with type 2 PrPres largely failed to transmit disease in the wild-mice. 
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Similarly, all three transgenic lines (HuMM, HuMV and HuVV) were readily 
susceptible to disease with the appearance of clinical signs following inoculation of a 
sCJD MM1 brain inoculum, whereas no evidence of a TSE was observed in any 
mouse following challenge with a sCJD MM2 brain inoculum (Bishop, 2008; Bishop 
et al., 2010). Thus in terms of risk assessment, both studies suggest that the MM1 
and MV1 subtypes, the most common “classical” form of sCJD, represent the 
greatest risk of secondary transmission of sCJD. Data from this thesis could also be 
used to suggest that the presence of type 2 PrPres in the brain of sCJD cases may offer 
reduced risk of secondary human transmission of sCJD. However, when the full data 
set including the human transgenic mice is considered, this is not the case. The 
HuVV mice challenged with type 2 PrPres from sCJD MV and VV donors produce 
the shortest incubation periods observed in any of the sCJD inoculations. In fact, data 
from the transgenic study suggest that VV individuals may be the most susceptible to 
secondary sCJD transmission with the observation that the HuVV mice developed 
clinical disease after challenge with five of the six brain inocula.  Therefore, the risk 
of transmission of sCJD may be a function of the nature and source of the infectivity 
and the PRNP codon 129 genotype of the exposed individuals.  
 
The relationship between transmissibility, host PRNP codon 129 genotype and the 
inoculation of different sCJD strains may already have been inadvertently 
demonstrated in humans. In a study investigating the distribution of PRNP codon 129 
in human growth hormone (hGH) transmitted CJD patients in France and UK, 
different genotypic distributions were observed between the two countries (Brandel 
et al., 2003). The French hGH related patients showed a biased towards the MM 
genotypes whereas UK patients showed a bias towards MV and VV genotypes. 
Mechanisms of production of the hGH, the number of hGH treatments received and 
the duration in treatment was similar in patients from both countries; however, the 
actual growth hormone was prepared independently in France and the UK. One of 
the possibilities raised in this study was that different contaminating sCJD subtypes 
were used in the preparation of hGH in France and the UK. If, as data in this thesis 
supports, the different sCJD subtypes reflect different sCJD strains, the distribution 
of PRNP codon 129 genotypes in the French and UK cases might be due to infection 
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with different contaminating CJD strains. If the results of the human transgenic mice 
are a true reflection of what occurs in the secondary transmission of sCJD, this would 
suggest that the French patients were more than likely infected with hGH 
contaminated from sCJD MM1 or MV1 patients whereas the UK patients were more 
than likely contaminated with hGH from either  sCJD MV2 or VV2 patients. 
 
Data from this thesis and that described by Bishop and co-workers also support 
findings from a large-scale biochemical study investigating PrPres types in 170 cases 
of sCJD (Head et al., 2004a). This study suggested that sCJD patients who have 
methionine homozygosity at PRNP codon 129 may be more predisposed to 
propagate type 1 PrPres in the brain, whereas patients who are valine homozygous are 
more predisposed to propagate type 2 PrPres. In this thesis, the propagation of type 1 
PrPres in a single RIII mouse following inoculation with brain homogenate from a 
sCJD MV2 patient is proposed to have resulted from the presence of a minority type 
1 component in the inoculum (Chapter 4). However, the possibility that this may be a 
result of a predisposition of the mice to propagate type 1 PrPres may be an alternative 
explanation. Results from the human transgenic mice provide supporting evidence 
for this proposition; the HuMM and HuMV mice also propagated type 1 PrPres 
following challenge with a sCJD MV2 inoculum, whereas a PrPres with a mobility 
associated with PrPres type 2 was detected in the HuVV mouse line following 
inoculation with the same brain homogenate. Nevertheless, the observation of PrPres 
type 2A in the mice in this thesis following challenge with brain homogenate from a 
sCJD MM2 case indicates that although there may be a bias to the propagation of 
type 1 PrPres, the propagation of a type 2 PrPres can be supported in the presence of 
the methionine allele at PRNP codon 129 in the donor tissue and host. This has also 
been supported by the successful transmission of vCJD in mice (Chapter 5).   
 
It is interesting that the one sCJD MM2 brain homogenate inoculated in the 
transgenic mouse lines showed no evidence of transmission (Bishop, 2008; Bishop et 
al., 2010).  As only a single MM2 case was used to challenge the transgenic mice the 
data must be interpreted with caution. However, Bishop and co-workers provide no 
alternative explanation of whether this lack of transmission may be attributed to a 
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resistance of the mice to infection from this sCJD subgroup or whether it may be a 
reflection of lower titres of infectivity in this inoculum. As brain homogenate from 
this same sCJD case produced evidence of a TSE in the wild-type mice in this thesis 
and in an earlier thesis using a different human transgenic mouse model (Wiseman, 
2006), and that in all three studies inoculum was prepared from the same brain 
region, it is therefore unlikely that low titres alone are the reason. It is noteworthy 
that the transmission of brain homogenate from this sCJD MM2 patient transmitted 
more readily in the wild-type mice than the transgenic mice, even in the HuMM 
mouse line which had PRNP codon 129 genotype matching the donor. This is similar 
to that found with vCJD. 
 
Conservation of PrPres type following transmission is an integral part of the proposal 
that differences in the biochemical properties of PrP (conformation and glycosylation 
states) may play a role in enciphering strain-specific differences. In general, PrPres 
typing data generated in this study supports this proposal. However, when combining 
the wild-type mouse data in this study with that generated from the human transgenic 
models described by Bishop and co-workers, in which alterations in the PrPres type 
are observed following transmission, a more likely explanation is that PrPres types are 
not a specific marker for agent strain, but are a result of the interaction between the 
strain and a host. 
 
7.2.2 The co-occurence of PrP
res
 types in sporadic CJD: implications for disease 
phenotype and agent strain 
At the outset of this thesis the question of distinct TSE strains in sCJD focused on the 
six clinico-pathological subtypes of sCJD described by Parchi and Gambetti (MM1 / 
MV1, VV1, MM2cortical, MM2thalamic, MV2 and VV2) (Parchi et al., 1999) and 
the proposal that strain-specific information in sCJD is encoded by which of the two 
PrPres types (type 1 or type 2A) is observed in individual cases combined with their 
PRNP codon 129 genotype. However, as this study has progressed, questions about 
the validity of this molecular-based sub-classification system and the relationship 
between disease phenotype, PrPres type and agent strain have arisen with reports that 
a much larger proportion of sCJD cases than initially described contain both type 1 
   
 278 
and type 2 (Puoti et al., 1999; Polymenidou et al., 2005; Yull et al., 2006; Schoch et 
al., 2006; Uro-Coste et al., 2008).  In response to these reports, two recent papers 
have re-addressed the sub-classification of sCJD proposing that mixed PrPres types in 
the brain are associated with further defined subtypes of sCJD (Parchi et al., 2009; 
Cali et al., 2009). Both reports propose that if thorough clinical investigations and 
extensive sampling of different brain regions, and the use of antibodies that have 
different affinities for types 1 and 2 are employed, then sCJD cases with mixed PrPres 
types can be distinguished from ‘pure type 1’ and ‘pure type 2’ sCJD cases as  
distinct clinico-pathological phenotypes. 
 
So what does this mean for the molecular definition of agent strain? Certainly, the 
data from this thesis and that of previous transmission studies in different animal 
models (Nonno et al., 2006; Bishop, 2008; Bishop et al., 2010) support the 
relationship between sCJD phenotypic variability and the propagation of unique 
strains. How these mixed PrPres types will propagate in the mice is uncertain. 
However, transmission of brain tissue from the probable case of mixed PrPres types 
carried out as part of this thesis does provide some preliminary evidence that is 
discussed later in this section. Will transmission of such cases produce a unique 
phenotype in the mice distinct from that observed from transmission of ‘pure type 1’ 
and ‘pure type 2’ cases, indicating the propagation of further distinct sCJD strains? 
As the sCJD phenotypes of these mixed PrPres types are characterised by a co-
existence of phenotypic features observed in ‘pure type 1’ and ‘pure type 2’ cases, it 
may be more likely that transmission studies may provide evidence of a co-infection 
of different TSE strains. In either case, transmission studies from mixed PrPres type 
brain homogenate will play a significant role in answering these questions and the 
sCJD transmissions carried out in this study will provide a valuable standard on 
which to compare data from such studies.  
 
Perhaps the most valuable information would come from the transmission of sCJD 
MM 1+2 cases in the wild-type panel and in the human transgenic lines used by 
Bishop and co-workers. Pure PrPres type 1 and type 2 cases in this genotype had 
shown the most observable difference in the clinico-pathological and biochemical 
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phenotype after transmission in both mouse models. If transmission of such cases 
results in co-infection with distinct TSE strains, it would be predicted that a 
proportion of wild-type mice challenged would demonstrate a type 1 disease 
phenotype and a proportion show type 2 phenotype. Alternatively, it may be that a 
single disease phenotype will be selected and amplified by the host, depending on the 
host PRNP codon 129 genotype. This may be an alternative explanation for the 
apparent selection of a type 1 disease phenotype in the wild-type mice following 
transmission with the probable mixed sCJD MM1 +2 case (CJD 11) investigated in 
this study. Such selection of a single disease phenotype following challenge with 
mixed sCJD PrPres types was demonstrated in a recent study investigating the clinico-
pathological and biochemical characteristics of the sCJD agent following 
transmission in the squirrel monkey (Williams et al., 2007). In this study, brain 
homogenate from a single sCJD MM1 and MV2 patient were pooled prior to 
inoculation. Biochemical typing of PrPres in frozen tissue samples from the frontal 
cortex of the sCJD inoculated squirrel monkeys detected only a single PrPres type 
with a glycoform ratio and mobility resembling type 1 PrPres. There are two possible 
explanations for these results. Firstly, squirrel monkeys, like wild-type mice, are 
uniformly homozygous for methionine at codon 129. Therefore, as suggested in this 
and in previous transmission studies, it may be that the MM1 component will 
transmit more successfully in MM hosts and will be replicate preferentially over the 
other sCJD MV2 component. This first alternative could be characterised as a 
competition/selection model. Alternatively, these results may provide further 
evidence that hosts who are methionine homozygous at codon 129 may be more 
predisposed to propagate type 1 PrPres in the brain, irrespective of the nature of the 
material used in the challenge. This second alternative has more in common with a 
mutation model in which there is a switch from one conformation to another due to a 
‘transmission barrier’. The current uncertainties surrounding mixed PrPres types raise 
the question of whether the existence of different sCJD strains can be properly 
investigated whilst the phenotypic variability of the disease has yet to be established 
and a full an accurate description of the contributions of different PrPres types is 
made. 
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7.2.3 Transmissions of variant CJD demonstrate uniform and conserved BSE- 
related phenotypic properties on primary passage in wild-type mice  
The remarkable uniformity observed in the clinical presentation and pathological 
features of vCJD patients, combined with the observation of a single PrPres type 
associated with vCJD cases lead to the proposal that this human TSE is caused by 
infection with a single strain of agent. Data from this thesis provides strong support 
for this hypothesis as illustrated by the remarkable similarity in the transmission 
properties in the wild-type panel following primary challenge with brain homogenate 
from 10 cases of vCJD. The findings from the vCJD transmissions carried out in this 
thesis were published in 2009 in the Journal of General Virology (JGV) (see 
appendix) and provide a full characterisation of the vCJD agent strain after primary 
transmission and on subsequent passage in mice, thus providing a baseline on which 
agent strain in any future cases of suspected vCJD in other PRNP codon 129 
subgroups (MV and VV) can be compared.   
 
Early epidemiological (Will et al., 1996), biochemical PrPres typing (Collinge et al., 
1996) and experimental transmission studies (Bruce et al., 1997) all supported the 
proposal that the single strain of agent responsible for BSE is also responsible for 
vCJD.  Data in this thesis provides further strong supportive evidence for this 
proposal. Incubation periods from the 10 vCJD challenges in this thesis are 
consistent with published data of BSE transmissions in the same mouse lines (Bruce 
et al., 1994; Bruce et al., 1997; Ritchie et al., 2009). Furthermore, the incubation 
period difference of around 100 days which is observed between the RIII and C57BL 
mice (both Prn-pa mice), which is characteristic of the BSE agent (Bruce et al., 1994; 
Ritchie et al., 2009), was replicated in all seven transmissions from vCJD cases in 
which both mouse lines were included. In addition, sub-passage of vCJD brain 
isolates in different mouse Prn-p genotypes resulted in the isolation of two distinct 
mouse-passaged strains, closely similar to the 301V and 301C strains which were 
derived by serial passage of BSE in VM and C57BL mice respectively (Bruce et al., 
2002; Ritchie et al., 2009). The biochemical phenotype of the vCJD inoculated mice 
in this study also mirrored that of BSE in cattle and the BSE agent in the same mouse 
lines, characterised by the predominance in the diglycosylated form of the protein.  
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In addition, the appearance of the unglycosylated fragment of the protein as a doublet 
in the vCJD inoculated mice after primary and on subsequent serial mouse passage 
also resembles a phenomenon previously reported to occur in BSE-derived 301V and 
301C strains (Somerville et al., 2005), thus providing a further biochemical 
characteristic shared by BSE and vCJD. 
 
The isolation of distinct mouse-passaged strains of agent on serial passage in 
different mouse Prn-p genotypes is not a unique feature of vCJD and BSE and has 
been reported previously in the mouse passage of different scrapie strains (Bruce et 
al., 2002). Interestingly in this thesis, sub-passage of sCJD MM1 brain isolates also 
resulted in two distinct mouse-passaged strains. Although different from the 
vCJD/BSE-passaged strains, the two sCJD-passaged strains were also isolated 
according to incubation period differences observed in the different mouse Prn-p 
genotypes. This may be indicative that the isolation of these two distinct disease 
phenotypes on serial passage of sCJD and vCJD may be consistent with host-
permitted selection of strains rather than any strain-specific differences in the TSE 
agent (Bruce, 2003). 
 
7.2.4 The vCJD/BSE agent is distinct from those of sCJD 
In the original vCJD strain typing paper, Bruce and co-workers showed that vCJD 
could be distinguished from the MM1 subgroup of sCJD by differences in the 
appearance of clinical signs and lesion profiles after inoculation of brain homogenate 
in RIII mice (Bruce et al., 1997). Furthermore, studies comparing the biochemical 
phenotype of vCJD with that of different sCJD subtypes following experimental 
challenge in humanised transgenic mice, also differentiated these two human TSEs 
(Collinge et al., 1996). These two studies provided early evidence that vCJD 
represented a new subtype of human TSE, distinct from sCJD. In this thesis, 
comparison of the transmission properties of mice following inoculation with brain 
homogenate from 10 vCJD patients (Chapter 5) with that of 27 sCJD patients from 
all six possible sCJD subgroups (Chapter 4), confirms these findings and extends the 
evidence that the vCJD strain is distinct from sCJD strains isolated in the wild-type 
panel. Overall, vCJD transmits disease efficiently in the wild-type mouse panel, 
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resulting in a progressive clinical disease with vacuolar degeneration in almost 100% 
of inoculated mice. Mice challenged with vCJD show a consistent heavy and 
widespread deposition of PrP in the brain following immunohistochemical analysis 
and demonstrate a unique PrPres type after Western blot analysis. In contrast, sCJD 
subgroups transmit less efficiently in the wild-type panel. The development of 
clinical disease was generally restricted to RIII mice challenged with one sCJD MM2 
brain homogenate with a mean incubation period of around 730 days, over 300 days 
longer that that of vCJD in the same mouse line. Targeting of vacuolar pathology in 
sCJD inoculated mice also differed to those observed in vCJD challenges. The 
similarity found in the lesion profiles between the different mouse Prn-p genotypes 
challenged with sCJD subgroups (MM1, MV1 and MM2 only) was in contrast to 
vCJD, in which the different mouse Prn-p genotypes were associated with different 
patterns of vacuolar pathology.  
 
In addition to clinical features, one of the most dramatic differences between the 
vCJD and sCJD inoculated mice was in the immunohistochemical analysis of the 
prion protein in which sCJD inoculated mice showed only small focal granular 
deposits of PrP in the brain compared to the intense and widespread PrP deposits 
observed in vCJD mice. What are the possible reasons for this discordance? One 
possibility is that the low levels of PrP in the sCJD challenged mice are a result of 
the mice having been sacrificed prior to the onset of clinical signs. However, this is 
unlikely as immunohistochemical analysis of the small numbers of sCJD challenged 
mice sacrificed with clinical TSE disease showed no obvious increase in the intensity 
or distribution of PrP in the mouse brain when compared to sCJD challenged mice 
sacrificed for reasons other than clinical TSE. Furthermore, Western blot analysis 
confirmed the presence of PrPres in CNS tissue from sCJD inoculated mice showing 
vacuolar pathology, with no observable differences in the intensity of the PrPres 
signal to that observed in mice after primary challenge with vCJD. Therefore, it may 
be that the differences observed in the PrP deposition between theses human TSEs in 
mice may relate to the methodologies employed. Western blot analysis has 
confirmed that the PrPres type differs between the sCJD and vCJD inoculated mice 
and that there are both conformational and glycosylation differences in the prion 
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protein in these two diseases. Such biochemical differences in PrP may result in 
sufficient alterations in the structure and folding of the prion protein such that the 
antigen retrieval methods used in the immunohistochemical analysis of PrP were 
sufficient to unmask the antigenic sites on mouse PrP in the vCJD inoculated mice 
but were unable to fully uncover those on PrP in the sCJD inoculated mice. In this 
study, immunohistochemical analysis was carried out with a single antibody raised 
against the prion protein (6H4). It might be useful to further investigate the 
deposition of the prion protein using a range of antibodies raised against different 
epitopes on the prion protein to fully evaluate the deposition and distribution of PrP 
in the sCJD inoculated mouse brain. However, preliminary investigations on a range 
of anti-PrP antibodies have provided no changes in the pattern of PrP deposition in 
sCJD inoculated mice. The demonstration that PrP staining patterns can vary 
depending on the primary antibody used in the analysis was reported in a study 
investigating PrP deposition in human TSEs, comparing 10 monoclonal antibodies 
raised against different epitopes on the prion protein. This study reported that a 
course and a plaque-like deposit successfully labelled with all 10 antibodies whereas, 
labelling of granular and synaptic deposits showed greater variation between the 
different antibodies (Kovacs et al., 2002a). In man, vCJD is associated with an 
intense peri-cellular PrP deposition with the formation of amyloid plaques and 
plaque-like deposits (Ironside et al., 1996; Ironside et al., 2000). In comparison to 
vCJD, granular and synaptic deposits of PrP are characteristic of the MM1 and MV1 
subtypes of sCJD (Parchi et al., 1999); these two sCJD subtypes showed the most 
efficient transmission in the mice used in this thesis. Therefore the different staining 
patterns observed between the sCJD and vCJD challenged mice may be a reflection 
of the differences in the aggregation state of PrPSc in the human donor tissue. 
Nevertheless, the immunohistochemical detection method used in this study was 
efficient in differentiating between vCJD and sCJD challenged mice. In conclusion, 
all transmission properties investigated in this thesis were able to differentiate 
between sCJD and vCJD inoculum, confirming that these two human TSEs represent 
distinct strains of agent.  
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7.2.5 No evidence of BSE-related strain properties in sCJD occurring in two 
dairy farmers  
It is noteworthy, that the original vCJD strain typing experiment described by Bruce 
and co-workers was carried out at a period of time in which the relationship between 
BSE, vCJD and sCJD was not clear. This is also the case for some of the earliest 
experimental challenges carried out as part of this thesis. Therefore, in addition to 
characterising the agent strain in vCJD and comparing with BSE, the original article 
also investigated whether there was any relationship between cases of sCJD and 
exposure to BSE. The case cohort described in Bruce et al. (1997) included two 
cases of CJD in dairy farmers who, having had BSE in their herds, had potentially 
been exposed to the BSE agent either from BSE-infected cattle or from contaminated 
animal feed (These two CJD cases are identified as CJD 2 and CJD 4 in this thesis). 
Both farmers were homozygous for methionine at codon 129 on the PRNP gene. The 
question raised was whether these cases of CJD showed any evidence of a BSE-
related strain. In the article, comparison of the clinical data and vacuolar pathology in 
RIII mice challenged with brain homogenate from these two sCJD cases showed no 
evidence of a BSE-related phenotype when compared to the same mouse line 
inoculated with vCJD and BSE. Furthermore, the clinical and pathological features 
were consistent with transmissions carried out with brain tissue from four further 
cases of sCJD in methionine homozygous individuals; two which had occurred after 
the BSE outbreak (identified in this thesis as CJD 1 and CJD 3) and two ‘historical’ 
cases in which the patients had died prior to the onset of BSE (identified in this thesis 
as CJD 5 and CJD 6). Data in this thesis confirms the initial findings and extends the 
analysis of these two incidences of sCJD in dairy farmers in a number of important 
aspects. Firstly, this thesis extended the analysis by increasing the number of 
transmitted cases of sCJD in methionine homozygous individuals to 12, providing 
complete analysis of clinical signs of disease and vacuolar pathology in a larger 
number of mouse lines. Secondly, this thesis included the biochemical analysis of 
PrPres in the mice following challenge with brain homogenate from the farmers and 
finally, the transmission characteristics of one of the farmers (patient CJD 2) was 
analysed after a further two passages in mice. Results showed that patterns of 
vacuolar pathology in the two farmers was consistent with that of the further eight 
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sCJD MM1 cases examined in this thesis. Crucially, Western blot analysis of PrPres 
in frozen mouse tissue from these two transmission experiments showed a 
glycosylation pattern and mobility in the unglycosylated form of the protein closely 
resembling that of type 1 sCJD. This PrPres type was consistent with that detected in 
the inocula used in the experimental challenges and consistent with the PrPres type 
observed in the mice after transmission of the other sCJD MM1 cases. In summary, 
the data presented in this study provides further evidence that the CJD diagnosed in 
these two dairy farmers was sporadic in nature and argues against a link between 
occupational exposure to the BSE agent and the development of CJD. 
 
7.2.6 No evidence of more than one vCJD/BSE-related agent strain 
The existence of more than one strain of cattle BSE has been proposed following the 
identification of two atypical molecular phenotypes (H and L-type) by Western blot 
analysis of cattle subjected to routine slaughterhouse testing (Biacabe et al., 2004; 
Casalone et al., 2004). Although defined primarily by differences in their 
biochemical properties, neuropathological analysis of the L-type of atypical BSE also 
showed some distinctions from classical BSE, with the observation of PrP-
immunopositive amyloid plaques in the brain. This provided further support that 
these atypical cases could represent further BSE strains (Casalone et al., 2004). 
Findings from the experimental transmission of BSE and vCJD in different lines of 
humanised transgenic mice and wild-type mice have also provided evidence for the 
existence of more than one BSE strain (Asante et al., 2002; Lloyd et al., 2004a; 
Beringue et al., 2008). 
 
In the first series of experiments investigating the BSE to human ‘species barrier’, 
two lines of humanised transgenic mice (Tg35 and Tg45) expressing human PrP and 
encoding methionine at codon 129, showed a complex pattern of transmission 
following challenge with BSE and vCJD isolates (Asante et al., 2002). In this study, 
vCJD transmission to both Tg35 and Tg45 mice produced a neuropathology and 
biochemical phenotype in the mice consistent with that of human vCJD. This vCJD-
like profile was also seen in the Tg45 mice challenged with BSE. However, 
transmission of BSE to Tg35 mice resulted in two distinct phenotypes; one which 
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was indistinguishable from that of vCJD challenged Tg35 and Tg45 mice; and a 
second which showed a biochemical phenotype more commonly associated with the 
transmission of sCJD in the Tg35 mice (Asante et al., 2002). This data suggested the 
isolation of two distinct BSE strains in Tg45 mice. A criticism of this study was that 
the Tg35 and Tg45 mice were produced on a mixed genetic background. The 
biological parameters (incubation period and lesion profile) that distinguish between 
different TSE strains are known to be modified by different genetic backgrounds 
(Bruce, 1993; Moore et al., 1998). Therefore, it was proposed that the different 
transmission properties seen in the BSE-challenged Tg35 mice may be due to 
differences in the genetic background of individual mice. This proposal was 
supported by findings from the same study which showed that different lines of wild-
type mice, challenge with either vCJD or BSE, produced two distinct biochemical 
profiles depending on the Prn-p genotype of the inoculated mice (Asante et al., 
2002). In order to address this criticism, a subsequent study carried out a further 
characterisation of these mouse-adapted BSE strains on serial passage in a single 
wild-type mouse line (SJL) (Lloyd et al. 2004). Analysis of incubation period, 
pattern of PrP deposition and PrPres type in the mice were consistent with the 
proposition that these mouse-adapted BSE strains represented the isolation of distinct 
BSE strains (Lloyd et al., 2004a).    
 
Such divergence in TSE strains has also been demonstrated in vCJD. In  a recent 
study, four vCJD isolates were transmitted to a different humanised transgenic 
mouse line (Tg650), also expressing human PrP encoding methionine at codon 129 
(Beringue et al., 2008). Three of the brain isolates faithfully propagated a vCJD-like 
neuropathology and biochemical profile in the mice. However, Tg650 mice 
challenged with the fourth vCJD isolate propagated two distinct phenotypes; one 
exhibiting the vCJD-like profile seen with the other vCJD isolates; and a second with 
a neuropathology and PrPres type which was more consistent with sCJD inoculated 
Tg650 mice (Beringue et al., 2008). Interestingly, analysis of the spleen from the 
Tg650 mice consistently demonstrated a vCJD-like PrPres type, even in the mice with 
a sCJD-like PrPres detected in the brain (Beringue et al., 2008).  
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The findings from these studies were interpreted by the authors as suggesting the 
existence of more than one strain of BSE. These studies also raised the possibility 
that some individuals infected with the BSE agent may present with a phenotype 
indistinguishable from that of sCJD; or that a variant strain of BSE agent is generated 
upon transmission from cattle to humans which could emerge following secondary 
human transmission of vCJD. This variant strain may also be indistinguishable from 
that of sCJD. Data from this thesis does not support the findings of the above, studies 
in a number of important aspects. Firstly in addressing the question of the existence 
of more than one BSE strain, this thesis has demonstrated that the transmission 
properties of all 10 vCJD isolates were highly reproducible in wild-type mice. This is 
consistent with the proposal that all 10 patients were infected with the same strain of 
agent. Secondly, in investigating the existence of novel BSE strains, this thesis has 
demonstrated that all mice analysed produced a neuropathology and PrPres type 
consistent with that of cattle BSE in the same mouse lines (Bruce et al., 1994; Bruce 
et al., 1997; Somerville et al., 1997; Brown et al., 2003; Ritchie et al., 2009). 
Therefore this thesis provides no evidence for a secondary or minor novel BSE 
strain, or of the generation of variant strains following cattle-to-human transmission 
of the BSE agent. Thirdly, the study described by Asante and co-workers suggested 
that some humans infected with BSE may develop a clinical disease which is 
indistinguishable from that of sCJD (Asante et al., 2002). Again, data from the 
extensive series of transmissions analysed in this thesis shows no evidence to support 
this proposition. The dramatic differences observed in the efficiency in the 
transmission of brain homogenate from vCJD patients compared to that observed 
with sCJD isolates would facilitate in the identification of any BSE-like strain 
properties within sCJD challenged mice. The lack of any clinical disease in the sCJD 
inoculated mice; the low levels of PrP deposition in the brain following 
immunohistochemical analysis, and the absence of any vCJD/BSE biochemical 
phenotype in mice inoculated with brain homogenate from different sCJD subgroups, 
provide no evidence of an association between the sCJD cases investigated in this 
thesis and infection with the BSE agent. Lastly, the study by Beringue and co-
workers proposes that a minor strain of BSE agent may be generated upon cattle-to-
human transmission which may emerge on subsequent human-to-human 
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transmissions. In this thesis, the lack of any evidence of a sCJD-like disease 
phenotype in any of the mice inoculated with vCJD is further evidence against the 
proposals made in these previous studies.   
 
More recently, a distinct biochemical phenotype has been observed following the 
experimental transmission of sCJD isolates in another humanised transgenic mouse 
model (Bishop, 2008; Bishop et al., 2010). In this mouse model, three transgenic 
mouse lines were produced using the gene targeting method by the direct 
replacement of the mouse prion protein open reading frame with the three different 
human PRNP sequence (129MM, MV and VV). Results from the inoculation of the 
different sCJD subgroups in these three transgenic mouse lines (HuMM, HuMV and 
HuVV) have been directly compared with the data presented in this study earlier in 
this Chapter (section 7.2.1.1). In these transgenic mouse models, inoculation of 
HuVV mice with a sCJD MV2 and a VV2 isolate, resulted in a PrPres type showing a 
predominance in the diglycosylated fragment and a mobility in the unglycosylated 
fragment of around 19kDa, a Western blot profile more commonly associated with 
vCJD and BSE (Bishop, 2008; Bishop et al., 2010). However, the clinical and 
neuropathological features of these mice were distinct from that of vCJD previously 
described in these transgenic mouse lines (Bishop et al., 2006).  No evidence of a 
vCJD/BSE-like biochemical profile was observed in any of the HuMM or HuMV 
challenged mice (Bishop, 2008; Bishop et al., 2010). The authors in this study were 
cautious not to draw any direct links between the detection of this PrPres glycoform 
profile and the implication of a BSE-like strain in these sCJD isolates. Although 
PrPres type is a valuable addition in the differentiation of the BSE strain, the same 
glycoform profile has been demonstrated in some experimental strains of scrapie 
(Somerville et al., 1997) and in FFI in humans (Telling et al., 1996). Furthermore, 
other changes in the PrPres type on transmission were observed in the study by 
Bishop and co-workers, specifically, the demonstration of a type 1 PrPres in the 
HuMM and HuMV lines following inoculation with brain homogenate from sCJD 
MV2 and VV2 subgroup. These findings suggest that the resulting PrPres type in the 
inoculated mouse may be influenced by the host genotype of the mouse in 
combination with agent strain rather than enciphered by agent strain alone. These 
   
 289 
transmission studies in transgenic mice further highlight the difficulties in fully 
understanding the relationship between PrPres type and TSE strain. Although PrPres 
isotyping may be a reliable diagnostic test, able to differentiate between vCJD and 
sCJD in people and may be a valuable addition in helping to define agent strain in 
experimental settings, such transgenic studies demonstrate the danger in over 
interpreting information on agent strain from the PrPres type alone.  
 
7.2.7 Experimental challenge of vCJD peripheral tissues shows no evidence of 
tissue-specific alterations in agent strain 
The demonstration of a vCJD-like clinico-pathological and biochemical phenotype in 
mice following challenge with different peripheral tissue homogenates is further 
support that vCJD has resulted from infection with a single strain of agent. Two of 
the vCJD patients investigated had disease onsets in the year 2000, three years on 
from the most recent vCJD case selected in the transmission of brain tissue. This is a 
further indication that there has been no significant alteration in the agent strain as 
the disease progressed. Furthermore, the demonstration that the strain properties of 
the vCJD agent in different tissue types is similar to those demonstrated by brain 
isolates suggests that the strain properties of vCJD are not substantially altered by the 
tissue in which it replicates. These findings confirm that of an earlier study showing 
conservation of the vCJD biochemical profile in the spleen on transmission to 
humanised transgenic mice (Beringue et al., 2008). Therefore, the subtle differences 
that have been observed in the biochemical phenotype in the different vCJD tissue 
types (Head et al., 2004b) may not be an essential part in enciphering agent strain.  
 
Data from this thesis indicates that strain typing in vCJD can be successfully carried 
out from tissues other than brain; however, the efficiency of the transmissions will 
vary between individual tissue types, presumably as a result of lower titres of 
infectivity in peripheral tissues. The ability to strain type from tissues other than 
brain, particularly from lymphoreticular tissues, may be valuable in future strain 
typing of cases of vCJD in other codon 129 PRNP genotype (MV and VV), should 
they occur. To date, evidence that these other PRNP genotypes are susceptible to 
infection with vCJD comes from asymptomatic individuals who had demonstrable 
   
 290 
levels of PrPSc in lymphoreticular tissues only (Peden et al., 2004; Hilton et al., 
2004b; Ironside et al., 2006; Peden et al., 2010).  Therefore, strain typing in these 
cases will rely on transmission from lymphoreticular tissues rather than brain. These 
studies are in progress. As part of the continuing collaboration between the 
NCJDRSU and the NPU/NPD, transmission experiments are underway with brain 
and spleen tissue sampled from an asymptomatic case of vCJD blood-borne infection 
in an MV individual, previously reported by Peden et al., (2004). This patient died of 
causes unrelated to a TSE but was known to have received a blood transfusion of 
non-leucodepleted red cells from a donor who subsequently went on to develop 
vCJD. Evidence of the abnormal prion protein in this patient was found in the spleen 
and a cervical lymph node but not in the brain. Inoculations of brain and spleen 
homogenate from this patient have been carried out in both humanised transgenic 
mouse lines (HuMM, HuMV and HuVV) and in a single wild-type line. Comparable 
inoculations are also underway with brain and spleen tissue from the vCJD blood 
donor to this patient. Preliminary data from these inoculations show clinical disease 
and vacuolar pathology, consistent with a TSE, in the transgenic and wild-type mice 
challenged with brain and spleen isolates from the vCJD donor. Furthermore, TSE 
disease has been confirmed in a proportion of the mice challenged with the spleen 
isolate from the asymptomatic MV blood recipient. No evidence of a TSE has been 
found in any mouse challenged with brain tissue from this same MV individual 
(unpublished data). Therefore, strain typing of the vCJD agent in the MV patient may 
rely solely on the transmission properties of the spleen homogenate. The 
characterisation of the vCJD agent in spleen tissue carried out in this thesis and 
published in the JGV (Ritchie et al., 2009), will be an important benchmark on which 
to compare the data from such future studies. The findings from this thesis and that 
of a previous study (Beringue et al., 2008) have shown that the strain properties of 
the agent are not substantially altered by the tissue in which it replicates. Therefore, 
any differences found in the transmission properties of the spleen isolates from the 
MV recipient and the vCJD blood donor will most likely be an indication that there 
are alterations in the agent strain associated with the different codon 129 genotype of 
the host, rather than associated with alterations associated with different tissue types. 
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7.2.8 The absence of any evidence of a TSE in mice challenged with non-CNS 
tissue does not rule out the presence of low levels of infectivity 
Overall, data from the experimental transmission of different lymphoid tissues, 
neural tissues and biological fluids have confirmed that the presence of infectivity is 
concurrent with the demonstration of PrPSc in tissues, with infectivity detected to 
some degree in vCJD spleen, tonsil, lymph node, appendix, peripheral nerve, DRG 
and TRG.  However, given the relative insensitivity of the mouse bioassay, the 
absence of any evidence of a TSE in the mice after challenge with vCJD CSF, bone 
marrow, buffy coat and plasma does not rule out the presence of low levels of 
infectivity in these tissues/fluids. This is best illustrated by the negative results from 
one vCJD lymph node (CJD 40), in which PrPSc had been confirmed by 
immunohistochemical analysis of this tissue at autopsy. Possible reasons for the 
failure of this tissue to transmit disease include the lower infectivity levels observed 
in peripheral tissues compare to that of vCJD brain, combined with the difficulties 
associated with the sampling of tissues showing a heterogeneous distribution of PrPSc 
as described in detail in Chapter 6.  
 
Experimental transmission of infectivity in sheep by transfusion of blood sampled 
during the clinical and preclinical phase of sheep naturally infected with scrapie or 
experimentally infected by an oral dose of BSE, confirmed that infectivity can 
efficiently be transmitted via blood transfusion (Hunter et al., 2002).  There is now 
convincing evidence to support the presence of infectivity in vCJD blood based on 
the five instances of vCJD infection (three clinical cases and two asymptomatic) 
following transfusion of blood and blood (Llewelyn et al., 2004; Peden et al., 2004; 
Wroe et al., 2006; Health Protection Agency, 2009b; Peden et al., 2010). However, 
the transmission of blood components (plasma and buffy coat) from four vCJD 
patients in this thesis failed to show any evidence of infection in the mice.  
 
What could the reasons be for the lack of transmission in the mice? The most likely 
explanation is that the relative volumes of primary inoculum injected into the mice 
were sufficiently low to prevent disease in the mice. Titres of infectivity in vCJD 
blood are not known. However, the findings from a hamster scrapie (hamster scrapie 
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263K strain) model suggest that the measured titre of infected hamster blood is on 
average 10 infectious doses (ID) per ml during the preclinical phase rising to 100 ID 
per ml during the clinical phase (Holada et al., 2002; Gregori et al., 2004; Gregori et 
al., 2006). If similar levels of infectivity are associated with blood from vCJD 
patients, and if blood is homogeneous, then a volume of 10-100µl or more would be 
required for the transmission of disease, even if there was no ‘species barrier’. In the 
inoculations carried out in this thesis, 20µl volumes of either buffy coat or plasma 
were inoculated intracerebrally. Depending on the exact levels of infectivity in 
human blood and the extent of the ‘species barrier’, then 20µl volumes may be at the 
border line for successful transmission and it might be predicted that the appearance 
of a TSE in the mice would appear a ‘hit or a miss’. This also explains why the sheep 
model has proven to be the most successful model for the demonstration of 
infectivity in blood collected from sheep incubating scrapie and experimental BSE 
(Houston et al., 2000; Hunter et al., 2002; Houston et al., 2008).  In these sheep 
studies, individual sheep were transfused with a minimum of 200ml of blood 
collected from TSE-infected sheep. If the ID present in blood collected from sheep 
infected with scrapie of experimental BSE is comparable to the measured titre of 
infected hamster blood (Holada et al., 2002; Gregori et al., 2004; Gregori et al., 
2006) this suggests that sheep transfused with TSE-infected blood would have 
received 2000 – 20,000 ID. This also explains the evidence for the successful 
secondary human transmission of vCJD by blood transfusion. In humans, the typical 
volume of blood transfused is one unit (around 400mls). Again, if similar to that 
measured in infected hamster blood, this would be associated with 4,000 ID in a 
(preclinical) vCJD-infected blood donation. It is also possible that the route of 
infection may be important in the transmission of infection from blood. It would 
appear through the secondary human transmission of infectivity via blood transfusion 
that the transmission of infection from vCJD blood is highly efficient via the 
intravenous route. In the experiments described in this study, all inoculations from 
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7.2.9 Detection of infectivity in sCJD blood and its implications 
Demonstrable levels of PrPSc have been found in the pituitary gland (Peden et al., 
2007), spleen and intramuscular nerve fibres in a proportion of sCJD patients 
(Glatzel et al., 2003; Peden et al., 2006). However, peripheral tissue involvement in 
sCJD is thought to be more limited than that of vCJD (Head et al., 2004b). In this 
thesis, the lack of any evidence of disease in mice following challenge with a sCJD 
spleen homogenate appears to support this position. Therefore, the detection of 
infectivity in a sCJD buffy coat sample was unexpected, particularly in view of the 
negative results obtained from the transmission of vCJD blood components. Data 
from this thesis is not the first evidence of infectivity in sCJD blood. Previous 
transmissions in different rodent models have also provided unconfirmed reports of 
the transmission of infectivity from buffy coat (Manuelidis et al., 1985) and from 
whole blood (Tateishi, 1985) taken at autopsy from sCJD patients. In this thesis, the 
evidence of infectivity in sCJD buffy coat is based on the neuropathological changes 
of a single VM mouse.  
 
One question which arises is whether this is true result or merely a laboratory error 
involving misidentification of samples. A laboratory error is thought to be highly 
improbable due to the procedures applied during these transmissions and an audit 
trail of this result failed to identify evidence of a misidentification of samples of 
mice. Therefore, it is assumed that this is a true result, which is to say that the mouse 
acquired a TSE which is consistent with the inoculum used to challenge it. 
Furthermore, immunohistochemical analysis for the prion protein in this one mouse 
showed the specific targeting and intensity of PrP deposits consistent with that of 
mice inoculated with sCJD brain isolates. Although contamination or experimental 
misidentification can not be completely ruled out, this result provides direct evidence 
of low levels of infectivity in sCJD blood and evidence supporting a peripheral 
involvement in sCJD. However, with such an unexpected result, it will be important 
to carry out further work to confirm it. This may involve the inoculation of this sCJD 
blood sample to humanised transgenic mice or analysis of the buffy coat sample 
biochemically, should a more sensitive method be available. If infectivity is 
associated with sCJD blood, one question that arises is why there are so few cases of 
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infectivity in the mice? Again the explanation may be associated with low infectious 
titres present in the inoculum. If at worst, titres of infectivity present in sCJD blood 
are similar to that of patients with vCJD then the transmission of disease in 
inoculations of animals with materials containing less that 1 ID per volume may 
become increasingly stochastic. However, it would be wrong to dismiss occasional 
positive transmission in such cases.  
 
What might the implications be for risk assessment associated with the use of blood 
and blood products from sCJD patients?  There have been a number of reports of 
sCJD arising in individuals who have had transfusion with blood or blood products 
(Klein and Dumble, 1993; Creange et al., 1995; de Silva, 1996; Patry et al., 1998; 
Hewitt et al., 2006); however, unlike vCJD, there is as yet no causal link between the 
blood donation in these cases and CJD in the blood donors. Therefore, the proposed 
risk from the secondary transmission of sCJD by blood products has been assumed to 
be theoretical and perceived to be much lower than that of vCJD. However, the 
results of this thesis suggests otherwise. What are the possible reasons for the 
apparent reduced risk in the secondary transmission of infectivity from sCJD blood 
compared to vCJD? In contrast to vCJD where the median age at death is 29 years, 
the median onset for sCJD is 68 years. In general, blood donations are made by 
younger people; however, the blood transfusion service states that any healthy 
individual between the age of 17 and 65 can donate blood 
(http:www.blood.co.uk/can-i-give-blood/who-can-give-blood/). The maximum age at 
which an individual can donate blood is younger than the average onset of sCJD, 
therefore the risk from sCJD-infected blood entering the blood pool is thought to be 
sufficiently low. Furthermore, the incubation period in sCJD may be short compared 
to vCJD further reducing the risk of sCJD patients donating blood while incubation 
the disease. Therefore although this study provides evidence of infectivity within 
sCJD blood the risks overall may be much lower for reasons on disease 




   
 295 
7.3 Summary of thesis findings 
Work presented in this extensive series of transmission experiments has provided a 
comprehensive and thorough characterisation of the sCJD and vCJD agent on 
transmission to wild-type mice. The overall objective of this thesis was to investigate 
the relationship between disease phenotype, PRNP codon 129 genotype, PrPres type 
and agent strain. In addition, this thesis also aimed to establish whether infectivity 
could be demonstrated in tissues other than brain in sCJD and vCJD and if so, 
whether there are any tissue-specific alterations in the agent strain in these tissue 
types. In addressing these aims, four specific questions were asked. These questions 
and the main findings from this thesis are summarised below. 
 
1. Do the six different sCJD subgroups, as classified by PRNP codon 129 
and PrP
res
 type behave as different strains of agent on transmission to wild-
type mice?  
Chapter 4 details the first direct comparison of all strain typing parameters in 
wild-type mice challenged with brain tissue from all six sCJD subgroups (as 
classified by PRNP codon 129 and PrPres type). The findings have provided 
evidence that the six sCJD subgroups propagate as three distinct sCJD strains on 
transmission to wild-type mice (MM1/MV1; MM2; MV2/VV1/VV2). Further 
analyses of the groupings indicate that the transmission properties of sCJD in 
the mice are attributed to a combination of PRNP codon 129 genotype and PrPres 
type of the donor. Tissue from patients with at least one methionine allele at 
codon 129 on the PRNP gene and who have a PrPres type 1 were found to 
transmit most efficiently in this mouse model. Furthermore, the findings that 
PrPres type is conserved on primary transmission and on subsequent serial mouse 
passage is consistent with the ‘prion hypothesis’ which proposes that distinct 
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2. How do transmissions from sCJD, proposed to have more than one strain 
of agent compare with vCJD, believed to be a single strain of agent?  
Data presented in Chapter 5 has provided a full characterisation of the vCJD 
agent in 10 vCJD brain isolates. Results were consistent with the proposal that 
all 10 patients were infected with the same strain of agent. Furthermore, 
transmission properties were consistent to those previously reported with BSE in 
the same mouse line, providing further evidence that BSE is the origin of these 
vCJD cases. Comparison of incubation period, lesion profile, patterns of PrP 
deposition and PrPres type in the brain of vCJD and sCJD inoculated mice were 
consistent with the proposal that vCJD represents a distinct strain of agent to 
those propagated in sCJD transmissions.   
 
3. Can the detection of infectivity in vCJD patients be extended to tissues 
other than brain, spleen and tonsil? Furthermore, can infectivity be detected 
outside the CNS in sCJD?  
Experimental transmissions outlined in Chapter 6 have extended the evidence for 
a widespread lymphoid tissue infection and have provided the first direct 
demonstration of the presence of vCJD infectivity in the peripheral nervous 
system. Infectivity was detected in vCJD spleen, tonsil, lymph node, appendix, 
DRG, TRG, spinal cord and peripheral nerve. Consistent with the proposal that 
sCJD has a more limited peripheral involvement to that of vCJD; no evidence of 
transmission was found following challenge with one sCJD spleen isolate. 
However, the observation of infectivity consistent with a TSE following 
inoculation of a sCJD buffy coat indicates that low levels of infectivity may be 
present in blood from clinical cases of sCJD.   
 
4. Is agent strain subject to any tissue specific modifications?  
Chapter 6 details the incubation period, lesion profile and pattern of PrPres 
deposition in mice challenged with different vCJD tissue types. The findings 
have shown a closely similar pattern to that found in vCJD brain transmissions 
(Chapter 5). This provides evidence that the vCJD agent is not substantially 
altered by the tissue in which it replicates.  
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7.4 Concluding remarks 
This thesis has used “classical” strain typing in wild-type mice to characterise the 
agent strain in sCJD and vCJD.  The majority of transmission work in TSEs now 
involves the use of humanised transgenic mouse models. Developed primarily to 
overcome the ‘species barrier’, transgenic models have also been used to investigate 
the effects of the polymorphism at codon 129 of the PRNP gene providing valuable 
information regarding the nature of TSE strains. Nevertheless, the findings from this 
thesis confirm that the traditional wild-type mouse panels developed at the NPU 
remain a highly successful and relevant tool in the investigation of human TSEs. 
This thesis demonstrates that wild-type mice are very efficient hosts for vCJD. This 
is in contrast to transgenic mice expressing human PrP which have been found to 
have a pronounced barrier to challenge with vCJD prions and are apparently resistant 
to infection with the BSE agent. Furthermore, the propagation of three sCJD strains 
in this thesis show close similarities to sCJD strains propagated in different 
humanised transgenic lines.  
 
However, the findings from this thesis raise a number of important issues regarding 
the continued use of wild-type mice in the investigation of human TSEs. Firstly, are 
wild-type mice a valid tool in the investigation of sCJD if not all cases transmit and 
very few animals develop clinical signs?  Secondly, this thesis has highlighted that 
the role of codon 129 in PRNP is paramount in influencing transmission. The 
difficulties observed in the transmission of some sCJD subgroups (MV1 and VV) to 
wild-type mice have been overcome using humanised transgenic mouse lines 
expressing the PRNP gene with the codon 129 MM, MV and VV genotypes.  This 
questions whether the problems associated with “classical” strain typing could be 
overcome using gene targeting to produce mice with valine at position 128 in the 
murine Prn-p gene? Finally, can strain typing in wild-type mice be justified in view 
of the long incubation times, costs and the ethical considerations associated with the 
numbers of animals sacrificed, particularly in view of the lack of success in the 
transmission of some sCJD subgroups?  
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Recently the development of in vitro assays such as CDI to probe abnormal prion 
protein conformation, and models such as PMCA and cell culture systems to 
examine replication in a cell-free and cellular systems, have been proposed as 
alternatives to the use of animals in TSE research models (reviewed in Ryou and 
Mays, 2008; Jones et al., 2010). Similarly to transgenic mouse models, in vitro 
assays are proving an important tool in the better understanding of the species barrier 
effect, the effects of the PRNP codon 129 genotype and more recently in the 
propagation of TSE strains. There are clear advantages to the development and 
application of in vitro assays over animal models in TSE research. Primarily they 
offer a faster and cheaper model for the conversion of PrPC or amplification of PrPSc. 
In addition, in vitro assays offer a more controllable environment in which to 
investigate TSEs. The ability to manipulate these in vitro are being utilised in the 
potential development of a sensitive diagnostic technique for TSE infectivity in, for 
example blood. Despite these technologies emerging as powerful tools they remain 
relatively poorly validated and incompletely understood. In the case of cell culture 
assays, there are currently no human cells that are able to stabily replicate human 
TSE strains. In addition, there are still questions surrounding several reports of 
spontaneous PrPSc generation using the PMCA PrPSc amplification technology. 
Fundamentally, these in vitro cell-free conversion assays investigate TSEs at a 
molecular level focussing almost exclusively on PrPSc conversion. Unlike animal 
models, in vitro assays are not able to replicate TSE disease as such nor are they able 
to study the pathogenesis of TSEs at the cellular and tissue level. Animal models are 
able to investigate important specific pathological features of TSEs, such as 
lymphoreticular involvement, neuroinvasion and the targeting of pathology to 
particular regions and cell types in the brain.  Therefore, at present this thesis 
contends that there remains a key role for the use of wild-type mice in the 
investigation of human TSEs. 




Data generated from this thesis was published in one article. The reprint of this 
article is presented in this appendix.  
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M.E. (2009). Transmissions of variant Creutzfeldt-Jakob disease from brain and 
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